NZ622702B2 - Anticancer pyridopyrazines via the inhibition of fgfr kinases - Google Patents
Anticancer pyridopyrazines via the inhibition of fgfr kinases Download PDFInfo
- Publication number
- NZ622702B2 NZ622702B2 NZ622702A NZ62270212A NZ622702B2 NZ 622702 B2 NZ622702 B2 NZ 622702B2 NZ 622702 A NZ622702 A NZ 622702A NZ 62270212 A NZ62270212 A NZ 62270212A NZ 622702 B2 NZ622702 B2 NZ 622702B2
- Authority
- NZ
- New Zealand
- Prior art keywords
- substituted
- 6alkyl
- formula
- 4alkyl
- optionally
- Prior art date
Links
- YEYHFKBVNARCNE-UHFFFAOYSA-N pyrido[2,3-b]pyrazine Chemical class N1=CC=NC2=CC=CN=C21 YEYHFKBVNARCNE-UHFFFAOYSA-N 0.000 title abstract 2
- 230000002401 inhibitory effect Effects 0.000 title description 70
- 108091000081 Phosphotransferases Proteins 0.000 title description 30
- 230000001093 anti-cancer Effects 0.000 title description 2
- 102000030951 Phosphotransferases Human genes 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 392
- -1 substituted Chemical class 0.000 claims description 131
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 88
- 125000000623 heterocyclic group Chemical group 0.000 claims description 79
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims description 71
- 229910052739 hydrogen Inorganic materials 0.000 claims description 65
- 239000001257 hydrogen Substances 0.000 claims description 65
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 64
- 125000005842 heteroatoms Chemical group 0.000 claims description 59
- 229910052736 halogen Inorganic materials 0.000 claims description 50
- 125000001424 substituent group Chemical group 0.000 claims description 49
- 125000005843 halogen group Chemical group 0.000 claims description 42
- 150000002367 halogens Chemical class 0.000 claims description 38
- 125000002950 monocyclic group Chemical group 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 31
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 22
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 22
- 125000004429 atoms Chemical group 0.000 claims description 18
- 229910052760 oxygen Inorganic materials 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 14
- 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 14
- 125000004452 carbocyclyl group Chemical group 0.000 claims description 14
- 229910007161 Si(CH3)3 Inorganic materials 0.000 claims description 10
- 125000001624 naphthyl group Chemical group 0.000 claims description 9
- 229910052717 sulfur Inorganic materials 0.000 claims description 7
- YCKRFDGAMUMZLT-UHFFFAOYSA-N fluorine atom Chemical group [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 claims description 4
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 3
- 239000011737 fluorine Chemical group 0.000 claims description 3
- 229910052731 fluorine Chemical group 0.000 claims description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 101700074271 CR18 Proteins 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 102
- 201000011510 cancer Diseases 0.000 abstract description 65
- 201000010099 disease Diseases 0.000 abstract description 63
- 238000000034 method Methods 0.000 abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 abstract description 14
- 239000000543 intermediate Substances 0.000 description 354
- 239000002904 solvent Substances 0.000 description 173
- 238000006243 chemical reaction Methods 0.000 description 136
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 123
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 118
- YMWUJEATGCHHMB-UHFFFAOYSA-N methylene dichloride Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 109
- BZKBCQXYZZXSCO-UHFFFAOYSA-N sodium hydride Chemical compound [H-].[Na+] BZKBCQXYZZXSCO-UHFFFAOYSA-N 0.000 description 105
- XEKOWRVHYACXOJ-UHFFFAOYSA-N acetic acid ethyl ester Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 103
- WYURNTSHIVDZCO-UHFFFAOYSA-N tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 93
- 239000002585 base Substances 0.000 description 91
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 86
- 102000027757 FGF receptors Human genes 0.000 description 81
- 108091008101 FGF receptors Proteins 0.000 description 81
- 239000011541 reaction mixture Substances 0.000 description 70
- 239000000203 mixture Substances 0.000 description 69
- 239000000243 solution Substances 0.000 description 69
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 59
- 150000003839 salts Chemical class 0.000 description 56
- 239000011780 sodium chloride Substances 0.000 description 56
- WEVYAHXRMPXWCK-UHFFFAOYSA-N acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 53
- 125000003118 aryl group Chemical group 0.000 description 51
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 50
- 235000019439 ethyl acetate Nutrition 0.000 description 49
- 239000002253 acid Substances 0.000 description 44
- 239000012044 organic layer Substances 0.000 description 44
- 102100018000 FGFR2 Human genes 0.000 description 43
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 43
- 230000035772 mutation Effects 0.000 description 40
- 230000000694 effects Effects 0.000 description 38
- 239000012071 phase Substances 0.000 description 38
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 38
- 108010081268 Type 2 Fibroblast Growth Factor Receptor Proteins 0.000 description 35
- 239000003112 inhibitor Substances 0.000 description 35
- 102000027766 FGFR3 Human genes 0.000 description 34
- 108010081267 Type 3 Fibroblast Growth Factor Receptor Proteins 0.000 description 34
- 239000012267 brine Substances 0.000 description 33
- 239000003795 chemical substances by application Substances 0.000 description 33
- 102000001253 Protein Kinases Human genes 0.000 description 32
- 102100017996 FGFR1 Human genes 0.000 description 31
- 108010081291 Type 1 Fibroblast Growth Factor Receptor Proteins 0.000 description 31
- 229910052757 nitrogen Inorganic materials 0.000 description 30
- 239000012453 solvate Substances 0.000 description 28
- 230000027455 binding Effects 0.000 description 27
- 125000002883 imidazolyl group Chemical group 0.000 description 27
- 229910002027 silica gel Inorganic materials 0.000 description 27
- 239000000741 silica gel Substances 0.000 description 27
- 238000004587 chromatography analysis Methods 0.000 description 26
- KWYUFKZDYYNOTN-UHFFFAOYSA-M potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 26
- 230000033115 angiogenesis Effects 0.000 description 25
- 210000004027 cells Anatomy 0.000 description 25
- 150000001204 N-oxides Chemical class 0.000 description 24
- DTQVDTLACAAQTR-UHFFFAOYSA-N trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 24
- 102100020189 FGFR4 Human genes 0.000 description 23
- 101700075612 FGFR4 Proteins 0.000 description 23
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 23
- 239000005457 ice water Substances 0.000 description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 22
- 239000000047 product Substances 0.000 description 22
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 21
- 150000002500 ions Chemical class 0.000 description 21
- 230000000069 prophylaxis Effects 0.000 description 21
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 20
- 229910020175 SiOH Inorganic materials 0.000 description 20
- 239000003814 drug Substances 0.000 description 20
- 239000003446 ligand Substances 0.000 description 20
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 19
- 125000002619 bicyclic group Chemical group 0.000 description 19
- 239000003054 catalyst Substances 0.000 description 19
- 125000004122 cyclic group Chemical group 0.000 description 19
- 150000002829 nitrogen Chemical group 0.000 description 19
- 125000003226 pyrazolyl group Chemical group 0.000 description 19
- 125000000714 pyrimidinyl group Chemical group 0.000 description 19
- 230000003827 upregulation Effects 0.000 description 19
- 125000001072 heteroaryl group Chemical group 0.000 description 18
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 18
- 230000001788 irregular Effects 0.000 description 18
- 230000001404 mediated Effects 0.000 description 18
- 239000002244 precipitate Substances 0.000 description 18
- 210000001519 tissues Anatomy 0.000 description 18
- 102100013180 KDR Human genes 0.000 description 17
- 230000004913 activation Effects 0.000 description 17
- 230000000051 modifying Effects 0.000 description 17
- 230000001681 protective Effects 0.000 description 17
- VEXZGXHMUGYJMC-UHFFFAOYSA-N HCl Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 16
- FPGGTKZVZWFYPV-UHFFFAOYSA-M Tetra-n-butylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 16
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 16
- 229910000027 potassium carbonate Inorganic materials 0.000 description 16
- 125000004076 pyridyl group Chemical group 0.000 description 16
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 15
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 15
- VHUUQVKOLVNVRT-UHFFFAOYSA-N ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 15
- 235000011114 ammonium hydroxide Nutrition 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 15
- 230000014509 gene expression Effects 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- FXHOOIRPVKKKFG-UHFFFAOYSA-N DMA Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 14
- 206010028980 Neoplasm Diseases 0.000 description 14
- MFRIHAYPQRLWNB-UHFFFAOYSA-N Sodium tert-butoxide Chemical compound [Na+].CC(C)(C)[O-] MFRIHAYPQRLWNB-UHFFFAOYSA-N 0.000 description 14
- 102100015249 VEGFA Human genes 0.000 description 14
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 14
- 125000001246 bromo group Chemical group Br* 0.000 description 14
- 125000001153 fluoro group Chemical group F* 0.000 description 14
- CSNNHWWHGAXBCP-UHFFFAOYSA-L magnesium sulphate Substances [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 14
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 14
- 238000000746 purification Methods 0.000 description 14
- YOQDYZUWIQVZSF-UHFFFAOYSA-N sodium borohydride Substances [BH4-].[Na+] YOQDYZUWIQVZSF-UHFFFAOYSA-N 0.000 description 14
- 102000018233 Fibroblast growth factor family Human genes 0.000 description 13
- 108050007372 Fibroblast growth factor family Proteins 0.000 description 13
- 101710030888 KDR Proteins 0.000 description 13
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 13
- 235000019341 magnesium sulphate Nutrition 0.000 description 13
- 201000009251 multiple myeloma Diseases 0.000 description 13
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 13
- 125000003373 pyrazinyl group Chemical group 0.000 description 13
- 125000001425 triazolyl group Chemical group 0.000 description 13
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 12
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M Lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 12
- 206010035226 Plasma cell myeloma Diseases 0.000 description 12
- 239000002246 antineoplastic agent Substances 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- JUJWROOIHBZHMG-UHFFFAOYSA-N pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 12
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 11
- XHXFXVLFKHQFAL-UHFFFAOYSA-N Phosphoryl chloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 11
- 206010060862 Prostate cancer Diseases 0.000 description 11
- 230000002159 abnormal effect Effects 0.000 description 11
- 125000004432 carbon atoms Chemical group C* 0.000 description 11
- 230000003287 optical Effects 0.000 description 11
- 230000002018 overexpression Effects 0.000 description 11
- 125000003386 piperidinyl group Chemical group 0.000 description 11
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 11
- 230000001225 therapeutic Effects 0.000 description 11
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 10
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 10
- 150000002148 esters Chemical class 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- 239000003102 growth factor Substances 0.000 description 10
- 201000005202 lung cancer Diseases 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- SECXISVLQFMRJM-UHFFFAOYSA-N n-methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 10
- QARBMVPHQWIHKH-UHFFFAOYSA-N Methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 9
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 9
- QTBSBXVTEAMEQO-UHFFFAOYSA-M acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 9
- 230000003213 activating Effects 0.000 description 9
- 238000007792 addition Methods 0.000 description 9
- 230000000259 anti-tumor Effects 0.000 description 9
- XTHFKEDIFFGKHM-UHFFFAOYSA-N dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 9
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 9
- 125000001715 oxadiazolyl group Chemical group 0.000 description 9
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052763 palladium Inorganic materials 0.000 description 9
- UQPUONNXJVWHRM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 UQPUONNXJVWHRM-UHFFFAOYSA-N 0.000 description 9
- 230000035755 proliferation Effects 0.000 description 9
- 102000005962 receptors Human genes 0.000 description 9
- 108020003175 receptors Proteins 0.000 description 9
- 125000003831 tetrazolyl group Chemical group 0.000 description 9
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 description 8
- 101700008564 CHIC2 Proteins 0.000 description 8
- 108091007929 PDGF receptors Proteins 0.000 description 8
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 8
- 210000003932 Urinary Bladder Anatomy 0.000 description 8
- 108090001123 antibodies Proteins 0.000 description 8
- 102000004965 antibodies Human genes 0.000 description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 8
- 201000011231 colorectal cancer Diseases 0.000 description 8
- 230000000875 corresponding Effects 0.000 description 8
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine hydrate Chemical compound O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 8
- SIKJAQJRHWYJAI-UHFFFAOYSA-N indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N iso-propanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- 125000002757 morpholinyl group Chemical group 0.000 description 8
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 8
- BDERNNFJNOPAEC-UHFFFAOYSA-N propanol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 8
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 8
- 229910000033 sodium borohydride Inorganic materials 0.000 description 8
- 239000000126 substance Substances 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 7
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-Methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 7
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 description 7
- GPAYUJZHTULNBE-UHFFFAOYSA-N Diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 description 7
- 102000004190 Enzymes Human genes 0.000 description 7
- 108090000790 Enzymes Proteins 0.000 description 7
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 description 7
- 210000004072 Lung Anatomy 0.000 description 7
- NLKNQRATVPKPDG-UHFFFAOYSA-M Potassium iodide Chemical compound [K+].[I-] NLKNQRATVPKPDG-UHFFFAOYSA-M 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 201000009030 carcinoma Diseases 0.000 description 7
- 239000000969 carrier Substances 0.000 description 7
- 230000010261 cell growth Effects 0.000 description 7
- 125000001309 chloro group Chemical group Cl* 0.000 description 7
- 239000012043 crude product Substances 0.000 description 7
- 238000010511 deprotection reaction Methods 0.000 description 7
- 238000003745 diagnosis Methods 0.000 description 7
- 230000012010 growth Effects 0.000 description 7
- 230000003211 malignant Effects 0.000 description 7
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 7
- 235000015320 potassium carbonate Nutrition 0.000 description 7
- 125000000168 pyrrolyl group Chemical group 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 125000001113 thiadiazolyl group Chemical group 0.000 description 7
- 125000005871 1,3-benzodioxolyl group Chemical group 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 6
- ZDZHCHYQNPQSGG-UHFFFAOYSA-N 1-naphthalen-1-ylnaphthalene Chemical compound C1=CC=C2C(C=3C4=CC=CC=C4C=CC=3)=CC=CC2=C1 ZDZHCHYQNPQSGG-UHFFFAOYSA-N 0.000 description 6
- 206010059512 Apoptosis Diseases 0.000 description 6
- 206010005003 Bladder cancer Diseases 0.000 description 6
- 108090000379 Fibroblast Growth Factor 2 Proteins 0.000 description 6
- 102000003974 Fibroblast Growth Factor 2 Human genes 0.000 description 6
- 206010021143 Hypoxia Diseases 0.000 description 6
- RAXXELZNTBOGNW-UHFFFAOYSA-N Imidazole Chemical compound C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
- 206010024324 Leukaemias Diseases 0.000 description 6
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 description 6
- 210000004185 Liver Anatomy 0.000 description 6
- JRMUNVKIHCOMHV-UHFFFAOYSA-M Tetra-n-butylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N Triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- 239000004480 active ingredient Substances 0.000 description 6
- 230000006907 apoptotic process Effects 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 125000002393 azetidinyl group Chemical group 0.000 description 6
- 238000004166 bioassay Methods 0.000 description 6
- 201000006934 chronic myeloid leukemia Diseases 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 230000004069 differentiation Effects 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000001146 hypoxic Effects 0.000 description 6
- 239000010410 layer Substances 0.000 description 6
- LRHPLDYGYMQRHN-UHFFFAOYSA-N n-butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 125000002971 oxazolyl group Chemical group 0.000 description 6
- 238000005897 peptide coupling reaction Methods 0.000 description 6
- 125000004193 piperazinyl group Chemical group 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 102000027656 receptor tyrosine kinases Human genes 0.000 description 6
- 108091007921 receptor tyrosine kinases Proteins 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
- 229910000029 sodium carbonate Inorganic materials 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 6
- 201000010874 syndrome Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 125000000335 thiazolyl group Chemical group 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- NPZTUJOABDZTLV-UHFFFAOYSA-N 1,2-dihydrobenzotriazol-4-one Chemical compound O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 5
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 5
- STQGQHZAVUOBTE-VGBVRHCVSA-N DAUNOMYCIN Chemical class O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 description 5
- 206010014733 Endometrial cancer Diseases 0.000 description 5
- 210000002889 Endothelial Cells Anatomy 0.000 description 5
- 206010017758 Gastric cancer Diseases 0.000 description 5
- 102000009465 Growth Factor Receptors Human genes 0.000 description 5
- 108010009202 Growth Factor Receptors Proteins 0.000 description 5
- 108020004999 Messenger RNA Proteins 0.000 description 5
- ATHHXGZTWNVVOU-UHFFFAOYSA-N N-methylformamide Chemical compound CNC=O ATHHXGZTWNVVOU-UHFFFAOYSA-N 0.000 description 5
- 229910019213 POCl3 Inorganic materials 0.000 description 5
- 201000004014 Pfeiffer syndrome Diseases 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 230000002491 angiogenic Effects 0.000 description 5
- 230000001419 dependent Effects 0.000 description 5
- 238000001514 detection method Methods 0.000 description 5
- 239000003937 drug carrier Substances 0.000 description 5
- 229940079593 drugs Drugs 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 230000002496 gastric Effects 0.000 description 5
- 230000004077 genetic alteration Effects 0.000 description 5
- 238000009396 hybridization Methods 0.000 description 5
- 150000002430 hydrocarbons Chemical group 0.000 description 5
- 229960004592 isopropanol Drugs 0.000 description 5
- 229920002106 messenger RNA Polymers 0.000 description 5
- YNAVUWVOSKDBBP-UHFFFAOYSA-N morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 5
- 229940113083 morpholine Drugs 0.000 description 5
- 125000006574 non-aromatic ring group Chemical group 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 230000011164 ossification Effects 0.000 description 5
- 125000003566 oxetanyl group Chemical group 0.000 description 5
- 230000037361 pathway Effects 0.000 description 5
- GLUUGHFHXGJENI-UHFFFAOYSA-N piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 5
- 239000001184 potassium carbonate Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000000651 prodrug Substances 0.000 description 5
- 229940002612 prodrugs Drugs 0.000 description 5
- 230000002062 proliferating Effects 0.000 description 5
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 5
- 230000002829 reduced Effects 0.000 description 5
- 201000011549 stomach cancer Diseases 0.000 description 5
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 201000002510 thyroid cancer Diseases 0.000 description 5
- 201000005161 thyroid carcinoma Diseases 0.000 description 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 description 4
- MHCVCKDNQYMGEX-UHFFFAOYSA-N 1,1'-biphenyl;phenoxybenzene Chemical group C1=CC=CC=C1C1=CC=CC=C1.C=1C=CC=CC=1OC1=CC=CC=C1 MHCVCKDNQYMGEX-UHFFFAOYSA-N 0.000 description 4
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 4
- HNJBEVLQSNELDL-UHFFFAOYSA-N 2-Pyrrolidone Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 4
- 206010000880 Acute myeloid leukaemia Diseases 0.000 description 4
- 206010003246 Arthritis Diseases 0.000 description 4
- 206010003571 Astrocytoma Diseases 0.000 description 4
- 210000004369 Blood Anatomy 0.000 description 4
- ILAHWRKJUDSMFH-UHFFFAOYSA-N Boron tribromide Chemical compound BrB(Br)Br ILAHWRKJUDSMFH-UHFFFAOYSA-N 0.000 description 4
- 210000001072 Colon Anatomy 0.000 description 4
- 229920002676 Complementary DNA Polymers 0.000 description 4
- 210000004714 Cranial Sutures Anatomy 0.000 description 4
- 208000009283 Craniosynostosis Diseases 0.000 description 4
- 230000004544 DNA amplification Effects 0.000 description 4
- UAOMVDZJSHZZME-UHFFFAOYSA-N Diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 4
- 229940088598 Enzyme Drugs 0.000 description 4
- 101710003421 FGF Proteins 0.000 description 4
- 102200143304 FGFR4 G388R Human genes 0.000 description 4
- 101710002377 FLG Proteins 0.000 description 4
- 206010016654 Fibrosis Diseases 0.000 description 4
- 206010018364 Glomerulonephritis Diseases 0.000 description 4
- 208000000265 Lobular Carcinoma Diseases 0.000 description 4
- INQOMBQAUSQDDS-UHFFFAOYSA-N Methyl iodide Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 4
- JFCHSQDLLFJHOA-UHFFFAOYSA-N N,N-dimethylsulfamoyl chloride Chemical compound CN(C)S(Cl)(=O)=O JFCHSQDLLFJHOA-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-Bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- 108020001305 NR1 subfamily Proteins 0.000 description 4
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 4
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 4
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 125000004423 acyloxy group Chemical group 0.000 description 4
- 239000000654 additive Substances 0.000 description 4
- 239000012472 biological sample Substances 0.000 description 4
- 238000001574 biopsy Methods 0.000 description 4
- 239000008280 blood Substances 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 125000002843 carboxylic acid group Chemical group 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000003034 chemosensitisation Effects 0.000 description 4
- 239000006114 chemosensitizer Substances 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical class [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- 239000002299 complementary DNA Substances 0.000 description 4
- 239000007822 coupling agent Substances 0.000 description 4
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 4
- 229920003013 deoxyribonucleic acid Polymers 0.000 description 4
- LCGLNKUTAGEVQW-UHFFFAOYSA-N dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 4
- 125000004185 ester group Chemical group 0.000 description 4
- 229940093499 ethyl acetate Drugs 0.000 description 4
- 230000004761 fibrosis Effects 0.000 description 4
- 230000003176 fibrotic Effects 0.000 description 4
- VLKZOEOYAKHREP-UHFFFAOYSA-N hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 4
- 238000007901 in situ hybridization Methods 0.000 description 4
- 125000001041 indolyl group Chemical group 0.000 description 4
- 230000001939 inductive effect Effects 0.000 description 4
- WMFOQBRAJBCJND-UHFFFAOYSA-M lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 4
- 201000007270 liver cancer Diseases 0.000 description 4
- 239000003550 marker Substances 0.000 description 4
- 125000002911 monocyclic heterocycle group Chemical group 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N oxygen atom Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 4
- MXQOYLRVSVOCQT-UHFFFAOYSA-N palladium;tritert-butylphosphane Chemical compound [Pd].CC(C)(C)P(C(C)(C)C)C(C)(C)C.CC(C)(C)P(C(C)(C)C)C(C)(C)C MXQOYLRVSVOCQT-UHFFFAOYSA-N 0.000 description 4
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- WTKZEGDFNFYCGP-UHFFFAOYSA-N pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- 230000012488 skeletal system development Effects 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 230000002194 synthesizing Effects 0.000 description 4
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 4
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 description 4
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
- 201000005112 urinary bladder cancer Diseases 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1E,4E)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 3
- MCGBIXXDQFWVDW-UHFFFAOYSA-N 4,5-dihydro-1H-pyrazole Chemical compound C1CC=NN1 MCGBIXXDQFWVDW-UHFFFAOYSA-N 0.000 description 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 3
- HONIICLYMWZJFZ-UHFFFAOYSA-N Azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 3
- 210000004204 Blood Vessels Anatomy 0.000 description 3
- 210000000481 Breast Anatomy 0.000 description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L Caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N Carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 206010049889 Craniosynostosis Diseases 0.000 description 3
- GHVNFZFCNZKVNT-UHFFFAOYSA-N Decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 description 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 description 3
- 208000005017 Glioblastoma Diseases 0.000 description 3
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 description 3
- 229910010084 LiAlH4 Inorganic materials 0.000 description 3
- 206010027476 Metastasis Diseases 0.000 description 3
- 206010028576 Myeloproliferative disease Diseases 0.000 description 3
- 108020005497 Nuclear hormone receptors Proteins 0.000 description 3
- 102000007399 Nuclear hormone receptors Human genes 0.000 description 3
- 229910003849 O-Si Inorganic materials 0.000 description 3
- 229910003872 O—Si Inorganic materials 0.000 description 3
- IUBQJLUDMLPAGT-UHFFFAOYSA-N Potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 3
- 108010029485 Protein Isoforms Proteins 0.000 description 3
- 102000001708 Protein Isoforms Human genes 0.000 description 3
- 108060006633 Protein Kinases Proteins 0.000 description 3
- 208000005069 Pulmonary Fibrosis Diseases 0.000 description 3
- MGADZUXDNSDTHW-UHFFFAOYSA-N Pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 3
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 3
- 210000003491 Skin Anatomy 0.000 description 3
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 description 3
- 206010041067 Small cell lung cancer Diseases 0.000 description 3
- 206010041823 Squamous cell carcinoma Diseases 0.000 description 3
- 239000005864 Sulphur Substances 0.000 description 3
- BRNULMACUQOKMR-UHFFFAOYSA-N Thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 3
- UCFGDBYHRUNTLO-QHCPKHFHSA-N Topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 3
- 206010046766 Uterine cancer Diseases 0.000 description 3
- 230000001594 aberrant Effects 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 230000000240 adjuvant Effects 0.000 description 3
- 239000002168 alkylating agent Substances 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 3
- 230000003042 antagnostic Effects 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M buffer Substances [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 3
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000002759 chromosomal Effects 0.000 description 3
- 230000001684 chronic Effects 0.000 description 3
- 229960004316 cisplatin Drugs 0.000 description 3
- 230000001809 detectable Effects 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 125000002587 enol group Chemical group 0.000 description 3
- 238000005755 formation reaction Methods 0.000 description 3
- 238000010914 gene-directed enzyme pro-drug therapy Methods 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 230000002489 hematologic Effects 0.000 description 3
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 3
- 125000000842 isoxazolyl group Chemical group 0.000 description 3
- HPQVWDOOUQVBTO-UHFFFAOYSA-N lithium aluminium hydride Substances [Li+].[Al-] HPQVWDOOUQVBTO-UHFFFAOYSA-N 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 3
- 201000003793 myelodysplastic syndrome Diseases 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N n-heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- 238000010606 normalization Methods 0.000 description 3
- 201000002740 oral squamous cell carcinoma Diseases 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 201000002511 pituitary cancer Diseases 0.000 description 3
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Substances [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 3
- 125000003367 polycyclic group Chemical group 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 230000001023 pro-angiogenic Effects 0.000 description 3
- 239000002534 radiation-sensitizing agent Substances 0.000 description 3
- 230000002285 radioactive Effects 0.000 description 3
- 239000003638 reducing agent Substances 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 230000001105 regulatory Effects 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 229910052708 sodium Inorganic materials 0.000 description 3
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 3
- 239000001187 sodium carbonate Substances 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- DZLFLBLQUQXARW-UHFFFAOYSA-N tetrabutylammonium Chemical compound CCCC[N+](CCCC)(CCCC)CCCC DZLFLBLQUQXARW-UHFFFAOYSA-N 0.000 description 3
- 229960000303 topotecan Drugs 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 description 3
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- DVQYFYUODSFBFS-UHFFFAOYSA-N (1-tritylimidazol-4-yl)methanol Chemical compound C1=NC(CO)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 DVQYFYUODSFBFS-UHFFFAOYSA-N 0.000 description 2
- CFCUWKMKBJTWLW-BGLFSJPPSA-N (2S,3S)-2-[(2S,4R,5R,6R)-4-[(2S,4R,5R,6R)-4-[(2S,4S,5R,6R)-4,5-dihydroxy-4,6-dimethyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-5-hydroxy-6-methyloxan-2-yl]oxy-3-[(1S,3S,4R)-3,4-dihydroxy-1-methoxy-2-oxopentyl]-6-[(2S,4R,5S,6R)-4-[(2S,4R,5S,6R)-4,5-dih Chemical compound O([C@@H]1C[C@@H](O[C@H](C)[C@@H]1O)OC=1C=C2C=C3C[C@H]([C@@H](C(=O)C3=C(O)C2=C(O)C=1C)O[C@@H]1O[C@H](C)[C@@H](O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O)[C@H](O[C@@H]3O[C@H](C)[C@@H](O)[C@@](C)(O)C3)C2)C1)[C@H](OC)C(=O)[C@@H](O)[C@@H](C)O)[C@H]1C[C@@H](O)[C@H](O)[C@@H](C)O1 CFCUWKMKBJTWLW-BGLFSJPPSA-N 0.000 description 2
- NRUKOCRGYNPUPR-QBPJDGROSA-N (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-thiophen-2-yl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 2
- CSNIZNHTOVFARY-UHFFFAOYSA-N 1,2-benzothiazole Chemical compound C1=CC=C2C=NSC2=C1 CSNIZNHTOVFARY-UHFFFAOYSA-N 0.000 description 2
- PIICEJLVQHRZGT-UHFFFAOYSA-N 1,2-ethanediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
- FTNJQNQLEGKTGD-UHFFFAOYSA-N 1,3-Benzodioxole Chemical compound C1=CC=C2OCOC2=C1 FTNJQNQLEGKTGD-UHFFFAOYSA-N 0.000 description 2
- BJMSXWLXFYZHIU-UHFFFAOYSA-N 1-methyl-3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound CN1C=CC(B2OC(C)(C)C(C)(C)O2)=N1 BJMSXWLXFYZHIU-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- OYJGEOAXBALSMM-UHFFFAOYSA-N 2,3-dihydro-1,3-thiazole Chemical compound C1NC=CS1 OYJGEOAXBALSMM-UHFFFAOYSA-N 0.000 description 2
- KEQTWHPMSVAFDA-UHFFFAOYSA-N 2,3-dihydro-1H-pyrazole Chemical compound C1NNC=C1 KEQTWHPMSVAFDA-UHFFFAOYSA-N 0.000 description 2
- SUXITUVUFUOAGT-UHFFFAOYSA-N 2,6-difluoro-3,5-dimethoxyaniline Chemical compound COC1=CC(OC)=C(F)C(N)=C1F SUXITUVUFUOAGT-UHFFFAOYSA-N 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N 2-Imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 2
- ZHUWTVUANDGPRC-UHFFFAOYSA-N 2-fluoro-3,5-dimethoxyaniline Chemical compound COC1=CC(N)=C(F)C(OC)=C1 ZHUWTVUANDGPRC-UHFFFAOYSA-N 0.000 description 2
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 2
- BOLCKGGORFPPJC-UHFFFAOYSA-N 3-bromo-6-chloropyrazin-2-amine Chemical compound NC1=NC(Cl)=CN=C1Br BOLCKGGORFPPJC-UHFFFAOYSA-N 0.000 description 2
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- JVVRCYWZTJLJSG-UHFFFAOYSA-N 4-Dimethylaminophenol Substances CN(C)C1=CC=C(O)C=C1 JVVRCYWZTJLJSG-UHFFFAOYSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-Toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- HPLNQCPCUACXLM-PGUFJCEWSA-N 4-[4-[[2-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-(dimethylamino)-1-phenylsulfanylbutan-2-yl]amino]-3-nitrophenyl]sulfonylbenzamide Chemical compound C([C@@H](CCN(C)C)NC=1C(=CC(=CC=1)S(=O)(=O)NC(=O)C=1C=CC(=CC=1)N1CCN(CC=2C(=CC=CC=2)C=2C=CC(Cl)=CC=2)CC1)[N+]([O-])=O)SC1=CC=CC=C1 HPLNQCPCUACXLM-PGUFJCEWSA-N 0.000 description 2
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 2
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 2
- 229940100198 ALKYLATING AGENTS Drugs 0.000 description 2
- 208000008919 Achondroplasia Diseases 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-N Adenosine triphosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-N 0.000 description 2
- YBBLVLTVTVSKRW-UHFFFAOYSA-N Anastrozole Chemical compound N#CC(C)(C)C1=CC(C(C)(C#N)C)=CC(CN2N=CN=C2)=C1 YBBLVLTVTVSKRW-UHFFFAOYSA-N 0.000 description 2
- 206010003210 Arteriosclerosis Diseases 0.000 description 2
- 206010003816 Autoimmune disease Diseases 0.000 description 2
- 229960002756 Azacitidine Drugs 0.000 description 2
- KTZQTRPPVKQPFO-UHFFFAOYSA-N Benzisoxazole Chemical compound C1=CC=C2C=NOC2=C1 KTZQTRPPVKQPFO-UHFFFAOYSA-N 0.000 description 2
- BNBQRQQYDMDJAH-UHFFFAOYSA-N Benzodioxan Chemical compound C1=CC=C2OCCOC2=C1 BNBQRQQYDMDJAH-UHFFFAOYSA-N 0.000 description 2
- 210000001124 Body Fluids Anatomy 0.000 description 2
- 208000003432 Bone Disease Diseases 0.000 description 2
- 210000001185 Bone Marrow Anatomy 0.000 description 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 description 2
- 102100006400 CSF2 Human genes 0.000 description 2
- VSJKWCGYPAHWDS-FQEVSTJZSA-N Camptothecin Chemical class C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 description 2
- GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 2
- 229960004117 Capecitabine Drugs 0.000 description 2
- 210000001736 Capillaries Anatomy 0.000 description 2
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N Caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 2
- 229960004562 Carboplatin Drugs 0.000 description 2
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 description 2
- 208000005623 Carcinogenesis Diseases 0.000 description 2
- 208000008787 Cardiovascular Disease Diseases 0.000 description 2
- 229960004630 Chlorambucil Drugs 0.000 description 2
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 description 2
- HAWPXGHAZFHHAD-UHFFFAOYSA-N Chlormethine Chemical compound ClCCN(C)CCCl HAWPXGHAZFHHAD-UHFFFAOYSA-N 0.000 description 2
- 206010008723 Chondrodystrophy Diseases 0.000 description 2
- VZWXIQHBIQLMPN-UHFFFAOYSA-N Chromane Chemical compound C1=CC=C2CCCOC2=C1 VZWXIQHBIQLMPN-UHFFFAOYSA-N 0.000 description 2
- WCZVZNOTHYJIEI-UHFFFAOYSA-N Cinnoline Chemical compound N1=NC=CC2=CC=CC=C21 WCZVZNOTHYJIEI-UHFFFAOYSA-N 0.000 description 2
- IAKHMKGGTNLKSZ-INIZCTEOSA-N Colchicine Natural products C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- ARUVKPQLZAKDPS-UHFFFAOYSA-L Copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 2
- 201000006526 Crouzon syndrome Diseases 0.000 description 2
- 229960004397 Cyclophosphamide Drugs 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 229960000975 Daunorubicin Drugs 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N Docetaxel Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 2
- 229960004679 Doxorubicin Drugs 0.000 description 2
- ZQZFYGIXNQKOAV-OCEACIFDSA-N Droloxifene Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=C(O)C=CC=1)\C1=CC=C(OCCN(C)C)C=C1 ZQZFYGIXNQKOAV-OCEACIFDSA-N 0.000 description 2
- 229950004203 Droloxifene Drugs 0.000 description 2
- 101710004859 ENG Proteins 0.000 description 2
- 229960005420 Etoposide Drugs 0.000 description 2
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 description 2
- YSFTYXKQUONNFY-NQXPEFQPSA-N FGF2 Chemical compound C([C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(O)=O)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](C)NC(=O)CNC(=O)[C@H](CO)NC(=O)CNC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H]1NCCC1)C1=CC=CC=C1 YSFTYXKQUONNFY-NQXPEFQPSA-N 0.000 description 2
- 102100006565 FLT1 Human genes 0.000 description 2
- 101710030892 FLT1 Proteins 0.000 description 2
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 2
- 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 description 2
- ODKNJVUHOIMIIZ-RRKCRQDMSA-N Floxuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(F)=C1 ODKNJVUHOIMIIZ-RRKCRQDMSA-N 0.000 description 2
- 229960002949 Fluorouracil Drugs 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N Guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 210000003128 Head Anatomy 0.000 description 2
- 206010019641 Hepatic cirrhosis Diseases 0.000 description 2
- 102000003964 Histone deacetylases Human genes 0.000 description 2
- 108090000353 Histone deacetylases Proteins 0.000 description 2
- 229940088597 Hormone Drugs 0.000 description 2
- 102100005044 IL11 Human genes 0.000 description 2
- 229960000908 Idarubicin Drugs 0.000 description 2
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin hydrochloride Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 2
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 2
- ZLTPDFXIESTBQG-UHFFFAOYSA-N Isothiazole Chemical compound C=1C=NSC=1 ZLTPDFXIESTBQG-UHFFFAOYSA-N 0.000 description 2
- 241000229754 Iva xanthiifolia Species 0.000 description 2
- 208000009289 Jackson-Weiss syndrome Diseases 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 description 2
- HPJKCIUCZWXJDR-UHFFFAOYSA-N Letrozole Chemical compound C1=CC(C#N)=CC=C1C(N1N=CN=C1)C1=CC=C(C#N)C=C1 HPJKCIUCZWXJDR-UHFFFAOYSA-N 0.000 description 2
- 208000000214 Leukemia, Myelomonocytic, Chronic Diseases 0.000 description 2
- 108009000252 Lung fibrosis Proteins 0.000 description 2
- 238000005004 MAS NMR spectroscopy Methods 0.000 description 2
- 206010025650 Malignant melanoma Diseases 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N MeOtBu Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229960004961 Mechlorethamine Drugs 0.000 description 2
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 229960004857 Mitomycin Drugs 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- JNLKKHIVNMWZQY-UHFFFAOYSA-N N,N-diethylethanamine;N,N-dimethylpyridin-2-amine Chemical compound CCN(CC)CC.CN(C)C1=CC=CC=N1 JNLKKHIVNMWZQY-UHFFFAOYSA-N 0.000 description 2
- 206010053643 Neurodegenerative disease Diseases 0.000 description 2
- OSTGTTZJOCZWJG-UHFFFAOYSA-N Nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 description 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Nitrumon Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 description 2
- 235000019502 Orange oil Nutrition 0.000 description 2
- 208000007571 Ovarian Epithelial Carcinoma Diseases 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 102100004939 PDGFRB Human genes 0.000 description 2
- 229960001592 Paclitaxel Drugs 0.000 description 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 description 2
- 241000282322 Panthera Species 0.000 description 2
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 description 2
- 229960003171 Plicamycin Drugs 0.000 description 2
- YJGVMLPVUAXIQN-XVVDYKMHSA-N Podophyllotoxin Chemical class COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-XVVDYKMHSA-N 0.000 description 2
- VZJVWSHVAAUDKD-UHFFFAOYSA-N Potassium permanganate Chemical compound [K+].[O-][Mn](=O)(=O)=O VZJVWSHVAAUDKD-UHFFFAOYSA-N 0.000 description 2
- 206010036790 Productive cough Diseases 0.000 description 2
- 210000002307 Prostate Anatomy 0.000 description 2
- GZUITABIAKMVPG-UHFFFAOYSA-N Raloxifene Chemical compound C1=CC(O)=CC=C1C1=C(C(=O)C=2C=CC(OCCN3CCCCC3)=CC=2)C2=CC=C(O)C=C2S1 GZUITABIAKMVPG-UHFFFAOYSA-N 0.000 description 2
- 229960004622 Raloxifene Drugs 0.000 description 2
- 102000004278 Receptor protein-tyrosine kinases Human genes 0.000 description 2
- 108090000873 Receptor protein-tyrosine kinases Proteins 0.000 description 2
- 208000006265 Renal Cell Carcinoma Diseases 0.000 description 2
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010070834 Sensitisation Diseases 0.000 description 2
- 210000002966 Serum Anatomy 0.000 description 2
- 108020004459 Small Interfering RNA Proteins 0.000 description 2
- 210000003802 Sputum Anatomy 0.000 description 2
- 210000002784 Stomach Anatomy 0.000 description 2
- 208000006011 Stroke Diseases 0.000 description 2
- WINHZLLDWRZWRT-ATVHPVEESA-N Sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 description 2
- 238000010928 TGA analysis Methods 0.000 description 2
- DHXVGJBLRPWPCS-UHFFFAOYSA-N THP Chemical compound C1CCOCC1 DHXVGJBLRPWPCS-UHFFFAOYSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 229960001603 Tamoxifen Drugs 0.000 description 2
- 229960001278 Teniposide Drugs 0.000 description 2
- RAOIDOHSFRTOEL-UHFFFAOYSA-N Tetrahydrothiophene Chemical compound C1CCSC1 RAOIDOHSFRTOEL-UHFFFAOYSA-N 0.000 description 2
- CBDKQYKMCICBOF-UHFFFAOYSA-N Thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 2
- 210000001685 Thyroid Gland Anatomy 0.000 description 2
- 229940035295 Ting Drugs 0.000 description 2
- XFCLJVABOIYOMF-QPLCGJKRSA-N Toremifene Chemical compound C1=CC(OCCN(C)C)=CC=C1C(\C=1C=CC=CC=1)=C(\CCCl)C1=CC=CC=C1 XFCLJVABOIYOMF-QPLCGJKRSA-N 0.000 description 2
- 108010010691 Trastuzumab Proteins 0.000 description 2
- 229960001727 Tretinoin Drugs 0.000 description 2
- SHGAZHPCJJPHSC-NWVFGJFESA-N Tretinoin Chemical compound OC(=O)/C=C(\C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NWVFGJFESA-N 0.000 description 2
- TUQOTMZNTHZOKS-UHFFFAOYSA-N Tributylphosphine Chemical compound CCCCP(CCCC)CCCC TUQOTMZNTHZOKS-UHFFFAOYSA-N 0.000 description 2
- PYOKUURKVVELLB-UHFFFAOYSA-N Trimethyl orthoformate Chemical compound COC(OC)OC PYOKUURKVVELLB-UHFFFAOYSA-N 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010001801 Tumor Necrosis Factor-alpha Proteins 0.000 description 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 description 2
- NMUSYJAQQFHJEW-KVTDHHQDSA-N U-18,496 Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 210000002700 Urine Anatomy 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N Valeric acid Natural products CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 description 2
- 229960003048 Vinblastine Drugs 0.000 description 2
- HOFQVRTUGATRFI-XQKSVPLYSA-N Vinblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 HOFQVRTUGATRFI-XQKSVPLYSA-N 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 241000863480 Vinca Species 0.000 description 2
- 229960004528 Vincristine Drugs 0.000 description 2
- GTLDTDOJJJZVBW-UHFFFAOYSA-N Zinc cyanide Chemical compound [Zn+2].N#[C-].N#[C-] GTLDTDOJJJZVBW-UHFFFAOYSA-N 0.000 description 2
- XRASPMIURGNCCH-UHFFFAOYSA-N Zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 2
- MOFINMJRLYEONQ-UHFFFAOYSA-N [N].C=1C=CNC=1 Chemical compound [N].C=1C=CNC=1 MOFINMJRLYEONQ-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating Effects 0.000 description 2
- 230000001058 adult Effects 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 235000019270 ammonium chloride Nutrition 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 229960002932 anastrozole Drugs 0.000 description 2
- 239000002870 angiogenesis inducing agent Substances 0.000 description 2
- 239000004037 angiogenesis inhibitor Substances 0.000 description 2
- 125000000129 anionic group Chemical group 0.000 description 2
- 230000003466 anti-cipated Effects 0.000 description 2
- 238000010913 antigen-directed enzyme pro-drug therapy Methods 0.000 description 2
- 201000001320 atherosclerosis Diseases 0.000 description 2
- 230000003305 autocrine Effects 0.000 description 2
- HTZCNXWZYVXIMZ-UHFFFAOYSA-M benzyl(triethyl)azanium;chloride Chemical compound [Cl-].CC[N+](CC)(CC)CC1=CC=CC=C1 HTZCNXWZYVXIMZ-UHFFFAOYSA-M 0.000 description 2
- 239000000090 biomarker Substances 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229960001467 bortezomib Drugs 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 229910000024 caesium carbonate Inorganic materials 0.000 description 2
- 239000003560 cancer drug Substances 0.000 description 2
- 150000001718 carbodiimides Chemical class 0.000 description 2
- 229960005243 carmustine Drugs 0.000 description 2
- 201000010881 cervical cancer Diseases 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000012320 chlorinating reagent Substances 0.000 description 2
- 201000010902 chronic myelomonocytic leukemia Diseases 0.000 description 2
- 238000002425 crystallisation Methods 0.000 description 2
- 230000005712 crystallization Effects 0.000 description 2
- 150000003950 cyclic amides Chemical group 0.000 description 2
- 125000000753 cycloalkyl group Chemical group 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- SNRCKKQHDUIRIY-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloromethane;dichloropalladium;iron(2+) Chemical compound [Fe+2].ClCCl.Cl[Pd]Cl.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.C1=C[CH-]C(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 SNRCKKQHDUIRIY-UHFFFAOYSA-L 0.000 description 2
- 230000002354 daily Effects 0.000 description 2
- 230000002074 deregulated Effects 0.000 description 2
- 229940043279 diisopropylamine Drugs 0.000 description 2
- 229960003668 docetaxel Drugs 0.000 description 2
- 238000002592 echocardiography Methods 0.000 description 2
- 238000003821 enantio-separation Methods 0.000 description 2
- 230000002357 endometrial Effects 0.000 description 2
- 239000000262 estrogen Substances 0.000 description 2
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- 210000002950 fibroblast Anatomy 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- KRHYYFGTRYWZRS-UHFFFAOYSA-M fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N furane Chemical compound C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 229960005277 gemcitabine Drugs 0.000 description 2
- 230000002068 genetic Effects 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 125000001475 halogen functional group Chemical group 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 239000008079 hexane Substances 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 150000004677 hydrates Chemical class 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- AVXURJPOCDRRFD-UHFFFAOYSA-N hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 2
- 201000009794 idiopathic pulmonary fibrosis Diseases 0.000 description 2
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 description 2
- YAMHXTCMCPHKLN-UHFFFAOYSA-N imidazolidin-2-one Chemical compound O=C1NCCN1 YAMHXTCMCPHKLN-UHFFFAOYSA-N 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 200000000018 inflammatory disease Diseases 0.000 description 2
- 230000000977 initiatory Effects 0.000 description 2
- 230000000302 ischemic Effects 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 125000000468 ketone group Chemical group 0.000 description 2
- 229960003881 letrozole Drugs 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 201000004044 liver cirrhosis Diseases 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 201000005244 lung non-small cell carcinoma Diseases 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N methanesulfonic acid Chemical class CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- XOBKSJJDNFUZPF-UHFFFAOYSA-N methoxyethyl Chemical group CCOC XOBKSJJDNFUZPF-UHFFFAOYSA-N 0.000 description 2
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 150000003833 nucleoside derivatives Chemical class 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000010502 orange oil Substances 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 238000006366 phosphorylation reaction Methods 0.000 description 2
- 230000000865 phosphorylative Effects 0.000 description 2
- 125000000587 piperidin-1-yl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 2
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 2
- 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 239000003600 podophyllotoxin derivative Substances 0.000 description 2
- 238000010837 poor prognosis Methods 0.000 description 2
- 230000003389 potentiating Effects 0.000 description 2
- 230000000750 progressive Effects 0.000 description 2
- 125000001042 pteridinyl group Chemical group N1=C(N=CC2=NC=CN=C12)* 0.000 description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 239000012440 retinoic acid metabolism blocking agent Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 230000001235 sensitizing Effects 0.000 description 2
- 231100000202 sensitizing Toxicity 0.000 description 2
- 239000002924 silencing RNA Substances 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 2
- 235000019187 sodium-L-ascorbate Nutrition 0.000 description 2
- 239000011755 sodium-L-ascorbate Substances 0.000 description 2
- ODGROJYWQXFQOZ-UHFFFAOYSA-N sodium;boron(1-) Chemical compound [B-].[Na+] ODGROJYWQXFQOZ-UHFFFAOYSA-N 0.000 description 2
- AGGHKNBCHLWKHY-UHFFFAOYSA-N sodium;triacetyloxyboron(1-) Chemical compound [Na+].CC(=O)O[B-](OC(C)=O)OC(C)=O AGGHKNBCHLWKHY-UHFFFAOYSA-N 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 229960001796 sunitinib Drugs 0.000 description 2
- 229930003347 taxol Natural products 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- 238000002411 thermogravimetry Methods 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- WYWHKKSPHMUBEB-UHFFFAOYSA-N tioguanine Chemical compound N1C(N)=NC(=S)C2=C1N=CN2 WYWHKKSPHMUBEB-UHFFFAOYSA-N 0.000 description 2
- 229960005026 toremifene Drugs 0.000 description 2
- 229960000575 trastuzumab Drugs 0.000 description 2
- 210000004881 tumor cells Anatomy 0.000 description 2
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 2
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 2
- 229960002066 vinorelbine Drugs 0.000 description 2
- 235000012431 wafers Nutrition 0.000 description 2
- 229960004276 zoledronic acid Drugs 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N β-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N (+)-tartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- HTVHTRWLBOLTDS-UHFFFAOYSA-N (1-trityltriazol-4-yl)methanol Chemical compound N1=NC(CO)=CN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 HTVHTRWLBOLTDS-UHFFFAOYSA-N 0.000 description 1
- ZROHGHOFXNOHSO-BNTLRKBRSA-L (1R,2R)-cyclohexane-1,2-diamine;oxalate;platinum(2+) Chemical compound [H][N]([C@@H]1CCCC[C@H]1[N]1([H])[H])([H])[Pt]11OC(=O)C(=O)O1 ZROHGHOFXNOHSO-BNTLRKBRSA-L 0.000 description 1
- MFPWEWYKQYMWRO-UHFFFAOYSA-M (2-methylpropan-2-yl)oxycarbonyl carbonate Chemical compound CC(C)(C)OC(=O)OC([O-])=O MFPWEWYKQYMWRO-UHFFFAOYSA-M 0.000 description 1
- SHGAZHPCJJPHSC-ZVCIMWCZSA-N (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid Chemical compound OC(=O)/C=C(\C)/C=C/C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-ZVCIMWCZSA-N 0.000 description 1
- JUOZAPMENHMSRK-OXJNMPFZSA-N (2S,3R)-3-hydroxy-2-(2-methylbenzoyl)-2-(2-methylbenzoyl)oxybutanedioic acid Chemical compound CC1=CC=CC=C1C(=O)O[C@]([C@@H](O)C(O)=O)(C(O)=O)C(=O)C1=CC=CC=C1C JUOZAPMENHMSRK-OXJNMPFZSA-N 0.000 description 1
- HOBJEFOCIRXQKH-BYPYZUCNSA-N (5S)-5-(hydroxymethyl)pyrrolidin-2-one Chemical compound OC[C@@H]1CCC(=O)N1 HOBJEFOCIRXQKH-BYPYZUCNSA-N 0.000 description 1
- OMJKFYKNWZZKTK-POHAHGRESA-N (5Z)-5-(dimethylaminohydrazinylidene)imidazole-4-carboxamide Chemical compound CN(C)N\N=C1/N=CN=C1C(N)=O OMJKFYKNWZZKTK-POHAHGRESA-N 0.000 description 1
- VWUXBMIQPBEWFH-WCCTWKNTSA-N (7R,8R,9S,13S,14S,17S)-13-methyl-7-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl]-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3[C@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)CC2=C1 VWUXBMIQPBEWFH-WCCTWKNTSA-N 0.000 description 1
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 229920000160 (ribonucleotides)n+m Polymers 0.000 description 1
- ASZLNPRMVCGYCI-UHFFFAOYSA-N 1$l^{2}-azolidine Chemical group C1CC[N]C1 ASZLNPRMVCGYCI-UHFFFAOYSA-N 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-Bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- OWQPOVKKUWUEKE-UHFFFAOYSA-N 1,2,3-benzotriazine Chemical compound N1=NN=CC2=CC=CC=C21 OWQPOVKKUWUEKE-UHFFFAOYSA-N 0.000 description 1
- UGUHFDPGDQDVGX-UHFFFAOYSA-N 1,2,3-thiadiazole Chemical compound C1=CSN=N1 UGUHFDPGDQDVGX-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- 125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
- XGYCWCIGCYGQFU-UHFFFAOYSA-N 1,2-thiazolidine 1,1-dioxide Chemical compound O=S1(=O)CCCN1 XGYCWCIGCYGQFU-UHFFFAOYSA-N 0.000 description 1
- 125000001781 1,3,4-oxadiazolyl group Chemical group 0.000 description 1
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- VMLKTERJLVWEJJ-UHFFFAOYSA-N 1,5-naphthyridine Chemical compound C1=CC=NC2=CC=CN=C21 VMLKTERJLVWEJJ-UHFFFAOYSA-N 0.000 description 1
- FLBAYUMRQUHISI-UHFFFAOYSA-N 1,8-naphthyridine Chemical compound N1=CC=CC2=CC=CN=C21 FLBAYUMRQUHISI-UHFFFAOYSA-N 0.000 description 1
- WVWOOAYQYLJEFD-UHFFFAOYSA-N 1-(2-nitroimidazol-1-yl)-3-piperidin-1-ylpropan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CCCCC1 WVWOOAYQYLJEFD-UHFFFAOYSA-N 0.000 description 1
- ZPIHRUCXNRKJIF-UHFFFAOYSA-N 1-(2-trimethylsilylethoxymethyl)imidazole-2-carbaldehyde Chemical compound C[Si](C)(C)CCOCN1C=CN=C1C=O ZPIHRUCXNRKJIF-UHFFFAOYSA-N 0.000 description 1
- OEWYWFJWBZNJJG-UHFFFAOYSA-N 1-(aziridin-1-yl)-3-(2-nitroimidazol-1-yl)propan-2-ol Chemical compound C1=CN=C([N+]([O-])=O)N1CC(O)CN1CC1 OEWYWFJWBZNJJG-UHFFFAOYSA-N 0.000 description 1
- ZFPGARUNNKGOBB-UHFFFAOYSA-N 1-ethylpyrrolidin-2-one Chemical compound CCN1CCCC1=O ZFPGARUNNKGOBB-UHFFFAOYSA-N 0.000 description 1
- UCNGGGYMLHAMJG-UHFFFAOYSA-N 1-methyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)pyrazole Chemical compound C1=NN(C)C=C1B1OC(C)(C)C(C)(C)O1 UCNGGGYMLHAMJG-UHFFFAOYSA-N 0.000 description 1
- PAMIQIKDUOTOBW-UHFFFAOYSA-N 1-methylpiperidine Chemical group CN1CCCCC1 PAMIQIKDUOTOBW-UHFFFAOYSA-N 0.000 description 1
- UDDMDSNULOKCLP-UHFFFAOYSA-N 1H-1,2,4-triazol-5-ylmethanol Chemical compound OCC1=NN=CN1 UDDMDSNULOKCLP-UHFFFAOYSA-N 0.000 description 1
- XYHKNCXZYYTLRG-UHFFFAOYSA-N 1H-imidazole-2-carbaldehyde Chemical compound O=CC1=NC=CN1 XYHKNCXZYYTLRG-UHFFFAOYSA-N 0.000 description 1
- MFJCPDOGFAYSTF-UHFFFAOYSA-N 1H-isochromene Chemical compound C1=CC=C2COC=CC2=C1 MFJCPDOGFAYSTF-UHFFFAOYSA-N 0.000 description 1
- AMFYRKOUWBAGHV-UHFFFAOYSA-N 1H-pyrazolo[4,3-b]pyridine Chemical compound C1=CN=C2C=NNC2=C1 AMFYRKOUWBAGHV-UHFFFAOYSA-N 0.000 description 1
- APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical compound N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 description 1
- MYIPEPGIRJMNHF-UHFFFAOYSA-N 2,3,4-trimethyl-3-(2,3,4-trimethylpentan-3-yloxy)pentane Chemical compound CC(C)C(C)(C(C)C)OC(C)(C(C)C)C(C)C MYIPEPGIRJMNHF-UHFFFAOYSA-N 0.000 description 1
- CTTUQCIBNSCQRH-UHFFFAOYSA-N 2,3,4-trimethylpentan-3-amine Chemical compound CC(C)C(C)(N)C(C)C CTTUQCIBNSCQRH-UHFFFAOYSA-N 0.000 description 1
- MXILHVKNAYIRPJ-UHFFFAOYSA-N 2,3,7,7a-tetrahydro-1H-triazolo[4,5-b]pyrazine Chemical compound N1C=CN=C2NNNC21 MXILHVKNAYIRPJ-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-Dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- OXBLVCZKDOZZOJ-UHFFFAOYSA-N 2,3-Dihydrothiophene Chemical compound C1CC=CS1 OXBLVCZKDOZZOJ-UHFFFAOYSA-N 0.000 description 1
- HBEDSQVIWPRPAY-UHFFFAOYSA-N 2,3-dihydrobenzofuran Chemical compound C1=CC=C2OCCC2=C1 HBEDSQVIWPRPAY-UHFFFAOYSA-N 0.000 description 1
- BPXKZEMBEZGUAH-UHFFFAOYSA-N 2-(chloromethoxy)ethyl-trimethylsilane Chemical compound C[Si](C)(C)CCOCCl BPXKZEMBEZGUAH-UHFFFAOYSA-N 0.000 description 1
- MIJDSYMOBYNHOT-UHFFFAOYSA-N 2-(ethylamino)ethanol Chemical compound CCNCCO MIJDSYMOBYNHOT-UHFFFAOYSA-N 0.000 description 1
- CMRFJAMFEWYMKE-UHFFFAOYSA-N 2-Oxaadamantane Chemical compound C1C(O2)CC3CC1CC2C3 CMRFJAMFEWYMKE-UHFFFAOYSA-N 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N 2-Piperidinone Chemical compound O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- ZWULFIBGPXWGFG-UHFFFAOYSA-N 2-methyl-1H-imidazole-5-carbaldehyde Chemical compound CC1=NC=C(C=O)N1 ZWULFIBGPXWGFG-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-M 2-methylbenzenesulfonate Chemical compound CC1=CC=CC=C1S([O-])(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-M 0.000 description 1
- 150000004959 2-nitroimidazoles Chemical class 0.000 description 1
- IMSODMZESSGVBE-UHFFFAOYSA-N 2-oxazoline Chemical compound C1CN=CO1 IMSODMZESSGVBE-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N 289-95-2 Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- CMLFRMDBDNHMRA-UHFFFAOYSA-N 2H-1,2-benzoxazine Chemical compound C1=CC=C2C=CNOC2=C1 CMLFRMDBDNHMRA-UHFFFAOYSA-N 0.000 description 1
- UMZCLZPXPCNKML-UHFFFAOYSA-N 2H-imidazo[4,5-d][1,3]thiazole Chemical compound C1=NC2=NCSC2=N1 UMZCLZPXPCNKML-UHFFFAOYSA-N 0.000 description 1
- VHMICKWLTGFITH-UHFFFAOYSA-N 2H-isoindole Chemical compound C1=CC=CC2=CNC=C21 VHMICKWLTGFITH-UHFFFAOYSA-N 0.000 description 1
- HEYGLTRAXBZNAD-UHFFFAOYSA-N 3,3-dimethylmorpholine Chemical group CC1(C)COCCN1 HEYGLTRAXBZNAD-UHFFFAOYSA-N 0.000 description 1
- BUDQDWGNQVEFAC-UHFFFAOYSA-N 3,4-dihydro-2H-pyran Chemical compound C1COC=CC1 BUDQDWGNQVEFAC-UHFFFAOYSA-N 0.000 description 1
- BVBFZHPACDJOFB-UHFFFAOYSA-N 3,5-bis(methoxymethyl)aniline Chemical compound COCC1=CC(N)=CC(COC)=C1 BVBFZHPACDJOFB-UHFFFAOYSA-N 0.000 description 1
- WNRGWPVJGDABME-UHFFFAOYSA-N 3,5-dimethoxyaniline Chemical compound COC1=CC(N)=CC(OC)=C1 WNRGWPVJGDABME-UHFFFAOYSA-N 0.000 description 1
- NUGLIYXAARVRPQ-UHFFFAOYSA-N 3-(2-nitroimidazol-1-yl)propane-1,2-diol Chemical compound OCC(O)CN1C=CN=C1[N+]([O-])=O NUGLIYXAARVRPQ-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- BUJCVBRLTBAYCW-UHFFFAOYSA-N 3-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-2-(2-methoxyphenoxy)propan-1-one Chemical compound COC1=CC=CC=C1OC(CO)C(=O)C1=CC=C(O)C(OC)=C1 BUJCVBRLTBAYCW-UHFFFAOYSA-N 0.000 description 1
- KISUPFXQEHWGAR-RRKCRQDMSA-N 4-amino-5-bromo-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound C1=C(Br)C(N)=NC(=O)N1[C@@H]1O[C@H](CO)[C@@H](O)C1 KISUPFXQEHWGAR-RRKCRQDMSA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
- IJCKDTZWAUQGJK-UHFFFAOYSA-N 4-chloro-2-[[2-(2,4-dichlorophenyl)-1,3-dioxolan-2-yl]methoxy]-1,3-benzothiazole Chemical compound ClC1=CC(Cl)=CC=C1C1(COC=2SC3=CC=CC(Cl)=C3N=2)OCCO1 IJCKDTZWAUQGJK-UHFFFAOYSA-N 0.000 description 1
- NXQFPXVEKFXZAV-UHFFFAOYSA-N 4-imino-3-N,3-N-dimethylhexane-1,3-diamine Chemical compound CCC(=N)C(N(C)C)CCN NXQFPXVEKFXZAV-UHFFFAOYSA-N 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- GDRVFDDBLLKWRI-UHFFFAOYSA-N 4H-quinolizine Chemical compound C1=CC=CN2CC=CC=C21 GDRVFDDBLLKWRI-UHFFFAOYSA-N 0.000 description 1
- UMEIYBJBGZKZOS-UHFFFAOYSA-N 5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine Chemical compound C1NCCN2C=NN=C21 UMEIYBJBGZKZOS-UHFFFAOYSA-N 0.000 description 1
- CQOAMXQYKCRSFJ-UHFFFAOYSA-N 5-(chloromethyl)-2-trityltetrazole Chemical compound N1=C(CCl)N=NN1C(C=1C=CC=CC=1)(C=1C=CC=CC=1)C1=CC=CC=C1 CQOAMXQYKCRSFJ-UHFFFAOYSA-N 0.000 description 1
- AEYQOYLTLFOCHR-UHFFFAOYSA-N 5-methyl-1H-imidazole-2-carbaldehyde Chemical compound CC1=CNC(C=O)=N1 AEYQOYLTLFOCHR-UHFFFAOYSA-N 0.000 description 1
- PLHJCIYEEKOWNM-HHHXNRCGSA-N 6-[(R)-amino-(4-chlorophenyl)-(3-methylimidazol-4-yl)methyl]-4-(3-chlorophenyl)-1-methylquinolin-2-one Chemical compound CN1C=NC=C1[C@](N)(C=1C=C2C(C=3C=C(Cl)C=CC=3)=CC(=O)N(C)C2=CC=1)C1=CC=C(Cl)C=C1 PLHJCIYEEKOWNM-HHHXNRCGSA-N 0.000 description 1
- QEIRYIILFUVXAM-UHFFFAOYSA-N 6-chloropyridine-2,3-diamine Chemical compound NC1=CC=C(Cl)N=C1N QEIRYIILFUVXAM-UHFFFAOYSA-N 0.000 description 1
- BMZKZBWPMWEQAY-UHFFFAOYSA-N 6H-1,2,5-thiadiazine Chemical compound C1SN=CC=N1 BMZKZBWPMWEQAY-UHFFFAOYSA-N 0.000 description 1
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 description 1
- 101710027366 ACVRL1 Proteins 0.000 description 1
- 206010065040 AIDS dementia complex Diseases 0.000 description 1
- 101700006234 AKT1 Proteins 0.000 description 1
- 102100001248 AKT1 Human genes 0.000 description 1
- 102100018024 ANG Human genes 0.000 description 1
- 229940100197 ANTIMETABOLITES Drugs 0.000 description 1
- 229940034982 ANTINEOPLASTIC AGENTS Drugs 0.000 description 1
- 229960003272 ASPARAGINASE Drugs 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N Abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- ORILYTVJVMAKLC-UHFFFAOYSA-N Adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 1
- 229960000643 Adenine Drugs 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Natural products NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000009956 Adenocarcinoma Diseases 0.000 description 1
- 206010001488 Aggression Diseases 0.000 description 1
- 210000004712 Air Sacs Anatomy 0.000 description 1
- 108010090838 Alemtuzumab Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- UUVWYPNAQBNQJQ-UHFFFAOYSA-N Altretamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N Aluminium hydride Chemical compound [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- PZZYQPZGQPZBDN-UHFFFAOYSA-N Aluminium silicate Chemical compound O=[Al]O[Si](=O)O[Al]=O PZZYQPZGQPZBDN-UHFFFAOYSA-N 0.000 description 1
- 206010001897 Alzheimer's disease Diseases 0.000 description 1
- 229960001097 Amifostine Drugs 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N Amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960003896 Aminopterin Drugs 0.000 description 1
- 229910000013 Ammonium bicarbonate Inorganic materials 0.000 description 1
- PRKQVKDSMLBJBJ-UHFFFAOYSA-N Ammonium carbonate Chemical compound N.N.OC(O)=O PRKQVKDSMLBJBJ-UHFFFAOYSA-N 0.000 description 1
- LDDQLRUQCUTJBB-UHFFFAOYSA-N Ammonium fluoride Chemical compound [NH4+].[F-] LDDQLRUQCUTJBB-UHFFFAOYSA-N 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 229940064005 Antibiotic throat preparations Drugs 0.000 description 1
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 229940042052 Antibiotics for systemic use Drugs 0.000 description 1
- 229940042786 Antitubercular Antibiotics Drugs 0.000 description 1
- 206010002967 Aplastic anaemia Diseases 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- BFYIZQONLCFLEV-DAELLWKTSA-N Aromasine Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(C(CC4)=O)[C@@H]4[C@@H]3CC(=C)C2=C1 BFYIZQONLCFLEV-DAELLWKTSA-N 0.000 description 1
- 102000014654 Aromatase Human genes 0.000 description 1
- 108010078554 Aromatase Proteins 0.000 description 1
- 206010003119 Arrhythmia Diseases 0.000 description 1
- 210000003567 Ascitic Fluid Anatomy 0.000 description 1
- 108010024976 Asparaginase Proteins 0.000 description 1
- 102000015790 Asparaginase Human genes 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 229940120638 Avastin Drugs 0.000 description 1
- 208000003950 B-Cell Lymphoma Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- MUALRAIOVNYAIW-UHFFFAOYSA-N BINAP Chemical compound C1=CC=CC=C1P(C=1C(=C2C=CC=CC2=CC=1)C=1C2=CC=CC=C2C=CC=1P(C=1C=CC=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 MUALRAIOVNYAIW-UHFFFAOYSA-N 0.000 description 1
- 102100015886 BMP4 Human genes 0.000 description 1
- 101700005069 BMP4 Proteins 0.000 description 1
- 101710042656 BQ2027_MB1231C Proteins 0.000 description 1
- ZSERVQBSOBTXFV-DHHJBRQQSA-M Bacteriochlorophyll A Chemical compound C1([C@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC([C@@H](CC)[C@@H]3C)=[N+]4C3=CC3=C(C(C)=O)C(C)=C5N3[Mg]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ZSERVQBSOBTXFV-DHHJBRQQSA-M 0.000 description 1
- 108010070075 Bacteriochlorophyll A Proteins 0.000 description 1
- XFILPEOLDIKJHX-QYZOEREBSA-N Batimastat Chemical compound C([C@@H](C(=O)NC)NC(=O)[C@H](CC(C)C)[C@H](CSC=1SC=CC=1)C(=O)NO)C1=CC=CC=C1 XFILPEOLDIKJHX-QYZOEREBSA-N 0.000 description 1
- 229950001858 Batimastat Drugs 0.000 description 1
- GQYIWUVLTXOXAJ-UHFFFAOYSA-N Belustine Chemical compound ClCCN(N=O)C(=O)NC1CCCCC1 GQYIWUVLTXOXAJ-UHFFFAOYSA-N 0.000 description 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N Benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 description 1
- IANQTJSKSUMEQM-UHFFFAOYSA-N Benzofuran Chemical compound C1=CC=C2OC=CC2=C1 IANQTJSKSUMEQM-UHFFFAOYSA-N 0.000 description 1
- BCMCBBGGLRIHSE-UHFFFAOYSA-N Benzoxazole Chemical compound C1=CC=C2OC=NC2=C1 BCMCBBGGLRIHSE-UHFFFAOYSA-N 0.000 description 1
- WGQKYBSKWIADBV-UHFFFAOYSA-N Benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 1
- 210000003445 Biliary Tract Anatomy 0.000 description 1
- 229940112871 Bisphosphonate drugs affecting bone structure and mineralization Drugs 0.000 description 1
- 229960001561 Bleomycin Drugs 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- WOVKYSAHUYNSMH-RRKCRQDMSA-N Bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 1
- RDHPKYGYEGBMSE-UHFFFAOYSA-N Bromoethane Chemical compound CCBr RDHPKYGYEGBMSE-UHFFFAOYSA-N 0.000 description 1
- 208000009899 Burkitt Lymphoma Diseases 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butanoic acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- 229910014033 C-OH Inorganic materials 0.000 description 1
- 229950001725 CARUBICIN Drugs 0.000 description 1
- UJKPHYRXOLRVJJ-MLSVHJFASA-N CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C Chemical class CC(O)C1=C(C)/C2=C/C3=N/C(=C\C4=C(CCC(O)=O)C(C)=C(N4)/C=C4\N=C(\C=C\1/N\2)C(C)=C4C(C)O)/C(CCC(O)=O)=C3C UJKPHYRXOLRVJJ-MLSVHJFASA-N 0.000 description 1
- 102100016492 CD34 Human genes 0.000 description 1
- 108060001251 CD34 Proteins 0.000 description 1
- 102100008838 CORO2A Human genes 0.000 description 1
- 101710032216 CORO2A Proteins 0.000 description 1
- 102100006435 CSF3 Human genes 0.000 description 1
- 102100014691 CXCL12 Human genes 0.000 description 1
- 101710043128 CXCL12 Proteins 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N C[N+](C)(C)CCO Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 240000002804 Calluna vulgaris Species 0.000 description 1
- 235000007575 Calluna vulgaris Nutrition 0.000 description 1
- DSSYKIVIOFKYAU-UHFFFAOYSA-N Camphor Chemical compound C1CC2(C)C(=O)CC1C2(C)C DSSYKIVIOFKYAU-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer pain Diseases 0.000 description 1
- 206010007521 Cardiac arrhythmias Diseases 0.000 description 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 description 1
- 210000000845 Cartilage Anatomy 0.000 description 1
- 210000003169 Central Nervous System Anatomy 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 108010022830 Cetuximab Proteins 0.000 description 1
- 206010008479 Chest pain Diseases 0.000 description 1
- JWBOIMRXGHLCPP-UHFFFAOYSA-N Chloditan Chemical compound C=1C=CC=C(Cl)C=1C(C(Cl)Cl)C1=CC=C(Cl)C=C1 JWBOIMRXGHLCPP-UHFFFAOYSA-N 0.000 description 1
- 229960001231 Choline Drugs 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010008943 Chronic leukaemia Diseases 0.000 description 1
- PTOAARAWEBMLNO-KVQBGUIXSA-N Cladribine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@H]1C[C@H](O)[C@@H](CO)O1 PTOAARAWEBMLNO-KVQBGUIXSA-N 0.000 description 1
- WDDPHFBMKLOVOX-AYQXTPAHSA-N Clofarabine Chemical compound C1=NC=2C(N)=NC(Cl)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1F WDDPHFBMKLOVOX-AYQXTPAHSA-N 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010048832 Colon adenoma Diseases 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229940097362 Cyclodextrins Drugs 0.000 description 1
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 description 1
- 102000003849 Cytochrome P450 Human genes 0.000 description 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytosar Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
- 229910014570 C—OH Inorganic materials 0.000 description 1
- IGXWBGJHJZYPQS-SSDOTTSWSA-N D-Luciferin Chemical compound OC(=O)[C@H]1CSC(C=2SC3=CC=C(O)C=C3N=2)=N1 IGXWBGJHJZYPQS-SSDOTTSWSA-N 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 102200158153 DNAH10 S167P Human genes 0.000 description 1
- 108010019673 Darbepoetin alfa Proteins 0.000 description 1
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N Decitabine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 108010002156 Depsipeptides Proteins 0.000 description 1
- 208000008334 Dermatofibrosarcoma Diseases 0.000 description 1
- 206010057070 Dermatofibrosarcoma protuberans Diseases 0.000 description 1
- 229960003957 Dexamethasone Drugs 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- XBPCUCUWBYBCDP-UHFFFAOYSA-N Dicyclohexylamine Chemical compound C1CCCCC1NC1CCCCC1 XBPCUCUWBYBCDP-UHFFFAOYSA-N 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N Diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N Diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 description 1
- CXWGKAYMVASWDQ-UHFFFAOYSA-N Dithiane Chemical compound C1CCSSC1 CXWGKAYMVASWDQ-UHFFFAOYSA-N 0.000 description 1
- 229940115080 Doxil Drugs 0.000 description 1
- NOTIQUSPUUHHEH-UXOVVSIBSA-N Drostanolone propionate Chemical compound C([C@@H]1CC2)C(=O)[C@H](C)C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](OC(=O)CC)[C@@]2(C)CC1 NOTIQUSPUUHHEH-UXOVVSIBSA-N 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 102000013460 EC 1.1.1.37 Human genes 0.000 description 1
- 108010026217 EC 1.1.1.37 Proteins 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102100009705 ENG Human genes 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N EPIRUBICIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- 229960001904 EPIRUBICIN Drugs 0.000 description 1
- 102100016662 ERBB2 Human genes 0.000 description 1
- 101700025368 ERBB2 Proteins 0.000 description 1
- 208000005679 Eczema Diseases 0.000 description 1
- 210000001161 Embryo, Mammalian Anatomy 0.000 description 1
- 210000004696 Endometrium Anatomy 0.000 description 1
- 210000002615 Epidermis Anatomy 0.000 description 1
- 206010015037 Epilepsy Diseases 0.000 description 1
- 229960001433 Erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N Erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 108090000394 Erythropoietin Proteins 0.000 description 1
- 102000003951 Erythropoietin Human genes 0.000 description 1
- 210000003238 Esophagus Anatomy 0.000 description 1
- 229960001842 Estramustine Drugs 0.000 description 1
- FRPJXPJMRWBBIH-RBRWEJTLSA-N Estramustine Chemical compound ClCCN(CCCl)C(=O)OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 FRPJXPJMRWBBIH-RBRWEJTLSA-N 0.000 description 1
- WCDWBPCFGJXFJZ-UHFFFAOYSA-N Etanidazole Chemical compound OCCNC(=O)CN1C=CN=C1[N+]([O-])=O WCDWBPCFGJXFJZ-UHFFFAOYSA-N 0.000 description 1
- 229950006566 Etanidazole Drugs 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
- 208000009745 Eye Disease Diseases 0.000 description 1
- 102100007155 FGF1 Human genes 0.000 description 1
- 101700064732 FGF1 Proteins 0.000 description 1
- 102100015614 FGF19 Human genes 0.000 description 1
- 101700047578 FGF19 Proteins 0.000 description 1
- 102100013182 FLT4 Human genes 0.000 description 1
- 102100008658 FN1 Human genes 0.000 description 1
- 102000007317 Farnesyltranstransferase Human genes 0.000 description 1
- 108010007508 Farnesyltranstransferase Proteins 0.000 description 1
- 206010016256 Fatigue Diseases 0.000 description 1
- PJMPHNIQZUBGLI-UHFFFAOYSA-N Fentanyl Chemical compound C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 PJMPHNIQZUBGLI-UHFFFAOYSA-N 0.000 description 1
- 229960002428 Fentanyl Drugs 0.000 description 1
- KTWOOEGAPBSYNW-UHFFFAOYSA-N Ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 229960004177 Filgrastim Drugs 0.000 description 1
- 108010029961 Filgrastim Proteins 0.000 description 1
- 229960002258 Fulvestrant Drugs 0.000 description 1
- JKFAIQOWCVVSKC-UHFFFAOYSA-N Furazan Chemical compound C=1C=NON=1 JKFAIQOWCVVSKC-UHFFFAOYSA-N 0.000 description 1
- 102100011343 GLB1 Human genes 0.000 description 1
- 210000000232 Gallbladder Anatomy 0.000 description 1
- 210000001035 Gastrointestinal Tract Anatomy 0.000 description 1
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N Gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 108010091266 Gemtuzumab Proteins 0.000 description 1
- 229960003297 Gemtuzumab ozogamicin Drugs 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 108010084340 Gonadotropin-Releasing Hormone Proteins 0.000 description 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
- 229960003690 Goserelin Acetate Drugs 0.000 description 1
- QBKSWRVVCFFDOT-UHFFFAOYSA-N Gossypol Chemical compound CC(C)C1=C(O)C(O)=C(C=O)C2=C(O)C(C=3C(O)=C4C(C=O)=C(O)C(O)=C(C4=CC=3C)C(C)C)=C(C)C=C21 QBKSWRVVCFFDOT-UHFFFAOYSA-N 0.000 description 1
- 239000007818 Grignard reagent Substances 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 229940093922 Gynecological Antibiotics Drugs 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N Hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 229960003911 Histrelin acetate Drugs 0.000 description 1
- 206010020243 Hodgkin's disease Diseases 0.000 description 1
- 201000006743 Hodgkin's lymphoma Diseases 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 240000006600 Humulus lupulus Species 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 206010048643 Hypereosinophilic syndrome Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 229960001101 Ifosfamide Drugs 0.000 description 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N Ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 1
- KTUFNOKKBVMGRW-UHFFFAOYSA-N Imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 1
- 229960003685 Imatinib mesylate Drugs 0.000 description 1
- HOBCFUWDNJPFHB-UHFFFAOYSA-N Indolizine Chemical compound C1=CC=CN2C=CC=C21 HOBCFUWDNJPFHB-UHFFFAOYSA-N 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 206010022114 Injury Diseases 0.000 description 1
- 229960003521 Interferon Alfa-2a Drugs 0.000 description 1
- 229960003507 Interferon Alfa-2b Drugs 0.000 description 1
- 108090000177 Interleukin-11 Proteins 0.000 description 1
- 229940074383 Interleukin-11 Drugs 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N Irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- UXGVMFHEKMGWMA-UHFFFAOYSA-N Isobenzofuran Chemical compound C1=CC=CC2=COC=C21 UXGVMFHEKMGWMA-UHFFFAOYSA-N 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N Isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 229940119837 Isopropyl Alcohol Drugs 0.000 description 1
- AWJUIBRHMBBTKR-UHFFFAOYSA-N Isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 1
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 description 1
- 229960005280 Isotretinoin Drugs 0.000 description 1
- CTAPFRYPJLPFDF-UHFFFAOYSA-N Isoxazole Chemical compound C=1C=NOC=1 CTAPFRYPJLPFDF-UHFFFAOYSA-N 0.000 description 1
- 208000007766 Kaposi Sarcoma Diseases 0.000 description 1
- 210000003734 Kidney Anatomy 0.000 description 1
- 208000001083 Kidney Disease Diseases 0.000 description 1
- 210000000822 Killer Cells, Natural Anatomy 0.000 description 1
- 102000003855 L-lactate dehydrogenases Human genes 0.000 description 1
- 108091000084 L-lactate dehydrogenases Proteins 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 239000005511 L01XE05 - Sorafenib Substances 0.000 description 1
- 239000002067 L01XE06 - Dasatinib Substances 0.000 description 1
- 239000002136 L01XE07 - Lapatinib Substances 0.000 description 1
- BCFGMOOMADDAQU-UHFFFAOYSA-N Lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 description 1
- GOTYRUGSSMKFNF-UHFFFAOYSA-N Lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 description 1
- 229940089022 Leuprolide Acetate Drugs 0.000 description 1
- 229960004338 Leuprorelin Drugs 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N Luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 210000001165 Lymph Nodes Anatomy 0.000 description 1
- 206010025323 Lymphomas Diseases 0.000 description 1
- 206010061232 Lymphoproliferative disease Diseases 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 101700067074 MAPK Proteins 0.000 description 1
- 101710041325 MAPKAPK2 Proteins 0.000 description 1
- 102100000165 MS4A1 Human genes 0.000 description 1
- 101710010909 MS4A1 Proteins 0.000 description 1
- 206010025421 Macule Diseases 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N Mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- OCSMOTCMPXTDND-OUAUKWLOSA-N Marimastat Chemical compound CNC(=O)[C@H](C(C)(C)C)NC(=O)[C@H](CC(C)C)[C@H](O)C(=O)NO OCSMOTCMPXTDND-OUAUKWLOSA-N 0.000 description 1
- 229950008959 Marimastat Drugs 0.000 description 1
- 229960004296 Megestrol Acetate Drugs 0.000 description 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N Meglumine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
- 229960003194 Meglumine Drugs 0.000 description 1
- 229960004635 Mesna Drugs 0.000 description 1
- NHQDETIJWKXCTC-UHFFFAOYSA-N Meta-Chloroperoxybenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 1
- 230000036740 Metabolism Effects 0.000 description 1
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 1
- 229960000282 Metronidazole Drugs 0.000 description 1
- 108060004843 Mical Proteins 0.000 description 1
- 229960000350 Mitotane Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N Mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 229960001156 Mitoxantrone Drugs 0.000 description 1
- 206010028003 Motor neurone disease Diseases 0.000 description 1
- 206010028537 Myelofibrosis Diseases 0.000 description 1
- 206010028549 Myeloid leukaemia Diseases 0.000 description 1
- 208000010125 Myocardial Infarction Diseases 0.000 description 1
- WHQSYGRFZMUQGQ-UHFFFAOYSA-N N,N-dimethylformamide;hydrate Chemical compound O.CN(C)C=O WHQSYGRFZMUQGQ-UHFFFAOYSA-N 0.000 description 1
- VMESOKCXSYNAKD-UHFFFAOYSA-N N,N-dimethylhydroxylamine Chemical compound CN(C)O VMESOKCXSYNAKD-UHFFFAOYSA-N 0.000 description 1
- KRKPYFLIYNGWTE-UHFFFAOYSA-N N,O-Dimethylhydroxylamine Chemical compound CNOC KRKPYFLIYNGWTE-UHFFFAOYSA-N 0.000 description 1
- HQABUPZFAYXKJW-UHFFFAOYSA-N N-Butylamine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 1
- UWYXLGUQQFPJRI-UHFFFAOYSA-N N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine;4-methylbenzenesulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1.O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 UWYXLGUQQFPJRI-UHFFFAOYSA-N 0.000 description 1
- GTWJETSWSUWSEJ-UHFFFAOYSA-N N-benzylaniline Chemical compound C=1C=CC=CC=1CNC1=CC=CC=C1 GTWJETSWSUWSEJ-UHFFFAOYSA-N 0.000 description 1
- MUTBJZVSRNUIHA-UHFFFAOYSA-N N-hydroxy-2-(4-naphthalen-2-ylsulfonylpiperazin-1-yl)pyrimidine-5-carboxamide Chemical compound N1=CC(C(=O)NO)=CN=C1N1CCN(S(=O)(=O)C=2C=C3C=CC=CC3=CC=2)CC1 MUTBJZVSRNUIHA-UHFFFAOYSA-N 0.000 description 1
- AAFYOVPTFNNVDN-UHFFFAOYSA-N N-methyl-N-phenacylnitrous amide Chemical group O=NN(C)CC(=O)C1=CC=CC=C1 AAFYOVPTFNNVDN-UHFFFAOYSA-N 0.000 description 1
- OHLUUHNLEMFGTQ-UHFFFAOYSA-N N-methylacetamide Chemical compound CNC(C)=O OHLUUHNLEMFGTQ-UHFFFAOYSA-N 0.000 description 1
- MHIITNFQDPFSES-UHFFFAOYSA-N N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 Chemical class N1C(C=C2C3=CC=CC=C3C(C=C3NC(=C4)C=C3)=N2)=CC=C1C=C1C=CC4=N1 MHIITNFQDPFSES-UHFFFAOYSA-N 0.000 description 1
- 102100014656 NOG Human genes 0.000 description 1
- 108060008492 NOG Proteins 0.000 description 1
- 101700050594 NR1K1 Proteins 0.000 description 1
- NPAGDVCDWIYMMC-IZPLOLCNSA-N Nandrolone Chemical compound O=C1CC[C@@H]2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 NPAGDVCDWIYMMC-IZPLOLCNSA-N 0.000 description 1
- 210000003739 Neck Anatomy 0.000 description 1
- IXOXBSCIXZEQEQ-UHTZMRCNSA-N Nelarabine Chemical compound C1=NC=2C(OC)=NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O IXOXBSCIXZEQEQ-UHTZMRCNSA-N 0.000 description 1
- 206010029113 Neovascularisation Diseases 0.000 description 1
- 208000007538 Neurilemmoma Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- MDJFHRLTPRPZLY-UHFFFAOYSA-N Nimorazole Chemical compound [O-][N+](=O)C1=CN=CN1CCN1CCOCC1 MDJFHRLTPRPZLY-UHFFFAOYSA-N 0.000 description 1
- 229960004918 Nimorazole Drugs 0.000 description 1
- KYRVNWMVYQXFEU-UHFFFAOYSA-N Nocodazole Chemical compound C1=C2NC(NC(=O)OC)=NC2=CC=C1C(=O)C1=CC=CS1 KYRVNWMVYQXFEU-UHFFFAOYSA-N 0.000 description 1
- 229950006344 Nocodazole Drugs 0.000 description 1
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 description 1
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 102000000623 Oestrogen receptor Human genes 0.000 description 1
- 108050008051 Oestrogen receptor Proteins 0.000 description 1
- 229920000272 Oligonucleotide Polymers 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 206010025310 Other lymphomas Diseases 0.000 description 1
- 210000001672 Ovary Anatomy 0.000 description 1
- AHHWIHXENZJRFG-UHFFFAOYSA-N Oxetane Chemical compound C1COC1 AHHWIHXENZJRFG-UHFFFAOYSA-N 0.000 description 1
- 102100018954 PECAM1 Human genes 0.000 description 1
- 101710027269 PECAM1 Proteins 0.000 description 1
- 229960002404 Palifermin Drugs 0.000 description 1
- YJVFFLUZDVXJQI-UHFFFAOYSA-L Palladium(II) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 1
- WRUUGTRCQOWXEG-UHFFFAOYSA-N Pamidronic acid Chemical compound NCCC(O)(P(O)(O)=O)P(O)(O)=O WRUUGTRCQOWXEG-UHFFFAOYSA-N 0.000 description 1
- 210000000496 Pancreas Anatomy 0.000 description 1
- 108010061219 Panitumumab Proteins 0.000 description 1
- 206010061536 Parkinson's disease Diseases 0.000 description 1
- 229960001373 Pegfilgrastim Drugs 0.000 description 1
- 229960002340 Pentostatin Drugs 0.000 description 1
- FPVKHBSQESCIEP-JQCXWYLXSA-N Pentostatin Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(N=CNC[C@H]2O)=C2N=C1 FPVKHBSQESCIEP-JQCXWYLXSA-N 0.000 description 1
- 210000001428 Peripheral Nervous System Anatomy 0.000 description 1
- 229940072417 Peroxidase Drugs 0.000 description 1
- 108090000437 Peroxidases Proteins 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- LFSXCDWNBUNEEM-UHFFFAOYSA-N Phthalazine Chemical compound C1=NN=CC2=CC=CC=C21 LFSXCDWNBUNEEM-UHFFFAOYSA-N 0.000 description 1
- XKJCHHZQLQNZHY-UHFFFAOYSA-N Phthalimide Chemical compound C1=CC=C2C(=O)NC(=O)C2=C1 XKJCHHZQLQNZHY-UHFFFAOYSA-N 0.000 description 1
- 208000000609 Pick Disease of the Brain Diseases 0.000 description 1
- 201000011585 Pick's disease Diseases 0.000 description 1
- IIMIOEBMYPRQGU-UHFFFAOYSA-L Picoplatin Chemical compound N.[Cl-].[Cl-].[Pt+2].CC1=CC=CC=N1 IIMIOEBMYPRQGU-UHFFFAOYSA-L 0.000 description 1
- 229950010456 Pimonidazole Drugs 0.000 description 1
- NJBFOOCLYDNZJN-UHFFFAOYSA-N Pipobroman Chemical compound BrCCC(=O)N1CCN(C(=O)CCBr)CC1 NJBFOOCLYDNZJN-UHFFFAOYSA-N 0.000 description 1
- 229960003073 Pirfenidone Drugs 0.000 description 1
- 206010035104 Pituitary tumour Diseases 0.000 description 1
- 210000002381 Plasma Anatomy 0.000 description 1
- 210000004910 Pleural fluid Anatomy 0.000 description 1
- 208000008696 Polycythemia Vera Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N Prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 1
- 208000003476 Primary Myelofibrosis Diseases 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N Procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 206010037211 Psychomotor hyperactivity Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- PBMFSQRYOILNGV-UHFFFAOYSA-N Pyridazine Chemical compound C1=CC=NN=C1 PBMFSQRYOILNGV-UHFFFAOYSA-N 0.000 description 1
- 101710037934 QRSL1 Proteins 0.000 description 1
- JWVCLYRUEFBMGU-UHFFFAOYSA-N Quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
- XSCHRSMBECNVNS-UHFFFAOYSA-N Quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 1
- PAWIYAYFNXQGAP-UHFFFAOYSA-N Quisinostat Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 description 1
- 238000010240 RT-PCR analysis Methods 0.000 description 1
- 229960000424 Rasburicase Drugs 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- 210000001525 Retina Anatomy 0.000 description 1
- 208000007014 Retinitis Pigmentosa Diseases 0.000 description 1
- 206010038932 Retinopathy Diseases 0.000 description 1
- 206010039083 Rhinitis Diseases 0.000 description 1
- 229920001914 Ribonucleotide Polymers 0.000 description 1
- 108010001645 Rituximab Proteins 0.000 description 1
- BZKICOFSQOWHPW-UHFFFAOYSA-N ST023535 Chemical compound C=1C(=C2OCCBr)CC(C=3OCCBr)=CC(C4(C)CCCCC4)=CC=3CC(C=3OCCBr)=CC(C4(C)CCCCC4)=CC=3CC(C=3OCCBr)=CC(C4(C)CCCCC4)=CC=3CC2=CC=1C1(C)CCCCC1 BZKICOFSQOWHPW-UHFFFAOYSA-N 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 210000003296 Saliva Anatomy 0.000 description 1
- 206010039667 Schwannoma Diseases 0.000 description 1
- 229940095743 Selective estrogen receptor modulators Drugs 0.000 description 1
- CYOHGALHFOKKQC-UHFFFAOYSA-N Selumetinib Chemical compound OCCONC(=O)C=1C=C2N(C)C=NC2=C(F)C=1NC1=CC=C(Br)C=C1Cl CYOHGALHFOKKQC-UHFFFAOYSA-N 0.000 description 1
- 241001243925 Sia Species 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M Sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- MNWBNISUBARLIT-UHFFFAOYSA-N Sodium cyanide Chemical compound [Na+].N#[C-] MNWBNISUBARLIT-UHFFFAOYSA-N 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N Sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 102000001854 Steroid 17-alpha-Hydroxylase Human genes 0.000 description 1
- 108010015330 Steroid 17-alpha-Hydroxylase Proteins 0.000 description 1
- 229960001052 Streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N Streptozotocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- HXJUTPCZVOIRIF-UHFFFAOYSA-N Sulfolane Chemical compound O=S1(=O)CCCC1 HXJUTPCZVOIRIF-UHFFFAOYSA-N 0.000 description 1
- MBDNRNMVTZADMQ-UHFFFAOYSA-N Sulfolene Chemical compound O=S1(=O)CC=CC1 MBDNRNMVTZADMQ-UHFFFAOYSA-N 0.000 description 1
- 206010048327 Supranuclear palsy Diseases 0.000 description 1
- 210000001744 T-Lymphocytes Anatomy 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 102100014320 TGFB1 Human genes 0.000 description 1
- 101700041213 TGFB1 Proteins 0.000 description 1
- YWBFPKPWMSWWEA-UHFFFAOYSA-O TRIAZOLOPYRIMIDINE Chemical compound BrC1=CC=CC(C=2N=C3N=CN[N+]3=C(NCC=3C=CN=CC=3)C=2)=C1 YWBFPKPWMSWWEA-UHFFFAOYSA-O 0.000 description 1
- NAVMQTYZDKMPEU-UHFFFAOYSA-N Targretin Chemical compound CC1=CC(C(CCC2(C)C)(C)C)=C2C=C1C(=C)C1=CC=C(C(O)=O)C=C1 NAVMQTYZDKMPEU-UHFFFAOYSA-N 0.000 description 1
- YVSQVYZBDXIXCC-INIZCTEOSA-N Telomestatin Chemical compound N=1C2=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(N=1)=COC=1C(=C(O1)C)N=C1C(=C(O1)C)N=C1[C@@]1([H])N=C2SC1 YVSQVYZBDXIXCC-INIZCTEOSA-N 0.000 description 1
- 229920000044 Telomestatin Polymers 0.000 description 1
- 208000001608 Teratocarcinoma Diseases 0.000 description 1
- 229960005353 Testolactone Drugs 0.000 description 1
- UWYZHKAOTLEWKK-UHFFFAOYSA-N Tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 1
- 229960003433 Thalidomide Drugs 0.000 description 1
- 229960005454 Thioguanine Drugs 0.000 description 1
- 229950009158 Tipifarnib Drugs 0.000 description 1
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 231100000765 Toxin Toxicity 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- RTKIYFITIVXBLE-QEQCGCAPSA-N Trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 description 1
- 229940035504 Tromethamine Drugs 0.000 description 1
- FRPZMMHWLSIFAZ-UHFFFAOYSA-N Undecylenic acid Chemical compound OC(=O)CCCCCCCCC=C FRPZMMHWLSIFAZ-UHFFFAOYSA-N 0.000 description 1
- 229940035893 Uracil Drugs 0.000 description 1
- 241001459538 Ute Species 0.000 description 1
- 210000004291 Uterus Anatomy 0.000 description 1
- ZOCKGBMQLCSHFP-KQRAQHLDSA-N Valrubicin Chemical compound O([C@H]1C[C@](CC2=C(O)C=3C(=O)C4=CC=CC(OC)=C4C(=O)C=3C(O)=C21)(O)C(=O)COC(=O)CCCC)[C@H]1C[C@H](NC(=O)C(F)(F)F)[C@H](O)[C@H](C)O1 ZOCKGBMQLCSHFP-KQRAQHLDSA-N 0.000 description 1
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 description 1
- 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 description 1
- 230000037113 Vdu Effects 0.000 description 1
- SGTNSNPWRIOYBX-UHFFFAOYSA-N Verapamil Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 description 1
- 229940046008 Vitamin D Drugs 0.000 description 1
- 229930003316 Vitamin D Natural products 0.000 description 1
- XLMPPFTZALNBFS-INIZCTEOSA-N Vorozole Chemical compound C1([C@@H](C2=CC=C3N=NN(C3=C2)C)N2N=CN=C2)=CC=C(Cl)C=C1 XLMPPFTZALNBFS-INIZCTEOSA-N 0.000 description 1
- 229940004212 Yondelis Drugs 0.000 description 1
- RQZAXGRLVPAYTJ-GQFGMJRRSA-N [(8R,9S,10R,13S,14S,17R)-17-acetyl-6,10,13-trimethyl-3-oxo-2,8,9,11,12,14,15,16-octahydro-1H-cyclopenta[a]phenanthren-17-yl] acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RQZAXGRLVPAYTJ-GQFGMJRRSA-N 0.000 description 1
- SRNKZYRMFBGSGE-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CN=C21 SRNKZYRMFBGSGE-UHFFFAOYSA-N 0.000 description 1
- LIQODXNTTZAGID-OCBXBXKTSA-N [4-[(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-8-oxo-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[5,6-f][1,3]benzodioxol-9-yl]-2,6-dimethoxyphenyl] dihydrogen phosphate Chemical compound COC1=C(OP(O)(O)=O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 LIQODXNTTZAGID-OCBXBXKTSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K [O-]P([O-])([O-])=O Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- IKDXDQDKCZPQSZ-JHYYTBFNSA-N acetic acid;(2S)-N-[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[(carbamoylamino)carbamoyl]pyrrolidin-1-yl]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-[(2-methylpropan-2-yl)oxy]-1-oxopro Chemical compound CC(O)=O.C([C@@H](C(=O)N[C@H](COC(C)(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NNC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 IKDXDQDKCZPQSZ-JHYYTBFNSA-N 0.000 description 1
- 150000007960 acetonitrile Chemical class 0.000 description 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 201000005510 acute lymphocytic leukemia Diseases 0.000 description 1
- 125000005042 acyloxymethyl group Chemical group 0.000 description 1
- 230000000996 additive Effects 0.000 description 1
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 229960005310 aldesleukin Drugs 0.000 description 1
- 229960000548 alemtuzumab Drugs 0.000 description 1
- 229960001445 alitretinoin Drugs 0.000 description 1
- 229910001413 alkali metal ion Inorganic materials 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 229930013930 alkaloids Natural products 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 229960000473 altretamine Drugs 0.000 description 1
- 229910000091 aluminium hydride Inorganic materials 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 150000001409 amidines Chemical class 0.000 description 1
- 235000012538 ammonium bicarbonate Nutrition 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 108010072788 angiogenin Proteins 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001772 anti-angiogenic Effects 0.000 description 1
- 230000003432 anti-folate Effects 0.000 description 1
- 230000000340 anti-metabolite Effects 0.000 description 1
- 239000002256 antimetabolite Substances 0.000 description 1
- 229940045696 antineoplastic drugs Podophyllotoxin derivatives Drugs 0.000 description 1
- 229940027983 antiseptics and disinfectants Quaternary ammonium compounds Drugs 0.000 description 1
- 210000000436 anus Anatomy 0.000 description 1
- 230000001640 apoptogenic Effects 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 229960002594 arsenic trioxide Drugs 0.000 description 1
- GOLCXWYRSKYTSP-UHFFFAOYSA-N arsenic trioxide Inorganic materials O1[As]2O[As]1O2 GOLCXWYRSKYTSP-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000035578 autophosphorylation Effects 0.000 description 1
- 125000000477 aza group Chemical group 0.000 description 1
- JXLHNMVSKXFWAO-UHFFFAOYSA-N azane;7-fluoro-2,1,3-benzoxadiazole-4-sulfonic acid Chemical compound N.OS(=O)(=O)C1=CC=C(F)C2=NON=C12 JXLHNMVSKXFWAO-UHFFFAOYSA-N 0.000 description 1
- 125000004069 aziridinyl group Chemical group 0.000 description 1
- 125000004602 benzodiazinyl group Chemical group N1=NC(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 125000004622 benzoxazinyl group Chemical group O1NC(=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 description 1
- 108010005774 beta-Galactosidase Proteins 0.000 description 1
- 229960002938 bexarotene Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- SIPUZPBQZHNSDW-UHFFFAOYSA-N bis(2-methylpropyl)aluminum Chemical compound CC(C)C[Al]CC(C)C SIPUZPBQZHNSDW-UHFFFAOYSA-N 0.000 description 1
- 150000004663 bisphosphonates Chemical class 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 201000004569 blindness Diseases 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- IYYIVELXUANFED-UHFFFAOYSA-N bromo(trimethyl)silane Chemical compound C[Si](C)(C)Br IYYIVELXUANFED-UHFFFAOYSA-N 0.000 description 1
- 229960002092 busulfan Drugs 0.000 description 1
- 229920005549 butyl rubber Polymers 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001733 carboxylic acid esters Chemical class 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-O carminomycin(1+) Chemical compound C1[C@H]([NH3+])[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-O 0.000 description 1
- 230000003197 catalytic Effects 0.000 description 1
- 230000024881 catalytic activity Effects 0.000 description 1
- 239000003729 cation exchange resin Substances 0.000 description 1
- 229940023913 cation exchange resins Drugs 0.000 description 1
- 150000001767 cationic compounds Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 238000002701 cell growth assay Methods 0.000 description 1
- 230000001413 cellular Effects 0.000 description 1
- 230000033077 cellular process Effects 0.000 description 1
- 230000036755 cellular response Effects 0.000 description 1
- 230000002490 cerebral Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 230000035572 chemosensitivity Effects 0.000 description 1
- 230000000973 chemotherapeutic Effects 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- QZHPTGXQGDFGEN-UHFFFAOYSA-N chromene Chemical compound C1=CC=C2C=C[CH]OC2=C1 QZHPTGXQGDFGEN-UHFFFAOYSA-N 0.000 description 1
- 229960002436 cladribine Drugs 0.000 description 1
- 229960000928 clofarabine Drugs 0.000 description 1
- 239000003426 co-catalyst Substances 0.000 description 1
- ZNEWHQLOPFWXOF-UHFFFAOYSA-N coenzyme M Chemical compound OS(=O)(=O)CCS ZNEWHQLOPFWXOF-UHFFFAOYSA-N 0.000 description 1
- 229960005188 collagen Drugs 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 201000010897 colon adenocarcinoma Diseases 0.000 description 1
- 201000010989 colorectal carcinoma Diseases 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 201000002574 conversion disease Diseases 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910000365 copper sulfate Inorganic materials 0.000 description 1
- 229910000366 copper(II) sulfate Inorganic materials 0.000 description 1
- GBRBMTNGQBKBQE-UHFFFAOYSA-L copper;diiodide Chemical compound I[Cu]I GBRBMTNGQBKBQE-UHFFFAOYSA-L 0.000 description 1
- 230000002596 correlated Effects 0.000 description 1
- 230000001808 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 150000004292 cyclic ethers Chemical group 0.000 description 1
- 150000004294 cyclic thioethers Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 229960005029 darbepoetin alfa Drugs 0.000 description 1
- 229960002448 dasatinib Drugs 0.000 description 1
- 229960003603 decitabine Drugs 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 230000003412 degenerative Effects 0.000 description 1
- 230000003413 degradative Effects 0.000 description 1
- 230000002939 deleterious Effects 0.000 description 1
- 229960002923 denileukin diftitox Drugs 0.000 description 1
- 108010017271 denileukin diftitox Proteins 0.000 description 1
- 230000003831 deregulation Effects 0.000 description 1
- 201000004624 dermatitis Diseases 0.000 description 1
- MQYQOVYIJOLTNX-UHFFFAOYSA-N dichloromethane;N,N-dimethylformamide Chemical compound ClCCl.CN(C)C=O MQYQOVYIJOLTNX-UHFFFAOYSA-N 0.000 description 1
- RSUZBZYVQMPODW-UHFFFAOYSA-N dicyclohexyl-[6-phenyl-2,3,4-tri(propan-2-yl)phenyl]phosphane Chemical group C1CCCCC1P(C1CCCCC1)C=1C(C(C)C)=C(C(C)C)C(C(C)C)=CC=1C1=CC=CC=C1 RSUZBZYVQMPODW-UHFFFAOYSA-N 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 229960004132 diethyl ether Drugs 0.000 description 1
- 238000000113 differential scanning calorimetry Methods 0.000 description 1
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical compound C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- QXNVGIXVLWOKEQ-UHFFFAOYSA-N disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 229940017743 dromostanolone propionate Drugs 0.000 description 1
- 229950004683 drostanolone propionate Drugs 0.000 description 1
- 231100001003 eczema Toxicity 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000010595 endothelial cell migration Effects 0.000 description 1
- 229940105423 erythropoietin Drugs 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 239000000328 estrogen antagonist Substances 0.000 description 1
- NUCWDCRUEIUKPN-UHFFFAOYSA-J ethane-1,2-diamine;palladium(2+);phosphonato phosphate Chemical compound [Pd+2].[Pd+2].NCCN.NCCN.[O-]P([O-])(=O)OP([O-])([O-])=O NUCWDCRUEIUKPN-UHFFFAOYSA-J 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- SXJDCULZDFWMJC-UHFFFAOYSA-N ethyl 2-amino-6-bromo-4-(1-cyano-2-ethoxy-2-oxoethyl)-4H-chromene-3-carboxylate Chemical compound C1=C(Br)C=C2C(C(C#N)C(=O)OCC)C(C(=O)OCC)=C(N)OC2=C1 SXJDCULZDFWMJC-UHFFFAOYSA-N 0.000 description 1
- QUSNBJAOOMFDIB-UHFFFAOYSA-N ethyl amine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 1
- 229960000752 etoposide phosphate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229960000255 exemestane Drugs 0.000 description 1
- 230000001747 exhibiting Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000003352 fibrogenic Effects 0.000 description 1
- 230000037320 fibronectin Effects 0.000 description 1
- 201000008808 fibrosarcoma Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 229960000390 fludarabine Drugs 0.000 description 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 1
- 125000003784 fluoroethyl group Chemical group [H]C([H])(F)C([H])([H])* 0.000 description 1
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- VVIAGPKUTFNRDU-ABLWVSNPSA-N folinic acid Chemical compound C1NC=2NC(N)=NC(=O)C=2N(C=O)C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 VVIAGPKUTFNRDU-ABLWVSNPSA-N 0.000 description 1
- 235000008191 folinic acid Nutrition 0.000 description 1
- 239000011672 folinic acid Substances 0.000 description 1
- 230000003325 follicular Effects 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 201000011240 frontotemporal dementia Diseases 0.000 description 1
- 125000003838 furazanyl group Chemical group 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- 229960000578 gemtuzumab Drugs 0.000 description 1
- 201000010915 glioblastoma multiforme Diseases 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 229950005277 gossypol Drugs 0.000 description 1
- 229930000755 gossypol Natural products 0.000 description 1
- 150000004795 grignard reagents Chemical class 0.000 description 1
- 229920000591 gum Polymers 0.000 description 1
- 230000003394 haemopoietic Effects 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- BKEMVGVBBDMHKL-VYFXDUNUSA-N histrelin acetate Chemical compound CC(O)=O.CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC(N=C1)=CN1CC1=CC=CC=C1 BKEMVGVBBDMHKL-VYFXDUNUSA-N 0.000 description 1
- 125000000717 hydrazino group Chemical group [H]N([*])N([H])[H] 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 229960001330 hydroxycarbamide Drugs 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- VSNHCAURESNICA-UHFFFAOYSA-N hydroxyurea Chemical compound NC(=O)NO VSNHCAURESNICA-UHFFFAOYSA-N 0.000 description 1
- 229940027318 hydroxyurea Drugs 0.000 description 1
- 229960002411 imatinib Drugs 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- IAVDUGKRMHOEPW-UHFFFAOYSA-N imidazo[1,2-a]imidazole Chemical compound C1=CN=C2N=C[CH]N21 IAVDUGKRMHOEPW-UHFFFAOYSA-N 0.000 description 1
- UFBBWLWUIISIPW-UHFFFAOYSA-N imidazo[2,1-b][1,3]thiazole Chemical compound C1=CSC2=NC=CN21 UFBBWLWUIISIPW-UHFFFAOYSA-N 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 description 1
- 125000003406 indolizinyl group Chemical group C=1(C=CN2C=CC=CC12)* 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000002757 inflammatory Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000007529 inorganic bases Chemical class 0.000 description 1
- 229910001411 inorganic cation Inorganic materials 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000000968 intestinal Effects 0.000 description 1
- 229940079866 intestinal antibiotics Drugs 0.000 description 1
- 230000003834 intracellular Effects 0.000 description 1
- 201000008255 invasive lobular carcinoma Diseases 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N iodine atom Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 230000002427 irreversible Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- HEBMCVBCEDMUOF-UHFFFAOYSA-N isochromane Chemical compound C1=CC=C2COCCC2=C1 HEBMCVBCEDMUOF-UHFFFAOYSA-N 0.000 description 1
- 125000004594 isoindolinyl group Chemical group C1(NCC2=CC=CC=C12)* 0.000 description 1
- 125000000904 isoindolyl group Chemical group C=1(NC=C2C=CC=CC12)* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 230000000155 isotopic Effects 0.000 description 1
- 201000002531 karyomegalic interstitial nephritis Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 229960004891 lapatinib Drugs 0.000 description 1
- 229960001320 lapatinib ditosylate Drugs 0.000 description 1
- 201000010901 lateral sclerosis Diseases 0.000 description 1
- 229960004942 lenalidomide Drugs 0.000 description 1
- 229960001691 leucovorin Drugs 0.000 description 1
- RGLRXNKKBLIBQS-XNHQSDQCSA-N leuprolide acetate Chemical compound CC(O)=O.CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)CC1=CC=C(O)C=C1 RGLRXNKKBLIBQS-XNHQSDQCSA-N 0.000 description 1
- 230000000670 limiting Effects 0.000 description 1
- 239000011981 lindlar catalyst Substances 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960002247 lomustine Drugs 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 239000002697 lyase inhibitor Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-L maleate(2-) Chemical compound [O-]C(=O)\C=C/C([O-])=O VZCYOOQTPOCHFL-UPHRSURJSA-L 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000003771 matrix metalloproteinase inhibitor Substances 0.000 description 1
- 229940121386 matrix metalloproteinase inhibitors Drugs 0.000 description 1
- 239000002609 media Substances 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 229960001924 melphalan Drugs 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 210000004914 menses Anatomy 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 230000035786 metabolism Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- DBTDEFJAFBUGPP-UHFFFAOYSA-N methanethione Chemical compound S=C DBTDEFJAFBUGPP-UHFFFAOYSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- 238000010208 microarray analysis Methods 0.000 description 1
- 229950010514 misonidazole Drugs 0.000 description 1
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 1
- 230000002297 mitogenic Effects 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- QDHHCQZDFGDHMP-UHFFFAOYSA-N monochloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
- 125000006682 monohaloalkyl group Chemical group 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 230000003387 muscular Effects 0.000 description 1
- 210000002346 musculoskeletal system Anatomy 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000002071 myeloproliferative Effects 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004719 nandrolone Drugs 0.000 description 1
- 125000004593 naphthyridinyl group Chemical group N1=C(C=CC2=CC=CN=C12)* 0.000 description 1
- 229960000801 nelarabine Drugs 0.000 description 1
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 230000000626 neurodegenerative Effects 0.000 description 1
- 101700087158 nhr-10 Proteins 0.000 description 1
- 101700061999 nhr-3 Proteins 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 125000000018 nitroso group Chemical group N(=O)* 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N o-xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 description 1
- 229960001840 oprelvekin Drugs 0.000 description 1
- 108010046821 oprelvekin Proteins 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007530 organic bases Chemical class 0.000 description 1
- 150000002892 organic cations Chemical class 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 230000002188 osteogenic Effects 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000016087 ovulation Effects 0.000 description 1
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- SWYHWLFHDVMLHO-UHFFFAOYSA-N oxetan-3-ylmethanol Chemical compound OCC1COC1 SWYHWLFHDVMLHO-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 150000002923 oximes Chemical class 0.000 description 1
- 125000000466 oxiranyl group Chemical group 0.000 description 1
- 229960002502 paclitaxel protein-bound Drugs 0.000 description 1
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 1
- 229940046231 pamidronate Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 229960001972 panitumumab Drugs 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological Effects 0.000 description 1
- 230000001991 pathophysiological Effects 0.000 description 1
- 229960001218 pegademase Drugs 0.000 description 1
- 108010027841 pegademase bovine Proteins 0.000 description 1
- 229960001744 pegaspargase Drugs 0.000 description 1
- 108010001564 pegaspargase Proteins 0.000 description 1
- 108010044644 pegfilgrastim Proteins 0.000 description 1
- 229960003931 peginterferon alfa-2b Drugs 0.000 description 1
- 108010092851 peginterferon alfa-2b Proteins 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- SCKXCAADGDQQCS-UHFFFAOYSA-N performic acid Chemical compound OOC=O SCKXCAADGDQQCS-UHFFFAOYSA-N 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000004965 peroxy acids Chemical class 0.000 description 1
- 230000002085 persistent Effects 0.000 description 1
- 229960002087 pertuzumab Drugs 0.000 description 1
- 108010042024 pertuzumab Proteins 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 238000002428 photodynamic therapy Methods 0.000 description 1
- 125000004592 phthalazinyl group Chemical group C1(=NN=CC2=CC=CC=C12)* 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- IWELDVXSEVIIGI-UHFFFAOYSA-N piperazin-2-one Chemical compound O=C1CNCCN1 IWELDVXSEVIIGI-UHFFFAOYSA-N 0.000 description 1
- 150000003053 piperidines Chemical class 0.000 description 1
- 229960000952 pipobroman Drugs 0.000 description 1
- ISWRGOKTTBVCFA-UHFFFAOYSA-N pirfenidone Chemical compound C1=C(C)C=CC(=O)N1C1=CC=CC=C1 ISWRGOKTTBVCFA-UHFFFAOYSA-N 0.000 description 1
- 230000004481 post-translational protein modification Effects 0.000 description 1
- 238000000634 powder X-ray diffraction Methods 0.000 description 1
- 229960004618 prednisone Drugs 0.000 description 1
- 230000002335 preservative Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 125000005767 propoxymethyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])[#8]C([H])([H])* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 201000001514 prostate carcinoma Diseases 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 230000002685 pulmonary Effects 0.000 description 1
- GTBORZCYFKUESX-UHFFFAOYSA-N purin-6-amine Chemical compound NC1=NC=NC2=NC=N[C]12 GTBORZCYFKUESX-UHFFFAOYSA-N 0.000 description 1
- XFTQRUTUGRCSGO-UHFFFAOYSA-N pyrazin-2-amine Chemical compound NC1=CN=CC=N1 XFTQRUTUGRCSGO-UHFFFAOYSA-N 0.000 description 1
- 150000003219 pyrazolines Chemical group 0.000 description 1
- DVUBDHRTVYLIPA-UHFFFAOYSA-N pyrazolo[1,5-a]pyridine Chemical group C1=CC=CN2N=CC=C21 DVUBDHRTVYLIPA-UHFFFAOYSA-N 0.000 description 1
- LDIJKUBTLZTFRG-UHFFFAOYSA-N pyrazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CC=C21 LDIJKUBTLZTFRG-UHFFFAOYSA-N 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000000246 pyrimidin-2-yl group Chemical group [H]C1=NC(*)=NC([H])=C1[H] 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 125000004929 pyrrolidonyl group Chemical group N1(C(CCC1)=O)* 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003242 quaternary ammonium salts Chemical class 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010084837 rasburicase Proteins 0.000 description 1
- 230000000306 recurrent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 200000000008 restenosis Diseases 0.000 description 1
- 229930002330 retinoic acid Natural products 0.000 description 1
- 230000000250 revascularization Effects 0.000 description 1
- 239000002336 ribonucleotide Substances 0.000 description 1
- 125000002652 ribonucleotide group Chemical group 0.000 description 1
- 229960004641 rituximab Drugs 0.000 description 1
- 101710024887 rl Proteins 0.000 description 1
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 description 1
- 229960002530 sargramostim Drugs 0.000 description 1
- 108010038379 sargramostim Proteins 0.000 description 1
- 238000000646 scanning calorimetry Methods 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 description 1
- 201000010208 seminoma Diseases 0.000 description 1
- 231100000489 sensitizer Toxicity 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 231100000486 side effect Toxicity 0.000 description 1
- 229910052814 silicon oxide Inorganic materials 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 230000022379 skeletal muscle tissue development Effects 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000000371 solid-state nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 101700045897 spk-1 Proteins 0.000 description 1
- 239000004544 spot-on Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 230000003637 steroidlike Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 235000011044 succinic acid Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 125000001174 sulfone group Chemical group 0.000 description 1
- 230000004083 survival Effects 0.000 description 1
- 230000002195 synergetic Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000003277 telomerase inhibitor Substances 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- BPEWUONYVDABNZ-DZBHQSCQSA-N testolactone Chemical compound O=C1C=C[C@]2(C)[C@H]3CC[C@](C)(OC(=O)CC4)[C@@H]4[C@@H]3CCC2=C1 BPEWUONYVDABNZ-DZBHQSCQSA-N 0.000 description 1
- 125000003039 tetrahydroisoquinolinyl group Chemical group C1(NCCC2=CC=CC=C12)* 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000000147 tetrahydroquinolinyl group Chemical group N1(CCCC2=CC=CC=C12)* 0.000 description 1
- 150000003536 tetrazoles Chemical group 0.000 description 1
- 201000003896 thanatophoric dysplasia Diseases 0.000 description 1
- HDGIJHACJMJAER-UHFFFAOYSA-N thiazepane 1-oxide Chemical compound O=S1CCCCCN1 HDGIJHACJMJAER-UHFFFAOYSA-N 0.000 description 1
- DNGMYXZLJGHHOM-UHFFFAOYSA-N thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCCCN1 DNGMYXZLJGHHOM-UHFFFAOYSA-N 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 102000002938 thrombospondin family Human genes 0.000 description 1
- 108060008245 thrombospondin family Proteins 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N tin hydride Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229960005267 tositumomab Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000440 toxicity profile Toxicity 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 108020003112 toxins Proteins 0.000 description 1
- 229960000977 trabectedin Drugs 0.000 description 1
- 230000002103 transcriptional Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming Effects 0.000 description 1
- 102000035402 transmembrane proteins Human genes 0.000 description 1
- 108091005683 transmembrane proteins Proteins 0.000 description 1
- 102000027575 transmembrane receptors Human genes 0.000 description 1
- 108091007901 transmembrane receptors Proteins 0.000 description 1
- 125000004306 triazinyl group Chemical group 0.000 description 1
- 150000003852 triazoles Chemical class 0.000 description 1
- INQOMBQAUSQDDS-FIBGUPNXSA-N trideuterio(iodo)methane Chemical compound [2H]C([2H])([2H])I INQOMBQAUSQDDS-FIBGUPNXSA-N 0.000 description 1
- 125000004205 trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 description 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 229960000281 trometamol Drugs 0.000 description 1
- 239000012441 tubuline-binding agent Substances 0.000 description 1
- 229910052721 tungsten Inorganic materials 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 1
- 229940121358 tyrosine kinase inhibitors Drugs 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 229960000653 valrubicin Drugs 0.000 description 1
- 229960001722 verapamil Drugs 0.000 description 1
- 235000019166 vitamin D Nutrition 0.000 description 1
- 239000011710 vitamin D Substances 0.000 description 1
- 150000003710 vitamin D derivatives Chemical class 0.000 description 1
- 229960001771 vorozole Drugs 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 238000002424 x-ray crystallography Methods 0.000 description 1
- 201000006083 xeroderma pigmentosum Diseases 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- PODBBOVVOGJETB-UHFFFAOYSA-N zinc phthalocyanine Chemical compound N1=C2C3=CC=CC=C3C(N=C3C4=CC=CC=C4C(=N4)N33)=[N]2[Zn]23N3C1=C1C=CC=CC1=C3N=C1[N]2=C4C2=CC=CC=C21 PODBBOVVOGJETB-UHFFFAOYSA-N 0.000 description 1
- OBBCSXFCDPPXOL-UHFFFAOYSA-N α-(methoxymethyl)-2-nitro-1H-Imidazole-1-ethanol Chemical compound COCC(O)CN1C=CN=C1[N+]([O-])=O OBBCSXFCDPPXOL-UHFFFAOYSA-N 0.000 description 1
- YEJRWHAVMIAJKC-UHFFFAOYSA-N γ-lactone 4-hydroxy-butyric acid Chemical compound O=C1CCCO1 YEJRWHAVMIAJKC-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Disclosed are Pyrido[2,3-b]pyrazine compounds of formula (IA) or (IB), pharmaceutical compositions comprising said compounds, processes for the preparation of said compounds and the use of said compounds in the treatment of diseases, e.g. cancer.
Description
ANTICANCER PYRIDOPYRAZINES VIA THE INHIBITION OF FGFR KINASES
FIELD OF THE INVENTION
The invention relates to new pyridopyrazine derivative compounds, to pharmaceutical
compositions comprising said compounds, to processes for the preparation of said
compounds and to the use of said compounds in the treatment of diseases, e.g. cancer.
SUMMARY OF THE INVENTION
ing to a first aspect of the invention there is provided compounds of formula (l):
N N N Y
UT/ /
(R2) N
" (l-A)
N N N Y
\ /
(R2) N
” (l-B)
including any tautomeric or stereochemically isomeric form thereof, wherein
each R2 is ndently selected from hydroxyl, halogen, cyano, C1-4alkyl, Cg_4alkenyl,
C2_4alkynyl, C1-4alkoxy, hydroxyC1-4alkyl, hydroxyC1-4alkoxy, _4alkyl, haloC1_
4alkoxy, hydroxyhaloC1_4alkyl, hydroxyhaloC1_4alkoxy, C1_4alkoxyC1-4alkyl, haloC1.
4alkoxyC1-4alkyl, C1_4alkoxyC1-4alkyl wherein each C1_4alkyl may optionally be substituted
with one or two yl groups, hydroxyhaloCi_4alkoxyC1-4alkyl, R13, C1_4alkyl
substituted with R13, C1_4alkyl substituted with -C(=O)—R13, C1_4alkoxy substituted with
R13, C1-4alkoxy substituted with -C(=O)-R13, -R13, kyl substituted with
, C1.4alkyl substituted with —C(=O)—NR7R8, C1_4alkoxy substituted with -NR7R8, C1.
4alkoxy substituted with —C(=O)—NR7R8, -NR7R8 and ~C(=O)—NR7R8; or when two R2
groups are ed to adjacent carbon atoms they may be taken together to form a
radical of formula:
-O-<C<R">2)p-O-;
-X-CH=CH-; or
-X-CH=N-; wherein R17 represents hydrogen or fluorine, p represents 1 or 2
and X represents 0 or S;
Y ents -CR"3=N-OR19 or -E-D;
D represents a 3 to 12 ring ed monocyclic or bicyclic carbocyclyl or a 3 to 12
ring membered clic or bicyclic heterocyclyl containing at least one heteroatom
selected from N, O or 8, wherein said carbocyclyl and heterocyclyl may each be
optionally tuted by one or more (eg. 1, 2 or 3) R1 groups;
E represents a bond, —(CR22R23)n—, Cg_4alkenediyl optionally substituted with R22, CZ-
ediyl optionally substituted with R22, -CO-(CR22R23)s-, —(CR22R23)S-CO—, —NR22-
(CR22R23)s-, —(CR22R23)S-NR22-, -O-(CR22R23)s-, -(CR22R23)S-O—, -S(O)m—(CR22R23)s—, _
(CR22R23)s-S(O)m-, —(CR22R23)s-c0-NRZZ-(CR22R23)S- or —(CR22R23)S-NR22-CO-
(CR22R23)s-;
R1 represents hydrogen, halo, cyano, C1_6alkyl, Ci_6alkoxy, -C(=O)-O- C1-6alkyl, CZ-
4alkenyl, hydroxyCi_5alkyl, haloC1-6alkyl, hydroxyhaloCi_6alkyl, cyanoC1_4alkyl, C1-
salkoxyC1_6alkyl wherein each C1_5alkyl may optionally be substituted with one or two
hydroxyl groups, -NR4R5, C1_6alkyl substituted with -O-C(=O)— C1-5alkyl, C1_6alkyl
substituted with -NR4R5, —-C(=O)-NR4R5, —C(=O)-C1-5alkyl-NR4R5, C1.5alkyl substituted
with —C(=O)-NR4R5, 2—C1_5alkyl, —S(=O)2-haloC1.6alkyl, -—S(=O)2—NR14R15, C1_6alkyl
substituted with -S(=O)2-C1_6alkyl, C1_6alkyl substituted with -S(=O)2-haloC1_salkyl, Ci-
galkyl substituted with —S(=O)2-NR14R15, C1-6alkyl substituted with —NH-S(=O)2-Ci_6alkyl,
C1_ealkyl substituted with =O)2-haloCi.6alkyl, C1-6alkyl substituted with ~NR12-
-NR14R15, R6, C1_6alkyl substituted with R6, ~—C(=O)—R6, c,-5alkyl substituted with —
R6, hydroxyC1_6alkyl substituted with R6, C1_6alkyl substituted with —Si(CH3)3, Ci-
salkyl substituted with -P(=O)(OH)2 or C1-6alkyl substituted with -P(=O)(OC1_6alkyl)2;
R3 ents hydroxyl, C1-6alkoxy, hydroxyCi_6alkoxy, C1-6alkoxy tuted with
-NR1°R“, C1.5alkyl, Cg-6alkenyl, kynyl, haloC1_6alkyl optionally substituted with —o-
C(=O)-C1-6alkyl, yC1.6alkyl optionally substituted with —O-C(=O)-Ci.ealkyl,
hydroxyC2-6alkenyl, hydroxyCz_6alkynyl, yhaloC1_6alkyl, 1_6alkyl, C1_5alkyl
substituted with carboxyl, kyl substituted with —C1_6alkyl. C1-6a|kyl substituted
with —C(=O)—O-Ct.6alkyl, C1_6alkyl substituted with C1-ealkoxyC1_6alkyl-O-C(=O)—-, Chsalkyl
substituted with C1.6alkoxyC1-6a|kyl—C(=O)—, C1.6alkyl substituted with —O-C(=O)—C1_
aalkyl, C1_6alkoxyC1-6alkyl n each C1_6a|kyl may optionally be substituted with one
or two hydroxyl groups or with —O-C(=O)—C1_6alkyl, Cgsealkenyl substituted with C1-
ealkoxy, 02-6alkynyl substituted with C1-6alkoxy, C1_6alkyl substituted with R9 and
optionally substituted with —O-C(=O)—C1_6alkyl, C1_6alkyl substituted with ~C(=O)—R9, C1-
6alkyl substituted with hydroxyl and R9, 02-6alkenyl tuted with R9, C2.6alkyny|
substituted with R9, C1_6alkyl substituted with -NR‘°R“, C2_6alkenyl substituted with
-NR1°R“, kynyl substituted with -NR1°R“, C1_6alkyl substituted with hydroxyl and
”. Chealkyl tuted with one or two halogens and -NR1°R“, -C1_5alkyl-
C(R12)=N-o-R12, cmaikyi substituted with —C(=O)—NR1°R“, C1-6alky| substituted with —
o-C(=0)-NR‘0R“, —S(=O)2-C1_6alkyl, —S(=O)2-hal001_6alkyl, —S(=0)2-NR14R15, C1_6a|kyl
substituted with —S(=O)2-C1_6a|kyl, C1_6a|kyl substituted with —S(=O)2-haloC1_6alkyl, C1-
salkyl substituted with —S(=O)2-NR14R15, C1_6alkyl substituted with ~NR‘2-S(=O)2-C1_
6alkyl, kyl substituted with —NH-S(=O)2-haloC1-6alkyl, C1-5a|kyl substituted with —
NR‘Z-S(=0)2-NR‘4R15, R13, C1.6alky| substituted with -P(=O)(OH)2 or C1_6alkyl substituted
with ~P(=O)(OC1_6alkyl)2;
R4 and R5 each ndently represent en, C1-6alkyl, C1-6alkyl substituted with -
NR14R15, hydroxyC1_6a|kyl, haloC1_6alkyl, hydroxyhaloC1_6alkyl, C1_6alkoxyC1_6alkyl
wherein each C1_6alkyl may optionally be substituted with one or two hydroxyl , —
S(=O)2-C1_6alkyl, —S(=O)2-ha|001_6alkyl, —S(=O)2-NR14R15, —C(=O)—NR14R15, —C(=O)—O-
C1_6a|kyl, -C(=O)-R13, kyl substituted with ~S(=O)2-C1_5alkyl, C1_6alkyl substituted
with -S(=O)2-haloC1_6alkyl, C1_6a|kyl substituted with —S(=0)2-NR14R15, C1.6alky|
substituted with —NH-S(=O)2-C1_6alkyl, kyl substituted with —NH-S(=O)2-hal001-
6eikyi, C1_6alkyl substituted with —NH- S(=0)2-NR14R15, R13 or C1.6alkyl substituted with
R13;
R6 represents Cg_gcycloalkyl, C3_gcycloalkenyl, phenyl, 4 to 7-membered monocyclic
heterocyclyl containing at least one heteroatom selected from N, O or 8; said C3-
acycloalkyl, C3-8cycloalkenyl, phenyl, 4 to 7-membered monocyclic heterocyclyl,
optionally and each independently being substituted by 1, 2, 3, 4 or 5 substituents, each
substituent independently being selected from cyano, C1_6alkyl, cyanoC1_6alkyl, hydroxyl,
carboxyl, hydroxyC1-6alkyl, halogen, haloC1_6alkyl, hydroxyhaloC1_6alkyl, C1_6alkoxy, C1-
ealkoxyC1.5alkyl, C1_6alkyl-O-C(=O)—,-NR14R15, —C(=O)-NR14R15, C1_5alkyl substituted with
-NR14R15, C1_ealkyl tuted with -C(=O)—NR14R15, -S(=O)2—C1.5alkyl, 2-haloC1_
salkyl, 2-NR14R15, C1.6alkyl substituted with —S(=O)2-Ci.6alkyl, C1-6alkyl substituted
with —S(=O)2-haloCi-6alkyl, C1_6alkyl tuted with —S(=O)2-NR14R15, C1_6alkyl
substituted with —NH-S(=O)2-Ci_ealkyl, C1_6alkyl substituted with =O)2-haloC1_
Balkyl or C1_6alkyl substituted with —NH-S(=O)2-NR14R15;
R7 and R8 each independently represent hydrogen, C1_6alkyl, hydroxyC1-6alkyl, haloC1_
salkyl, hydroxyhaloC1_6alkyl or koxyC1_6alkyl;
Rg ents C3-gcycloalkyl, 03.8cycloalkenyl, phenyl, yl, or 3 to 12 membered
monocyclic or bicyclic heterocyclyl containing at least one atom selected from N,
O or 8, said 03-3cycloalkyl, C3_gcycloalkenyl, phenyl, naphthyl, or 3 to 12 ed
monocyclic or bicyclic heterocyclyl each optionally and each independently being
substituted with 1, 2, 3, 4 or 5 substituents, each substituent independently being
selected from :0, C1_4alkyl, hydroxyl, carboxyl, yCMalkyl, cyano, cyanoCMalkyl,
C1_4alkyl-O-C(=O)-, Ci_4alkyl substituted with C1_4alkyl-O-C(=O)-, C1-4alkyl-C(=O)-, C1-
4alkoxyC1_4alkyl wherein each C1_4alkyl may optionally be substituted with one or two
hydroxyl groups, halogen, haloC1_4alkyl, hydroxyhaloC1-4alkyl, -NR14R15, —C(=O)—NR14R15,
CMalkyl substituted with -NR14R‘5, Cl-4alkyl substituted with -C(=O)—NR14R15, C1_4alkoxy,
-S(=O)2-C1.4alkyl, —S(=O)2-haloC1.4alkyl, —S(=O)2—NRMR15, C1-4alkyl substituted with —
S(=O)2-NR14R15, C1_4alkyl substituted with -NH-S(=O)2-C1_4alkyl, C1-4alkyl substituted
with —-NH-S(=O)2-haloC1-4alkyl, Ci_4alkyl substituted with —NH-S(=O)2-NR14R15, R13, -
C(=O)-R13, C1.4alkyl substituted with R13, phenyl optionally substituted with R16,
phenle1-6alkyl wherein the phenyl is optionally tuted with R16, a 5 or 6-membered
aromatic monocyclic heterocyclyl containing at least one heteroatom selected from N, O
or 8 wherein said heterocyclyl is optionally substituted with R16;
or when two of the substituents of R9 are attached to the same atom, they may be taken
together to form a 4 to 7-membered saturated clic heterocyclyl containing at
least one atom selected from N, O or S;
R1‘) and R11 each independently represent hydrogen, carboxyl, C1_6all<y|, 1.6alkyl,
C1.6alkyl substituted with —NR14R15, C1.5alkyl substituted with —C(=O)—NR14R15, haloC1_
salkyl, hydroxyC1_6alkyl, hydroxyhaloC1_6alkyl, C1_5alkoxy, C1_6alkoxy01-6alkyl wherein
each Cmalkyl may optionally be substituted with one or two hydroxyl groups, R6, C1-
ealkyl substituted with R6, -C(=O)—R6, —C1_ealkyl,—C(=O)—hydroxyC1_6alkyl, —
haloC1-6alkyl,-C(=O)—hydroxyhaloC1_6alkyl, C1_6alkyl substituted with —Si(CH3)3, —S(=O)2-
C1_6alkyl, ——S(=O)2-haloC1_6alkyl, -S(=O)2-NR14R15, C1_6alkyl tuted with -S(=O)2—C1_
aalkyl, Cmalkyl substituted with 2-haloC1-6alkyl, Ct.6alkyl substituted with —S(=O)2-
NR14R15, Cmalkyl substituted with =O)2-Ci_6alkyl, kyl substituted with —NH-
S(=O)2-haloC1_6alkyl, C1_5alkyl substituted with carboxyl, or C1_6alkyl substituted with —
O)2—NR14R15;
R12 represents hydrogen or C1-4alkyl optionally substituted with C1_4alkoxy;
R13 represents C3_8cycloalkyl or a saturated 4 to 6-membered monocyclic heterocyclyl
containing at least one heteroatom selected from N, O or S, wherein said C3-gcycloalkyl
or clic heterocyclyl is optionally substituted with 1, 2 or 3 substituents each
independently selected from halogen, hydroxyl, C1_6alkyl, haloC1_5alkyl, =0, cyano, -
C(=O)—Ct.6alkyl, Cmalkoxy, or -NR14R15;
R14 and R15 each independently represent hydrogen, or haloCMalkyl, or C1-4alkyl
optionally substituted with a tuent selected from hydroxyl, CMalkoxy, amino or
mono-or di(Ct-4alkyl)amino;
R16 represents hydroxyl, halogen, cyano, C1-4alkyl, C1.4alkoxy, —NR14R15 or —
C(=O)NR‘4R‘5;
R18 represents hydrogen, CH; alkyl, 03-8 cycloalkyl, C1_4alkyl substituted with C3_8
cycloalkyl;
R19 represents hydrogen; C16 alkyl; 03-8 cycloalkyl; C1_6alkyl substituted with -O-R2°; -
(CH2),-CN; —(CH2)r—CONR2°R21; ,1-NR20R21; -(CH2),1-NRZ"COR21 ; -(CH2),1-NR2°-
(CH2)S-soz-R2‘; —(CH2)r1—NH-SOg-NR2°R21 ; -(CH2),1—NR2°C02R21 ; -(CH2),-sozNR2°R2‘;
phenyl ally substituted with 1, 2 , 3, 4 or 5 substituents each independently
selected from halogen, kyl, C1-4alkyloxy, cyano or amino; a 5- or 6-membered
aromatic monocyclic heterocycle containing at least one heteroatom selected from N, O
or 8, said heterocycle being optionally substituted with 1, 2 3 or 4 substituents each
independently selected from halogen, C1.4alkyl, kyloxy, cyano or amino; wherein
said 01-6 alkyl and C3_8 lkyl, may be optionally substituted by one or more R20
groups
R20 and R21 independently represent hydrogen, C14; alkyl, CH; alkanol -(CH2),,-O-C1_
Salkyl, or when attached to a nitrogen atom R20 and R21 can be taken together to form
with the nitrogen atom to which they are attached a monocyclic saturated 4, 5 or 6-
membered ring which optionally contains a further heteroatom selected from O, S or N;
R22 and R23 independently represent hydrogen, CH, alkyl, or hydroxyC1_6alkyl;
m independently represents an integer equal to O, 1 or 2;
n independently represents an integer equal to O, 1, 2, 3 or 4;
s ndently represents an integer equal to O, 1, 2, 3 or 4;
r independently represent an integer equal to 1, 2, 3, or 4;
r1 independently represent an integer equal to 2, 3 or 4;
the es thereof, the pharmaceutically able salts thereof or the solvates
thereof.
WO1999/17759, /092430, W02008/003702, W001/68047, W02005/007099,
W02004/098494, W02009/141386, , , WO
2011/026579, , WO 26, W02008/138878, W02004/104003,
W02004/104002, W02007/079999, W02007/054556, W02010/084152,
/0272736, U82005/0272728, /0123494, WO2011/135376 which each
disclose a series of heterocyclyl derivatives.
DETAILED DESCRIPTION OF THE lNVENTlON
Unless the context indicates otherwise, references to formula (l) in all sections of this
document (including the uses, methods and other s of the invention) include
references to all other sub-formula (e.g. l-A, l-B, l-C, l-D), sub-groups, preferences,
ments and examples as defined .
The prefix “CM,” (where x and y are integers) as used herein refers to the number of
carbon atoms in a given group. Thus, a C1_6alkyl group ns from 1 to 6 carbon
atoms, a C3_6cycloalkyl group ns from 3 to 6 carbon atoms, a C1_4alkoxy group
contains from 1 to 4 carbon atoms, and so on.
The term ‘halo’ or ‘halogen’ as used herein refers to a fluorine, chlorine, bromine or
iodine atom.
The term lkyl’, or ‘C1_6alkyl’ as used herein as a group or part of a group refers to a
linear or branched ted hydrocarbon group containing from 1 to 4 or 1 to 6 carbon
atoms. Examples of such groups include methyl, ethyl, n-propyl, isopropyl, n-butyl,
isobutyl, sec-butyl, tert-butyl, n-pentyl, isopentyl, neopentyl or hexyl and the like.
The term ‘Cz.4alkenyl’ or ‘C2_6alkenyl’ as used herein as a group or part of a group refers
to a linear or branched hydrocarbon group ning from 2 to 4 or 2 to 6 carbon atoms
and containing a carbon carbon double bond.
The term ‘Cz_4alkynyl’ or ‘Czealkynyl’ as used herein as a group or part of a group refers
to a linear or branched hydrocarbon group having from 2 to 4 or 2 to 6 carbon atoms
and containing a carbon carbon triple bond.
The term ‘C1-4alkoxy’ or ‘C1_6alkoxy’ as used herein as a group or part of a group refers
to an —O-C1_4alkyl group or an —O-C1_6alkyl group n C1_4alkyl and C1_6alkyl are as
defined herein. Examples of such groups include methoxy, ethoxy, propoxy, butoxy, and
the like.
The term ‘C1_4alkoxyC1_4alkyl’ or ‘C1_6alkoxyC1_6alkyl’ as used herein as a group or part of
a group refers to a C1_4alkyl—O-C1-4alkyl group or a C1_6alkyl—O-C1_6alkyl group wherein
C1_4alkyland C1-6alkyl are as defined herein. Examples of such groups include
methoxyethyl, ethoxyethyl, propoxymethyl, butoxypropyl, and the like.
The term ‘Cg-gcycloalkyl’ as used herein refers to a saturated clic hydrocarbon
ring of 3 to 8 carbon atoms. es of such groups include cyclopropyl, cyclobutyl,
cyclopentyl, cyclohexyl, cycloheptyl or cyclooctyl and the like.
The term ‘C3-gcycloalkenyl’ as used herein refers to a monocyclic hydrocarbon ring of 3
to 8 carbon atoms having a carbon carbon double bond.
The term xyC1_4alkyl’ or ‘hydroxyC1_5alkyl’ as used herein as a group or part of a
group refers to a C1-4alkyl or C1_6alkyl group as defined herein wherein one or more than
one hydrogen atom is replaced with a hydroxyl group. The terms ‘hydroxyC1_4alkyl’ or
‘hydroxyC1_6alkyl’ therefore include monohydroxyC1-4alkyl, monohydroxyC1.6alkyl and
also polyhydroxyC1_4alkyl and polyhydroxyC1_6alkyl. There may be one, two, three or
more hydrogen atoms replaced with a hydroxyl group, so the hydroxyC1.4alkyl or
hydroxyC1_6a|kyl may have one, two, three or more hydroxyl groups. Examples of such
groups include hydroxymethyl, hydroxyethyl, hydroxypropyl and the like.
The term ‘haloC1-4alkyl’ or ‘haloC1_6alkyl’ as used herein as a group or part of a group
refers to a C1_4alkyl or Cmalkyl group as defined herein wherein one or more than one
hydrogen atom is replaced with a halogen. The term ‘haloC1-4alkyl’ or 1_5alkyl'
therefore include monohaloC1-4alkyl, loC1_6alkyl and also polyhaloCMalkyl and
polyhaloC1.6alkyl. There may be one, two, three or more hydrogen atoms ed with
a halogen, so the haloCMalkyl or haloC1_6alkyl may have one, two, three or more
halogens. Examples of such groups include fluoroethyl, fluoromethyl, trifluoromethyl or
trifluoroethyl and the like.
The term ‘hydroxyhaloC1_4alkyl’ or ‘hydroxyhaloC1_5alkyl’ as used herein as a group or
part of a group refers to a C1_4alkyl or C1-5alkyl group as d herein n one or
more than one hydrogen atom is replaced with a hydroxyl group and one or more than
one hydrogen atom is replaced with a halogen. The term ‘hydroxyhaloC1_4alkyl’ or
‘hydroxyhaloC1-6alkyl’ therefore refers to a C1_4alkyl or C1_6alkyl group wherein one, two,
three or more hydrogen atoms are ed with a hydroxyl group and one, two, three or
more hydrogen atoms are replaced with a halogen.
The term ‘hydroxyC1_4a|koxy’ or ‘hydroxyC1_5alkoxy’ as used herein as a group or part of
a group refers to an ——O-C1_4a|kyl group or an —O-C1_6alkyl group wherein the C1_4alkyl
and C1_5alkyl group is as defined above and one or more than one hydrogen atom of the
C1_4a|kyl or C1_6alky| group is replaced with a hydroxyl group. The term ‘hydroxyC1_
4alkoxy’ or ‘hydroxyC1_5a|koxy’ therefore include monohydroxyC1-4alkoxy,
monohydroxyC1_6alkoxy and also polyhydroxyC1-4alkoxy and polyhydroxyC1_6alkoxy.
There may be one, two, three or more en atoms replaced with a hydroxyl group
so the hydroxyC1-4alkoxy or hydroxyCHsalkoxy may have one, two, three or more
hydroxyl . Examples of such groups include hydroxymethoxy, hydroxyethoxy,
hydroxypropoxy and the like.
The term ‘haloC1_4alkoxy’ or ‘haloC1-6alkoxy’ as used herein as a group or part of a group
refers to a —O-C1-4alkyl group or a —O-C1_6 alkyl group as d herein wherein one or
more than one hydrogen atom is replaced with a halogen. The terms ‘haloC1_4alkoxy’ or
‘haloC1_6a|koxy’ therefore include monohaloC1_4alkoxy, monohaloC1_6alkoxy and also
polyhaloC1_4alkoxy and polyhaloC1_6alkoxy. There may be one, two, three or more
hydrogen atoms replaced with a halogen, so the haloC1_4alkoxy or haloC1_6alkoxy may
have one, two, three or more halogens. Examples of such groups include fluoroethyloxy,
difluoromethoxy or trifluoromethoxy and the like.
The term ‘hydroxyhaloC1-4alkoxy’ as used herein as a group or part of a group refers to
an —O-C1.4alky| group wherein the kyl group is as defined herein and wherein one
or more than one hydrogen atom is replaced with a hydroxyl group and one or more
than one hydrogen atom is replaced with a halogen. The term ‘hydroxyhaloC1_4alkoxy’
therefore refers to a —O—C1_4alkyl group n one, two, three or more hydrogen atoms
are replaced with a hydroxyl group and one, two, three or more hydrogen atoms are
ed with a n.
The term ‘haloC1_4a|koxyC1-4alkyl’ as used herein as a group or part of a group refers to
a C1-4alkyl—O-C1_4alkyl group n C1-4alkyl is as defined herein and wherein in one or
both of the C1_4alky| groups one or more than one hydrogen atom is replaced with a
halogen. The term ‘haloCM CMalkyl’ therefore refers to a C1.4a|ky|—O-C1_4alkyl
group wherein in one or both of the kyl groups one, two, three or more hydrogen
atoms are replaced with a halogen and wherein 01-4 alkyl is as defined herein.
ably, in one of the C1-4alkyl groups one or more than one hydrogen atom is
ed with a halogen. Preferably, haloC1_4alkoxyC1-4alkyl means C1_4alkyl substituted
with haloC1-4alkoxy.
The term ‘hydroxyhaloC1_4alkoxyC1-4alkyl’ as used herein refers to a kyl—O-C1-4alkyl
group wherein C1.4alkyl is as defined herein and wherein in one or both of the C1_4alkyl
groups one or more than one hydrogen atom is replaced with a hydroxyl group and one
or more than one hydrogen atom is replaced with a halogen. The terms ‘hydroxyhaloC1_
yC1_4alkyl’ therefore refers to a C1.4alkyl—O-C1_4alkyl group wherein in one or both
of the C1-4alkyl groups one, two, three or more hydrogen atoms are replaced with a
hydroxyl group and one, two, three or more hydrogen atoms are replaced with a halogen
and wherein C1-4alkyl is as defined herein.
The term ‘hydroxyCZ-6alkenyl’ as used herein refers to a C2-6alkenyl group wherein one
or more than one hydrogen atom is ed with a hydroxyl group and wherein C2-
salkenyl is as defined herein.
The term ‘hydroxy02_6alkynyl' as used herein refers to a Czfialkynyl group wherein one
or more than one hydrogen atom is replaced with a hydroxyl group and wherein CZ-
ealkynyl is as defined herein.
The term phenle1-5alkyl as used herein refers to a C1-6alkyl group as defined herein
which is substituted with one phenyl group.
The term cyanoC1-4alkyl or cyanoC1.ealkyl as used herein refers to a C1_4alkyl or C1_6alkyl
group as defined herein which is substituted with one cyano group.
The term “heterocyclyl” as used herein shall, unless the context indicates othenNise,
include both aromatic and non-aromatic ring systems. Thus, for example, the term
“heterocyclyl group” includes within its scope aromatic, omatic, rated,
partially saturated and fully saturated cyclyl ring systems. In general, unless the
context indicates otherwise, such groups may be clic or bicyclic and may
n, for example, 3 to 12 ring members, more usually 5 to 10 ring members.
Reference to 4 to 7 ring members include 4, 5, 6 or 7 atoms in the ring and reference to
4 to 6 ring members e 4, 5, or 6 atoms in the ring. es of monocyclic groups
are groups containing 3, 4, 5, 6, 7 and 8 ring members, more usually 3 to 7, and
ably 5, 6 or 7 ring members, more preferably 5 or 6 ring members. Examples of
bicyclic groups are those containing 8, 9, 10, 11 and 12 ring members, and more usually
9 or 10 ring members. Where reference is made herein to heterocyclyl groups, the
heterocyclyl ring can, unless the context indicates othen/vise, be optionally substituted
(i.e. unsubstituted or substituted) by one or more substituents as discussed herein.
The heterocyclyl groups can be heteroaryl groups having from 5 to 12 ring members,
more usually from 5 to 10 ring members. The term “heteroaryl” is used herein to denote
a heterocyclyl group having aromatic character. The term “heteroaryl” embraces
polycyclic (e.g. bicyclic) ring systems n one or more rings are non-aromatic,
provided that at least one ring is aromatic. in such polycyclic s, the group may
be attached by the ic ring, or by a non-aromatic ring.
Examples of heteroaryl groups are monocyclic and bicyclic groups containing from five
to twelve ring members, and more usually from five to ten ring members. The aryl
group can be, for example, a five membered or six membered monocyclic ring or a
bicyclic structure formed from fused five and six membered rings or two fused six
membered rings, or two fused five membered rings. Each ring may contain up to about
five heteroatoms typically ed from nitrogen, sulphur and oxygen. Typically the
heteroaryl ring will contain up to 4 heteroatoms, more typically up to 3 heteroatoms,
more y up to 2, for example a single heteroatom. in one embodiment, the
heteroaryl ring contains at least one ring nitrogen atom. The nitrogen atoms in the
heteroaryl rings can be basic, as in the case of an imidazole or pyridine, or essentially
non—basic as in the case of an indole or pyrrole nitrogen. In general the number of basic
nitrogen atoms present in the heteroaryl group, including any amino group substituents
of the ring, will be less than five.
Examples of five membered heteroaryl groups e but are not limited to pyrrole,
furan, thiophene, imidazole, furazan, oxazole, oxadiazole, azole, isoxazole,
le, thiadiazole, isothiazole, pyrazole, triazole and tetrazole groups.
Examples of six membered aryl groups include but are not limited to pyridine,
pyrazine, pyridazine, pyrimidine and ne.
A bicyclic heteroaryl group may be, for e, a group selected from:
a) a benzene ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring
heteroatoms;
b) a pyridine ring fused to a 5- or 6—membered ring containing 0, 1, 2 or 3 ring
heteroatoms;
C) a pyrimidine ring fused to a 5— or 6—membered ring containing 0, 1 or 2 ring
heteroatoms;
d) a pyrrole ring fused to a 5- or 6-membered ring containing 0, 1, 2 or 3 ring
atoms;
e) a pyrazole ring fused to a 5- or 6—membered ring containing 0, 1 or 2 ring
heteroatoms;
f) an imidazole ring fused to a 5- or ered ring containing 0, 1 or 2 ring
heteroatoms;
9) an oxazoie ring fused to a 5- or 6—membered ring containing 0, 1 or 2 ring
heteroatoms;
h) an isoxazoie ring fused to a 5- or 6—membered ring ning 0, 1 or 2 ring
heteroatoms;
i) a thiazole ring fused to a 5- or 6—membered ring containing 0, 1 or 2 ring
heteroatoms;
l) an isothiazole ring fused to a 5- or 6-membered ring containing 0, 1 or 2 ring
heteroatoms;
k) a thiophene ring fused to a 5- or 6—membered ring ning 0, 1, 2 or 3 ring
heteroatoms;
l) a furan ring fused to a 5- or 6-membered ring containing 0, 1, 2 or 3 ring
heteroatoms;
m) a cyclohexyl ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring
heteroatoms; and
a cyciopentyl ring fused to a 5- or 6-membered ring containing 1, 2 or 3 ring
heteroatoms.
Particular examples of bicyclic heteroaryl groups containing a five membered ring fused
to another five membered ring include but are not limited to imidazothiazole (e.g.
imidazo[2,1—b]thiazole) and oimidazole (e.g. imidazo[1,2—a]imidazole).
ular examples of bicyclic heteroaryl groups ning a six membered ring fused
to a five membered ring e but are not limited to benzofuran, hiophene,
benzimidazole, benzoxazole, isobenzoxazole, benzisoxazole, iazole,
benzisothiazole, isobenzofuran, indole, isoindole, indolizine, indoline, isoindoline, purine
(e.g., e, guanine), le, pyrazolopyrimidine (e.g. pyrazolo[1,5-a]pyrimidine),
triazolopyrimidine (e.g. [1,2,4]triazolo[1,5-a]pyrimidine), benzodioxole, imidazopyridine
and pyrazolopyridine (e.g. pyrazolo[1,5-a]pyridine) groups.
Particular examples of bicyclic heteroaryl groups containing two fused six membered
rings include but are not limited to quinoline, isoquinoline, chroman, roman,
chromene, isochromene, chroman, isochroman, benzodioxan, quinolizine, benzoxazine,
benzodiazine, pyridopyridine, quinoxaline, quinazoline, cinnoline, phthalazine,
naphthyridine and pteridine groups.
Examples of polycyclic heteroaryl groups containing an aromatic ring and a non-
aromatic ring include, tetrahydroisoquinoline, ydroquinoline, dihydrobenzthiene,
dihydrobenzfuran, 2,3-dihydro-benzo[1,4]dioxine, benzo[1,3]dioxole, -
tetrahydrobenzofuran, tetrahydrotriazolopyrazine (e.g. 5,6,7,8—tetrahydro—
[1 ,2,4]triazolo[4,3-a]pyrazine), indoline and indane groups.
A nitrogen-containing heteroaryl ring must contain at least one ring nitrogen atom. Each
ring may, in addition, contain up to about four other atoms lly selected from
nitrogen, sulphur and oxygen. Typically the heteroaryl ring will contain up to 3
heteroatoms, for example 1, 2 or 3, more usually up to 2 nitrogens, for example a single
nitrogen. The nitrogen atoms in the heteroaryl rings can be basic, as in the case of an
imidazole or pyridine, or essentially non-basic as in the case of an indole or pyrrole
nitrogen. in general the number of basic nitrogen atoms present in the heteroaryl group,
including any amino group substituents of the ring, will be less than five.
WO 61080
Examples of nitrogen-containing heteroaryl groups include, but are not limited to, pyridyl,
pyrrolyl, imidazolyl, yl, oxadiazolyl, thiadiazolyl, oxatriazolyl, isoxazolyl, thiazolyl,
isothiazolyl, furazanyl, pyrazolyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazinyl, triazolyl
(e.g., 1,2,3-triazolyl, 1,2,4-triazolyl), tetrazolyl, quinolinyl, isoquinolinyl, benzimidazolyl,
benzoxazolyl, benzisoxazole, benzthiazolyl and benzisothiazole, indolyl, 3H-indolyl,
isoindolyl, indolizinyl, isoindolinyl, l (e.g., adenine [6-aminopurine], guanine [2-
amino-6—hydroxypurinel), indazolyl, quinolizinyl, benzoxazinyl, benzodiazinyl,
pyridopyridinyl, quinoxalinyl, quinazolinyl, cinnollnyl, phthalazinyl, naphthyridinyl and
pteridinyl.
Examples of nitrogen-containing polycyclic heteroaryl groups containing an aromatic
ring and a non-aromatic ring include tetrahydroisoquinolinyl, tetrahydroquinolinyl, and
indolinyl.
The term “non-aromatic group” embraces, unless the context indicates othen/vise,
unsaturated ring systems without aromatic character, partially saturated and fully
saturated heterocyclyl ring systems. The terms “unsaturated” and “partially saturated”
refer to rings wherein the ring structure(s) contains atoms sharing more than one
valence bond i.e. the ring ns at least one multiple bond e.g. a C=C, CsC or N=C
bond. The term “fully saturated” refers to rings where there are no multiple bonds
between ring atoms. ted heterocyclyl groups include piperidine, morpholine,
thiomorpholine, piperazine. Partially saturated heterocyclyl groups include pyrazolines,
for example 2—pyrazoline and 3-pyrazoline.
Examples of non-aromatic heterocyclyl groups are groups having from 3 to 12 ring
members, more usually 5 to 10 ring members. Such groups can be clic or
ic, for example, and typically have from 1 to 5 heteroatom ring s (more
usually 1, 2, 3 or 4 heteroatom ring members), usually selected from nitrogen, oxygen
and r. The heterocyclyl groups can contain, for example, cyclic ether moieties
(e.g. as in ydrofuran and dloxane), cyclic thioether moieties (e.g. as in
tetrahydrothiophene and dithiane), cyclic amine moieties (e.g. as in pyrrolidlne), cyclic
amide moieties (e.g. as in pyrrolidone), cyclic thioamides, cyclic thioesters, cyclic ureas
(e.g. as in olidin-Z-one) cyclic ester moieties (e.g. as in butyrolactone), cyclic
sulphones (e.g. as in sulpholane and sulpholene), cyclic sulphoxides, cyclic
sulphonamides and combinations thereof (e.g. thiomorpholine).
Particular examples e morpholine, dine (e.g. 1-piperidinyl, 2-piperidinyl, 3—
piperidinyl and 4-piperidinyl), done, pyrrolidine (e.g. 1—pyrrolidinyl, 2—pyrrolidinyl
and 3—pyrrolidinyl), pyrrolidone, azetidine, pyran (2H-pyran or 4H-pyran),
dihydrothiophene, dihydropyran, dihydrofuran, dihydrothiazole, tetrahydrofuran,
tetrahydrothiophene, dioxane, tetrahydropyran (e.g. 4-tetrahydro pyranyl), imidazoline,
imidazolidinone, oxazoline, thiazoline, 2—pyrazoline, pyrazolidine, piperazone,
piperazine, and N-alkyl piperazines such as N-methyl piperazine. In general, preferred
non-aromatic heterocyclyl groups include saturated groups such as piperidine,
pyrrolidine, azetidine, morpholine, piperazine and N-alkyl piperazines.
In a nitrogen—containing non-aromatic cyclyl ring the ring must contain at least one
ring nitrogen atom. The heterocylic groups can contain, for example cyclic amine
moieties (e.g. as in idine), cyclic amides (such as a pyrrolidinone, piperidone or
caprolactam), cyclic sulphonamides (such as an isothiazolidine 1,1-dioxide,
[1 ,2]thiazinane 1,1—dioxide or [1,2]thiazepane oxide) and ations thereof.
Particular examples of nitrogen-containing non-aromatic heterocyclyl groups include
aziridine, morpholine, thiomorpholine, dine (e.g. 1-piperidinyl, 2—piperidinyl, 3-
piperidinyl and 4-piperidinyl), pyrrolidine (e.g. 1-pyrrolidinyl, 2-pyrrolidinyl and 3-
pyrrolidinyl), pyrrolidone, dihydrothiazole, imidazoline, imidazolidinone, ine,
thiazoline, 6H—1,2,5-thiadiazine, 2-pyrazoline, 3-pyrazoline, pyrazolidine, piperazine, and
N-alkyl piperazines such as N-methyl piperazine.
The cyclyl groups can be clic fused ring systems or bridged ring systems
such as the oxa- and aza analogues of bicycloalkanes, tricycloalkanes (e.g.
adamantane and oxa-adamantane). For an explanation of the distinction between fused
and bridged ring systems, see Advanced Organic Chemistry, by Jerry March, 4th Edition,
Wiley cience, pages 3, 1992.
The heterocyclyl groups can each be unsubstituted or substituted by one or more
substituent groups. For example, heterocyclyl groups can be unsubstituted or
substituted by 1, 2, 3 or 4 substituents. Where the heterocyclyl group is monocyclic or
bicyclic, typically it is tituted or has 1, 2 or 3 substituents.
The term “carbocyclyl” as used herein shall, unless the context indicates othen/vise,
include both ic and non-aromatic ring systems. Thus, for example, the term
cyclyl group” includes within its scope aromatic, non-aromatic, unsaturated,
partially saturated and fully saturated yclyl ring systems. in general, unless the
context indicates othenNise, such groups may be clic or bicyclic and may
contain, for example, 3 to 12 ring members, more usually 5 to 10 ring members.
Reference to 4 to 7 ring members include 4, 5, 6 or 7 atoms in the ring and reference to
4 to 6 ring s include 4, 5, or 6 atoms in the ring. Examples of monocyclic groups
are groups containing 3, 4, 5, 6, 7 and 8 ring members, more usually 3 to 7,
preferably 5, 6 or 7 ring members, more preferably 5 or 6 ring members. Examples of
bicyclic groups are those containing 8, 9, 10, 11 and 12 ring s, and more usually
9 or 10 ring s. Where reference is made herein to carbocyclyl groups, the
carbocyclyl ring can, unless the context indicates othenNise, be optionally substituted
(i.e. unsubstituted or substituted) by one or more substituents as discussed herein.
The term carbocyclyl comprises aryl, C3_gcycloalkyl, C3_gcycloalkenyl.
The term aryl as used herein refers to carbocyclyl aromatic groups including phenyl,
naphthyl, l, and tetrahydronaphthyl groups.
Whenever used hereinbefore or hereinafter that substituents can be selected each
independently out of a list of us definitions, all possible combinations are
intended which are chemically possible. er used hereinbefore or hereinafter
that a particular substituent is r substituted with two or more groups, such as for
example hydroxyhaloC1-4alkyl, hydroxyhaloC1_4alkoxy, all possible combinations are
intended which are chemically possible.
In one embodiment, the invention relates to a compound of formula (l-A).
In one embodiment, the invention relates to a compound of formula (l—B).
WO 61080
in one embodiment, Y represents -CR18=N-OR19. In particular wherein R18 and R19
ent kyl.
In one embodiment, Y represents —E—D wherein E represents a bond.
In one embodiment, Y ents a 3 to 12 ring membered monocyclic or bicyclic
carbocyciyl or a 3 to 12 ring membered monocyclic or bicyclic heterocyclyl containing at
least one heteroatom selected from N, O or 8, wherein said carbocyciyl and heterocyclyl
may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
in one embodiment, Y represents a 5 to 12 ring membered monocyclic or bicyclic
yciyl or a 5 to 12 ring membered monocyclic or bicyclic heterocyclyl containing at
least one heteroatom selected from N, O or 8, wherein said carbocyciyl and cyclyl
may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
in one embodiment, Y represents an ic 3 to 12, in particular an ic 5 to 12,
ring membered monocyclic or ic carbocyciyl or an aromatic 3 to 12, in particular an
aromatic 5 to 12, ring membered monocyclic or bicyclic cyclyl containing at least
one heteroatom selected from N, O or 8, n said carbocyciyl and heterocyclyl may
each be optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
In one embodiment, Y represents an aromatic 3 to 12 (e.g. 5 to 10) ring membered
monocyclic or bicyclic carbocyciyl, wherein said carbocyciyl may be optionally
substituted by one or more (e.g. 1, 2 or 3) R1 groups.
In one embodiment, Yrepresents phenyl or naphthyl, wherein said phenyl or naphthyl
may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
in one embodiment, Y represents a 5 to 12 ring membered monocyclic or bicyclic
heterocyclyl containing at least one heteroatom selected from N, O or 8, wherein said
heterocyclyl may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1
groups.
WO 61080
In one embodiment, Yrepresents an aromatic 5 to 12 ring membered monocyclic
heterocyclyl containing at least one heteroatom selected from N, O or 8, wherein said
heterocyclyl group may each be ally tuted by one or more (e.g. 1, 2 or 3) R1
groups.
In one embodiment, Y represents a 5 or 6 ring membered monocyclic heterocyclyl
containing at least one heteroatom selected from N, O or 8, wherein said heterocyclyl
may each be optionally tuted by one or more (e.g. 1, 2 or 3) R1 groups.
in one embodiment, Y represents an aromatic 5 or 6 ring membered monocyclic
heterocyclyl ning at least one heteroatom selected from N, O or 8, wherein said
heterocyclyl may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1
groups.
in one embodiment, Yrepresents a 5 ring membered monocyclic heterocyclyl containing
at least one heteroatom selected from N, O or S, wherein said heterocyclyl may each be
optionally substituted by one or more (e.g. 1, 2 or 3) R1 .
In one ment, Y represents a 5 ring membered monocyclic aromatic heterocyclyl
containing at least one heteroatom selected from N, O or 8, n said heterocyclyl
may each be ally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
in one embodiment, Y represents pyrazolyl (e.g. pyrazol-4yl), wherein said pyrazolyl
may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
In one embodiment, Y represents a 6 ring membered monocyclic heterocyclyl containing
at least one heteroatom selected from N, O or 8, wherein said heterocyclyl may each be
optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
In one embodiment, Y represents a 6 ring membered monocyclic aromatic heterocyclyl
containing at least one heteroatom selected from N, O or 8, wherein said cyclyl
may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
In one embodiment, Yrepresents a 12 ring membered bicyclic heterocyclyi containing at
least one heteroatom selected from N, O or 8, wherein said heterocyclyi may each be
optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
In one embodiment, Yrepresents a 12 ring membered bicyclic ic cyclyi
containing at least one heteroatom selected from N, O or 8, wherein said heterocyclyl
may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups.
Rla /
l \N
in one embodiment Y represents R121 wherein R1 represents hydrogen, C1-
salkyl, Cz_4alkenyl, hydroxyC1_6alkyl, haloC1_6alkyl, hydroxyhaloC1_6alkyl, cyanoC1_4alkyl,
C1_6alkoxyC1_6alkyl wherein each 01-6alkyl may optionally be substituted with one or two
hydroxyl groups, C1-6alkyl substituted with -NR4R5, kyl substituted with —C(=O)—
NR4R5, 2-C1_6alkyl, —S(=O)2—haloC1_5alkyl, —S(=O)2—NR14R15, 01-6alkyl substituted
with -S(=O)2-C1_6alkyl, Ctaalkyl substituted with -S(=O)2-haloC1_6alkyl, C1_6alkyl
substituted with 2-NR‘4R15, kyl substituted with —NH—S(=O)2-C1_6alkyl, c1.
Balkyl substituted with -NH-S(=O)2—haloC1_6alkyl, C1_6alkyl substituted with —NR12-S(=O)2-
NR14R‘5, R6, 01.6alkyl substituted with R6, c,_6aikyi tuted with —C(=O)—R6,
hydroxyC1_5alkyl substituted with R6, C1_6alkyl substituted with —Si(CH3)3, C1_6alkyl
substituted with (OH)2 or C1_galkyl substituted with -P(=O)(OC1_6alkyl)2; and each
R1&1 is independently selected from hydrogen, C1-4alkyl, yC1-4alkyl, C1_4alkyl
tuted with amino or mono- or di(C1.4alkyl)amino or -NH(Cg-8cycloalkyl), cyanoC1_
4alkyl, C1-4alkoxyC1_4alkyl, and C1_4alkyl substituted with one or more fluoro atoms. In
one ment, R” is independently selected from hydrogen and C1_4alkyl. In one
embodiment, R”1 is hydrogen.
In one ment, Y represents /\/ wherein R1 represents hydrogen, C1-
6aIkyI, C2_4aIkenyl, hydroxyC1_6aIkyI, _6alkyI, hydroxyhanC1_6alkyI, C1_6alkoxyCi_
5aIkyI wherein each Ci_6alkyl may optionally be substituted with one or two hydroxyl
groups, yi substituted with , C1_6alky| substituted with —C(=O)—NR4R5, —
S(=O)2-C1_6alkyl, —S(=O)2-haloC1_6alkyI, —S(=O)2-NR14R15, kyI substituted with -
S(=O)2-Ci_6alkyi, C1-6alkyl substituted with -S(=O)2-haloC1-5alkyI, C1-5aIkyI substituted
with —S(=O)2-NR14R15, kyi substituted with —NH-S(=O)2-Ci_salkyl, c,_6aikyi
substituted with —NH-S(=O)2-hanC1.6alkyl, c,_6aikyi substituted with —NR12-S(=O)2-
NR14R15, R6, C1_6aIkyI substituted with R6, Ci.6a|kyI substituted with -R6,
yCHgalkyI substituted with R6, Cideaikyl substituted with -Si(CH3)3, Cmalkyl
substituted with -P(=O)(OH)2 or C1_6alkyI substituted with -P(=O)(OCi-6alkyI)2.
In one embodiment, E represents a bond, Cz_4alkenediyl optionaIIy substituted with R22, -
CO-(CR22R23)s-, —(CR22R23)s-CO-, -NR22-(CR22R23 -(CR22R23)s-NR22-, -O—(CR22R23)s-, —
(CR22R23)3-CO-NRZZ-(CR22R23)S- or —(CR22R23)s-NRZZ-CO-(CR22R23)S-.
In one embodiment, E represents a bond, 02,4alkenediyl, -CO-(CR22R23)s-, -(CR22R23)S-
00-, -NR22-(CR22R23)S-, -(CR22R23)S-NR22-, —(CR22R23)s—CO—NR22-(CR22R23)S— or —
(CR22R23)s-NRZZ-CO-(CR22R23)S-.
In one embodiment, E represents 02-4aIkenedin, -CO-(CR22R23)S-, -(CR22R23)s—CO-, -
NR22'(CR22R23)5', R23)S'NR22', —(CR22R23)3‘CO'NR22'(CR22R23)S' or _(CR22R23)S_
NR22-CO-(CR22R23)S-.
In one embodiment, E represents a bond.
In one embodiment, Y ents —E—D, wherein E is other than a bond.
In one embodiment, Y represents —E-D, wherein E is other than a bond and D
represents any one of the following :
- a 3 to 12 ring membered monocycIic or bicycIic carbocyclyi or a 3 to 12 ring ed
monocycIic or bicyclic heterocycIyI containing at least one heteroatom selected from N,
O or 8, wherein said carbocyclyl and heterocyclyl may each be optionally substituted by
one or more (e.g. 1, 2 or 3) R1 groups;
- a 5 to 12 ring membered monocyclic or ic carbocyclyl or a 5 to 12 ring membered
monocyclic or bicyclic heterocyclyl containing at least one heteroatom ed from N,
O or 8, wherein said carbocyclyl and heterocyclyl may each be optionally substituted by
one or more (e.g. 1, 2 or 3) R1 groups;
- phenyl or naphthyl, wherein said phenyl or naphthyl may each be optionally substituted
by one or more (e.g. 1, 2 or 3) R1 groups;
- a 5 to 12 ring membered monocyclic or bicyclic cyclyl containing at least one
atom selected from N, O or 8, wherein said heterocyclyl may each be optionally
substituted by one or more (e.g. 1, 2 or 3) R1 groups;
- a 5 or 6 ring membered monocyclic heterocyclyl containing at least one heteroatom
selected from N, O or 8, wherein said heterocyclyl may each be ally substituted by
one or more (e.g. 1, 2 or 3) R1 groups;
- a 5 ring membered monocyclic heterocyclyl ning at least one heteroatom
selected from N, O or 8, wherein said heterocyclyl may each be optionally substituted by
one or more (e.g. 1, 2 or 3) R1 ;
- a 5 ring membered monocyclic aromatic heterocyclyl containing at least one
heteroatom selected from N, O or 8, wherein said heterocyclyl group may each be
optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups;
- a 6 ring membered monocyclic heterocyclyl containing at least one heteroatom
selected from N, O or 8, wherein said cyclyl may each be optionally substituted by
one or more (e.g. 1, 2 or 3) R1 groups;
- a 6 ring membered monocyclic aromatic heterocyclyl containing at least one
heteroatom selected from N, O or 8, wherein said heterocyclyl may each be optionally
substituted by one or more (e.g. 1, 2 or 3) R1 groups;
- a 12 ring membered bicyclic heterocyclyl containing at least one heteroatom selected
from N, O or 8, wherein said cyclyl may each be optionally substituted by one or
more (e.g. 1, 2 or 3) R1 groups;
- a 12 ring membered bicyclic aromatic heterocyclyl ning at least one heteroatom
selected from N, O or 8, wherein said heterocyclyl may each be optionally tuted by
one or more (e.g. 1, 2 or 3) R1 groups;
- Rla wherein R1 ents hydrogen, Ct-6alkyl, C2_4alkenyl, hydroxyC1_6alkyl,
haloCt_6alkyl, hydroxyhaloC1_6alkyl, cyanoCMalkyl, C1_6alkoxth_5alkyl wherein each C1.
6alkyl may optionally be substituted with one or two hydroxyl groups, C1_6alkyl
substituted with -NR4R5, Ctsalkyl substituted with —C(=O)-NR4R5, 2-C1.6alkyl, —
S(=O)2-haloC1_6alkyl,—S(=O)2-NR14R15, C1_6alkyl substituted with -S(=O)2-Ct_5alkyl, o1.
Galkyl tuted with -S(=O)2-haloC1-5alkyl, l substituted with 2-NR14R15,
C1_6alkyl substituted with —NH-S(=O)2—C1_6alkyl, Cmalkyl tuted with —NH-S(=O)2-
haloC1_6alkyl, C1.6alkyl substituted with —NR12—S(=O)2—NR14R15, R6, C1.6alkyl substituted
with R6, Ctsalkyl substituted with —C(=O)—R6, hydroxyC1_6alkyl substituted with R6, C1-
Galkyl substituted with —Si(CH3)3, C1_5alkyl substituted with -P(=O)(OH)2 or C1_6alkyl
substituted with -P(=O)(OC1-6alkyl)2; and each R1&1 is independently selected from
hydrogen, C1.4alkyl, hydroxyC1_4alkyl, Ct_4alkyl substituted with amino or mono- or di(C1_
4alkyl)amino or -NH(Cg-8cycloalkyl), 1_4alkyl, C1_4alkoxth-4alkyl, and C1_4alkyl
substituted with one or more fluoro atoms;
- L/Nwherein R1 represents hydrogen, C1_6alkyl, C2-4alkenyl, hydroxyC1-6alkyl,
haloC1-5alkyl, hydroxyhaloC1-6alkyl, Ct_6alkoxyC1_5alkyl wherein each C1_6alkyl may
optionally be substituted with one or two yl groups, Ctealkyl substituted with
-NR4R5, kyl tuted with —C(=O)-NR4R5, -S(=O)2-C1.6alkyl, —S(=O)2-haloC1_
ealkyl, —S(=0)2-NR‘4R‘5, C1-6alkyl substituted with -S(=O)2-Ct.6alkyl, 01.6alkyl substituted
with -S(=O)2-haloC1_6alkyl, 01.6alkyl substituted with —S(=O)2—NR14R15, C1_5alkyl
tuted with —NH-S(=O)2-C1_5alkyl, C1_5alkyl substituted with —NH-S(=O)2—haloct_
, C1_6alkyl substituted with —NR12-S(=O)2—NR14R15, R6, C1-6alkyl substituted with R6,
C1_6alkyl substituted with —C(=O)—R6, hydroxth_6alkyl substituted with R6, C1-5alkyl
substituted with —Si(CH3)3, C1-6alkyl tuted with -P(=O)(OH)2 or Ctsalkyl substituted
with -P(=O)(OCt.6alkyl)2.
2012/052672
In one embodiment, D is other than pyrazolyl, in particular D is piperidinyl, nyl,
phenyl, pyrolyl, imidazolyl, triazolyl, pyrolopyridinyl, 1,3—benzodioxolyl, l, thiazolyl,
cyclopentyl, azetidinyl, morpholinyl, tetrazolyl, oxazolyl, piperazinyl, 1,2,3,6-
tetrahydropyridinyl, 2,5-dihydropyrolyl, pyrimidinyl, dinyl, thiadiazolyl, oxadiazolyl,
said rings being optionally substituted. Said optional tuents may represent halo,
cyano, Ctealkyl, C1_6alkoxy, -C(=O)—O-Ci_6alkyl, hydroxyC1.5alkyl, -NR4R5, C1_5alkyl
substituted with —O—C(=O)— Cmalkyl, C1_6alkyl substituted with -NR4R5,—C(=O)-NR4R5, —
C(=O)—C1.6a|kyI-NR4R5, R6, C1_6alkyl substituted with R6.
In one embodiment, E is other than a bond and D is other than lyl, in particular D
is piperidinyl, pyridinyl, , pyrrolyl, imidazolyl, triazolyl, pyrrolopyridinyl, 1,3—
benzodioxolyl, indolyl, thiazolyl, cyclopentyl, azetidinyl, morpholinyl, tetrazolyl, oxazolyl,
zinyl, 1,2,3,6-tetrahydropyridinyl, 2,5-dihydropyrolyl, pyrimidinyl, pyrrolidinyl,
thiadiazolyl, oxadiazolyl, said rings being optionally substituted.
In one embodiment, E is a bond and D is optionally substituted zolyl. In one
embodiment, E is a bond and D is 4-pyrazolyl substituted at the 1 position with C1_6alkyl
for example methyl.
In one embodiment, E is a bond and D is 1—pyrazolyl or 2-pyrazolyl, both may optionally
be substituted.
In one embodiment, E is other than a bond and D is 1-pyrazolyl or 2—pyrazolyl, both may
optionally be substituted.
In one embodiment, E is other than a bond and D is optionally substituted pyrazolyl.
In one embodiment, E is a bond and D is an optionally tuted 6 membered
carbocyclyl or an optionally substituted 5 or 6 membered saturated or aromatic
heterocyclyl, such as for example an ally substituted phenyl, pyrazolyl, pyrrolyl,
nyl, morpholino, piperazinyl or piperidinyl; more in particular D is an optionally
substituted pyrazolyl; even more in particular D is pyrazolyl substituted with kyl.
In one embodiment R1 represents hydrogen, Ci_6alkyl, C2.4alkenyl, hydroxyC1_6alkyl,
haloCmalkyl, hydroxyhaloC1_6alkyl, cyanoC1-4alkyl, C1_6alkoxyC1_6alkyl wherein each Ci-
WO 61080
5alkyl may optionally be substituted with one or two hydroxyl groups, kyl
substituted with -NR4R5, Cmalkyl substituted with —C(=O)—NR4R5, —S(=O)2-C1_6alkyl, —
S(=O)2-haloC1-6alkyl, 2-NR14R15, C1_6alkyl tuted with -S(=O)2-C1.6alkyl, c1-
6alkyl substituted with -S(=O)2-hal001_6alkyl, C1_6alkyl substituted with —S(=0)2-NR‘4R15,
C1_6alkyl substituted with —NH—S(=O)2-C1.6alkyl, C1_6alkyl substituted with —NH-S(=O)2—
haloC1-6alkyl, C1_6alkyl substituted with —NR12-st=0)2-NR‘4R15, R6, C1,6alkyl substituted
with R6, Chgalkyl substituted with —C(=O)—R6, hydroxyC1_5alkyl tuted with Re, C1.
6alkyl substituted with —Si(CH3)3, C1_6alkyl substituted with -P(=O)(OH)2 or C1-6alkyl
substituted with -P(=O)(OC1-6alkyl)2.
In one embodiment R1 represents hydrogen, C1_5alkyl, Cg_4alkenyl, hydroxth-5alkyl,
haloCmalkyl, C1_5alkoxyC1_6alkyl wherein each C1_6alkyl may optionally be substituted
with one or two hydroxyl groups, C1-6alkyl substituted with -NR4R5, C1_5alkyl substituted
with -—C(=O)-NR4R5, —S(=O)2-C1.6alkyl, —S(=0)2-NR14R‘5, Ct.6alkyl substituted with -
—Ct.6alkyl, C1_6alkyl tuted with —NH-S(=O)2-Ct-6alkyl, R6, C1-6alkyl substituted
with R6, C1_5alkyl substituted with —C(=O)—R6, hydroxyC1_5alkyl substituted with R6, or c1-
6alkyl substituted with 3)3.
in one embodiment R1 represents hydrogen.
in one embodiment R1 represents C1-6alkyl, hydroxyC1-5alkyl, hydroxyhaloC1-6alkyl, C1-
yC1.5alkyl wherein each kyl may optionally be substituted with one or two
hydroxyl groups, C1_ealkyl substituted with , Chealkyl substituted with -S(=O)2-C1_
salkyl, R6, C1-5alkyl substituted with R6, more in particular R1 ents C1_6alkyl. in one
embodiment R1 represents methyl.
In one embodiment each R2 is independently selected from hydroxyl, halogen, cyano,
kyl, Cg_4alkenyl, C1_4alkoxy, hydroxyC1_4alkyl, hydroxyC1-4alkoxy. haloC1_4alkyl,
haloCMalkoxy, C1_4alkoxyC1-4alkyl, R13, C1-4alkoxy substituted with R13, -C(=O)-R13, C1-
4aikyi substituted with NR7R8, C1_4alkoxy substituted with NR7R8, -NR7R8 and -C(=O)-
NR7R8; or when two R2 groups are attached to adjacent carbon atoms they may be
taken together to form a radical of formula -O-(C(R17)2)p-O- wherein R17 represents
hydrogen or fluorine and p represents 1 or 2.
In one embodiment each R2 is independently seIected from hydroxyl, halogen, cyano,
kyI, C2_4aIkenyl, C1_4aIkoxy, hydroxyCi_4alkyl, hydroxyC1_4aIkoxy, haloC1_4aIkoxy, Ci-
4alkoxyC1.4aIkyI, R13, C1.4aIkoxy substituted with R13, -C(=O)—R13, Ci_4a|ky| substituted
with NR7R8, Ci_4aIkoxy substituted with NR7R8, —NR7R8 or -C(=O)-NR7R8.
In one embodiment one or more R2 represents Ci_4alkoxy, for exampIe CH30-, halogen,
for example fluoro or chloro, hydroxyI, C1_4alkyl, for example methyl, or —C(=O)—NR7R8,
in particular one or more R2 represents C1_4alkoxy, for example CH30-, or halogen, for
example fluoro.
In one embodiment one or more R2 represents C1_4alkoxy, for example CH30-.
In one embodiment n is equal to O. In one embodiment n is equal to 1. In one
ment n is equal to 2. In one embodiment n is equal to 3. In one embodiment n is
equal to 4.
In one embodiment, n is equal to 2, 3 or 4, in ular n is equal to 3 or 4.
In one embodiment n is equal to 2 and one Rzis present at the tion and the other
is present at the 5-position.
In one ment n is equal to 2 and one R2 is t at the 3-position and the other
is present at the 5-position and each R2 represents C1_4aIkoxy, for example each R2
ents CH30—.
In one embodiment n is equal to 3 and one R2 is present at the 2—position, one R2 is
present at the 3-position and one R2 is present at the 5-position.
In one embodiment n is equal to 3 and one R2 is present at the 3-position and represents
C1_4a|koxy, for example CH30-; one R2 is t at the 5—position and represents C1-
4alkoxy, for example CH30-; one R2 is present at the 2-position and represents hangen,
for e fluoro.
In one embodiment n is equal to 4 and one R2 is t at the 2-position, one R2 is
present at the 3-position, one R2 is present at the 5-position and one R2 is present at the
6—position.
in one embodiment n is equal to 4 and one R2 is present at the 3-position and represents
C1_4alkoxy, for example CH30-; one Rzis present at the 5-position and represents Ci-
4alkoxy, for example CH30-; one R2 is present at the 2-position and represents halogen,
for example fluoro, and one R2 is t at the 6-position and represents halogen, for
example fluoro.
In one embodiment, R3 represents C1-6alkyl, hydroxyC1_6alkyl, hydroxyhaloC1-6alkyl,
hydroxyC2_6alkynyl, haloC1_6alkyl, haloCt_6alkyl optionally substituted (e.g. substituted)
with —O-C(=O)—C1.6alkyl, Ci_5alkyl substituted with )—C1_6alkyl, C1_6alkoxyC1-5alkyl
wherein each Cmalkyl may optionally be substituted with one or two hydroxyl groups,
C1_5alkoxyC1V6alkyl wherein each Cmalkyl may optionally be tuted with one or two
hydroxyl groups or with —O-C(=O)—C1_5alkyl, C1_6alkyl substituted with R9, C1-6alkyl
tuted with -NR‘°R“, C1.6alkyl substituted with hydroxyl and -NR1°R“, ci_5aikyi
substituted with one or two halogens and “, Ct-6alkyl substituted with —C(=O)-O—
C1_salkyl, C1-6alkyl substituted with —C(=O)-NR1°R“, C1_6alkyl substituted with carboxyl,
C1_6alkyl tuted with —O-C(=O)-NR1°R“, C1_5alkyl substituted with —NR12-S(=O)2-C1-
salkyl, Cmalkyl substituted with S(=0)2-NR14R15, C1.6alkyl substituted with R9 and
ally substituted with —O-C(=O)—C1_5alkyl, C1-6alkyl substituted with hydroxyl and R9,
-C1_5alkyl-C(R12)=N-O-R12, —S(=O)2-NR14R15, 01.5alkyl tuted with —S(=O)2—C1.6alkyl,
Cisalkyl substituted with —C(=O)-NR1°R“, C1.6alkyl substituted with —C(=O)—R9, cg.
salkenyl substituted with -5alkynyl substituted with R9, hydroxyC1_5alkoxy, CZBalkenyl
, kynyl, R13, C1_6alkyl substituted with C1.5alkoxyC1-6alkyl-C(=O)— or c1.
salkyl substituted with -P(=O)(OC1_6alkyl)2.
In one embodiment R3 represents Ct.6alkyl, hydroxyC1.6alkyl, hydroxyhaloC1_5alkyl,
haloC1_6alkyl, C1-6alkyl tuted with —C(=O)—C1_6alkyl, C1-6alkoxyC1-5alkyl wherein
each C1.6alkyl may optionally be substituted with one or two yl groups, C1_5alkyl
substituted with R9, C1.6alkyl substituted with -NR‘°R“, C1_6alkyl substituted with
hydroxyl and -NR1°R“, 01.6alkyl substituted with one or two halogens and -NR1°R“' C1-
salkyl tuted with —C(=O)-O-C1_ealkyl, kyl substituted with —C(=O)-NR1°R“, oi-
2012/052672
salkyl substituted with carboxyl, C1.6alkyl substituted with —O-C(=O)-NR1°R“, c,_6aikyi
tuted with —NR12-S(=O)2-C1_6alkyl, C1.6alkyl substituted with —NR12-S(=O)2-NR14R15,
Cmalkyl substituted with hydroxyl and R9, —01.ealkyl-C(R12)=N-O—R12, c,_6aikyi
substituted with —C(=O)—NR1°R“, Chealkyl substituted with —C(=O)-R9, C2_6alkynyl
substituted with R9, hydroxyC1_6alkoxy, C2_6alkenyl, C2-6alkynyl, R13 or Chsalkyl
substituted with C1-6alkoxy01.6alkyl—C(=O)—.
in one embodiment R3 represents 01.6alkyl, hydroxyC1_6alkyl, haloC1_6alkyl, haloCt-6alkyl
optionally tuted with —-O-C(=O)—C1_6alkyl, hydroxyhaloC1-5alkyl, hydroxyCz_6alkynyl,
C1.6alkyl substituted with —C(=O)-Ct_6alkyl, C1_6alkoxyC1-6alkyl wherein each Cmalkyl
may optionally be tuted with one or two hydroxyl groups or with —O-C(=O)—C1_
6eikyi, C1-6alkyl substituted with R9, cyanoC1.6alkyl, kyl substituted with -NR1°R“,
C1_6alkyl substituted with hydroxyl and -NR1°R“, C1-6alkyl substituted with one or two
halo atoms and -NR1°R“. C1_5alkyl substituted with -—C(=O)—O-C1-6alkyl, Cmalkyl
substituted with C1_6alkoxyC1.6alkyl-C(=O)—, C1_6alkyl substituted with -NR1°R“,
C1_6alkyl substituted with -C(=O)—NR14R15, C1_6alkyl substituted with carboxyl, kyl
substituted with O)~NR1°R“, C1_6alkyl substituted with —NR12—S(=O)2-C1_6alkyl, c1.
Galkyl substituted with —NR12-S(=O)2-NR14R15, C1_6alkyl substituted with R9and
substituted with —O—C(=O)-C1_6alkyl, C1_6alkyl substituted with yl and R9, -C1.6alkyl-
C(R12)=N-o-R12,—S(=0)2-NR14R‘5, c,_6aikyi substituted with -S(=O)2-C1.6alkyl, Cmalkyl
substituted with —C(=O)—R9, Cz_6alkenyl substituted with R9, C2-6alkynyl substituted with
R9, C1_6a|kyloxyC1_6alkyl wherein each C1_6alkyl may optionally be substituted with one or
two hydroxyl groups, C2_6alkenyl, C2_6alkynyl, R”, or C1-5alkyl substituted with -
OC1_6alkyl)2.
in one embodiment, R3 ents C1_6alkyl, hydroxyC1_6alkyl, hydroxyhaloC1_6alkyl,
haloC1_6alkyl, C1.6alkyl substituted with —C(=O)-C1_6alkyl, C1_5alkoxyC1_6alkyl wherein
each C1_6alkyl may optionally be substituted with one or two hydroxyl groups, C1_6alkyl
substituted with R9, C1_6alkyl substituted with -NR‘°R“, C1.6alkyl substituted with
hydroxyl and -NR1°R“, C1_6alkyl substituted with one or two halogens and -NR1°R“, c1.
ealkyl substituted with —C(=O)—O-C1_6alkyl, Cmalkyl substituted with —-O—C(=O)—NR1°R“,
C1_5alkyl substituted with carboxyl, C1_5alkyl substituted with -NR12-S(=O)2—C1-5alkyl, c1.
ealkyl substituted with —NR‘2-S(=0)2-NR‘4R15, kyl substituted with hydroxyl and R9,
—C1.6alkyl-C(R12)=N-O-R12, C1_6alkyl tuted with —NR1°R“, C1.ealkyl
substituted with —C(=O)—R9, kynyl substituted with R9, hydroxyC1-5alkoxy, Cg-
salkenyl, C2_6alkynyl or R”.
In one embodiment R3 represents Cg_6alkynyl, haloC1-5alkyl optionally substituted with —
O-C(=O)-Ci_6alkyl, hydroxyC1_6alkyl optionally substituted with —O-C(=O)-C1_6alkyl,
hydroxyhaloCt-5alkyl, C1-6alkoxyC1_5alkyl wherein each C1-6alkyl may optionally be
substituted with one or two hydroxyl groups or with —O-C(=O)—C1_ealkyl, C1_6alkyl
substituted with R9, C2_5alkynyl substituted with R9,C1-6alkyl substituted with -NR1°R“, or
C1-ealkyl tuted with —o-C(=O)-NR‘°R“.
In one embodiment R3 represents hydroxyCi_6alkyl, hydroxyhaloC1_6alkyl, C1-6alkyl
substituted with R9, C1_6alkyl substituted with -NR1°R“, Cz_6alkynyl substituted with R9, or
kynyl.
In one embodiment R3 represents Ci_6alkyl, hydroxyC1-6alkyl, hydroxyhaloC1_6alkyl,
cyanoCi_6alkyl, 01-6alkyl substituted with carboxyl, C1_6alkyl tuted with —C(=O)-O-
C1-6alkyl, Ctsalkyl substituted with R9, C1_6alkyl substituted with —C(=O)—R9, C1-6alkyl
substituted with yl and R9, C1-6alkyl substituted with -NR‘°R“, C1.5alkyl substituted
with —C(=0)-NR‘°R“, kyl substituted with —S(=O)2-C1_5alkyl, C1_6alkoxyC1-6alkyl
wherein each C1_6alkyl may optionally be tuted with one or two hydroxyl groups or
with —O—C(=O)-C1.6alkyl, kynyl substituted with R9, or C2_ealkynyl. In one
embodiment, R3 represents hydroxth_6alkyl, haloC1-5alkyl, Ct.6alkyl tuted with R9,
C1.5alkyl substituted with -NR‘°R“, koxyC1_6alkyl, or C2-6alkynyl.
in one embodiment R3 represents hydroxyC1_6alkyl, hydroxyhaloC1_6alkyl, Ci_6alkyl
substituted with R9, C1-6alkyl substituted with -NR1°R“, 01.6alkoxyC1_6alkyl wherein each
C1_6alkyl may optionally be substituted with one or two hydroxyl groups or with —O-
C(=O)-C1_6alkyl, 02.6alkynyl substituted with R9, or C2-6alkynyl.
in one embodiment R3 represents hydroxyC1_6alkyl, hydroxyC1-6alkoxy|, hydroxyhaloC1_
, Crealkyl substituted with R9, Ct_6alkyl substituted with -NR1°R“, C2_5alkynyl or C2.
6alkynyl tuted with R9.
In one embodiment R3 represents kynyl. R3 may represent ‘CHZ'CEC_H.
In one embodiment when R3 represents kyl (e.g. C1_4alkyl) tuted with R9. R9
represents an optionally substituted aromatic 5 or 6 membered monocyclic heterocyclyl,
for example optionally substituted imidazolyl, pyrimidinyl, or pyrazinyl.
In one embodiment when R3 ents C1_6alkyl (e.g. C1_4alkyl) substituted with R9,
n R9 ents an optionally substituted aromatic 6 membered monocyclic
heterocyclyl containing one or two nitrogen atom, for example pyrimidinyl or
pyrazinyl.
In one embodiment when R3 represents C1_4alkyl (e.g. methyl) substituted with R9,
wherein R9 represents tituted imidazolyl (e.g. imidazol-Z-yl), unsubstituted
pyrimidinyl (e.g. pyrimidin-Z-yl), unsubstituted pyrazinyl, or imidazolyl substituted with —
S(O)2-N(CH3)2.
in one embodiment R3 represents C2_6alkynyl (e.g. -—CH2 “CEC" ) substituted with R9.
R9 may represent an optionally substituted aromatic 6-membered monocyclic
heterocycle containing one or two nitrogen heteroatoms, for example pyridinyl. The
heterocyclyl may be substituted, for example substituted with one C1_4alkoxyl
substituent, for example —OCH3. R3 may represent —CH2 —CEC— (3-methoxy-pyridin-
2-yl).'
ln one ment R3 represents C1_6alkyl substituted with hydroxyl, halo and/or -
NRTOR“. In one embodiment R3 represents Cmalkyl substituted with hydroxyl, halo or
NR1°R11, wherein the C1_6alkyl group is a straight chain alkyl group e.g. 2-ethyl, n—propyl,
n—butyl. In a further ment R3 represents C1-6alkyl substituted with hydroxyl or
-NR1OR11.
In one ment R3 represents hydroxyC1-6alkyl. R3 may represent —CH2CH20H or -
CHZCHZCHZOH.
In one embodiment R8 ents hydroxyhaloC1_6alkyl, for example R3 may represent ——
CHZCHOHCF3.
in one embodiment R3 represents C1_6alkoxyC1_6alkyl wherein each C1_6alkyl may
optionally be substituted with one or two hydroxyl groups, for example R3 may represent
—CHZCHOHCHZOCH3.
In one embodiment R3 represents C1_6alkyl (e.g. C1_4alkyl) substituted with R9 or C1_5alkyl
substituted with -NR1°R11. In particular, R3 represents C1_6alkyl (e.g. C1_4alkyl)
substituted with R9 wherein R9 represents an optionally substituted 5 membered
saturated heterocycle, such as for example pyrrolidinonyl or oxazolidinonyl, or an
optionally substituted 5 membered ic heterocycle, such as for example imidazolyl
or triazolyl, or R3 represents C1_5alkyl substituted with -NR1°R11 wherein R10 and R11
each independently ent hydrogen, -C(=O)—C1_6alkyl or R6.
in a yet further embodiment R3 represents Cmalkyl tuted with -NR1°R“.
in one embodiment R3 represents C1_4alkyl substituted with -NR1°R“. In one
embodiment R3 represents C1-4alkyl substituted -NR1°R“, wherein the kyl group is
a straight chain alkyl group e.g. 2-ethyl, n-propyl. in one ment R3 ents C1-
4alkyl tuted with -NR1°R11, n the CMalkyl group is an ethylene group (-
CH2CH2-).
In one embodiment when R3 represents C1_6alkyl (e.g. 2-ethyl, n-propyl) tuted with
“, wherein R10 and R11 are independently selected from hydrogen, C1-6alkyl and
haloC1_6alkyl (e.g. hydrogen, iso-propyl or -CHZCF3).
in one embodiment when R3 represents C1_6alkyl substituted with -NR1°R“, and one of
R10 and R11 represents hydrogen and the other represents C1-6alkyl, for example —CH3
or —CH(CH3)2. R3 may represent —CHZCH2NHCH3 or—CHgCHzNHCH(CH3)2;
In one embodiment R3 represents —CHZCH2NHCH(CH3)2.
In one embodiment, R9 is selected from :
an optionally substituted Cg.gcycloalkyl,
an optionally substituted aromatic 5 membered monocyclic heterocyclyl,
an optionally substituted ted 6 membered monocyclic heterocyclyl.
a saturated or an aromatic 3, 4, 5 or 6 membered monocyclic heterocyclyl ning
one or two oxygen heteroatoms,
an optionally tuted 4 membered heterocyclyl containing one oxygen heteroatom,
an optionally substituted aromatic 6 membered monocyclic heterocycle containing one
or two nitrogen heteroatoms,
a partially saturated 6 membered monocyclic heterocyclyl containing one nitrogen
heteroatom which may optionally be substituted,
an optionally tuted saturated 4 membered monocyclic heterocyclyl containing one
nitrogen atom,
a saturated 5 membered monocyclic heterocyclyl containing one nitrogen heteroatom,
a saturated 6 ed monocyclic heterocyclyl ning one nitrogen heteroatom,
a bicyclic heterocyclyl containing a benzene ring fused to a 5- or 6—membered ring
containing 1, 2 or 3 ring heteroatoms,
a 4, 5 or 6 membered monocyclic saturated heterocycle substituted with two
substituents which are attached to the same atom and which are taken together to form
a 4 to 7—membered saturated monocyclic heterocyclyl containing at least one
heteroatom selected from N, O or S,
an optionally substituted aromatic 5 membered monocyclic heterocyclyl containing one
sulphur heteroatom,
an optionally substituted aromatic 5 membered monocyclic heterocyclyl containing one
sulphur and one en heteroatom,
a saturated 6 membered monocyclic heterocyclyl containing two nitrogen atoms,
an aromatic 5 membered clic heterocyclyl containing four nitrogen atoms,
an aromatic 5 membered monocyclic cyclyl ning one oxygen and two
nitrogen atoms, .
an optionally substituted aromatic 5 membered monocyclic heterocyclyl containing two
nitrogen atoms,
an optionally tuted aromatic 5 membered monocyclic heterocyclyl containing three
nitrogen heteroatoms,
a saturated 5 membered monocyclic heterocyclyl containing one nitrogen and one
oxygen heteroatom,
a saturated 6 membered monocyclic heterocyclyl containing one nitrogen and one
sulphur heteroatom,
a saturated 7 membered monocyclic heterocyclyl containing two nitrogen heteroatoms,
a saturated 7 membered clic cyclyl containing one nitrogen and one
oxygen heteroatom, and
phenyl or naphthyl, in particular phenyl.
in one embodiment, R9 represents an optionally substituted 4 membered saturated
heterocycle, such as for example oxetanyl; an optionally substituted 5 membered
saturated heterocycle, such as for example pyrrolidinonyl, tetrahydrofuranyl or
oxazolidinonyl; an optionally substituted 5 membered aromatic heterocycle, such as for
example imidazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl, or pyrazolyl; an
optionally substituted 6 ed saturated heterocycle, such as for example
tetrahydropyranyl or morpholino; an optionally substituted 6 membered aromatic
heterocycle, such as for example pyridyl, pyrimidinyl or pyrazinyl; an optionally
substituted bicyclic cycle, such as for e benzimidazolyl or
imidazotetrahydropyridinyl (3H imidazo[4,5-c]4,5,6,7-tetrahydropyridinyl); or Cg-
acycloalkyl, such as for example cyclopropyl. in one embodiment, R9 represents an
optionally tuted 5 membered aromatic heterocycle, such as for example
imidazolyl, or an optionally substituted 6 ed aromatic heterocycle, such as for
example l, dinyl or pyrazinyl. al substituents may represent C1-
4alkoxy or 2-NR14R15.
In one embodiment R9 represents an optionally substituted 5 membered saturated
heterocycle, such as for example pyrrolidonyl or oxazolidinonyl, or an optionally
substituted 5 membered aromatic heterocycle, such as for example imidazolyl or
triazolyl.
In one embodiment, R9 represents an optionally substituted 5 membered aromatic
heterocycle, such as for example olyl. Optional substituents may represent —
S(=O)2-NR14R15.
In one embodiment, R9 represents an optionally substituted 6 membered aromatic
heterocycle, such as for example pyridinyl or pyrimidinyl. Optional substituents may
represent C1-4alkoxy.
In one embodiment, R9 represents an optionally tuted 5 membered aromatic or
saturated heterocycle, such as for example imidazolyl, pyrolidinyl, oxazolidinyl. Optional
substituents may ent =0, a 5 or ered aromatic monocyclic heterocyclyl
containing at least one heteroatom selected from N, O or 8 wherein said cyclyl is
optionally substituted with R16; or —S(=O)2-NR14R15.
In one ment, R9 represents C3_ecycloalkyl, such as for example cyclopropyl, a 3
ed saturated heterocyclyl, such as for example oxiranyl, an optionally
substituted 5 membered ted heterocycle, such as for example pyrolidinonyl, an
optionally substituted 6 membered aromatic or saturated heterocycle, such as for
example pyridyl, pyrimidinyl, pyrazinyl, piperazinyl, or morpholinyl, an optionally
substituted bicyclic heterocycle, such as for example indol-1,3-dione. Optional
substituents may represent :0, Ct_4alkoxy, C1-4alkyl substituted with ~NR14R15,
hydroxyCMalkyl, or C1_4alkyl-C(=O)-..
In one embodiment, optional substituents of R9 are hydroxyl, oxo, Ct_4alkyl, for example
methyl, hydroxth_4alkyl, Ct_4alkoxy01.4alkyl, halogen, -NR14R‘5, Ct_4alkyl substituted
with -NR14R15, C1_4alkoxy, -S(=0)2-NR‘4R‘5, in particular oxo.
In one embodiment R10 represents hydrogen or C1-6alkyl.
In one embodiment R” is hydrogen.
In one embodiment R11 represents hydrogen, C1-5alkyl, haloC1_6alkyl, —C(=O)—Ct-6alkyl, —
S(=O)2—Ct.6alkyl, —S(=O)2-NR14R15, hydroxyC1_ealkyl, -C(=O)—hydroxyhaI001.6alkyl, -
C(=O)-R6, cyanoC1_6alkyl, R6, -C(=O)-R6, C1.6alkyl substituted with R6,-C(=O)-haloC1_
6alkyl, C1-6alkyl substituted with —Si(CH3)3, Ctealkyl substituted with 15, Ctealkyl
substituted with —C(=O)-NR14R15, C1-6alkoxy, hydroxyhaloC1-6alkyl, carboxyl, or C1-
salkoxyC1-6alkyl.
In one ment R10 and R11 represent hydrogen, C1_5alkyl, hydroxth_6alkyl, -C(=O)-
kyl, or R6. In one embodiment R10 and R11 ent hydrogen or C1_6alkyl.
In one embodiment, R6 represents a 6—membered monocyclic ted heterocyclyl
which is optionally substituted. For example piperazinyl or morpholinyl or
tetrahydropyranyl, optionally substituted with halogen, C1_6alkyl, or C1-5alkyI—O-C(=O)-.
In one embodiment, R6 represents a 6-membered monocyclic aromatic heterocyclyl
which is optionally substituted. For example pyridinyl, optionally substituted with
halogen, C1_5alkyl, or C1.6alkyI-O-C(=O)-.
In one embodiment, R6 represents a 4 membered monocyclic saturated heterocycle,
such as for example oxetanyl; or a 6—membered monocyclic saturated heterocyclyl, such
as for example piperidinyl, or a 5-membered monocyclic ic heterocycle, such as
for example imidazolyl.
In one embodiment, R4 and R5 represent hydrogen.
In one ment, R7 and R8 each independently represent hydrogen or Cmalkyl, for
example methyl.
In one embodiment, R12 represents hydrogen or kyl optionally substituted with C1-
4alkyloxy.
In one embodiment, R13 ents a saturated 4 to 6-membered monocyclic
cyclyl ning at least one heteroatom selected from N or O.
In one embodiment, R14 and R15 each independently represent en or C1_4alkyl
optionally substituted with hydroxyl. In one embodiment, R14 and R15 each
independently represent hydrogen or C1_4alkyl.
In one embodiment, R22 and R23 each independently represent hydrogen.
In one embodiment of the invention, n represents an integer equal to 2, 3 or 4; and each
R2 represents C1_4alkoxy, for example CH3O-, or halogen, for example fluoro; R3
represents hydroxyC1_6alkyl, hydroxyhaloC1_6alkyI, C1_6alkyl tuted with R9, C1_6alkyl
substituted with -NR1°R“, C1_ealkoxyC1.6alkyl wherein each C1_5alkyl may optionally be
substituted with one or two yl groups or with O)—C1_6alkyl, Cg_6alkynyl
substituted with R9, 02.6alkynyl; Y represents —-E-D wheren E represents a bond and D
represents ally substituted pyrazoiyl.
in one embodiment of the invention, n ents an integer equal to 2, 3 or 4; and each
R2 represents C1_4alkoxy, for example CHgO-, or halogen, for example fiuoro; R3
represents hydroxyC1-6alkyl, hydroxyhaioC1_6a|kyi, kyt substituted with R9, C1_5alkyl
substituted with —NR1°R“, C1_6alkoxyC1_6alkyl wherein each C1_6alkyl may optionally be
substituted with one or two hydroxyl groups or with ——O-C(=O)-C1_6alkyl, Czealkynyl
substituted with R9, Czsalkynyl; Y represents —E—D wheren E represents a bond and D
represents pyrazolyl substituted with C1-6alkyl; R10 and R11 represent hydrogen or C1-
ealkyl; R9 represents an optionally tuted 5 membered aromatic heterocycle, such
as for example imidazolyl, or an optionally substituted 6 ed aromatic
cyole, such as for example pyridyl, dinyl or pyrazinyl.
In one embodiment of the invention, n represents an integer equal to 2, 3 or 4; and each
R2 represents C1_4alkoxy, for example CH30-, halogen, for example fiuoro or chloro,
hydroxyl, C1-4aikyl, for example methyl, or -—C(=O)—NR7R8, for example —C(=O)—NH-CH3;
R3 represents C1_6alkyl, for example methyl or ethyl, hydroxyC1_6alkyl, hydroxyhaloC1_
6alkyl, cyanoC1_6alkyl, kyl substituted with carboxyl, C1.6alkyl tuted with —-
C(=O)—O-C1_6aikyl, kyl substituted with R9, C1_6aiky| substituted with —C(=O)-R9, C1.
Galkyl tuted with hydroxyl and R9, C1_6alkyl substituted with -NR1°R“, C1_6alkyl
substituted with —C(=O)—NR1°R“, C1-5alkyi tuted with —S(=O)2-C1_6alkyl, c1.
yC1-6alkyl wherein each C1_5alkyi may optionally be substituted with one or two
hydroxyl groups or with —O-C(=O)-C1_5alkyl, 02-5GIKYHYI substituted with R9, C2_5alkynyl;
Y represents —E-D wheren E represents a bond and D represents an optionally
substituted clic 6 membered carbocyclyl, for example phenyl, or an optionally
substituted 5 or 6 membered monocyclic heterocyclyl, for example an optionally
substituted 5 or 6 membered saturated or aromatic heterocyclyl, such as for example
pyrazolyl, pyrrolyl, pyridinyl, morpholino, zinyl or ininyi, in particuiariy D
represents pyrazolyl optionally substituted with C1_6alkyl, more in particular D represents
pyrazolyl substituted with C1_6aikyi.
In one embodiment of the invention, n represents an integer equal to 2, 3 or 4; and each
R2 represents C1-4alkoxy, for example CH30—, halogen, for example fiuoro or chioro,
hydroxyl, Ci-4alkyl, for e methyl, or —C(=O)-NR7R8, for example —C(=O)-NH-CH3;
R3 represents C1-6alkyl, for example methyl or ethyl, hydroxyCi-6alkyl, hydroxyhaloC1-
6alkyl, cyanoCmalkyl, Ci_6alkyl substituted with carboxyl, C1-6alkyl substituted with —
C(=O)—O-Ci_6alkyl, C1.6alkyl substituted with R9, Cmalkyl substituted with —C(=O)—R9, c1-
6alkyl substituted with hydroxyl and R9, Ci_ealkyl substituted with -NR1°R“, Ctsalkyl
substituted with —C(=0)-NR‘°R“, Ct_6alkyl substituted with 2-C1_6alkyl, c1.
6alkoxyC1-6alkyl wherein each C1_6alkyl may optionally be substituted with one or two
hydroxyl groups or with O)—C1_6alkyl, CzsaalkanI substituted with R9, C2-6alkynyl;
Y represents —E-D wheren E represents a bond and D represents an optionally
substituted monocyclic 6 membered carbocyclyl, for e phenyl, or an optionally
substituted 5 or 6 membered monocyclic heterocyclyl, for example an optionally
substituted 5 or 6 membered ted or aromatic heterocyclyl, such as for e
pyrazolyl, pyrrolyl, nyl, morpholino, piperazinyl or dinyl, in ularly D
represents pyrazolyl optionally substituted with Ct.6alkyl, more in particular D represents
pyrazolyl substituted with C1_6alkyl; R1 represents kyl, hydroxyC1-6alkyl,
hydroxyhaloC1_6alkyl, Ci-5alkoxy01-6alkyl wherein each C1_6alkyl may optionally be
substituted with one or two hydroxyl groups, Ci_6alkyl substituted with -NR4R5, C1_5alkyl
substituted with -S(=O)2-C1.5a|kyl, R6, C1_5alkyl tuted with R6, more in ular R1
represents kyl, for example ; R9 represents an optionally substituted 4
membered saturated heterocycle, such as for example oxetanyl; an optionally
substituted 5 membered saturated heterocycle, such as for example pyrrolidinonyl,
tetrahydrofuranyl or oxazolidinonyl; an optionally substituted 5 membered aromatic
heterocycle, such as for example imidazolyl, oxadiazolyl, isoxazolyl, triazolyl, tetrazolyl,
as for
or pyrazolyl; an optionally substituted 6 ed saturated heterocycle, such
example tetrahydropyranyl or morpholino; an optionally substituted 6 membered
aromatic heterocycle, such as for example pyridyl, pyrimidinyl or pyrazinyl; an optionally
substituted bicyclic heterocycle, such as for example benzimidazolyl or
otetrahydropyridinyl (3H o[4,5-c]4,5,6,7-tetrahydropyridinyl); or Cgacycloalkyl
, such as for example cyclopropyl, more in particular R9 represents an
optionally substituted 5 membered ted heterocycle, such as for example
pyrrolidinonyl or oxazolidinonyl, or an optionally substituted 5 membered ic
heterocycle, such as for example imidazolyl or triazolyl; R10 and R11 represent hydrogen,
Cmalkyl, hydroxth.6alkyl, -C(=O)—Ci_5alkyl, or R6; in particular R10 and R11 represent
hydrogen, -C(=O)-Ct-5alkyl, or Re; R6 represents a 4 membered monocyclic saturated
heterocycle, such as for example oxetanyl; or a 6-membered monocyclic saturated
heterocyclyl, such as for example piperidinyl; or a ered monocyclic aromatic
heterocycle, such as for example imidazolyl; R4 and R5 represent hydrogen; R7 and R8
each independently represent hydrogen or C1_6alkyl, for example methyl, R14 and R15
each independently represent hydrogen or C1_4alkyl optionally substituted with hydroxyl.
in one embodiment, Y is ~E—D, n E is a bond and D is a 5 or 6 membered
monocyclic aromatic heterocyclyl, wherein said heterocyclyl may optionally be
substituted by one or more (eg. 1, 2 or 3) R1 groups, and wherein one or more of the
following applies :
n is 2;
R2 is C1_6alkyloxy;
R2 is placed in on 3 and 5.
In one embodiment, Y is —E—D, wherein E is a bond and D is piperidinyl, pyridinyl,
phenyl, pyrrolyl, imidazolyl, triazolyl, pyrrolopyridinyl, 1,3—benzodioxolyl, l, thiazolyl,
cyclopentyl, azetidinyl, morpholinyl, tetrazolyl, oxazolyl, piperazinyl, 1,2,3,6-
tetrahydropyridinyl, 2,5-dihydropyrolyl, pyrimidinyl, pyrrolidinyl, thiadiazolyl, oxadiazolyl,
said rings being optionally substituted, more in particular D is piperidinyl, pyridinyl,
phenyl, yl, olyl, triazolyl, pyrrolopyridinyl, 1,3—benzodioxolyl, l, lyl,
entyl, azetidinyl, morpholinyl, tetrazolyl, oxazolyl, zinyl, 1,23,6-
tetrahydropyridinyl, 2,5-dihydropyrolyl, pyrimidinyl, pyrrolidinyl, thiadiazolyl, oxadiazolyl,
said rings being optionally substituted and n is 2, even more in particular D is piperidinyl,
pyridinyl, phenyl, yl, imidazolyl, triazolyl, pyrrolopyridinyl, 1,3—benzodioxolyl, indolyl,
thiazolyl, cyclopentyl, azetidinyl, morpholinyl, tetrazolyl, oxazolyl, piperazinyl, -
ydropyridinyl, 2,5-dihydropyrolyl, pyrimidinyl, pyrrolidinyl, thiadiazolyl, oxadiazolyl,
said rings being optionally substituted; n is 2, R2 is C1_6alkyloxy, even further in particular
D is piperidinyl, pyridinyl, phenyl, pyrolyl, imidazolyl, triazolyl, pyrolopyridinyl, 1,3-
benzodioxolyl, indolyl, thiazolyl, cyclopentyl, azetidinyl, morpholinyl, olyl, oxazolyl,
piperazinyl, 1,2,3,6—tetrahydropyridinyl, 2,5-dihydropyrolyl, pyrimidinyl, pyrrolidinyl,
thiadiazolyl, oxadiazolyl, said rings being ally substituted; n is 2, R2 is C1_6alkyloxy
and said R2 is placed in on 3 and 5.
In one embodiment there is provided compounds of formula (I):
N N N Y
UT/ /
2 N
“”1 (l-A)
N N N Y
\ /
2 N
(M (1—13)
including any tautomeric or stereochemically ic form thereof, wherein
each R2 is independently selected from C1_4alkoxy, for example CH30-, or n, for
example fluoro;
Y represents —E-D;
D represents a 3 to 12 ring membered monocyclic or bicyclic carbocyclyl or a 3 to 12
ring membered clic or bioyclic heterocyclyl containing at least one heteroatom
selected from N, O or S, for example pyrazolyl, wherein said carbocyclyl and
heterocyclyl may each be optionally substituted by one or more (eg. 1, 2 or 3) R1
groups;
E represents a bond;
R1 represents C1.6alkyl, for example methyl;
R3 represents
- hydroxyC1_6alkyl, for e —CHZCH20H or —CHQCH2CHZOH,
- hydroxyhaloC1_6alkyl, for e -CHZCHOHCF3,
- C1_6alkyl substituted with R9, for example —CH2- substituted with imidazol-2—yl, -CH2-
substituted with imidazol-Z-yl substituted in the 1 on with —S(O)2-N(CH3)2, -CH2-
substituted with pyrimidinyl, -CH2- substituted with pyrazinyl,
- Cmalkyl substituted with -NR1°R“, for example —CHZCH2NHCH3 or—
CH20H2NHCH(CH3)2,
- C1_6alkoxyC1-6alkyl wherein each C1V6alkyl may optionally be substituted with one or
two hydroxyl groups, for example —CH2CHOHCHZOCH3,
- kynyl substituted with R9, for example ——CH2 —CEC‘_ (3-methoxy-pyridin—2-yl),
— kynyl, for example EC‘H; and
n independently represents an r equal to 2, 3 or 4;
the N-oxides thereof, the pharmaceutically acceptable salts thereof or the solvates
thereof.
In one embodiment there is provided compounds of formula (l)
3 N/
N N\ N\1L/
(R )n
(I-C)
3 N/
’T‘ / \
\ /
(R2) N
" (1-D)
including any tautomeric or stereochemically isomeric form thereof;
wherein n, R2 and R3 are as defined herein;
the N-oxides thereof, the pharmaceutically acceptable salts thereof or the solvates
thereof.
In one embodiment there is provided compounds of formula (l-C) or Formula (l-D)
including any tautomeric or stereochemically isomeric form thereof, n:
R2 represents C1_4alkoxy (for example CH30—) or halogen (for e fluoro); and
R3 represents hydroxyC1_6a|kyl (e.g. —CHZCH20H or —CHZCHZCH20H), C1-6alkoxyC1.
Balkyl wherein each C1_6alkyl may optionally be tuted with one or two hydroxyl
groups (e.g. —CH2CHOHCHZOCH3), hydroxyhaloC1-6alkyl (e.g. —CHZCHOHCF3), C1-
6alkyl (e.g. C1-4alkyl) substituted with R9(e.g. wherein R9 represents an optionally
substituted aromatic 5 or 6 membered monocyclic heterocyclyl, for example optionally
substituted imidazolyl, pyrimidinyl, or pyrazinyl), C1_Ba|kyl (e.g. C1-4alkyl) tuted with
-NR1°R11 wherein R10 and R11 are independently selected from en, C1_5alkyl and
haloC1_6alkyl (e.g. hydrogen, iso—propyl or -CH2CF3), 02.6aikynyl (e.g. ‘CHZ'CEC_H) or
02-6aikynyl (e.g. -CH2 ‘CEC‘ ) substituted with R9 (e.g. R9 represents an optionally
substituted aromatic 6-membered monocyclic heterocycle containing one or two
nitrogen heteroatoms, for example pyridinyl);
the N-oxides thereof, the pharmaceutically acceptable salts thereof or the solvates
thereof.
In one embodiment there is provided compounds of formula (l-C) or Formula (l-D)
including any tautomeric or stereochemically ic form thereof, wherein:
R2 represents C1-4alkoxy (for e CH3O-) or halogen (for example fluoro); and
R3 represents hydroxyC1_6alkyl (e.g. —CHZCH20H or —CHZCH2CHZOH), CmalkoxyC1_
ealkyl wherein each kyl may optionally be substituted with one or two hydroxyl
groups (e.g. —CH20HOHCHZOCH3), hydroxyhaloCi-5alkyl (e.g. —CHZCHOHCF3), C1-
4alkyl (e.g. methyl) substituted with R9(e.g. wherein R9 represents an optionally
substituted ic 5 or 6 membered monocyclic heterocyclyl, for example
unsubstituted imidazolyl (e.g. imidazol-2—yl), unsubstituted pyrimidinyl (e.g. pyrimidin—2-
yl), unsubstituted pyrazinyl, or imidazolyl substituted with —S(O)2-N(CH3)2), Ci.4aikyl (e.g.
-CHZCH2-) substituted with -NR1°R11 wherein one of R10 and R11 represents hydrogen
and the other represents C1_6a|kyl, for example -CH3 or —CH(CH3)2 (e.g. R3 ents —
CHZCHZNHCHg or—CHZCHZNHCH(CH3)2), Cg_6alkynyl (e.g. -CH2-CEC—H) or 02.6alkynyl
(e.g. —CH2 “—CEC“ ) substituted with R9 (e.g. —CH2 —CEC— (3-methoxy-pyridinyl);
the N-oxides f, the pharmaceutically acceptable salts thereof or the es
thereof.
in one embodiment there is provided nds of formula (I-C) or Formula (l-D)
including any tautomeric or stereochemically isomeric form thereof, n:
R2 represents C1-4alkoxy (for example CH30-) or halogen (for example ) or
hydroxyl; R3 represents C1-4a|kyl (e.g. —CH2- or —CH2-CH2-CH2-) substituted with R9(e.g.
wherein R9 represents an optionally substituted aromatic 5 ed clic
heterocyclyl, for example unsubstituted imidazolyl (e.g. imidazol-Z-yl), or unsubstituted
triazolyl riazolyl) or R9 ents an optionally substituted saturated 5
membered monocyclic heterocyclyl, for example 2-pyrrolidinonyl (e.g. 2-pyrrolidinon-5—yl
or 2—pyrrolidinon-1—yl) or 2-oxazolidinonyl (e.g. 2—oxazolidinonyl)) or R3 represents C1-
4alkyl (e.g. -CHzCH2-) substituted with -NR1°R11 wherein one of R10 and R11 represents
hydrogen and the other represents C1_6a|kyl, for example -CH3 or —CH(CH3)2 (e.g. R3
represents —CH2CH2NHCH3 or —CH2CH2NHCH(CH3)2), or —C(=O)—C1_5alkyl, for example
—-C(=O)-CH3 (e.g. R3 represents 2NH-C(=O)-CH3), or R6 (e.g. wherein R6
represents an optionally substituted 4 membered saturated heterocycle (e.g. oxetanyl));
n is 2,3, or 4;
the N-oxides thereof, the pharmaceutically acceptable salts thereof or the es
thereof.
In one embodiment there is provided compounds of formula (l—C) including any
tautomeric or stereochemically isomeric form thereof, wherein:
R2 represents C1_4alkoxy (for example CH30-) or halogen (for e fluoro); R3
represents C1_4alkyl (e.g. ~CH2-) tuted with R9(e.g. wherein R9 represents an
optionally substituted aromatic 5 membered monocyclic heterocyclyl, for example
unsubstituted olyl (e.g. imidazolyl)) or R3 represents C1_4alkyl (e.g. -CH2CH2-)
substituted with -NR1°R11 wherein one of R10 and R11 represents hydrogen and the other
represents C1_6a|kyl, for example -CH3 (e.g. R3 ents —CH2CH2NHCH3 ); in
particular R3 ents C1_4alkyl (e.g. —CH2-) substituted with R9 (e.g. wherein R9
represents an ally substituted aromatic 5 membered monocyclic heterocyclyl, for
example unsubstituted imidazolyl (e.g. imidazol-2—y|)); n is 2, 3, or 4, in particular 3;
the N-oxides thereof, the pharmaceutically acceptable salts thereof or the solvates
thereof.
In one embodiment there is provided compounds of formula (I-C) including any
tautomeric or chemically isomeric form thereof, wherein:
R2 represents C1_4alkoxy (for example CH30-) or halogen (for example fluoro); and
R3 represents hydroxyC1_6alkyl (e.g. —CHZCH20H or —CHZCHZCHZOH), C1.6alkoxyC1_
6alkyl wherein each C1_6alkyl may optionally be substituted with one or two hydroxyl
groups (e.g. ~CH2CHOHCHZOCH3), hydroxyhaloC1_5alky| (e.g. ~CH2CHOHCF3), C1-
5alkyl (e.g. C1-4alkyl) tuted with . wherein R9 represents an ally
tuted ic 5 or 6 membered monocyclic heterocyclyl, for example optionally
substituted imidazolyl, pyrimidinyl, or pyrazinyl), C1_6a|kyl (e.g. C1_4a|ky|) substituted with
-NR1°R11 wherein R10 and R11 are independently selected from hydrogen, C1.5alkyl and
haloC1_6alkyl (e.g. en, iso-propyl or -CHZCF3), 02-6alkynyl (e.g. 'CHZ'CEC_H) or
Cz_6alkynyl (e.g. —CH2 _CEC— ) substituted with R9 (e.g. R9 represents an optionally
substituted aromatic 6-membered monocyclic heterocycle ning one or two
nitrogen heteroatoms, for e pyridinyl);
the N—oxides thereof, the pharmaceutically acceptable salts thereof or the solvates
thereof.
In one embodiment there is provided compounds of Formula (l-D) including any
eric or stereochemically isomeric form thereof, wherein:
R2 represents koxy (for example CHsO-) or halogen (for example fluoro); and
R3 ents C1_6alkyl (e.g. C1_4alkyl) substituted with -NRwR11 wherein R10 and R11 are
independently selected from hydrogen, C1_6alkyl and haloC1_5alkyl (e.g. hydrogen, iso—
propyl or -CHgCF3) (e.g. R3 represents -—CHgCH2NHCH3 or—CHZCHZNHCH(CH3)2);
the N-oxides thereof, the pharmaceutically acceptable salts thereof or the solvates
thereof.
In one embodiment the compound of formula (I) is a nd of formula (l-C):
R3 N\
:11 l N
N N /
\ \
/ /
(R2) N
" 0-0)
n n, R1, R2 and R3 are as defined herein.
In one embodiment the compound of formula (I) is a compound of formula (l-C):
3 N/
R \
' I N
QNUN\ /
\ /
(Rzln N
0-9)
wherein n, R1, R2 and R3 are as defined herein.
In one embodiment, the t invention relates to any one of the following compounds
a /
/ N/
/ p“
o N‘
: N N
/ \
_O F /
w \ /'I‘
/ (\N
o N‘
< >~N
/ \
no /
2012/052672
F N
o N N N /N
/ \ \
/ /
F N
a N-oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
In one embodiment, the present invention relates to any one of the following compounds
70 F x N /
\:\ \ /’|“
Ne
/ (\N
QNZg N / \
#0 N \/
7 \ /“|‘
l ”\N
/o N IN\ N\ /
F N/
a N—oxide thereof, a pharmaceutically acceptable salt thereof or a solvate thereof.
In one ment, the present invention relates to any one of the following compounds
WO 61080
S /
F N\
o N§ N N\ /
\ /
F N
F R N\
o N§ N N\ /
\ /
F R N\
o N N N /
\ \
/ /
H N/\o
H N /\> s /
F o
F (KN N I I N\N /
i I \N o N N /
N /N N\ / / N\
O I
l \ /
\ / N
a N—oxide thereof, a pharmaceutically acceptable salt
thereof or a solvate thereof.
For the avoidance of doubt, it is to be understood that each general and specific
preference, embodiment and example for one substituent may be combined, whenever
le, with. each general and specific preference, embodiment and example for one
or more, preferably, all other substituents as d herein and that all such
ments are embraced by this application.
Methods for the Preparation of Compounds of Formula (I)
In this section, as in all other sections of this application unless the context tes
otherwise, references to formula (I) also e all other sub-groups and examples
thereof as defined herein.
in general, compounds of formula (l-A) wherein Y is D (E is a bond), said compounds
being represented by formula (l-Aa), can be prepared ing to the following reaction
Scheme 1.
W2 N\ N\ D I?“
UI/ /
N Q//
(R2)n
(XXIII)
(“0/ \ NH2
(XXIH') /
// (R2)n/(V
RystK1‘ /C a1k1W 16 Y 3
R2 W
R)n U::”———,», 4/ U:j\ N
$2 wfi—RR..)”(R
Ry—Zi—Rx 0"" C(vlzifikyl—W3 (VI) 0 )
R. R.
I (XXH)R"—C—OH
(limalkyl CH2
O/NUN\ / \ N
(R )n / (R2): U“I
(VIII) CI .ealkyl
UUI W6-C1_6alkyl-NR1°P (I-Aa-c-l)
l tetrabutylammoniumfluoride ac'dI II‘IRIOP I|\II~IR10
1 6 alkyl C alk 1
1-6 y
OH l
l \ N N N D N
C1_6a1ky1 \ \ \
l I ———-->
\ N N\ N\ D / /
/ N (/R2//
(IAab1)
// U 3/ (XXX)
(R2)n / N/ Q
(I—Aa-a)
150' ,
Cl l1_6alkyl
/ \ N N N D
O \ \
2// I
(R )n / I
Cl _6a1ky1 NRIORII
GNU j/D é,6a1kyi
NHRiORll
(R2)n //\ N
(IX) : R" is ~O-S(=O)2-CH3 \m 022),? U:I
(IX'):R”1's-C1 (I-Aa-b)
In scheme 1, an intermediate of formula (IV) is d with an intermediate of formula
(V) in the presence of a suitable catalyst, such as for example palladium (ll) acetate, a
le base, such as sodium tert-butoxide or 032003, a suitable ligand, such as for
example 1,1'-[1,1'-binaphthalene]—2,2'-diylbis[1,1-diphenylphosphine], and a suitable
solvent or solvent mixture, such as for example dioxane or ethylene glycol dimethylether
and water or N-methyl—pyrrolidone or e and N-methyl-pyrrolidone, resulting in an
intermediate of formula (VI). Or alternatively an intermediate of formula (IV) is reacted
with an intermediate of formula (V) in the presence of a suitable solvent, such as for
example an alcohol, e.g. n-propanol, and optionally in the ce of a suitable acid,
such as for example hydrochloric acid. Or alternatively, an intermediate of formula (IV)
is reacted with an intermediate of formula (V) in the presence of potassium
bis(trimethylsilyl)amide in the presence of a le solvent such as for example
tetrahydrofuran or methylformamide. Said intermediate of formula (VI) can then
be reacted with an intermediate of formula (Vll) wherein W3 represents a suitable
leaving group, such as for example halo, e.g. bromo and wherein RX and Ry ent
C1_4alkyl, and R2 represent C1.4alkyl or phenyl, for instance RX and Ry represent CH3 and
RZ represents C(CH3)3 or phenyl, in the presence of a suitable base, such as for
example sodium hydride, and a suitable solvent, such as for example N,N-
dimethylformamide or N,N-dimethylacetamide, resulting in an intermediate of formula
(Vlll). This type of on can also be performed to introduce a -C1-6alkyl-O-
Si(Rx)(Ry)(RZ) group on an appropriate R9 ring within the R3 definition or on an
appropriate D moiety. The resulting intermediate can then react with
tetrabutylammonium de in the presence of a suitable solvent, such as for example
tetrahydrofuran, to result in a compound of a (I) wherein the appropriate R9 ring is
substituted with hydroxyCLealkyl or the appropriate D moiety is substituted with
hydroxyC1-6alkyl. Intermediates of formula (Vlll) or intermediates of formula (Vlll)
wherein the R1 tuent carries a suitable tive group can also be prepared by
reacting an intermediate of formula (IV) or an intermediate of formula (IV) wherein the R1
substituent s a suitable tive group with an intermediate of formula (XXIII’)
wherein R3“, represent -C1.6alkyl-O-Si(RX)(Ry)(RZ) in the presence of a suitable catalyst,
such as for example palladium (ll) acetate, a le ligand, such as for example
racemic -2,2’-bis(diphenylphosphino)—1,1’—binaphtyl or 2-dicyclohexylphosphino-Z’,4’,6’-
propyl-1,1’-biphenyl, a le base, such as for example 052003, and a suitable
solvent, such as for example 1,2-dimethoxyethane or dioxane. Intermediates of formula
(Vlll) can be converted into a compound of formula (I) wherein R3 represents —C1_6alkyl-
OH, said compounds being represented by a (l-Aa-a) or compounds of formula (I-
Aa) n the R1 substituent carries a suitable protective group, by reaction with
tetrabutylammonium fluoride in the presence of a suitable solvent, such as for example
2012/052672
tetrahydrofuran. This type of reaction can also be performed in the presence of a
le acid, such as for example acetic acid or HCI, and a le solvent, such as for
example tetrahydrofurane or dioxane. Alternatively, an intermediate of formula (VI) can
react with an intermediate of formula (VII’) wherein W3 represents a suitable leaving
group, such as for example halo, e.g. bromo and the like, in the presence of a suitable
base, such as for example sodium hydride, and a suitable solvent, such as for example
N,N—dimethylformamide or N,N-dimethylacetamide, resulting in an intermediate of
formula (XXV) which can then be ected in the presence of a suitable acid, such as
for example HCI, and a suitable solvent, such as for example an alcohol, e.g. methanol
or panol, to give a compound of formula (I-Aa-a).The compounds of formula (I-Aa—
a) or compounds of formula (I-Aa—a) wherein the R1 substituent s a suitable
protective group can be reacted with methanesulfonyl chloride in the presence of a
suitable base, such as for e ylamine, diisopropylethanamine or N,N-
dimethyI—4-aminopyridine, and a suitable solvent, such as for example dichloromethane
or tetrahydrofuran, to result in an intermediate of formula (IX) (mesylate derivative) or an
intermediate of formula (IX’) (chloride derivative) or intermediates of formula (IX) or (IX’)
n the R1 substituent carries a suitable protective group. In particular, this type of
reaction is used to prepare ediates of formula (IX) or (IX’) wherein C1_6alkyl
represents C3-ea|kyl. For some variants of ediates of formula (IX) or (IX’), e.g.
wherein C1_6alkyl represents kyl it might be preferred to perform the reaction in non
basic conditions. Intermediates of formula (IX) or (IX’) can then be d with an
intermediate of formula (X) to obtain a compound of formula (la) wherein R3 represents
C1_6alkyl substituted with NRmR“, said compounds being represented by formula (l-Aab
) or nds of formula (I-Aa-b) wherein the R1 substituent carries a suitable
protective group. This reaction may optionally be performed in the presence of a
suitable base, such as for example triethylamine, K2003, Na2003 or sodium hydride and
optionally a suitable solvent, such as for example acetonitrile, tetrahydrofuran, dioxane,
N,N-dimethylformamide, 1-methyI-pyrrolidinone, a suitable alcohol, e.g. 1—butanol and
the like. This type of reaction can also be performed with a suitable salt of the
ediate of formula (X), e.g. HCI salt of intermediate of formula (X), or may be
performed in the presence of potassium iodide. In this way compounds wherein R3
ents iodoC1_6alkyI can be obtained. Compounds of formula (Ia-b) wherein the R1
substituent carries a suitable protective group can be ted in a compound of
2012/052672
formula (l-Aa-b) by reaction with a suitable acid, such as for example trifluoroacetic acid,
in the presence of a suitable solvent, such as for example romethane.
Intermediates of formula (IX) can also react with a suitable nitrogen containing ring
within the definition of R9, said ring being represented by formula (XXI) or a suitable salt
of an intermediate of formula (XXI), in the presence of a suitable solvent, such as for
example acetonitrile, 1-methyIpyrrolidinone, or an l, e.g. 1-butanol, optionally in
the presence of potassium iodide or a suitable base, such as for example N82003,
K2C03 or triethylamine, resulting in a compound of formula (l-Aa-d). ediates of
formula (IX) can also react with an intermediate of formula (X-a) wherein P represents a
suitable protective group, such as for example —C(=O)-O-C(CH3)3, in the ce of a
suitable base, such as for example sodium hydride, and a suitable solvent, such as for
example dimethylacetamide, resulting in an intermediate of a (XXX) which can be
deprotected to a compound of formula (l-Aa-b-1) in the presence of a suitable acid, such
as for example HCI or trifluoroacetic acid, and a suitable t, such as for e
dichloromethane or an alcohol, e.g. methanol. Intermediates of formula (XXX) can also
be prepared by reacting an ediate of formula (VI) with an intermediate of formula
We-C1_6alkyl-NR1°P wherein we represents a suitable leaving group, such as for example
halo, e.g. bromo and the like, or O)2-CH3, and P is as defined above, in the
suitable
presence of a suitable base, such as for example sodium hydride, and a
solvent, e.g. methylformamide or methylacetamide. Alternatively
compounds of formula (l—Aa-d) or (l-Aa-b-l) can also be prepared by ng
tively an intermediate of formula (VI) with an intermediate of formula W6-C1_5alkyl-
Ncycle or Wg-C1_6alkyl-NHR10 wherein we is as defined above.
Intermediates of formula (VI) can react with We-R3d wherein W5 represents a suitable
leaving group, such as for example halo, e.g. bromo, chloro, and the like, or -O-S(=O)2-
CH3 or p-toluenesulfonate, and Rad represents optionally tuted C1.6alkyl, such as
for example —CH2-C3H5, in the presence of a suitable base, such as for example sodium
hydride, 082003, potassium utoxyde or potassium hydroxide, optionally a suitable
phase transfer agent, such as for example tetrabutylammonium bromide, and a suitable
solvent, such as for example N,N-dimethylformamide, N,N-dimethylacetamide, 2-
methyltetrahydrofuran, tetrahydrofuran, water or acetonitrile, resulting in a compound of
formula (l-Aa-c). In this way, nds of formula (l-Aa-c) wherein R3 represents —
S(=O)2—N(CH3)2 can also be prepared by reacting an intermediate of formula (VI) with
dimethylsulfamoyl chloride, in the presence of a suitable base, such as for example
WO 61080
NaH, and a suitable solvent, such as for example N,N-dimethylformamide. This type of
reaction can also be used to prepare an intermediate wherein the R3d moiety is
protected by an appropriate protective group, such as for example triphenylmethyl or —
CH2'O'CH2'CH2‘Si(CH3)3 , which can then be deprotected to a compound of formul (l-
Aa-c) in the presence of a suitable acid, such as for example HCI or trifluoroacetic acid,
in a suitable solvent, such as for e dichloromethane or acetonitrile, or by reaction
with a suitable phase er agent, such as for example tetrabutylammonium fluoride
in the presence of a suitable solvent, such as for example tetrahydrofuran. This type of
reaction can also be used to prepare a compound of formula (l—Ba) (see hereinafter).
Compounds of formula (l-Aa-c) n R“ represents —CH2—C(OH)(R’)(R”) wherein R’
represents optionally substituted kyl and R” represents hydrogen or optionally
substituted C1_4alky|, said compounds being represented by formula (l—Aa-c-1 ), can be
prepared by reacting the intermediate of formula (VI) with an intermediate of formula
(XXII) in the presence of a suitable base, such as for example sodium hydride, Cs2C03,
or potassium hydroxide, and a le solvent, such as for e N,N-
dimethylformamide, N,N-dimethylacetamide, acetonitrile or water. This type of reaction
can also be used to prepare a compound of formula (l—Bb).
1{'\/1{Il
EXOH)
/ \ N\ N N\ D
// UK I
(R \
n N
(I'Bb) This type of on can also be used to introduce a —CH2-
C(OH)(R’)(R”) group on a D .
Compounds of formula (l-Aa-b) wherein R11 is C1_6alkyl substituted with amino, said
compounds being represented by formula b-2), can also be prepared according to
the following reaction Scheme 1A.
Scheme 1A
o NH
N 3
C1'5a|kyl C1 ealkyl
NHR10 NR“) NRIO
c alkl 01'63IKY'
C1-ealkyl 16 y
,NQiU”j\ N QUM: ”QUIR,
(I‘Aa'b‘z)
(I—Aa-b-l) (XXXVI)
In Scheme 1A, a compound of formula (l-Aa-b-f) is reacted with N-(haloC1_
6alkyl)phtalimide in the presence of a le base, such as for example potassium
carbonate, and a suitable solvent, such as for example acetonitrile, resulting in an
ediate of formula ) which can be converted into a compound of a (I—
Aa—b—2) by reaction with ine in the presence of a suitable solvent, such as for
example an alcohol, e.g. ethanol.
Compounds of formula (l-Aa) wherein R3 represents optionally substituted C2_6alkynyl,
said compounds being represented by formula (l-Aa-k), can be prepared according to
reaction Scheme 18.
Scheme1B
Wll'R3e
Q“U: R3e
——» / \ ~ x w
(R // |
(R / /
n N
(VI)
ln Scheme 18, an intermediate of formula (VI) is reacted with an intermediate of formula
W11-R3e wherein R39 ents optionally substituted 02-5alkynyl and W11 represents a
suitable leaving group such as for example halo, e.g. chloro, or —O-S(=O)2-CH3, in the
and a suitable solvent, such as
presence of a suitable base, such as for e NaH,
for example N,N-dimethylformamide. The intermediate WH-R3e wherein W11 represents
—O-S(=O)2-CH3, can be prepared by reacting the corresponding alcohol derivative with
methanesulfonyl chloride in the ce of a suitable base, such as for example
triethylamine or 4-dimethylaminopyridine, and a suitable solvent, such as for example
dichloromethane.
Compounds of formula (l-Aa-k), wherein R363 represents C2.6alkynyl substituted with
hydroxyl, said compounds being represented by a (l-Aa-k-1 ), can be prepared
according to the following reaction Scheme 10.
Scheme 1C
IIR/RXY
RZ—Sli
H RV\ RX 0
/ \ N N N D ‘—
Z /Sl 0—C2 6alkynleSOZ CH3- - - - 1k
\ j R ynyl
// | C2-6a
(R / \ N
n N/
(XXXVHI) (R/ n/ UNNjD
(V1)
QUEC2—6alkynyl
(I-Aa-k-l)
In Scheme 1C, an intermediate of formula (VI) is reacted with an intermediate of formula
(XXXVlII) in the presence of a suitable base, such as for example NaH, and a suitable
solvent, such as for example N,N—dimethylformamide, resulting in an intermediate of
to formula (Vlll’), which is ted into a compound of formula (I—Aa-k-1) by reaction with
a suitable acid, such as for example trifluoroacetic acid, in the presence of a suitable
solvent, such as for e tetrahydrofuran. This reaction can also be performed with
tetrabutyl ammonium fluoride in the presence of a suitable t such as for e
tetrqahydrofuran.
Alternatively, instead of an intermediate of formula (XXXVIII), halo-szaalkynyl-O-
Si(RX)(Ry)(RZ) can also be used.
Compounds of formula (l-Aa-k), wherein R3e represents Cg.6alkynyl, said compounds
being ented by formula (l-Aa-k-2), can be prepared according to the following
reaction Scheme 1D.
Scheme 1D
H3C\ [CH3 1
/ \ N\ N\j H3C/Si—C2—6alkynyl-Wl3 C2-6alkyny1
(V1)
(XXXXH)
kynyl
/ \ IL N\ N\ D
(I-Aa-k-Z)
In Scheme 1D, a compound of formula (l-Aa—k-2) is prepared by deprotecting an
intermediate of formula (XXXXll) in the presence of a suitable base, such as for example
K2003, and a suitable solvent, such as for example an alcohol, e.g. methanol and the
like. Said ediate of formula l) can be prepared by reacting an intermediate
of formula (VI) with W13-C2_6alkynyl-Si(CH3) 3 wherein W13 is a suitable leaving group,
such as for example halogen, in the presence of a suitable base, such as for example
NaH, and a le solvent, such as for example N,N-dimethylformamide.
Compounds of formula (l-Aa), wherein R3 represents ethyl substituted with —P(=O)(OC1-
6alkyl)2, said compounds being represented by formula (l-Aa-l), can be prepared
according to the following reaction Scheme 1E.
Scheme 1E
C1'6alkylx (H) 1kyl
o\P/o
H . .
\ N D d1(C1_6a1ky1)V1nylphosphonate (CH2)2
/ N\ NT |
I \ D
(R// N
/ / N\ N\
n N / / I
(R / /
n N
(I-Aa—l)
In scheme 1E, an intermediate of formula (VI) is reacted with di(C1-
)vinylphosphonate in the presence of a suitable catalyst, such as for example tri-N-
butylphosphine, and a suitable solvent, such as for e acetonitrile resulting in a
compound of formula (la—l).
Intermediates of formula (N) can be ed according to the following reaction
Scheme 2.
N Br Vko/ 0
t lN\ 1
___, t I
/ /
N 2
C1 NH2 N NH2 i /“IV0—
Cl C1 N NH2
0\ /D \ 3
W1 N\ N\ D HO N\ N\ D :Krd
UI N\ \
<— l +____
/j / / / / /
N N i lA/L
Br N N OH
(IV)
In Scheme 2, the following reaction conditions apply:
1 : in the presence of a suitable leaving group introducing agent, such as for example N-
bromosuccinimide, and a le solvent, such as for example chloroform (We
represents a suitable leaving group, such as for e a halo, e.g. chloro.
2 : in the presence of a suitable catalyst, such as for example bis(tri-tert—butyl-
phosphine)palladium(0),a le base, such as for example triethylamine, and a
suitable solvent, such as for example N,N—dimethylformamide.
3 : in the presence of a suitable acid, such as for example HBr/acetic acid.
4 : in the presence of a suitable catalyst, such as for example
tetrakis(triphenylphosphine)palladium, a suitable base, such as for example N32C03,
and a suitable t, such as for example 1,2-dimethoxyethane and water.
: in the presence of a suitable leaving group introducing agent, such as for example
POCI3.
Intermediates of formula (N) can also be prepared according to the following reaction
Scheme 2A.
Scheme 2A
O\/D
(5 CIN\N\D
CINNBH4
j/—-——> I —-——> Ur/N/
// N
HN/’\O Cl N\ N\ Nd
Cl UI ~N\ N\ Cl \J U 1/
/ /
/ /
In Scheme 2A, the following reaction conditions apply :
1: in the presence of POCl3 and a suitable solvent, such as for example N,N-
dimethylformamide or 1,2—dichloroethane.
2 : in the presence of a suitable catalyst, such as for example
tetrakis(triphenylphosphine)palladium, a suitable base, such as for example Na2003,
and a suitable solvent, such as for example methoxyethane and water,
ylether. Or
3 : in the presence of a le base, such as for example triethylamine, and a suitable
solvent, such as for example romethane.
In general, compounds of formula (l-B) wherein Y is D (E is a bond), said compounds
being represented by formula (l-Ba), can be prepared according to the following
reactions in Scheme 3.
Scheme 3
(RZ/)n/ (VDU j/W6-R3d(R/// UNNjD
$2 (I—Ba)
Ry... -_SI Rx OH
tetrabutylammonium
O fluoride C1-6a1ky1
C1—6a1ky1 GNU}: j/D mg)“
(R)nGNU}: j/D 2) (I-Aa-a)
(VIII)
RY—Si—R" 9H
(5 tetrabutylammonium C 1 —6alky1
I fluoride
fil-éakyl
/ \ N N GNU j/D (R2)n
/ \IN
(R2)n ]/D (I-Ba-a)
(VIII')
in Scheme 3, an intermediate of formula (VI) can react with We-R3 wherein W6
represents a suitable leaving group, such as for example halo, e.g. bromo and the like,
or —O-S(=O)2—CH3 or p-toluenesulfonate, in the presence of a suitable base, such as for
example potassium hydroxide or sodium hydride, and optionally a suitable phase
transfer agent, such as for e tetrabutylammonium bromide and, and a suitable
solvent, such as for example 2-methyltetrahydrofuran and water or N,N-
dimethylformamide, resulting in a nd of a (l-Ba).
intermediates of formula (Vlll) can react with tetrabutylammonium fluoride, in the
ce of a suitable solvent, such as for example tetrahydrofuran, ing in a
compound of formula (l—Aa—a). This type of on can also be used to prepare a
compound of formula a).
Intermediates of formula (Vlll’) wherein D is a ring moiety containing a nitrogen atom,
can be further reacted according to the following reaction Scheme 4.
Scheme 4
$2 Ry—— 1—1C"
Rx I
RY—. '_31 R" I 1|1alo Ry—Si—R" R6
C1 6a1kyl l
C1 éalkyl C a1 1
lill'éNky 16_ aIkyI
\ y1
F://\ N QUND1N \ N
(R ///
( n (R n
(v111'-b)
(VHF-a) (VHH)
Z RZ
OH I. P 1"
Ry—Si—R" y 1
R6 R —Sl—‘R 1&6 136
l OH
O 1 C — alky1
Ci‘éalky—>1 C at 1 16
‘6 L’
01 1a1ky1 016a1ky1 $1-6a1ky1 mlu
U:1N\ :rDN 112/QNlU:1:rDN )Q/N N\ Nj
(VHP‘C'I) -c--2) (XXXIX)
R6 C
NR10R11 1'36 :6
C16alkyl (I216aIkYI 10 11 R“
NR R C1 salkyl
C1 6alky1
\ N
C 1-621“(1y
n(R)2 UT?)NQ/NlCl -6alky1
n(R2)/ my 76011]U:jjDN
(I-Ab-4) (XXXX)
(xxxx1)
in Scheme 4, the D’N moiety represents a —D moiety wherein the D ring moiety contains
a nitrogen atom. Intermediates of a (Vlll’) wherein D represents D’NH, said
intermediates being ented by formula (Vlll’—a), can be converted into an
intermediate of formula (Vlll’-b) by reaction with W12-C1_6alkyl—halo wherein W12
represents a suitable leaving group, such as for example halo, e.g. chloro, in the
suitable solvent, such as
presence of a suitable base, such as for example NaH, and a
for example methylformamide. Said intermediates of formula (Vlll’-b) can be
ted into an intermediate of formula (Vlll’~c) by reaction with R6 in the presence of
a suitable base, such as for example K2003, and a suitable t, such as for example
acetonitrile. When in an intermediate of formula (Vll|’-c) the R6 carries a hydroxyl group
as in an intermediate of formula (Vlll’-c—1), then said hydroxyl group can be protected by
a suitable protective group P, such as for example —O-C(=O)—C1_6alkyl, by on with
C1_6a|kyl—C(=O)-W12, in the presence of a suitable base, such as for example
triethylamine, 4-dimethylaminopyridine, and a suitable t, such as for example
dichloromethane, ing in an intermediate of formula (Vlll’—c-2) which can be
converted into an intermediate of formula (XXXIX) by reaction with tetrabutylammonium
fluoride in the presence of a suitable solvent, such as for example tetrahydrofuran. Said
intermediate of formula ) can be converted into an intermediate of formula
(XXXX) wherein Ru represents —SOZCH3,by reaction with methane sulfonyl chloride in
the presence of a suitable base, such as for example triethylamine, and a suitable
solvent, such as for example dichloromethane. in ular, this type of reaction is used
to prepare ediates of formula (XXXX) wherein C1-6alkyl represents 03-6alkyl. For
some variants of intermediates of formula (XXXX), e.g. wherein C1_6alkyl represents C1-
Zalkyl, it might be preferred to m the reaction in non basic conditions.
Intermediates of formula (XXXX) can be converted into an intermediate of formula
(XXXXl) by reaction with an intermediate of a (X) in a suitable solvent, such as for
example acetonitrile. Said intermediate of formula (XXXXI) can then be deprotected into
a compound of formula (l-Aa-b-4) in the presence of a suitable base, such as for
example K2C03, and a le solvent, such as for example an alcohol, e.g. methanol
and the like. It is considered to be within the knowledge of the person skilled in the art
to recognize for which other D ring moieties the described reactions also apply.
Intermediates of formula (Vlll’) can also be reacted to prepare compounds of the t
invention according to the reaction schemes as presented in Scheme 1. It is considered
to be within the knowledge of the skilled person to recognize in which condition and for
which definitions of R1 on the D ring moiety a protective group may be riate for
the reactions to be carried out. For instance, a hydroxyl group within the definition of R1
may be protected with a tert. butyldimethylsilyl moiety; a NH group within the definition
of R1 may be protected with a —C(=O)—O-C(CH3)3 group.
It is also considered to be within the knowledge of the skilled person to recognize
appropriate deprotection reactions.
nds of a c) can alternatively also be prepared according to the
below reaction Scheme 5.
Scheme 5
R3dNH2 om
W2 N\ N\ D (Ron
U j ——-> HNUNNjD (XIV)
/ N/ ——-——-————-—->
(XX)
(I-Aa—c)
In Scheme 5, an intermediate of formula (W) is reacted with R3d-NH2 in the ce of
a suitable catalyst, such as for example palladium (ll) acetate, a le base, such as
for example sodium tert—butoxide, and a suitable ligand, such as for example 1,1'-[1,1'—
binaphthalene]-2,2'—diylbis[1,1-diphenylphosphine], resulting in an intermediate of
formula (XX) which is reacted in a next step with an intermediate of a (XlV) in the
presence of a suitable st, such as for example palladium (ll) acetate or Pd2(dba)3
(tris(dibenzylidene acetone) dipalladium (0)), a suitable ligand such as for example 2-
dicyclohexylphosphino-tris-isopropyl-biphenyl or 1,1'-[1,1'—binaphthalene]—2,2'—
diylbis[1,1-diphenylphosphine], a suitable base, such as for example sodium tert-
butoxide, and a suitable solvent, such as for e ne glycol dimethylether.
Compounds of formula (I) wherein R3 is C1_6alkyl substituted with 5-amino-1,3,4—
oxadiazolyl or with 1,3,4-oxadiazolyl or with 2(3H)~1,3,4-oxadiazolonyl can be prepared
according to the below reaction Scheme 6.
Scheme 6
C(=O)oC1-4alkyl HzN
C1-6alkyl NHZ-NHZ C(=O)NHNH2 >‘N
RQU 8-
/ \ N 1;“|N\ N\:(Y—-—> C1-6alkyl
(I--Ac 1) (Rzln/
<thGNU:
(XXXI)
(1 Ac 2)
I IN‘
HNf0
HN-<O 3
N, N90
\ 0 C1 ea'ky'
my. \ N c1 ealkyl
/ \ N IN\ NjY (R)nQU:
(RQU:In
(R23: (1N:
In Scheme 6, a nd of formula 1) is reacted with NHg-NHZ in the presence of
a suitable solvent, such as for example an alcohol, e.g. ethanol resulting in an
intermediate of a (XXXI) which is then reacted in a next step with Ws-CN, wherein
W8 represents a suitable leaving group, such as for example halo, e.g. bromo, in the
presence of a suitable base, such as for example NaHCog, and a suitable solvent, such
as for example water or e. ediates of formula (XXXI) can further be reacted
as described in step 1 in the above scheme in the presence of 1,1’—carbonyldiimidazole
and a suitable solvent, such as for example e. Or intermediates of formula (XXXI)
can be reacted as descrinbed in step 2 in the above scheme in the presence of
trimethylorthoformate. The resulting intermediate can further be reacted as described in
step 3 in the above scheme in the presence of xylene.
Reaction Schemes 6 A describes the ation of compounds of formula (I) wherein
R3 is C1_6alkyl substituted with 5-methyl-1,2,4-oxadiazolyl.
Scheme 6A
(131-6alkyl HzNfl—OH
O/N N\ N\ Y C1—6alkyl NO‘(
// l j _-1—:©/NU\ (R)n2) UN/ LID/U2)(R) \ C1-6alkNylN
In Scheme 6A, the ing on conditions apply:
1: in the ce of hydroxylamine HCI, a suitable base, such as for example
triethylamine, and a suitable solvent, such as for example an alcohol, e.g. ethanol.
2 ; in the presence of sodium ethoxide and a suitable t, such as for example an
alcohol, e.g. ethanol.
Compounds of formula (l) wherein R3 is C1_6alkyl substituted with 3,3-dimethyl-
morpholine can be prepared according to the below reaction Scheme 7.
Scheme 7
NH/P
0 km:
HOV 0
HO 0
C1—ealkyl P
(SQ/U\ N C16alkyl
UUj\N
C16alkyl
(R2)
(th13’”
(xxxm)
(xxxu)
(I-Ac-3)
NH/P
\ ” o o
,,S\ o
O// 0% gg—OV 0%
\ :1Galkyl C1"631;“
(R2)QUZ: N/ “(Q/NU_—>\\(NHN(R)2)
(XXXIV)
(XXXV) (l-Ac4)
ln Scheme 7, a compound of formula (l-Ac-3) is reacted with 2-amino-2—methyI
propanol in the presence of a suitable base, such as for example NaH and in the
2012/052672
presence of a suitable solvent, such as for e N,N—dimethylformamide ing in
an intermediate of formula (XXXll) of which the NH2 moiety is protected by a suitable
protecting group P, such as for example —O-C(CH3)3, by reaction with for
instance t—butyl dicarbonate in the presence of a suitable solvent, such as for
example dioxane, and a suitable base, such as for example NaHCOg, resulting in an
intermediate of formula (XXXlll). in a next step, said intermediate is reacted with
methanesulfonyl chloride in the presence of a le solvent, such as for example
dichloromethane, and a suitable base, such as for example triethylamine resulting in an
intermediate of formula (XXXIV). In particular, this type of reaction is used to prepare
intermediates of formula (XXXIV) wherein C1‘6alkyl represents Cg_6alkyl. For some
variants of intermediates of formula (XXXIV), e.g. wherein C1-5alkyl represents Cmalkyl it
might be preferred to perform the on in non basic conditions. Intermediates of
formula (XXXIV) are converted into an intermediate of formula (XXXV) by reaction with a
suitable acid, such as for example trifluoroacetic acid, in the presence of a suitable
solvent, such as for e dichloromethane. The intermediate of formula (XXXV) is
converted into a compound of formula (l-Ac—4) by reaction with a suitable base, such as
for example N, N-diisopropylethylamine and triethylamine in the presence of a suitable
solvent, such as for e an alcohol, e.g. methanol.
As already shown above, compounds of formula (I) or some of the above-described
intermediates can be prepared by deprotecting the corresponding protected compounds.
Other protection-deprotection ons are shown in the following reaction Scheme 8.
swim
o-1>
P’—O- C1-6alkyl—W9 N\(|:|1-63IkyI
(R2),,QNfi j“GNU j” (th
“ (XXVI) a01d or base-
C1-4a1ky1—O— C_C1-6a1ky1—W9
(XXVH) (PH
f1 - a6 IkyI
3 O-C1-4alky1
(l:(=0)
C1—6alkyl
(RI)GNU jYN :rl 2)
(R2):
(X VIII)
4 9H <9
C1—6alkyl
(l:(=0)
\ NU :(YN H/IO C1—6alkyl
(XXI) 1,1 I
(R237 / \ N W
N\ N\
(XXIX) (RN/)n/ UNI
(13(4))
C1 —ealkyl
ln S)cheme 8, the Y’N moiety represents an —E-D moiety wherein the D ring moiety
contains a nitrogen atom. Compounds of formula (I) wherein R1 ents hydroxyC1_
Balkyl can be prepared by deprotecting an intermediate of formula (XXVI) in the
presence of a suitable acid, such as for example HCI or oroacetic acid, or a suitable
de-silylating agent, such as for example utyl ammonium fluoride, and a suitable
solvent, such as an alcohol, e.g. methanol, or tetrahydrofuran (step 2). ediates of
formula (XXVI) can be ed by reacting a compound of formula (I) wherein R1 is
WO 61080
hydrogen with an intermediate of a (XXIV) wherein W9 represents a suitable
leaving group, such as for example halo, e.g. bromo and the like, and P represents a
suitable protective group, such as for example —Si(CH3)2(C(CH3)3) or in the
presence of a suitable base, such as for example sodium hydride or K2CO3, and a
suitable solvent, such as for example N,N-dimethylformamide or acetonitrile (step 1).
Compounds of formula (l) wherein R1 ents C1_6a|kyl substituted with —C(=O)—R6
wherein R6 is an appropriate nitrogen containing ring linked to the C(=O) moiety via the
nitrogen atom can be prepared by reacting an intermediate of formula (XXIX) with an
intermediate of formula (XXI) in the presence of suitable e coupling reagents such
as, oxy-benzotriazole and 1~(3-dimethylaminopropyl)—3-ethy| carbodiimide HCI
(step 5). Intermediates of formula (XXIX) can be prepared by reacting an intermediate
of formula (XXVIII) with LiOH in the presence of a suitable solvent, such as for example
tetrahydrofuran or water (step 4). Intermediates of formula (XXVIII) can be prepared by
as depicted in step 3 with an intermediate of formula (XXVII) wherein W9 is as defined
above, in the presence of a suitable base, such as for example sodium hydride, and a
suitable t, such as for example N,N-dimethylformamide.
Step 6 depicts the preparation of compounds of formula (I) starting from an intermediate
of formula (XXIX) by reaction with NHR4R5 in the ce of le peptide coupling
ts such as 1-hydroxy—benzotriazole and 1-(3-dimethylaminopropyl)—3-ethyl
carbodiimide HCI and a suitable base, such as triethylamine, and a suitable solvent,
such as for example dichloromethane.
Further tion-deprotection reactions can also be used as outlined in the following
reaction Scheme 9.
Scheme 9
(3—1)
YNH P—O—Cmalkyl—Wg
w2 N N
\ \ '01-salkyi @NH2
(XXIV) 2’/
l w2 N YN (R )n ()V
—, N
/ /
1 N
(IV-a) 2
(IV-P)
C1-6alkyl
‘3 ml
R24, (R2)n/ / N/
[DA/V5l (VI-P1)
(R2)n-1 <V-P)
Y ,
H2N N\ Nj P_RZ\ III
l \ N N N\ Y
/ N/
3 4/ U 1
(R )“'1 /
(X111) N
R8R7N-R2\ If
(R2)n.1@ij// / N/
7 8
NHR R
Ho—R2‘\ 1'13 I 7
[E/N N\ NjY 4 1'13
(R23/ 1 H3C-(O=)2S-O-R2\
N Y
/ / N\ N\
"‘1 N [ \
C1-S(=O)2-CH3 2/ / I
(R )n—1 / N/
1 NH
0 o
HzN—RZ' R3
\\ I 6
[JR] Y N—RZ' R3
N\ N\ 4—— \ i
[ \ N N\ N\ Y
2// U /
(R )n-1 / N/
In Scheme 9, the ing reaction conditions apply:
1 ; in the presence of a suitable base, such as for e sodium hydride, and a
suitable solvent, such as for example N,N-dimethylformamide.
2 : in the presence of a suitable catalyst, such as for example palladium (ll)acetate, a
suitable base, such as for example sodium tert-butoxide, a suitable ligand, such as for
2012/052672
example l,1'-[1,1'-binaphthalene]-2,2'-diylbis[1,1-diphenylphosphine], and a suitable
solvent, such as for example dioxane or ethylene glycol ylether.
3 : in the presence of a le catalyst, such as for example palladium (ll)acetate, a
suitable base, such as for example sodium tert—butoxide, a suitable ligand, such as for
example 1,1'-binaphtha|ene]—2,2'-diylbis[1,1—diphenylphosphine], and a suitable
solvent, such as for example dioxane or ethylene glycol dimethylether.
4 : in the presence of a suitable base, such as for e triethylamine, and a suitable
solvent, such as for example dichloromethane.
: in the presence of a suitable base, such as for example K2003, and a suitable
solvent, such as for example 1~methylpyrrolidinone.
6 : in the presence of hydrazine monohydrate, and a suitable t, such as for
example an alcohol, e.g. ethanol.
7 : in the presence of a suitable base, such as for example K2C03, and a suitable
solvent, such as for example tetrahydrofuran.
Compounds of formula (l-A) can also be prepared as outlined in the following reaction
Scheme 10.
POCI3
HOUNI ——* HOUNI ”—’ UION
( )n N W ~R3d6
\ N\ N\ CN
__» l |
3 2/)/ / N/ / sodium azide
(R n
lhydroolysw—w—>‘ hydrolys1s'
6 HN/NN
UUZJU UUZECOOHRN
(Ran
(Mn2) 111 HNMeOMe
NRZZR" ’ |
7 I[{3d \N/o
UziU3*? ~
(R2)n
RNMNNl12 W6_R3d
(R2): 0UfioN\ N\ N\
(R2)n N
HZNORIQ J
($22)”
In Scheme 10, the following reaction conditions apply:
1 : in the presence of zinc cyanide, a le catalyst such as for example
tetrakis(triphenylphosphine)palladium, a suitable ligand, such as for example
triphenylphosphine, and a suitable solvent, such as for example acetonitrile
2 : in the presence of a chlorinating agent such as for example POCI3
3: in the presence of a le solvent, such as for e an alcohol, e.g. n-propanol
4 : in the presence of a suitable base, such as for e sodium hydride, 032003, or
potassium hydroxide and a suitable phase transfer agent, such as for example
utylammonium bromide, and a suitable solvent, such as for example N,N-
dimethylformamide, N,N-dimethylacetamide, 2-methyltetrahydrofuran, water or
acetonitrile
: in the presence of ammonium de and a suitable solvent, such as for example
N,N-dimethylformamide
6-7 : first hydrolysis of the CN to the acid according to art-known methods, followed by
reacting the resulting acid with NH(CH3)(OCH3) in the presence of a suitable coupling
agent, such as for example N-3—(ethylcarbonimidoy|)—N1,N1-dimethyl-1,3-
ropanediamine, hydrochloride (1:1), a le peptide coupling agent such as for
example hydroxybenzotriazole, and a suitable solvent, such as for example
tetrahydrofuran or dichloromethane
8: reaction with a suitable Grignard reagent in the presence of a suitable t, such
as for example tetrahydrofuran
9 : in the presence of pyridine and a suitable solvent, such as for example an alcohol,
e.g. ethanol
10 : hydrolysis of the CN to the acid according to own methods
11 : in the ce of a suitable coupling agent, such as for example N
(ethylcarbonimidoyl)—N1,N1-dimethyl-1,3-propanediamine, hydrochloride (1:1), a
suitable peptide coupling agent such as for e hydroxybenzotriazole, and a
suitable solvent, such as for example tetrahydrofuran or dichloromethane. RX represents
-(CR22R23)s-D.
12 : in the presence of a suitable base, such as for example sodium hydride, ngCOg, or
potassium ide and a suitable phase transfer agent, such as for example
tetrabutylammonium bromide, and a suitable solvent, such as for example N,N—
dimethylformamide, N,N-dimethylacetamide, 2—methyltetrahydrofuran, water or
acetonitrile
Compounds of formula (l-A) can also be prepared as outlined in the ing reaction
Scheme 1 1.
Scheme 1 1
Sli:
HOUNNj/B P003 GUNj/Br-———>\/src=*CH UZD/
ll: (F8)n
4 l W6-R3d
@Nu/
j/E formaldehyde R301
I /
/ \ N N\ N\ /
(R2): sodium azide l
(szn/ / /
In Scheme 11, the following reaction conditions apply:
1 : in the presence of a chlorinating agent such as for example POCl3
2 : in the presence of a suitable catalyst, such as for example
dichIorobis(triphenylphosphine) ium (II) and copper iodide, optionally a suitable
ligand, such as for example triphenylphosphine, a suitable base, such as for example
triethylamine, and a suitable solvent, such as for example N,N-dimethylformamide
3: in the presence of a suitable solvent, such as for example an alcohol, e.g. n-propanol
4 ; in the presence of a suitable base, such as for example sodium hydride, 032003, or
potassium hydroxide and a le phase er agent, such as for example
tetrabutylammonium bromide, and a suitable solvent, such as for e N,N-
dimethylformamide, N,N-dimethylacetamide, 2-methyltetrahydrofuran, water or
acetonitrile
5 : in the presence of a suitable base, such as for example sodium hydroxyde, and a
suitable solvent, such as for example an alcohol, e.g. ol.
6 : in the presence of a suitable catalyst, such as for example copper sulfate and sodium
L ascorbate, and a suitable solvent, such as for example dioxane and acetic acid
nds of formula (l-A) can also be prepared as outlined in the following reaction
Scheme 12.
Scheme 12
NRX ©an
(R),,2) UI —> U:IfR' ’
(R2)QNUleN/ N/
3 l w6_R3d
RX deprotection
(R2)orNfi: N areN//(R
In Scheme 12, the ing reaction conditions apply:. RX represents -(CR22R23)s-D, and
R’ represents R22 or a suitable protecting group, such as for example benzyl
1 : in the presence of a le base, such as for example cesium carbonate,and a
suitable solvent, such as for example N,N-dimethylformamide
2 ; in the presence of a le solvent, such as for example an alcohol, e.g. n-
ol. atively such reaction could also be performed in the presence of a
suitable catalyst, such as for example palladium (ll) acetate, a suitable base, such as
sodium tert—butoxide or Cs2C03, a suitable ligand, such as for example 1,1’-[1,1'-
binaphthalene]-2,2'—diylbis[1,1-diphenylphosphine], and a suitable solvent or solvent
mixture, such as for example dioxane or ethylene glycol dimethylether and water or N—
methyl-pyrrolidone
3 : in the ce of a suitable base, such as for example sodium hydride, ngcog, or
potassium hydroxide and a le phase transfer agent, such as for example
tetrabutylammonium bromide, and a suitable solvent, such as for example N,N-
dimethylformamide, N,N-dimethylacetamide, 2-methyltetrahydrofuran, water or
acetonitrile
4 : deprotection according to art-known methods in case R’ is a suitable protecting
group.
It is to be considered to be within the knowledge of the person skilled in the art to
ize which of the reactions described above for compounds of (l-A) are also
applicable for compounds of formula (l-B).
It is considered to be within the knowledge of the person skilled in the art to recognize in
which ion and on which part of the molecule a protective group may be
appropriate. For instance, protective group on the R1 substituent or on the D moiety, or
protective group on the R3 substituent or on the R2 substituent or combinations thereof.
The skilled person is also considered to be able to ize the most le
protective group, such as for e —C(=O)—O-C1-4alkyl or or —
Si(CH3)2(C(CH3)3) or -CH2-O-CH2CH2-O-CH3 or -CH2-O-CH2-CH2-Si(CH3) 3.The skilled
person is also considered to be able to recognize the most feasible deprotection
on conditions, such as for example suitable acids, e.g. trifluoroacetic acid,
hydrochloric acid, or suitable salts, such as for example tetrabutylammonium fluoride.
Reference herefore is also made to the es described in the Experimental Part
hereinafter.
The skilled person is also ered to be able to recognize that when R1 represents
C(=O)—morpholinyl, said R1 can be prepared from —C(=O)—NH-CHZ'CHQ-O'CHz-CHQ-O'
802methylphenyl, in the presence of sodium hydride, and a suitable solvent, such as
for example N,N-dimethylformamide. Or that when R1 represents —NH-C(=O)-
morpholinyl, said R1 can be prepared from —NH-C(=O)—O-C(CH3)3 in the presence of
morpholine, and a suitable solvent, such as for e 1-methyl-2—pyrrolidinone.Or that
when R1 represents hydroxle1_6alkyl, e.g. —CH2—CH2-OH, said R1 can be prepared from
the corresponding alkoxycarbonyl intermediate, e.g. —CH2-C(=O)-O-CH2-CH3, in the
for example
presence of Dibal-H 1M in hexane, and a suitable solvent, such as
tetrahyd rofuran.
The present invention also ses deuterated compounds. These deuterated
compounds may be prepared by using the appropriate deuterated intermediates during
the synthesis process. For instance an intermediate of formula (IV-a)
(OH)n can be converted into an intermediate of formula (IV-b)
(OCD3)n by reaction with iodomethane-D3 in the presence of a suitable base,
such as for example cesium carbonate, and a le t, such as for example
acetonitrile.
The compounds of formula (I) may also be converted into each other via art—known
reactions or functional group transformations.
For instance, compounds of formula (I) wherein R1 represents tetrahydropyranyl can be
converted into a compound of formula (I) wherein R1 represents hydrogen, by on
IO with a suitable acid, such as for example HCI or trifluoroacetic acid, in the presence of a
le solvent, such as for example dichloromethane, dioxane, or an l, e.g.
methanol, isopropanol and the like.
Compounds of formula (I) wherein R1 or R3 ent monohaloalkyl, can be converted
into a compound of formula (I) wherein R1 or R3 represent C1_6alkyl substituted with a
ring moiety as defined hereinabove by the intermediate of formula (XXI) and linked to
the C1-5a|ky| moiety by the nitrogen atom, by reaction with an intermediate of formula
(XXI) optionally in the presence of a suitable base, such as for example triethylamine or
K2003 or sodium hydride, and optionally in the presence of a suitable solvent, such as
for example acetonitrile, N,N—dimethylformamide or 1-methyIpyrrolidinone. For the R3
moiety, this type of reaction is in particular used to prepare compounds wherein C1_6alkyl
represents 03-6alkyl. For some variants of the compounds, e.g. wherein C1_6alkyl
represents C1_2alkyl, it might be preferred to perform the reaction in non basic
conditions.
Compounds of formula (I) n R1 or R3 represents C1.6alkyI-OH, can be converted
into a compound of formula (I) wherein R1 or R3 represent C1-6alkyI-F by reaction with
laminosulfur trifluoride in the presence of a suitable solvent, such as for example
dichloromethane and in the ce of catalytic amounts of an alcohol, such as for
example l. Likewise, a compound of formula (I) wherein R1 or R3 represent C1-
Balkyl substituted with R6 or R9 n said R6 or R9 is substituted with CH, can be
converted into a compound of a (I) wherein R1 or R3 represent C1_6alkyl
substituted with R6 or R9 wherein said R6 or R9 is tuted with F, by reaction with
laminosulfur oride in the presence of a suitable solvent, such as for example
dichloromethane.
Compounds of formula (I) wherein R1 or R3 represent C1_6alkyl substituted with R6 or R9
wherein said R6 or R9 is substituted with —C(=O)—O-C1_6alkyl, can be converted into a
compound of formula (I) wherein R1 or R3 represent kyl substituted with R6 or R9
wherein said R6 or R9 is substituted with —CH2-OH, by reaction with LiAIH4 in the
presence of a suitable solvent, such as for example tetrahydrofuran.
Compounds of formula (I) wherein R3 represents C1_5alkyl substituted with 1,3—dioxo-2H-
isoindoI-Z-yl, can be converted into a nd of formula (I) n R3 represents C1-
6alkyl substituted with amino, by reaction with hydrazine monohydrate in the presence of
a suitable solvent, such as for example an alcohol, e.g. ethanol.
Compounds of a (I) wherein R1 or R3 represent Ci-6alkyl substituted with amino,
can be converted into a compound of formula (I) wherein R1 or R3 represents C1,6alkyl
substituted with —NH-S(=O)2-C1_6alkyl, by reaction with Cl-S(=O)2-C1-5alkyl in the
suitable solvent,
presence of a suitable base, such as for example triethylamine, and a
such as for e dichloromethane.
Compounds of formula (I) n R1 or R3 represents kyl substituted with halo,
can be converted into a compound of formula (I) wherein R1 or R3 represent C1_6alkyl
substituted with NR4R5 or NR10R“, by reaction with NHR4R5 or NHR10R“, either using
such amino in large excess or in the presence of a le base, such as for example
K2C03, and a suitable t, such as for example itrile, N,N-dimethylacetamide
or 1-methyI—pyrrolidinone. For the R3 moiety, this type of reaction is in particular used to
prepare compounds wherein C1_6alkyl represents C3-6alkyl. For some variants of the
compounds, e.g. wherein C1_6alkyl represents Cmalkyl, it might be preferred to perform
the reaction in non basic conditions.
nds of formula (I) wherein R1 represents hydrogen, can be converted into a
compound of formula (I) wherein R1 represents polyhaloC1-6aIkyl or polyhydroxyC1_6alkyl
or C1_6alkyl or —S(=0)2-NR‘4R15 or 2-C1_6alkyl, by reaction with polyhanC1_6alkyl-
w or polyhydroxyC1.ealkyl-W or C1.6alkyI-W or W-S(=O)2-NR14R15 or W-S(=O)2—C1.6alkyl,
wherein W represents a suitable g group, such as for example halo, e.g. bromo
and the like, in the presence of a suitable base, such as for example sodium hydride or
K2003 or triethylamine or 4-dimethylamino-pyridine or diisopropylamine, and a suitable
solvent, such as for e N,N-dimethylformamide or acetonitrile or dichloromethane.
Compounds of formula (I) wherein R1 represents hydrogen can also be converted into a
compound of formula (I) wherein R1 represents C1_5alkyI-OH, by reaction with W-C1_
5alkyl-O-Si(CH3)2(C(CH3)3) in the presence of a suitable base, such as for e
sodium hydride, and a le solvent, such as for example N,N-dimethylformamide.
Compounds of formula (l) n R1 represents hydrogen, can also be converted into
compound of formula (I) wherein R1 represents ethyl substituted with 2-C1.6alkyl,
by reaction with C1_6alkyI-vinylsulfone, in the presence of a suitable base, such as for
example triethylamine, and a suitable solvent, such as for example an alcohol, e.g.
methanol or by reaction with C1-6alkyl—2-bromoethylsulfone in the presence of a suitable
onating agent, such as for example NaH, and a suitable solvent, such as for
example dimethyformamide.
Compounds of formula (I) wherein R1 represents en can also be converted into a
compound of a (I) wherein R1 represents HOH—CH2 Q, by reaction
0&9in the presence of a suitable base, such as for example sodium
hydride, and a suitable solvent, such as for e N,N-dimethylformamide, wherein
YbO represents a suitable nitrogen containing ring within the definition of R6.
Compounds of formula (I) wherein R1 represents C1_6alkyl tuted with R6 wherein
said R6 is substituted with —C(=O)—O-C1_salkyl or —S(=0)2-NR14R15 or wherein R3
represents C1_6alkyl substituted with R9 wherein said R9 is substituted with —C(=O)—O-C1_
salkyl or —-S(=O)2-NR14R15, can be converted into a compound of formula (I) wherein the
R6 or R9 is unsubstituted, by reaction with a suitable acid, such as for example HCI and
a suitable solvent, such as for e e, acetonitrile or an alcohol, e.g.
isopropylalcohol. Compounds of formula (I) wherein R1 represents kyl substituted
with R6 wherein said R6 is a ring moiety comprising a nitrogen atom which is substituted
with -CH2-OH or wherein R3 represents C1_6alkyl substituted with R9 wherein said R9 is a
ring moiety comprising a nitrogen atom which is substituted with H, can be
converted into a compound of formula (I) wherein the R6 or R9 is unsubstituted, by
reaction with sodium hydroxide, in the presence of a suitable solvent, such as for
example tetrahydrofuran.
nds of formula (I) n R1 represents C1_5alkyl substituted with R6 or R3
represents C1_6alkyl substituted with R9, wherein said R6 or said R9 is unsubstituted, can
be converted into a compound of formula (I) wherein said R6 or said R9 is substituted
with C1-6alkyl, by on with W-C1_6alkyl wherein W is as defined above, in the
presence of a suitable base. Such as for example sodium hydride, and a suitable
solvent, such as for example N,N-dimethylformamide.
Compounds of formula (l) wherein R1 or R3 represent hydroxyC1_6alkyl, can be
converted into the corresponding carbonyl compound, by reaction with dess—Martin—
inane, in the presence of a suitable solvent, such as for example
dichloromethane.
Compounds of formula (I) wherein R1 represents C1_6alkyl substituted with R6 or R3
represents kyl substituted with R9, wherein said R6 or said R9 is tuted with C1.
salkyI—halo, can be converted into a compound of formula (I) wherein said R6 or said R9
is substituted with C1.6alkyI-CN, by reaction with sodium cyanide, in the presence of a
suitable solvent, such as for example water or an alcohol, e.g. ethanol.
nds of formula (I) wherein R1 represents C1-6alkyl substituted with R6 wherein
said R6 is unsubstituted or wherein R3 represents C1-6alkyl substituted with R9 wherein
said R9 is unsubstituted, can be converted into a nd of formula (I) wherein R6 or
R9 is substituted with —CH3 or —-CH(CH3)2, by reaction with formaldehyde or e and
N, in the presence of a le t, such as for example tetrahydrofuran or
an alcohol, e.g. methanol.
Compounds of formula (I) wherein R1 contains a R6 substituent substituted with OH or
wherein R3 contains a R9 substituent substituted with OH, can be converted into a
compound of formula (I) wherein the R6 or R9 substituent is substituted with C1-6alkyloxy,
by reaction with W-C1-6alkyl, in the presence of a suitable base, such as for example
sodium hydride, and a suitable solvent, such as for example N,N-dimethylformamide.
Compounds of formula (I) wherein R1 contains a R6 tuent substituted with C1-
5alkyloxy or wherein R3 contains a R9 tuent substituted with kyloxy, can be
converted into a compound of formula (I) wherein the R6 or R9 substituent is substituted
with —OH by reaction with a suitable acid, such as for example hydrochloric acid.
Compounds of formula (I) wherein R1 contains a R6 substituent substituted with halo or
wherein R3 ns a R9 substituent substituted with halo can be converted into a
compound of formula (I) wherein the R6 or R9 substituent is substituted with —NR14R15 by
reaction with NHRMR15 in a suitable sovent, such as for example 1-methyl—pyrrolidinone.
Compounds of formula (I) wherein R3 represents C1_6alkyl substituted with —C(=O)—O-C1_
6alkyl, can be converted into a compound of formula (I) wherein R3 represents kyl
substituted with COOH, by reaction with LiOH in the presence of a suitable solvent,
such as for example tetrahydrofuran. Said compounds of formula (I) wherein R3
represents kyl substituted with COOH, can be converted into a compound of
formula (I) wherein R3 represents kyl substituted with —C(=O)—NH2 or —C(=O)—
NHCH3 or —C(=O)NR1°R“, by reaction with CH3)3)2 or MeNchr or NHR‘OR“ in
the presence of suitable peptide coupling ts such as for example 1-(3—
dimethylaminopropyl)—3-ethylcarbodiimide HCI and 1-hydroxybenzotriazole, a suitable
base, such as for example ylamine and a suitable solvent such as for example
dichloromethane or N,N-dimethylformamide. Compounds of formula (I) wherein R3
represents C1-6alkyl substituted with —C(=O)—O—C1-5alkyl, can also be converted into a
compound of formula (I) wherein R3 represents C1_6alkyl substituted with 4,5-dihydro-
ol-Z—yl, by reaction under N2 with ethylenediamine and hylaluminium in the
presence of a suitable solvent, such as for e toluene and heptane. Compounds
of formula (I) wherein R3 represents C1-6alkyl substituted with COOH, can also be
converted into a compound of formula (I) wherein R3 ents C1_6alkyl tuted
with —C(=O)—N(CH3)(OCH3) by reaction with dimethylhydroxylamine, in the presence of
carbonyldiimidazole and a suitable solvent, such as for example dichloromethane.
Compounds of formula (I) wherein R3 represents C1_6alkyl tuted with can be
converted into a compound of formula (I) wherein R3 ents C1-6alkyl substituted
with 2 OH’s, by on with a suitable acid, such as for example trifluoroacetic acid,
and a suitable solvent, such as for example dioxane or water. These compounds of
formula D
(I) wherein R3 represents kyl substituted with can also be converted
into a compound of formula (I) wherein R3 represents C1_6alkyl substituted with OH and
NR10R“, by reaction with NH2R1°R11 optionally in salt form, such as for example
NHRmRWCI', optionally in the presence of a suitable base, such as for e sodium
hydride or Na2C03 or triethylamine, a suitable additive such as for example KI, and in
the presence of a suitable solvent, such as for example N,N-dimethylformamide or an
alcohol, e.g. 1-butanol or ethanol.
Compounds of formula (I) wherein R3 represents C1_3alkyl substituted with —C(=O)—O-C1_
Galkyl, can be converted into a compound of formula (I) wherein R3 represents C1_3alkyl
substituted with —C(CH3)2-OH, by reaction with iodomethane and Mg poWder, in the
presence of a suitable solvent, such as for example diethylether or tetrahydrofuran.
Compounds of formula (I) wherein R3 represents C1_5alkyl substituted with —C(=O)—O-C1-
Galkyl, can be ted into a compound of formula (I) wherein R3 represents C1_6alkyl
tuted with —OH, by reaction with LiAIH4 in a suitable solvent, such as for example
tetrahydrofuran.
nds of formula (I) n R3 ents kyl substituted with —OH, can be
converted into a compound of formula (I) wherein R3 represents C1_5alkyl substituted
with -O-C(=O)-C1_6alkyl by reaction with Cl-C(=O)—Ct—6alkyl in the presence of a
suitable base, such as for example NaH, and a suitable solvent, such as for example
tetrahyd rofu ran.
Compounds of formula (I) wherein R3 ents —CH2-CH=CH2, can be converted into
a compound of formula (I) wherein R3 represents —CH2-CHOH-CH2-OH, by reaction with
potassium permanganate, and a suitable solvent, such as for example acetone or water.
Compounds of formula (I) wherein R3 represents C1_6alkyl substituted with —C(=O)—C1_
, can be converted into a compound of formula (I) wherein R3 represents kyl
substituted with —C(C1.4alkyl)=N-OH, by reaction with hydroxylamine, in the presence of
a suitable base, such as for e pyridine, and a suitable solvent, such as for
example an alcohol, e.g. ethanol.
Compounds of formula (I) wherein R3 represents C1_6alkyl substituted with NH2, can be
converted into a compound of a (I) wherein R3 represents C1-6alkyl substituted
with -NH-C(=O)—R6 or with -NH-C(=O)—C1-6alkyl or with -NH-C(=O)—polyhydroxyC1-6alkyl
or with -NH-C(=O)—polyhaloC1.5alkyl or with -NH-C(=O)-polyhydroxypolyhanC1-6aIkyl, by
reaction with the corresponding COOH analogue, e.g. Rs-COOH or CH3)(OH)-
COOH and the like, in the ce of suitable peptide coupling reagents such as 1-
hydroxy-benzotriazole and 1-(3-dimethylamino)propyl)carbodiimide optionally in the
presence of a suitable base, such as for example triethylamine. Said compounds of
formula (I) wherein R3 represents C1_6alkyl tuted with NH2, can also be converted
into a compound of formula (I) wherein R3 represents C1.6alkyl substituted with NH-
C(=O)-CF3, by reaction with oroacetic anhydride, in the presence of a suitable base,
such as for example triethylamine, and a suitable solvent, such as for example
tetrahydrofuran. Said nds of formula (I) wherein R3 represents C1_6alkyl
substituted with NH2, can also be converted into a compound of formula (I) wherein R3
represents C1_6a|kyl substituted with ~NH-polyhanC1-6alkyl, e.g. —NH-CH2—CH2—F, by
reaction with polyhaloC1_6alkyI-W, with W as defined above, e.g. iodoquoroethane, in
the presence of a suitable base, such as for example K2CO3, and a suitable solvent,
such as for example N,N-dimethylformamide or dioxane. Said compounds of formula (I)
wherein R3 represents Cmaikyl substituted with NH2 can also be converted into a
compound of formula (I) wherein R3 represents C1-6alkyl substituted with —NH-R6 or —
N(R6)2 wherein R6 represents for example oxetane, by reaction with the appropriate R6
in the presence of a suitable reducing agent, such as for e sodium
triacetoxyborohydride, a suitable acid, such as for example acetic acid, and a suitable
solvent, such as for example 1,2-dichloroethane.
Compounds of formula (I) wherein R3 represents C1_6aIkyI substituted with cyano, can be
converted into a compound of a (I) n R3 ents C1_6alkyI substituted
with tetrazolyl by reaction with sodium azide, and NHICI' in the presence of a suitable
solvent, such as for example methylformamide.
Compounds of formula (I) wherein R3 represents 'CHZ-CECH, can be converted into a
-CH2‘</\III/\H/OV
compound of formula (I) wherein R3 represents N; reaction
, by
with ethyl cetate in the presence of GUI and a le base, such as for e
diisopropylamine, and a suitable solvent, such as for example tetraydrofuran.
Compounds of formula (I) n R3 represents -CH2-CECH, can be converted into a
—CH2 \ 15 ,OH
compound of formula (I) n R3 represents N by reaction with
sodium azide and formaldehyde, in the presence of a suitable catalyst, such as for
e CuSO4 and sodium L ascorbate, a suitable acid, such as for e acetic
acid, and a suitable solvent, such as for example dioxane.
Compounds of formula (I) wherein R3 represent C2_6alkynyi, can be converted into a
nd of formula (I) wherein R3 represents Cz-6alkynyl substituted with R9, by
reaction with W-R9 wherein W is as defined above, in the presence of a suitable
st, such as for example dichIorobis(triphenylphosphine)palladium, a suitable co-
catalyst such as Cul, a suitable base, such as for example triethyIamine, and a suitable
solvent, such as for example dimethylsulfoxide.
Compounds of formula (I) wherein R3 comprises R9 substituted with halo, can be
ted into a compound of formula (I) wherein R3 comprises R9 substituted with —
NRMR15 by reaction with NHRMR15 in the presence of a suitable solvent, such as for
example 1-methylpyrrolidinone.
Compounds of a (l) n R3 comprises C2-5alkynyl, can be hydrogenated into a
compound of formula (I) wherein R3 comprises C2_6alkyl in the presence of a le
catalyst, such as for example palladium on charcoal, and a suitable solvent, such as for
example ethylacetate.
nds of formula (l) wherein R3 comprises C2_6alkynyl, can be hydrogenated into a
compound of formula (I) wherein R3 comprises C2_5alkenyl in the presence of a suitable
catalyst, such as for example Lindlar catalyst, and a suitable solvent, such as for
example ethylacetate.
Compounds of formula (I) wherein R3 represents C1_6alkyl substituted with -P(=O)(OC1_
6alky|)2 can be converted into a compound of formula (I) wherein R3 represents C1_6alkyl
substituted with -P(=O)(OH)2 by reaction with bromotrimethylsilane in the ce of a
suitable solvent, such as for example romethane.
Compounds of formula (l) wherein the R9 substituent is substituted with =0, can be
converted into the corresponding reduced R9 substituent by on with a suitable
reducing agent, such as for example LiAlH4 in a suitable solvent, such as for example
tetrahydrofuran.
Compounds of formula (I) wherein R3 represents C1.5alkyl substituted with —C(=O)-R9
can be ted into a compound of formula (I) wherein R3 ents C1_5alkyl
substituted with hydroxyl and R9 by reaction with a le reducing agent, such as for
example sodium borohydride, in the presence of a suitable solvent, such as for e
an alcohol, e.g. methanol.
Compounds of formula (I) wherein R3 comprises -NHR10 can be converted into a
compound of formula (I) wherein R3 comprises —NR1°-(C=O)-optionally substituted C1-
ealkyl, by reaction with the corresponding W-(C=O)-optionally substituted C1_6alkyl
wherein W represents a le leaving group, such as for example halo, e.g. chloro
and the like, in the presence of a le base, such as for example triethylamine, and
a suitable solvent, such as for example acetonitrile or dichloromethane.
Compounds of a (l) wherein R3 represents C1_5alkyl substituted with NR1°(benzyl)
can be converted into a nd of formula (I) wherein R3 represents C1_6alkyl
substituted with NHR‘O, by reaction with roethylchloroformate in the presence of a
suitable solvent, such as for example dichloromethane
WO 61080
nds of formula (I) n R1 represents unsubstituted piperidine, can be
converted into a compound of formula (l) wherein R1 represents 1—methyl-piperidine, by
reaction with iodomethane in the presence of a suitable base, such as for example
potassium carbonate, and a suitable solvent, such as for example acetonitrile.
Compounds of formula (l) wherein R1 represents hydrogen can be converted into a
compound of formula (I) wherein R1 represents optionally substituted C1.6alkyl, by
on with optionally substituted C1_5alkyl-W wherein W represents a suitable leaving
group, such as for example halo, e.g. bromo and the like, in the ce of a suitable
base, such as for example potassium carbonate, and a suitable solvent, such as for
example acetonitrile.
Compounds of formula (I) wherein R2 represents halo, e.g. bromo, can be converted into
a compound of a (I) wherein R2 represents cyano, by reaction with zinc cyanide,
in the presence of a suitable catalyst, such as for example Pd2(dba)3 and a suitable
, such as for example 1,1-bis(diphenylphosphino)ferrocene, in the ce of a
suitable t, such as for example N,N-dimethylformamide.
Said R2 substituent being cyano can be converted into —CH2-NH2 by hydrogenation in
the presence of NH3 and Nickel.
Compounds of formula (I) wherein R2 represents —OCH3 can be converted into a
compounds of formula (l) wherein R2 represents —OH by on with boron tribromide
in the presence of a suitable solvent, such as for example dichloromethane.
Compounds of formula (I) n R2 represents —OH can be converted into a
compounds of formula (I) wherein R2 represents —OCH3 by reaction with methyl iodine in
the presence of a suitable base, such as for example potassium carbonate, and a
suitable solvent, such as for example N,N—dimethylformamide.
Compounds of formula (I) wherein R2 represents hydrogen, can be converted into a
compound of formula (I) wherein R2 represents —CHOH-CF3 by reaction with
oroacetaldehyde methyl hemiketal.
For the conversion reactions, nce is also made to the examples described in the
Experimental Part hereinafter.
A r aspect of the invention is a process for the preparation of a nd of
formula (I) as defined herein, which process comprises:
(i) deprotecting a compound of formula (XXX) wherein P represents a suitable
protective group, such as for example a butyloxycarbonyl-group ( —C02C(CH3)3) in the
presence of a suitable acid, such as for example HCI or oroacetic acid;
NR‘°P
C1 -6a1kyl
(R2>GNU
(XXX) or
(ii) the reaction of a compound of the formula (IX) or (lX’):
C1-6a1k1:1
}: 2) ]/D
(IX) : R“ is -O-(S=O)2-CH3
(IX’) : Ru is Cl
or a protected form thereof, with an appropriately substituted amine or a reactive
derivative thereof, such as for example NHRWR11 (X), NHR1°P (X-a) or H’I‘Q (XXI),
for example in a sealed vessel, in the presence of a suitable base, such as for example
sodium e and/or in the presence or absence of a solvent such as acetonitrile, N,N-
dimethylformamide or N,N-dimethylacetamide; or
(iii) the reaction of a compound of the formula (Vl):
G/N N\ N\ D
2/ / l
(R )n / I
N (VI)
or a protected form thereof, with a compound of formula 5alkyl-NR1°P wherein P
represents a suitable protective group and We represents a suitable leaving group, such
as for example halo, e.g. bromo and the like, or —O-S(=O)2-CH3, in the ce of a
suitable base, such as for example sodium hydride, and a suitable t, e.g. N,N-
dimethylformamide or N,N-dimethylacetamide, followed by removing P and optionally
removing any further protecting group present; or
(iv) the reaction of a compound of the formula (VI):
Q/N N\ N\ D
(RZ/ / )n / I
N (VI)
or a protected thereof, with a compound of formula W‘s-Cmalkyl-NHR10 wherein we
represents a suitable leaving group, such as for example halo, e.g. bromo and the like,
or ——O-S(=O)2-CH3, in the presence of a suitable base, such as for e sodium
hydride, and a suitable solvent, e.g. N,N—dimethylformamide or N,N-dimethylacetamide;
(v) the reaction of a nd of formula (XXXVI)
0 N
Crealkyl
I{IRlo
('31—5alkyl
QN N N D
(R n U7
/ N/
with ine in the presence of a suitable solvent, such as for example an alcohol,
e.g. ethanol;
(vi) the reaction of a compound of formula (IX-1) wherein R” represents —O-S(=O)2-
CH3,
C1 l
(R /
n N/
(IX-1)
with an intermediate of formula (X) in the presence of a suitable solvent, such as for
example acetonitrile;
(vii) the reaction of a compound of formula (Vl)
6% N\ |
(R2)n/ / Nj/D N/ (V1)
with an ediate of formula W11-R3b wherein R3b represents optionally tuted C2-
yl and W11 represents a le leaving group such as for example halo, e.g.
chloro, or —O-S(=O)2-CH3, in the presence of a suitable base, such as for example NaH,
and a suitable solvent, such as for example N,N-dimethylformamide;
(viii) the reaction of a compound of formula (Vlll’) wherein RX and Ry represent C1-
4alkyl, and RZ represent C1_4alkyl or phenyl,
QU’;1C2--6alkynyl
(VIII‘)
with a suitable acid, such as for example trifluoroacetic acid, in the presence of a
le solvent, such as for example tetrahydrofuran;
(viii) deprotecting a compound of formula (XXXXll)
QU:1C2-6a1kyny1
(xxxxn)
in the presence of a suitable base, such as for example K2C03, and a suitable solvent,
such as for example an alcohol, e.g. methanol and the like;
(ix) the reaction of a compound of formula (VI)
(R’n9%: j/D(INF (VI)
with di(C1-ealkyl)vinylphosphonate in the presence of a suitable catalyst, such as for
example tri-N-butylphosphine, and a suitable solvent, such as for e acetonitrile;
(x) deprotecting a compound of formula (XXXXI) wherein the D’N moiety represents
a D moiety wherein the D moiety contains a nitrogen atom
NR‘OR“ $6
(111-6alky1 fréalkyl
GM N\ N\ D'N
n<R2>// ]
(xxxxn
in the presence of a le base, such as for example K2C03, and a suitable solvent,
such as for example an l, e.g. methanol and the like;
(xi) the reaction of a compound of formula (XXXI)
$(=O}NH-NH2
C1-6alkyl
(R2>n/ / N/
(XXXI)
with Wg-CN, wherein W8 ents a suitable leaving group, such as for example halo,
e.g. bromo, in the presence of a suitable base, such as for example NaH003, and a
suitable solvent, such as for example water or dioxane;
(xii) the reaction of a compound of formula (XXXV)
o (RNHz
\\ O
as~0%
(Ereaikyl
0/“! NjY
(Rzgn/ UN/N\
(XXXV)
with a suitable base, such as for example N, N-diisopropylethylamine and triethylamine,
in the presence of a suitable solvent, such as for example an alcohol, e.g. methanol;
(xiii) deprotecting a nd of formula (XXVI) wherein P represents a suitable
Go—0
protective group such as for example —O—Si(CH3)2(C(CH3)3) or wherein
Y’N ents an —E-D moiety n the D ring moiety ns a nitrogen atom
1‘13 /C1-6a|kyl
@N YN
N\ N\
(Rzgn/ UNI
(XXVI)
in the presence of a suitable acid, such as for e HCI or trifluoroacetic acid, or a
suitable de-silylating agent, such as for example tetrabutyl ammonium fluoride, and a
suitable solvent, such as an alcohol, e.g. methanol, or tetrahydrofuran;
(xiv) the reaction of a compound of formula (XXIX) wherein Y’N represents an —E-D
moiety wherein the D ring moiety contains a nitrogen atom, with a compound of formula
(XXI)
C|)H
(l3(=0)
$3 /C1-6a|ky|
@N N\ YN
N\ H’@
+ (XXI)
// U j
<R2>n / N/
(XXIX)
in the presence of le peptide coupling reagents such as, 1—hydroxy-benzotriazole
and 1-(3-dimethylaminopropyl)—3-ethyl carbodiimide HCI;
(xv) the reaction of a compound of formula (XXiX) wherein Y’N represents an —E-D
moiety n the D ring moiety contains a nitrogen atom
§<=0>
3 C1-6alkyl
\ E N “/1
UUT//
(R2)n / N/
(XXIX)
with NHR4R5 in the presence of suitable peptide ng reagents such as 1—hydroxy-
benzotriazole and 1—(3—dimethylaminopropyl)—3-ethyl carbodiimide HCI and a suitable
base, such as triethylamine, and a suitable solvent, such as for example
dichloromethane;
(xvi) ng the below compound
H3C—(o:)2s—o—R2' 3
\ FF
[E/N N\ N\ Y
,/ l
(R2)n-1 uN/j :
with NHR7R8 in the presence of a suitable base, such as for example K2C03, and a
suitable solvent, such as for example ydrofuran;
(xvii) deprotecting the below compound
in the presence of hydrazine monohydrate, and a le solvent, such as for example
an alcohol, e.g. ethanol;
(xvii) reacting an intermediate of formula (Vl)
/ \ N N\ N\ D
(R )n U I/ N/
with W6-R3d wherein W6 represents a suitable leaving group, such as for example halo,
e.g. bromo, , and the like, or —O-S(=O)2-CH3 or p-toluenesulfonate, and R3d
ents optionally substituted C1-6alkyl, such as for example —CH2-CgH5, in the
presence of a suitable base, such as for example sodium hydride, 032C03, potassium
utoxyde or potassium hydroxide, optionally a suitable phase transfer agent, such
as for example tetrabutylammonium bromide, and a suitable solvent, such as for
example N,N-dimethyIformamide, N,N-dimethylacetamide, 2-methyltetrahydrofuran,
tetrahyd rofuran, water or acetonitriIe.
wherein the variables are as defined herein; and optionally thereafter converting
one compound of the formuIa (I) into another compound of the formula (I).
A further embodiment is a s for synthesis of a compound of formula (VI) n:
I —> H
/j/ / |
(IV) Gnu-12 GNUNj/D/
(R23/ (Rhn/ / N/
(V) (VI)
a compound of a (IV) is reacted with an intermediate of formula (V) in the
presence of a suitable catalyst, such as for example palladium (II) acetate, a suitable
base, such as sodium tert-butoxide or CszCO3, a suitable ligand, such as for example
1,1'—[1,1'—binaphthalene]—2,2'-diylbis[1,1-diphenylphosphine], and a suitable solvent or
solvent mixture, such as for example dioxane or ne glycol dimethyiether and
water.
AIternatively a compound of formula (IV) is d with an intermediate of formula (V) in
the presence of a suitable solvent such as for e an alcohol, e.g. isopropanoI, and
optionaily in the presence of a suitable acid such as for example hydrochloric acid.
Alternatively a compound of formuIa (IV) is reacted with an intermediate of formula (V) in
the presence of a suitable deprotonating agent such as for example lithium
bis(trimethylsinI)amide, in the presence of a suitable sovent such as for example N<N-
dimethylformamide or tetrahydrofuran.
In a further embodiment the invention provides a novel intermediate. In one ment
the invention es a novel intermediate as described . In another ment
the invention provides a novel intermediate of formula (VI) or formula (IX).
In one embodiment, the present invention also relates to a compound having the
following formula :
(RQHUT// /
n N/
/ \ H N\ N\
e U I
(R n N
\ H E'-D
/ N\ N\
e U I
(R n N
including any stereochemically ic form thereof;
wherein Y represents N—OR19 or —D’ or —E’-D;
D’ represents a 3 to 12 ring membered monocyclic or ic heterocyciyl containing at
least one heteroatom selected from N, O or 8, wherein said carbocyclyl and heterocyciyl
may each be optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups;
wherein E’ represents R23)n—, C2-4a|kenediyi optionally substituted with R22, c2.
4alkynediyl optionally substituted with R22, —CO-(CR22R23)s-, -(CR22R23)S-CO-, -NR22—
(CR22R23)s-, -(CR22R23)S—NR22-, ~O-(CR22R23 _
-, -(CR22R23)s-O-, -S(O)m-(CR22R23)s-,
(CR22R23)s—S(O)m-, —(CR22R23)s-CO—NRZZ-(CR22R23)S- or —(CR22R23)s-NR22-CO-
(CR22R23)S-; and
n D, R2 and n are as defined for a compound of formula (I) above;
a N-oxide thereof, a pharmaceutically acceptable salt thereof or a soivate thereof.
Pharmaceutically Acceptable Salts, Solvates or tives thereof
In this section, as in all other sections of this ation, unless the context indicates
othenivise, references to formula (I) include references to all other sub-groups,
preferences, embodiments and examples thereof as defined herein.
2012/052672
Unless otherwise specified, a reference to a ular nd also includes ionic
forms, salts, solvates, isomers, tautomers, N-oxides, esters, prodrugs, isotopes and
protected forms thereof, for example, as discussed below; preferably, the ionic forms, or
salts or tautomers or isomers or N-oxides or solvates thereof; and more preferably, the
ionic forms, or salts or tautomers or solvates or protected forms thereof, even more
preferably the salts or tautomers or es thereof. Many compounds of the formula (I)
can exist in the form of salts, for exampIe acid on salts or, in certain cases salts of
organic and inorganic bases such as carboxylate, sulphonate and phosphate salts. AII
such salts are within the scope of this invention, and references to compounds of the
formula (I) include the salt forms of the nds. It will be appreciated that
references to “derivatives” include references to ionic forms, salts, solvates, isomers,
tautomers, N-oxides, esters, gs, isotopes and protected forms thereof.
According to one aspect of the invention there is ed a compound as defined
herein or a salt, tautomer, N-oxide or solvate thereof. ing to a further aspect of
the invention there is provided a compound as defined herein or a salt or solvate
thereof. References to compounds of the formula (I) and sub-groups thereof as defined
herein include within their scope the salts or solvates or tautomers or N-oxides of the
compounds.
The salt forms of the compounds of the ion are typically pharmaceutically
acceptable salts, and examples of pharmaceutically able salts are discussed in
Berge et al. (1977) "Pharmaceutically Acceptable Salts," J. Pharm. Sci., Vol. 66, pp. 1-
19. However, salts that are not pharmaceutically acceptable may also be prepared as
intermediate forms which may then be converted into pharmaceutically acceptable salts.
Such non-pharmaceutically acceptable salts forms, which may be useful, for example, in
the purification or separation of the compounds of the invention, also form part of the
invenfion.
The salts of the present ion can be sized from the parent compound that
contains a basic or acidic moiety by conventional chemical methods such as methods
described in Pharmaceutical Salts: Properties, Selection, and Use, P. Heinrich StahI
(Editor), Camille G. Wermuth (Editor), ISBN: 3026—8, Hardcover, 388 pages,
August 2002. Generally, such salts can be prepared by reacting the free acid or base
forms of these compounds with the appropriate base or acid in water or in an organic
solvent, or in a mixture of the two; generally, nonaqueous media such as ether, ethyl
e, l, isopropanol, or acetonitrile are used. The nds of the ion
may exist as mono- or di-salts depending upon the pKa of the acid from which the salt is
formed.
Acid on salts may be formed with a wide variety of acids, both inorganic and
organic. Examples of acid addition salts include salts formed with an acid selected from
the group consisting of acetic, 2,2—dichloroacetic, adipic, alginic, ascorbic (e.g. L—
ascorbic), L-aspartic, benzenesulphonic, benzoic, 4—acetamidobenzoic, butanoic, (+)
camphoric, camphor—sulphonic, (+)-(1S)—camphorsulphonic, capric, caproic, caprylic,
cinnamic, citric, cyclamic, dodecylsulphuric, ethane-1,2-disulphonic, sulphonic, 2-
hydroxyethanesulphonic, formic, fumaric, galactaric, ic, glucoheptonic, D-gluconic,
glucuronic (e.g. D-glucuronic), ic (e.g. L-glutamic), d—oxoglutaric, glycolic,
hippuric, romic, hydrochloric, hydriodic, isethionic, lactic (e.g. (+)—L-lactic, (i)-DL-
lactic), lactobionic, maleic, malic, (-)—L—malic, malonic, (i)—DL-mandelic,
methanesulphonic, naphthalenesulphonic (e.g.naphthalene-Z-sulphonic), naphthalene-
1,5-disulphonic, 1-hydroxy—2—naphthoic, nicotinic, nitric, oleic, orotic, oxalic, ic,
pamoic, phosphoric, propionic, L-pyroglutamic, pyruvic, salicylic, 4-amino-salicylic,
sebacic, stearic, succinic, sulphuric, tannic, (+)-L-tartaric, thiocyanic, toluenesulphonic
(e.g. p—toluenesulphonic), undecylenic and valeric acids, as well as acylated amino acids
and cation exchange resins.
One particular group of salts consists of salts formed from acetic, hydrochloric,
dic, phosphoric, nitric, sulphuric, citric, lactic, succinic, maleic, malic, onic,
fumaric, benzenesulphonic, toluenesulphonic, methanesulphonic (mesylate),
ethanesulphonic, alenesulphonic, valeric, acetic, propanoic, ic, malonic,
glucuronic and lactobionic acids. Another group of acid addition salts includes salts
formed from acetic, , ascorbic, aspartic, citric, DL-Lactic, fumaric, gluconic,
glucuronic, hippuric, hydrochloric, glutamic, DL-malic, methanesulphonic, sebacic,
stearic, succinic and tartaric acids.
If the compound is anionic, or has a functional group which may be anionic (e.g.,
-COOH may be -COO‘), then a salt may be formed with a le cation. Examples of
suitable inorganic cations include, but are not limited to, alkali metal ions such as Na+
and W, alkaline earth metal cations such as Ca2+ and Mg2+, and other cations such as
Al”. Examples of le organic cations include, but are not limited to, ammonium ion
(i.e., NH4+) and substituted um ions (e.g., NH3R+, NH2R2+, NHR3+, NRJ).
Examples of some le substituted ammonium ions are those derived from:
ethylamine, diethylamine, dicyclohexylamine, triethylamine, butylamine,
ethylenediamine, ethanoiamine, diethanolamine, piperazine, benzylamine,
phenylbenzylamine, choline, meglumine, and tromethamine, as well as amino acids,
such as lysine and arginine. An e of a common quaternary ammonium ion is
Where the compounds of the formula (l) contain an amine function, these may form
quaternary ammonium salts, for example by reaction with an alkylating agent according
to methods well known to the skilled person. Such quaternary ammonium compounds
are within the scope of formula (I). Compounds of the formula (I) containing an amine
function may also form N-oxides. A reference herein to a compound of the formula (I)
that contains an amine function also includes the N-oxide. Where a compound contains
several amine ons, one or more than one nitrogen atom may be oxidised to form
an N-oxide. Particular examples of N—oxides are the N-oxides of a tertiary amine or a
en atom of a nitrogen—containing heterocycle. N-Oxides can be formed by
treatment of the corresponding amine with an oxidizing agent such as hydrogen
peroxide or a per-acid (e.g. a peroxycarboxylic acid), see for example Advanced
Organic Chemistry, by Jerry March, 4th Edition, Wiley Interscience, pages. More
particularly, N-oxides can be made by the procedure of L. W. Deady (Syn. Comm.
(1977), 7, 509-514) in which the amine compound is reacted with m-
chloroperoxybenzoic acid ), for example, in an inert solvent such as
dichloromethane.
The compounds of the invention may form solvates, for example with water (i.e.,
hydrates) or common organic ts. As used , the term te” means a
physical association of the compounds of the present ion with one or more solvent
molecules. This physical association involves varying degrees of ionic and covalent
bonding, including hydrogen g. in certain ces the solvate will be capable of
ion, for example when one or more solvent molecules are incorporated in the
crystal lattice of the crystalline solid. The term “solvate” is intended to encompass both
solution-phase and isolatabIe solvates. Non-Iimiting es of suitable solvates
include compounds of the invention in combination with water, isopropanol, ethanol,
methanol, DMSO, ethyl acetate, acetic acid or ethanolamine and the like. The
compounds of the invention may exert their biological effects whilst they are in solution.
Solvates are well known in pharmaceutical chemistry. They can be important to the
processes for the preparation of a substance (e.g. in on to their purification, the
storage of the nce (e.g. its stability) and the ease of handling of the substance
and are often formed as part of the isolation or purification stages of a chemical
sis. A person skilled in the art can determine by means of standard and long
used techniques r a hydrate or other solvate has formed by the isolation
conditions or cation conditions used to prepare a given compound. es of
such techniques include thermogravimetric analysis (TGA), differentiaI scanning
calorimetry (DSC), X—ray crystallography (e.g. single crystal X-ray crystallography or X-
ray powder diffraction) and SoIid State NMR (SS-NMR, also known as Magic Angle
Spinning NMR or MAS-NMR). Such techniques are as much a part of the standard
icaI toolkit of the skiIIed chemist as NMR, IR, HPLC and MS. Alternatively the
skilled person can deliberately form a solvate using crystallisation conditions that include
an amount of the solvent required for the ular solvate. Thereafter the standard
methods described above, can be used to ish r solvates had formed. Also
encompassed by formula (I) are any complexes (e.g. inclusion xes or clathrates
with compounds such as cyclodextrins, or complexes with metals) of the compounds.
Furthermore, the compounds of the present invention may have one or more polymorph
(crystalline) or amorphous forms and as such are intended to be included in the scope of
the invention.
Compounds of the formula (I) may exist in a number of different geometric isomeric, and
tautomeric forms and references to compounds of the formula (I) include aII such forms.
For the avoidance of doubt, where a compound can exist in one of several geometric
isomeric or tautomeric forms and only one is specifically described or shown, all others
are nevertheless embraced by formula (I). Other examples of tautomeric forms include,
for example, keto-, enol-, and e-forms, as in, for example, the following eric
pairs: keto/enol (illustrated below), imine/enamine, amide/imino alcohol,
amidine/enediamines, nitroso/oxime, thioketone/enethiol, and nitro/aci-nitro.
fi‘ 00 \ /OH H+ o
—C“C : CZC : C:C/
I \ / \ H+ / \
keto enol enolate
Where compounds of the formula (I) contain one or more chiral s, and can exist in
the form of two or more optical isomers, nces to nds of the formula (I)
include all optical isomeric forms thereof (e.g. enantiomers, epimers and
reoisomers), either as individual optical isomers, or mixtures (e.g. racemic
mixtures) of two or more optical isomers, unless the context requires ise. The
optical isomers may be characterised and identified by their optical activity (i.e. as + and
— isomers, or d and I isomers) or they may be characterised in terms of their absolute
stereochemistry using the “R and S” nomenclature developed by Cahn, lngold and
Prelog, see Advanced Organic Chemistry by Jerry March, 4th Edition, John Wiley &
Sons, New York, 1992, pages 109-114, and see also Cahn, lngold & Prelog (1966)
Angew. Chem. Int. Ed. Eng/., 5, 385-415. Optical isomers can be ted by a
number of techniques including chiral chromatography (chromatography on a chiral
support) and such techniques are well known to the person skilled in the art. As an
alternative to chiral chromatography, optical s can be ted by forming
diastereoisomeric salts with chiral acids such as (+)-tartaric acid, roglutamic acid,
(-)—di-toluoyl-L-tartaric acid, (+)-mandelic acid, (-)—malic acid, and (-)-camphorsulphonic,
separating the diastereoisomers by preferential crystallisation, and then dissociating the
salts to give the dual enantiomer of the free base.
Where compounds of the formula (I) exist as two or more optical isomeric forms, one
enantiomer in a pair of enantiomers may exhibit advantages over the other enantiomer,
for example, In terms of biological activity. Thus, in certain circumstances, it may be
desirable to use as a therapeutic agent only one of a pair of enantiomers, or only one of
a plurality of diastereoisomers. Accordingly, the invention provides compositions
containing a compound of the formula (I) having one or more chiral centres, wherein at
least 55% (e.g. at least 60%, 65%, 70%, 75%, 80%, 85%, 90% or 95%) of the
nd of the formula (I) is present as a single optical isomer (e.g. enantiomer or
diastereoisomer). In one general embodiment, 99% or more (e.g. substantially all) of
the total amount of the compound of the formula (I) may be present as a single optical
isomer (e.g. enantiomer or diastereoisomer). When a specific isomeric form is identified
(e.g. 8 configuration, or E isomer), this means that said isomeric form is substantially
free of the other (s), i.e. said ic form is present in at least 55%, 60%, 65%,
70%, 75%, 80%, 85%, 90%, 95%, 99% or more (e.g. substantially all) of the total
amount of the compound of the ion.
The compounds of the invention include compounds with one or more isotopic
substitutions, and a reference to a particular t includes within its scope all
isotopes of the element. For example, a reference to hydrogen includes within its scope
1H, 2H (D), and 3H (T). Similarly, references to carbon and oxygen include within their
scope respectively 12C, 130 and 14C and 16O and 18O. The isotopes may be radioactive or
non-radioactive. In one embodiment of the invention, the compounds n no
radioactive isotopes. Such compounds are preferred for therapeutic use. In another
embodiment, r, the compound may contain one or more radioisotopes.
Compounds containing such radioisotopes may be useful in a diagnostic context.
Esters such as carboxylic acid esters and acyloxy esters of the compounds of formula (I)
bearing a carboxylic acid group or a hydroxyl group are also embraced by formula (l). in
one embodiment of the invention, formula (I) includes within its scope esters of
compounds of the formula (l) bearing a carboxylic acid group or a hydroxyl group. In
another embodiment of the invention, formula (l) does not include within its scope esters
of compounds of the formula (I) bearing a carboxylic acid group or a hydroxyl group.
Examples of esters are compounds containing the group -C(=O)OR, wherein R is an
ester substituent, for example, a 01.6 alkyl group, a heterocyclyl group, or a 05-20 aryl
group, preferably a 01.6 alkyl group. Particular examples of ester groups include, but are
not limited to, OCH3, -C(=O)OCH2CH3, -C(=O)OC(CH3)3, and -C(=O)OPh.
Examples of acyloxy (reverse ester) groups are represented by -OC(=O)R, wherein R is
an acyloxy tuent, for example, a 01-7 alkyl group, a 03-20 heterocyclyl group, or a
05-20 aryl group, preferably a 01-7 alkyl group. Particular examples of acyloxy groups
e, but are not d to, -OC(=O)CH3 (acetoxy), -OC(=O)CH2CH3,
-OC(=O)C(CH3)3, ~OC(=O)Ph, and -OC(=O)CH2Ph.
For e, some prodrugs are esters of the active compound (e.g., a physiologically
acceptable metabolically labile ester). By “prodrugs” is meant for example any
compound that is converted in vivo into a ically active compound of the formula (I).
During metabolism, the ester group (-C(=O)OR) is cleaved to yield the active drug.
Such esters may be formed by esterification, for example, of any of the carboxylic acid
groups (-C(=O)OH) in the parent compound, with, where appropriate, prior protection of
any other ve groups present in the parent compound, followed by deprotection if
required.
Examples of such metabolically labile esters include those of the formula -C(=O)OR
wherein R is: C1-6alkyl (e.g., -Me, -Et, -nPr, -iPr, -nBu, -sBu, -iBu, -tBu); C1_6aminoalkyl
[e.g., aminoethyl; 2-(N,N-diethylamino)ethyl; 2-(4-morpholino)ethyl); and y-
C1_7alkyl [e.g., acyloxymethyl; acyloxyethyl; pivaloyloxymethyl; acetoxymethyl;
1-acetoxyethyl; 1-(1-methoxymethyl)ethyl-carbonyloxyethyl; 1-(benzoyloxy)ethyl;
isopropoxy-carbonyloxymethyl; 1-isopropoxy-carbonyloxyethyl; cyclohexylcarbonyloxymethyl
; 1—cyclohexyl-carbonyloxyethyl; cyclohexyloxy—carbonyloxymethyl; 1-
cyclohexyloxy-carbonyloxyethyl; (4-tetrahydropyranyloxy) carbonyloxymethyl; 1-(4—
ydropyranyloxy)carbonyloxyethyl; (4-tetrahydropyranyl)carbonyloxymethyl; and
etrahydropyranyl)carbonyloxyethyl]. Also, some prodrugs are activated
enzymatically to yield the active compound, or a compound which, upon further
chemical on, yields the active compound (for example, as in antigen-directed
enzyme pro-drug therapy (ADEPT), gene-directed enzyme pro-drug therapy (GDEPT)
and ligand-directed enzyme pro-drug therapy (LlDEPT) etc.). For example, the prodrug
may be a sugar derivative or other glycoside ate, or may be an amino acid ester
derivative.
Protein Tyrosine Kinases (PTK)
The compounds of the invention described herein inhibit or modulate the activity of
certain tyrosine kinases, and thus the nds will be useful in the treatment or
laxis, in ular the treatment, of disease states or conditions mediated by
those tyrosine kinases, in particular FGFR.
FGFR
The fibroblast growth factor (FGF) family of protein tyrosine kinase (PTK) receptors
regulates a diverse array of physiologic functions including nesis, wound healing,
cell differentiation and angiogenesis, and development. Both normal and malignant cell
growth as well as proliferation are ed by s in local concentration of FGFs,
extracellular ling molecules which act as autocrine as well as paracrine factors.
Autocrine FGF signalling may be particularly important in the progression of steroid
hormone-dependent cancers to a hormone independent state. FGFs and their receptors
are expressed at increased levels in several tissues and cell lines and pression is
believed to contribute to the malignant phenotype. Furthermore, a number of oncogenes
are homologues of genes encoding growth factor receptors, and there is a ial for
aberrant activation of FGF-dependent signalling in human pancreatic cancer (Knights et
al., Pharmacology and Therapeutics 2010 125:1 (105-117); Korc M. et al Current
Cancer Drug Targets 2009 9:5 (639-651)).
The two prototypic s are acidic fibroblast growth factor (aFGF or FGF1) and
basic fibroblast growth factor (bFGF or FGF2), and to date, at least twenty distinct FGF
family members have been identified. The cellular response to FGFs is transmitted via
four types of high affinity transmembrane protein tyrosine-kinase last growth factor
receptors (FGFR) numbered 1 to 4 (FGFR1 to .
Disruption of the FGFR1 pathway should affect tumor cell proliferation since this kinase
is activated in many tumor types in addition to proliferating endothelial cells. The over—
expression and activation of FGFR1 in tumor— associated vasculature has suggested a
role for these molecules in tumor angiogenesis.
A recent study has shown a link between FGFR1 expression and tumorigenicity in
Classic Lobular Carcinomas (CLC). CLCs account for 10-15% of all breast cancers and,
in general, lack p53 and Her2 expression whilst retaining expression of the oestrogen
receptor. A gene amplification of 8p12—p11.2 was demonstrated in ~50% of CLC cases
and this was shown to be linked with an sed expression of FGFR1. Preliminary
studies with siRNA directed against FGFR1, or a small molecule inhibitor of the
or, showed cell lines harbouring this amplification to be particularly sensitive to
inhibition of this signalling pathway. Rhabdomyosarcoma (RMS) is the most common
pediatric soft tissue sarcoma likely results from abnormal proliferation and differentiation
during skeletal myogenesis. FGFR1 is over-expressed in y rhabdomyosarcoma
tumors and is associated with hypomethylation of a 5' CpG island and abnormal
sion of the AKT1, NOG, and BMP4 genes. FGFR1 has also been linked to
squamous lung cancer, colorectal cancer, glioblastoma, astrocytomas, prostate cancer,
small cell lung cancer, melanoma, head and neck cancer, d cancer, uterine
cancer.
Fibroblast growth factor receptor 2 has high affinity for the acidic and/or basic fibroblast
growth factors, as well as the nocyte growth factor s. Fibroblast growth
factor receptor 2 also propagates the potent osteogenic effects of FGFs during
osteobiast growth and differentiation. ons in fibroblast growth factor receptor 2,
leading to complex functional alterations, were shown to induce abnormal ossification of
cranial sutures (craniosynostosis), implying a major role of FGFR signalling in
intramembranous bone formation. For example, in Apert (AP) syndrome, characterized
by ure cranial suture ossification, most cases are associated with point mutations
engendering gain-of—function in fibroblast growth factor or 2. in addition, mutation
screening in patients with mic craniosynostoses indicates that a number of
recurrent FGFR2 mutations accounts for severe forms of Pfeiffer syndrome. Particular
mutations of FGFR2 include W290C, D321A, Y34OC, C342R, C3428, C342W, N549H,
K641R in FGFR2.
Several severe abnormalities in human skeletal development, ing Apert, n,
Jackson-Weiss, Stevenson cutis gyrata, and Pfeiffer syndromes are associated
with the occurrence of mutations in fibroblast growth factor receptor 2. Most, if not all,
cases of Pfeiffer Syndrome (P8) are also caused by de novo mutation of the fibroblast
growth factor receptor 2 gene, and it was recently shown that mutations in fibroblast
growth factor receptor 2 break one of the cardinal rules governing ligand specificity.
Namely, two mutant splice forms of fibrobiast growth factor receptor, FGFR2c and
FGFR2b, have acquired the ability to bind to and be activated by atypical FGF ligands.
This loss of ligand specificity leads to aberrant signalling and ts that the severe
phenotypes of these disease syndromes result from ectopic ligand-dependent activation
of fibroblast growth factor receptor 2.
Genetic aberrations of the FGFR3 receptor ne kinase such as chromosomal
translocations or point mutations result in ectoplcally expressed or deregulated,
constitutively active, FGFR3 receptors. Such abnormalities are linked to a subset of
multiple myelomas and in bladder, hepatocellular, oral squamous cell carcinoma and
cervical carcinomas. Accordingly, FGFR3 inhibitors would be useful in the treatment of
multiple myeloma, bladder and cervical carcinomas. FGFR3 is also over-expressed in
bladder cancer, in particular invasive bladder cancer. FGFR3 is frequently activated by
mutation in urothelial oma (UC). Increased sion was associated with
on (85% of mutant tumors showed high—level sion) but also 42% of tumors
with no detectable mutation showed over—expression, including many muscle-invasive
. FGFR3 is also linked to endometrial and thyroid cancer.
Over expression of FGFR4 has been linked to poor prognosis in both te and
thyroid omas. in addition a germline polymorphism (Gly388Arg) is associated with
increased incidence of lung, breast, colon, liver (HCC) and prostate cancers. In addition,
a truncated form of FGFR4 (including the kinase domain) has also been found to be
present in 40% of pituitary tumours but not present in normal tissue. FGFR4
pression has been observed in liver, colon and lung tumours. FGFR4 has been
implicated in colorectal and liver cancer where expression of its ligand FGF19 is
frequently elevated. FGFR4 is also linked to astrocytomas, rhabdomyosarcoma.
Fibrotic conditions are a major medical problem resulting from abnormal or excessive
deposition of fibrous tissue. This occurs in many diseases, including liver cirrhosis,
glomerulonephritis, ary fibrosis, systemic fibrosis, rheumatoid arthritis, as well as
the natural process of wound healing. The mechanisms of pathological is are not
fully tood but are thought to result from the actions of various cytokines (including
tumor necrosis factor (TNF), last growth factors (FGF's), platelet derived growth
factor (PDGF) and transforming growth factor beta. (TGFB) involved in the proliferation
of fibroblasts and the deposition of extracellular matrix proteins (including collagen and
fibronectin). This results in tion of tissue structure and function and subsequent
pathology.
A number of preclinical studies have demonstrated the up-regulation of fibroblast growth
factors in preclinical models of lung fibrosis. TGF[31 and PDGF have been reported to
be ed in the fibrogenic s and further published work suggests the elevation
of FGF’s and consequent increase in fibroblast proliferation, may be in response to
elevated TGFBt. The potential therapeutic benefit of targeting the fibrotic mechanism in
conditions such as idiopathic pulmonary fibrosis (lPF) is suggested by the reported
clinical effect of the ibrotic agent pirfenidone . idiopathic pulmonary is (also
referred to as Cryptogenic fibrosing itis) is a progressive condition involving
scarring of the lung. Gradually, the air sacs of the lungs become replaced by fibrotic
tissue, which becomes thicker, causing an irreversible loss of the tissue’s ability to
transfer oxygen into the bloodstream. The symptoms of the condition e shortness
of breath, chronic dry coughing, fatigue, chest pain and loss of appetite resulting in rapid
weight loss. The condition is extremely s with approximately 50% mortality after 5
years.
As such, the compounds which inhibit FGFR will be useful in providing a means of
preventing the growth or inducing apoptosis in tumours, particularly by inhibiting
enesis. it is therefore anticipated that the compounds will prove useful in treating
or ting proliferative disorders such as cancers. In particular tumours with
ting mutants of receptor tyrosine s or upregulation of receptor tyrosine
kinases may be particularly sensitive to the inhibitors. Patients with activating mutants of
any of the isoforms of the specific RTKs discussed herein may also find ent with
RTK inhibitors particularly beneficial.
Vascular Endothelial Growth Factor (VEGFR)
Chronic proliferative diseases are often accompanied by profound angiogenesis, which
can contribute to or maintain an inflammatory and/or proliferative state, or which leads to
tissue destruction through the invasive proliferation of blood vessels. .
Angiogenesis is lly used to describe the development of new or replacement
blood vessels, or neovascularisation. It is a necessary and physiological normal process
by which vasculature is established in the embryo. Angiogenesis does not occur, in
general, in most normal adult tissues, exceptions being sites of ovulation, menses and
wound healing. Many diseases, however, are characterized by tent and
unregulated angiogenesis. For instance, in arthritis, new capillary blood vessels invade
the joint and y cartilage. in diabetes (and in many different eye diseases), new
vessels invade the macula or retina or other ocular structures, and may cause
blindness. The process of sclerosis has been linked to angiogenesis. Tumor
growth and metastasis have been found to be enesis—dependent.
The recognition of the involvement of angiogenesis in major diseases has been
accompanied by research to identify and develop inhibitors of angiogenesis. These
inhibitors are generally classified in response to discrete s in the angiogenesis
cascade, such as activation of endothelial cells by an angiogenic ; synthesis and
e of degradative enzymes; endothelial cell migration; proliferation of endothelial
cells; and formation of capillary tubules. Therefore, enesis occurs in many stages
and attempts are underway to discover and develop compounds that work to block
angiogenesis at these various stages.
There are publications that teach that inhibitors of angiogenesis, working by diverse
mechanisms, are beneficial in diseases such as cancer and metastasis, ocular
diseases, arthritis and hemangioma.
Vascular endothelial growth factor (VEGF), a ptide, is mitogenic for endothelial
cells in vitro and stimulates angiogenic responses in vivo. VEGF has also been linked to
inappropriate angiogenesis. VEGFR(s) are protein tyrosine kinases (PTKs). PTKs
catalyze the phosphorylation of ic tyrosine residues in proteins ed in cell
on thus regulating cell growth, survival and differentiation.
Three PTK receptors for VEGF have been fied: VEGFR-1 (Flt-1) ; VEGFR-2 (FIk—1
or KDR) and VEGFR—3 (Flt-4). These receptors are involved in angiogenesis and
participate in signal transduction. Of ular interest is VEGFR-Z, which is a
transmembrane receptor PTK expressed primarily in endothelial cells. Activation of
VEGFR-Z by VEGF is a critical step in the signal transduction pathway that initiates
tumour angiogenesis. VEGF expression may be constitutive to tumour cells and can
also be upregulated in response to certain stimuli. One such stimuli is hypoxia, where
VEGF sion is upregulated in both tumour and associated host tissues. The VEGF
ligand activates VEGFR-2 by binding with its extracellular VEGF binding site. This leads
to or dimerization of VEGFR5 and autophosphorylation of tyrosine residues at the
intracellular kinase domain of VEGFR- 2. The kinase domain operates to transfer a
phosphate from ATP to the tyrosine residues, thus providing binding sites for signalling
proteins downstream of VEGFR-2 leading ultimately to tion of angiogenesis.
inhibition at the kinase domain binding site of VEGFR-2 would block phosphorylation of
tyrosine residues and serve to disrupt initiation of enesis.
enesis is a physiologic process of new blood vessel formation mediated by
various cytokines called angiogenic factors. Although its potential pathophysiologic role
in solid tumors has been extensively studied for more than 3 decades, enhancement of
angiogenesis in chronic lymphocytic leukemia (CLL) and other malignant hematological
disorders has been recognized more recently. An increased level of angiogenesis has
been documented by various experimental methods both in bone marrow and lymph
nodes of patients with CLL. Although the role of enesis in the pathophysiology of
this disease remains to be fully elucidated, experimental data suggest that several
angiogenic factors play a role in the e progression. Biologic s of
angiogenesis were also shown to be of prognostic relevance in CLL. This indicates that
VEGFR inhibitors may also be of benefit for patients with leukemia’s such as CLL.
In order for a tumour mass to get beyond a critical size, it must develop an associated
ature. It has been proposed that targeting a tumor vasculature would limit tumor
expansion and could be a useful cancer therapy. Observations of tumor growth have
indicated that small tumour masses can persist in a tissue without any tumour-specific
vasculature. The growth arrest of nonvascularized tumors has been attributed to the
effects of hypoxia at the center of the tumor. More recently, a variety of proangiogenic
and antiangiogenic s have been identified and have led to the concept of the
“angiogenic switch,” a process in which disruption of the normal ratio of angiogenic
stimuli and inhibitors in a tumor mass allows for autonomous arization. The
enic switch appears to be governed by the same c alterations that drive
malignant conversion: the activation of oncogenes and the loss of tumour suppressor
genes. Several growth factors act as positive regulators of angiogenesis. Foremost
among these are vascular elial growth factor (VEGF), basic fibroblast growth
factor (bFGF), and angiogenin. Proteins such as thrombospondin (Tsp-i), angiostatin,
and endostatin function as negative tors of angiogenesis.
2012/052672
Inhibition of VEGFR2 but not VEGFR1 markedly disrupts angiogenic switching,
persistent angiogenesis, and initial tumor growth in a mouse model. In late-stage
, phenotypic resistance to VEGFR2 blockade emerged, as tumors regrew during
treatment after an initial period of growth suppression. This resistance to VEGF
blockade involves reactivation of tumour angiogenesis, independent of VEGF and
associated with hypoxia-mediated induction of other proangiogenic s, ing
s of the FGF family. These other proangiogenic signals are functionally
implicated in the revascularization and regrowth of tumours in the evasion phase, as
FGF blockade impairs progression in the face of VEGF inhibition.
There is evidence for normalization of glioblastoma blood s in patients treated
with a pan-VEGF receptor tyrosine kinase inhibitor, AZD2171, in a phase 2 study. MRI
determination of vessel normalization in combination with circulating biomarkers
provides for an effective means to assess response to antiangiogenic agents.
PDGFR
A ant tumour is the t of uncontrolled cell proliferation. Cell growth is
controlled by a delicate balance between growth—promoting and growth-inhibiting
factors. In normal tissue the production and activity of these factors results in
differentiated cells growing in a lled and regulated manner that maintains the
normal integrity and functioning of the organ. The malignant cell has evaded this control;
the natural balance is disturbed (via a variety of mechanisms) and unregulated, nt
cell growth occurs. A growth factor of importance in tumour development is the et-
derived growth factor (PDGF) that comprises a family of peptide growth factors that
signal through cell surface tyrosine kinase receptors (PDGFR) and stimulate various
cellular functions including growth, proliferation, and differentiation.
Advantages of a selective tor
Development of FGFR kinase inhibitors with a differentiated selectivity profile provides a
new opportunity to use these targeted agents in patient sub-groups whose disease is
driven by FGFR deregulation. Compounds that exhibit reduced inhibitory action on
additional kinases, particularly VEGFR2 and PDGFR-beta, offer the opportunity to have
a differentiated side-effect or toxicity profile and as such allow for a more effective
ent of these indications. Inhibitors of VEGFR2 and PDGFR—beta are associated
with toxicities such as hypertension or oedema respectively. in the case of VEGFR2
inhibitors this ensive effect is often dose limiting, may be contraindicated in certain
patient populations and requires clinical management.
Biological Activity and Therapeutic Uses
The compounds of the invention, and subgroups thereof, have fibroblast growth factor
receptor (FGFR) inhibiting or modulating activity and/or vascular elial growth
factor receptor (VEGFR) inhibiting or modulating activity, and/or platelet derived growth
factor receptor (PDGFR) inhibiting or modulating activity, and which will be useful in
preventing or treating disease states or conditions described herein. In addition the
compounds of the invention, and subgroups f, will be useful in preventing or
treating es or condition mediated by the kinases. References to the preventing or
prophylaxis or treatment of a disease state or condition such as cancer include within
their scope alleviating or reducing the nce of cancer.
As used herein, the term "modulation", as applied to the activity of a kinase, is intended
to define a change in the level of biological activity of the protein kinase. Thus,
modulation encompasses physiological changes which effect an increase or decrease in
the relevant protein kinase activity. In the latter case, the modulation may be bed
as "inhibition". The modulation may arise directly or indirectly, and may be mediated by
any mechanism and at any physiological level, including for example at the level of gene
expression (including for example transcription, translation and/or post-translational
modification), at the level of expression of genes encoding regulatory elements which
act directly or indirectly on the levels of kinase activity. Thus, modulation may imply
elevated/suppressed expression or over- or under-expression of a , including
gene amplification (i.e. multiple gene copies) and/or increased or decreased expression
by a riptional effect, as well as hyper- (or hypo-)activity and (de)activation of the
protein kinase(s) (including (de)activation) by on(s). The terms ated”,
“modulating" and “modulate” are to be interpreted accordingly.
As used herein, the term “mediated”, as used e.g. in conjunction with a kinase as
described herein (and applied for example to various physiological processes, diseases,
states, conditions, ies, treatments or interventions) is intended to operate
tively so that the various ses, diseases, states, conditions, ents and
interventions to which the term is applied are those in which the kinase plays a biological
role. In cases where the term is applied to a disease, state or condition, the biological
role played by a kinase may be direct or ct and may be necessary and/or ient
for the manifestation of the symptoms of the disease, state or ion (or its aetiology
or progression). Thus, kinase activity (and in particular aberrant levels of kinase activity,
e.g. kinase over—expression) need not necessarily be the proximal cause of the disease,
state or condition: rather, it is contemplated that the kinase mediated diseases, states or
ions include those having actorial aetiologies and complex progressions in
which the kinase in on is only partially involved. In cases where the term is
applied to treatment, laxis or intervention, the role played by the kinase may be
direct or indirect and may be necessary and/or sufficient for the operation of the
treatment, prophylaxis or outcome of the intervention. Thus, a disease state or condition
mediated by a kinase includes the development of resistance to any particular cancer
drug or treatment.
Thus, for example, the compounds of the invention may be useful in alleviating or
ng the incidence of cancer.
More particularly, the compounds of the formulae (I) and oups thereof are
inhibitors of FGFRs. For example, compounds of the invention have activity against
FGFR1, FGFR2, FGFR3, and/or FGFR4. and in particular FGFRs ed from
FGFR1, FGFR2 and FGFRS; or in particular the compounds of formula (I) and sub-
groups thereof are inhibitors of FGFR4.
Preferred compounds are compounds that inhibit one or more FGFR selected from
FGFR1, FGFR2, FGFRS, and FGFR4. Preferred compounds of the ion are those
having lC50 values of less than 0.1 pM.
Compounds of the invention also have activity against VEGFR.
In addition many of the compounds of the invention exhibit selectivity for the FGFR 1, 2,
and/or 3, and/or 4 compared to VEGFR (in particular VEGFR2) and/or PDGFR and such
compounds represent one preferred embodiment of the invention. In particular, the
compounds exhibit selectivity over VEGFR2. For example, many compounds of the
invention have lC5o values against FGFR1, 2 and/or 3 and/or 4 that are between a tenth
and a dth of the leo against VEGFR (in particular ) and/or PDGFR B. In
ular red compounds of the invention have at least 10 times greater activity
against or inhibition of FGFR in particular FGFR1, FGFR2, FGFR3 and/or FGFR4 than
VEGFRZ. More preferably the compounds of the invention have at least 100 times
greater activity against or inhibition of FGFR in particular FGFR1, FGFR2, FGFR3
and/or FGFR4 than VEGFRZ. This can be determined using the methods described
herein.
As a consequence of their ty in modulating or inhibiting FGFR, and/or VEGFR
kinases, the compounds will be useful in providing a means of preventing the growth or
inducing apoptosis of neoplasias, particularly by inhibiting angiogenesis. it is therefore
anticipated that the compounds will prove useful in treating or preventing proliferative
disorders such as cancers. in addition, the compounds of the invention could be useful
in the treatment of es in which there is a disorder of proliferation, apoptosis or
differentiation.
in particular tumours with activating mutants of VEGFR or upregulation of VEGFR and
patients with elevated levels of serum lactate dehydrogenase may be particularly
sensitive to the compounds of the invention. Patients with activating mutants of any of
the isoforms of the specific RTKs discussed herein may also find treatment with the
nds of the invention particularly beneficial. For example, VEGFR
overexpression in acute leukemia cells where the clonal progenitor may express
VEGFR. Also, particular tumours with activating mutants or upregulation or
overexpression of any of the isoforms of FGFR such as FGFR1, FGFR2 or FGFR3 or
FGFR4 may be particularly sensitive to the compounds of the invention and thus
patients as discussed herein with such particular tumours may also find treatment with
the nds of the invention particularly beneficial. it may be red that the
treatment is related to or ed at a d form of one of the receptor tyrosine
kinases, such as discussed . Diagnosis of tumours with such mutations could be
med using techniques known to a person skilled in the art and as described herein
such as RTPCR and FISH.
Examples of cancers which may be treated (or inhibited) include, but are not limited to, a
carcinoma, for example a carcinoma of the bladder, breast, colon (e.g. colorectal
carcinomas such as colon adenocarcinoma and colon adenoma), kidney, urothelial,
uterus, epidermis, liver, lung (for example adenocarcinoma, small cell lung cancer and
non-small cell lung carcinomas, squamous lung cancer), oesophagus, head and neck,
gall bladder, ovary, as (e.g. ne pancreatic carcinoma), stomach,
gastrointestinal (also known as c) cancer (e.g. gastrointestinal stromal tumours),
, endometrium, d, prostate, or skin (for example squamous cell carcinoma or
dermatofibrosarcoma protuberans); pituitary cancer, a hematopoietic tumour of id
lineage, for example leukemia, acute lymphocytic leukemia, chronic lymphocytic
leukemia, B-cell lymphoma (e.g. diffuse large B-cell lymphoma), T-cell lymphoma,
Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, hairy cell lymphoma, or Burkett's
lymphoma; a poietic tumour of myeloid lineage, for example leukemias, acute
and chronic myelogenous leukemias, chronic myelomonocytic leukemia (CMML),
myeloproliferative disorder, myeloproliferative me, myelodysplastic syndrome, or
promyelocytic leukemia; multiple myeloma; thyroid follicular ; hepatocellular
cancer, a tumour of mesenchymal origin (e.g. Ewing’s sarcoma), for example
fibrosarcoma or rhabdomyosarcoma; a tumour of the central or peripheral nervous
system, for example astrocytoma, neuroblastoma, glioma (such as glioblastoma
multiforme) or schwannoma; melanoma; seminoma; teratocarcinoma; osteosarcoma;
xeroderma pigmentosum; keratoctanthoma; d ular cancer; or Kaposi's
sarcoma. In particular, squamous lung , breast cancer, colorectal cancer,
glioblastoma, astrocytomas, prostate cancer, small cell lung cancer, ma, head
and neck cancer, thyroid cancer, uterine cancer, gastric cancer, hepatocellular cancer,
cervix cancer, multiple a, bladder , endometrial cancer, urothelial cancer,
colon cancer, rhabdomyosarcoma, pituitary gland cancer.
n cancers are resistant to treatment with particular drugs. This can be due to the
type of the tumour or can arise due to treatment with the compound. In this regard,
references to multiple myeloma es bortezomib sensitive le myeloma or
refractory multiple myeloma. Similarly, references to chronic myelogenous leukemia
includes imitanib sensitive c myelogenous leukemia and refractory chronic
myelogenous leukemia. Chronic myelogenous leukemia is also known as chronic
myeloid leukemia, chronic granulocytic leukemia or CML. Likewise, acute myelogenous
leukemia, is also called acute myeloblastic leukemia, acute granulocytic leukemia, acute
phocytic leukaemia or AML.
The compounds of the invention can also be used in the treatment of hematopoetic
diseases of abnormal cell eration whether pre-malignant or stable such as
myeloproliferative diseases. Myeloproliferative diseases ("MPD"s) are a group of
diseases of the bone marrow in which excess cells are produced. They are related to,
and may evolve into, myelodysplastic syndrome. roliferative diseases include
polycythemia vera, essential ocythemia and y myelofibrosis. A r
haematological er is hypereosinophilic syndrome. T-cell lymphoproliferative
diseases include those derived from natural Killer cells.
In addition the compounds of the invention can be used to intestinal (also known
as gastric) cancer e.g. gastrointestinal l tumours. Gastrointestinal cancer refers
to malignant conditions of the gastrointestinal tract, including the esophagus, stomach,
liver, biliary system, pancreas, bowels, and anus.
Thus, in the pharmaceutical compositions, uses or methods of this invention for treating
a disease or condition comprising abnormal cell growth, the disease or condition
comprising abnormal cell growth in one ment is a cancer.
Particular subsets of cancers include multiple myeloma, bladder, cervical, prostate and
thyroid carcinomas, lung, breast, and colon cancers.
A further subset of cancers includes multiple myeloma, bladder, hepatocellular, oral
squamous cell carcinoma and cervical carcinomas.
The nd of the invention, having FGFR such as FGFR1 inhibitory activity, may be
particularly useful in the treatment or prevention of breast cancer in particular Classic
Lobular Carcinomas (CLC).
As the compounds of the invention have FGFR4 ty they will also be useful in the
treatment of prostate or pituitary cancers, or they will be useful in the treatment of breast
cancer, lung cancer, prostate cancer, liver cancer (HCC) or lung cancer.
In particular the compounds of the ion as FGFR inhibitors, are useful in the
treatment of le a, myeloproliferatoive disorders, endometrial cancer,
prostate cancer, bladder cancer, lung cancer, ovarian cancer, breast , gastric
cancer, colorectal cancer, and oral squamous cell carcinoma.
Further subsets of cancer are multiple myeloma, endometrial cancer, bladder cancer,
al cancer, prostate cancer, lung cancer, breast cancer, colorectal cancer and
thyroid carcinomas.
In particular the compounds of the invention are useful in the treatment of multiple
myeloma (in ular multiple myeloma with t(4;14) translocation or overexpressing
FGFR3), prostate cancer (hormone refractory ate carcinomas), endometrial cancer
(in particular trial s with activating mutations in FGFR2) and breast
cancer (in particular lobular breast cancer).
In particular the nds are useful in the treatment of lobular carcinomas such as
CLC ic lobular carcinoma).
As the compounds have activity against FGFR3 they will be useful in the treatment of
multiple myeloma and bladder cancer.
In particular the compounds are useful for the treatment of t(4;14) translocation positive
multiple myeloma.
In one embodiment the compounds may be useful for the treatment of sarcoma. In one
embodiment the compounds may be useful for the treatment of lung cancer, e.g.
squamous cell carcinoma.
As the compounds have activity against FGFR2 they will be useful in the treatment of
endometrial, ovarian, gastric, hepatocellular, uterine, cervix and colorectal cancers.
FGFR2 is also pressed in epithelial ovarian cancer, therefore the compounds of
the invention may be specifically useful in treating ovarian cancer such as epithelial
ovarian cancer.
In one embodiment, the compounds may be useful for the treatment of lung cancer, in
particular NSCLC, squamous cell carcinoma, liver cancer, kidney cancer, breast cancer,
colon cancer, colorectal cancer, prostate cancer.
In one embodiment, the compounds may be useful for the treatment of prostate cancer,
bladder , lung cancer such as NSCLC, breast cancer, gastric cancer,and liver
cancer (HCC (hepatocellular cancer)).
Compounds of the ion may also be useful in the treatment of tumours pre-treated
with VEGFR2 tor or VEGFR2 antibody (e.g. Avastin).
In particular the compounds of the invention may be useful in the treatment of VEGFR2-
resistant tumours. VEGFR2 inhibitors and antibodies are used in the treatment of
thyroid and renal cell carcinomas, therefore the nds of the invention may be
useful in the ent of VEGFR2-resistant thyroid and renal cell carcinomas.
The cancers may be cancers which are sensitive to inhibition of any one or more FGFRs
selected from FGFR1, FGFR2, FGFR3, FGFR4, for example, one or more FGFRs
selected from FGFR1, FGFR2 or FGFR3.
Whether or not a particular cancer is one which is sensitive to inhibition of FGFR or
VEGFR signalling may be determined by means of a cell growth assay as set out below
or by a method as set out in the section headed “Methods of Diagnosis”.
The compounds of the invention, and in particular those nds having FGFR, or
VEGFR inhibitory activity, may be ularly useful in the treatment or prevention of
cancers of a type associated with or characterised by the presence of elevated levels of
FGFR, or VEGFR, for example the cancers referred to in this t in the introductory
section of this ation.
The compounds of the present invention may be useful for the treatment of the adult
population. The compounds of the t invention may be useful for the treatment of
the pediatric population.
It has been ered that some FGFR inhibitors can be used in combination with other
anticancer agents. For example, it may be beneficial to e an inhibitor that
induces apoptosis with another agent which acts via a different mechanism to regulate
cell growth thus treating two of the characteristic features of cancer development.
Examples of such combinations are set out below.
The compounds of the invention may be useful in ng other conditions which result
from disorders in proliferation such as type II or non-insulin dependent diabetes mellitus,
autoimmune diseases, head , stroke, epilepsy, neurodegenerative diseases such
as Alzheimer’s, motor neurone disease, ssive supranuclear palsy, corticobasal
degeneration and Pick’s disease for example autoimmune diseases and
neurodegenerative es.
One sub—group of disease states and conditions that the compounds of the invention
wound
may be useful consists of inflammatory diseases, cardiovascular diseases and
FGFR, and VEGFR are also known to play a role in apoptosis, angiogenesis,
proliferation, differentiation and transcription and therefore the compounds of the
invention could also be useful in the treatment of the following diseases other than
cancer; chronic inflammatory diseases, for example systemic lupus erythematosus,
autoimmune mediated glomerulonephritis, toid arthritis, psoriasis, inflammatory
bowel disease, mune diabetes mellitus, Eczema hypersensitivity reactions,
asthma, COPD, rhinitis, and upper atory tract disease; cardiovascular diseases for
example cardiac hypertrophy, restenosis, atherosclerosis; neurodegenerative disorders,
for example Alzheimer’s disease, AIDS-related dementia, Parkinson’s disease,
amyotropic lateral sclerosis, retinitis pigmentosa, spinal muscular atropy and cerebellar
degeneration; glomerulonephritis; myelodysplastic syndromes, ischemic injury
associated myocardial infarctions, stroke and reperfusion injury, arrhythmia,
atherosclerosis, toxin-induced or alcohol related liver es, haematological
es, for example, chronic anemia and aplastic anemia; degenerative es of
the musculoskeletal system, for example, osteoporosis and arthritis, aspirin—sensitive
inusitis, cystic fibrosis, multiple sclerosis, kidney diseases and cancer pain.
ln addition, mutations of FGFR2 are associated with several severe abnormalities in
human skeletal development and thus the compounds of invention could be useful in the
treatment of abnormalities in human skeletal development, including abnormal
ossification of cranial sutures (craniosynostosis), Apert (AP) syndrome, Crouzon
syndrome, Jackson-Weiss syndrome, Beare-Stevenson cutis gyrate syndrome, and
Pfeiffer syndrome.
The compound of the invention, having FGFR such as FGFR2 or FGFR3 inhibitory
activity, may be particularly useful in the treatment or prevention of the skeletal
diseases. Particular skeletal diseases are achondroplasia or thanatophoric sm
(also known as thanatophoric dysplasia).
The nd of the invention, having FGFR such as FGFR1, FGFR2 or FGFR3
inhibitory activity, may be ularly useful in the treatment or prevention in
pathologies in which progressive fibrosis is a symptom. Fibrotic conditions in which the
compounds of the inventions may be useful in the treatment of include diseases
exhibiting abnormal or excessive deposition of fibrous tissue for example in liver
cirrhosis, glomerulonephritis, pulmonary fibrosis, systemic fibrosis, rheumatoid arthritis,
as well as the natural process of wound healing. In particular the compounds of the
inventions may also be useful in the treatment of lung fibrosis in particular in idiopathic
pulmonary fibrosis.
The xpression and activation of FGFR and VEGFR in tumor— ated
vasculature has also ted a role for compounds of the invention in preventing and
disrupting initiation of tumor enesis. In ular the compounds of the invention
may be useful in the treatment of cancer, metastasis, leukemia’s such as CLL, ocular
diseases such as age-related r degeneration in particular wet form of age-related
macular ration, ischemic erative retinopathies such as retinopathy of
prematurity (ROP) and diabetic retinopathy, rheumatoid arthritis and hemangioma.
The activity of the compounds of the invention as tors of 4, VEGFR and/or
PDGFR A/B can be measured using the assays set forth in the examples below and the
level of activity exhibited by a given compound can be defined in terms of the lC5o value.
Preferred compounds of the present invention are compounds having an leo value of
less than 1|JM, more preferably less than 0.1 uM.
The invention es compounds that have FGFR inhibiting or modulating activity, and
which may be useful in preventing or treating disease states or ions mediated by
FGFR kinases.
in one embodiment, there is provided a compound as defined herein for use in therapy,
for use as a ne. in a further embodiment, there is provided a compound as
defined herein for use in the prophylaxis or treatment, in particular in the treatment, of a
disease state or condition ed by a FGFR kinase.
Thus, for example, the compounds of the invention may be useful in alleviating or
reducing the incidence of cancer. Therefore, in a further embodiment, there is provided
a compound as defined herein for use in the prophylaxis or treatment, in particular the
treatment, of cancer. In one embodiment, the compound as defined herein is for use in
the prophylaxis or treatment of FGFR-dependent cancer. In one embodiment, the
compound as defined herein is for use in the laxis or treatment of cancer
mediated by FGFR kinases.
Accordingly, the invention provides inter alia:
— A method for the prophylaxis or treatment of a disease state or condition
mediated by a FGFR kinase, which method comprises administering to a subject
in need thereof a compound of the formula (I) as defined herein.
— A method for the prophylaxis or treatment of a disease state or condition as
described herein, which method comprises administering to a subject in need
thereof a compound of the formula (I) as defined herein.
— A method for the prophylaxis or treatment of cancer, which method ses
administering to a subject in need thereof a compound of the formula (I) as
defined .
— A method for alleviating or reducing the incidence of a disease state or condition
mediated by a FGFR kinase, which method comprises stering to a subject
in need thereof a nd of the formula (I) as d herein.
— A method of inhibiting a FGFR , which method comprises contacting the
kinase with a kinase-inhibiting compound of the formula (I) as defined herein.
A method of modulating a cellular s (for e cell division) by inhibiting
the activity of a FGFR kinase using a compound of the formula (I) as defined
A compound of a (I) as defined herein for use as a tor of a cellular
process (for example cell division) by inhibiting the activity of a FGFR kinase.
A compound of formula (I) as defined herein for use in the prophylaxis or
treatment of cancer, in particular the treatment of cancer.
A compound of formula (I) as defined herein for use as a modulator (e.g.
inhibitor) of FGFR.
The use of a compound of formula (I) as defined herein for the manufacture of a
medicament for the prophylaxis or treatment of a disease state or condition
mediated by a FGFR kinase, the compound having the formula (I) as defined
herein.
The use of a compound of formula (I) as d herein for the manufacture of a
medicament for the prophylaxis or treatment of a disease state or condition as
described herein.
The use of a compound of formula (I) as d herein for the manufacture of a
medicament for the prophylaxis or treatment, in particular the treatment, of
cancen
The use of a compound of formula (I) as defined herein for the manufacture of a
medicament for modulating (e.g. inhibiting) the activity of FGFR.
Use of a compound of formula (I) as defined herein in the manufacture of a
medicament for modulating a ar process (for example cell division) by
inhibiting the activity of a FGFR kinase.
The use of a compound of the formula (I) as defined herein for the manufacture
of a medicament for prophylaxis or treatment of a disease or ion
characterised by up-regulation of a FGFR kinase (e.g. FGFR1 or FGFR2 or
FGFR3 or FGFR4).
The use of a compound of the formula (I) as defined herein for the cture
of a medicament for the prophylaxis or treatment of a cancer, the cancer being
one which is characterised by up-regulation of a FGFR kinase (e.g. FGFR1 or
FGFR2 or FGFR3 or FGFR4).
— The use of a compound of the formula (I) as defined herein for the manufacture
of a medicament for the prophylaxis or treatment of cancer in a patient selected
from a sub-population possessing a genetic aberrations of FGFR3 kinase.
—- The use of a compound of the formula (I) as defined herein for the cture
of a medicament for the prophylaxis or treatment of cancer in a patient who has
been sed as forming part of a sub-population possessing a genetic
aberrations of FGFR3 .
— A method for the prophylaxis or treatment of a disease or condition characterised
by up-regulation of a FGFR kinase (e.g. FGFR1 or FGFR2 or FGFR3 or FGFR4),
the method comprising administering a nd of the formula (I) as defined
herein.
— A method for alleviating or reducing the incidence of a e or condition
characterised by up-regulation of a FGFR kinase (e.g. FGFR1 or FGFR2 or
FGFR3 or FGFR4), the method comprising administering a nd of the
formula (I) as d herein.
— A method for the prophylaxis or treatment of (or alleviating or reducing the
incidence of) cancer in a patient suffering from or suspected of suffering from
cancer; which method comprises (i) subjecting a patient to a diagnostic test to
determine whether the patient possesses a genetic aberrations of FGFR3 gene;
and (ii) where the patient does possess the said variant, thereafter stering
to the patient a nd of the formula (I) as defined herein having FGFR3
kinase inhibiting activity.
— A method for the prophylaxis or treatment of (or alleviating or reducing the
incidence of) a disease state or condition characterised by up-regulation of an
FGFR kinase (e.g. FGFR1 or FGFR2 or FGFR3 or FGFR4); which method
comprises (i) subjecting a patient to a diagnostic test to detect a marker
characteristic of up-regulation of a FGFR kinase (e.g. FGFR1 or FGFR2 or
FGFR3 or FGFR4) and (ii) where the diagnostic test is indicative of ulation
of a FGFR kinase, thereafter administering to the patient a compound of the
a (I) as defined herein having FGFR kinase inhibiting activity.
In one embodiment, the disease mediated by FGFR kinases is a oncology related
disease (e.g. cancer). In one embodiment, the disease mediated by FGFR kinases is a
non-oncology related disease (e.g. any disease disclosed herein ing cancer). In
one embodiment the disease mediated by FGFR kinases is a condition described
herein. in one embodiment the disease mediated by FGFR kinases is a skeletal
condition described . ular alities in human skeletal development,
include abnormal ossification of cranial sutures (craniosynostosis), Apert (AP)
syndrome, Crouzon syndrome, Jackson-Weiss syndrome, Bears-Stevenson cutis gyrate
syndrome, Pfeiffer syndrome, achondroplasia and thanatophoric sm (also known
as thanatophoric sia).
Mutated Kinases
Drug resistant kinase mutations can arise in patient populations treated with kinase
inhibitors. These occur, in part, in the regions of the protein that bind to or ct with
the particular inhibitor used in therapy. Such mutations reduce or increase the capacity
of the inhibitor to bind to and inhibit the kinase in on. This can occur at any of the
amino acid residues which interact with the inhibitor or are important for supporting the
binding of said inhibitor to the target. An inhibitor that binds to a target kinase without
requiring the interaction with the mutated amino acid residue will likely be unaffected by
the mutation and will remain an effective inhibitor of the enzyme.
A study in gastric cancer patient samples showed the presence of two mutations in
FGFR2, Ser167Pro in exon llla and a splice site on 940-2A—G in exon lllc. These
ons are identical to the germline activating mutations that cause craniosynotosis
syndromes and were observed in 13% of primary gastric cancer tissues studied. in
addition activating mutations in FGFRS were observed in 5% of the patient samples
tested and overexpression of FGFRs has been correlated with a poor prognosis in this
patient group.
In addition there are chromosomal translocations or point mutations that have been
observed in FGFR which give rise to f—function, over-expressed, or constitutively
active biological states.
The compounds of the invention would ore find particular application in relation to
cancers which express a mutated molecular target such as FGFR. Diagnosis of
tumours with such mutations could be med using ques known to a person
skilled in the art and as described herein such as RTPCR and FISH.
It has been suggested that mutations of a conserved threonine residue at the ATP
binding site of FGFR would result in inhibitor resistance. The amino acid valine 561 has
been mutated to a methionine in FGFR1 which corresponds to usly reported
mutations found in Abl (T315) and EGFR (T766) that have been shown to confer
resistance to ive inhibitors. Assay data for FGFR1 V561 M showed that this
mutation conferred resistance to a ne kinase inhibitor compared to that of the wild
type.
Methods of Diagnosis
Prior to administration of a compound of the formula (l), a patient may be screened to
determine whether a disease or condition from which the patient is or may be suffering
is one which would be susceptible to treatment with a compound having activity against
FGFR, and/or VEGFR.
For example, a biological sample taken from a t may be analysed to determine
whether a condition or disease, such as cancer, that the patient is or may be suffering
from is one which is characterised by a genetic abnormality or al protein
expression which leads to up—regulation of the levels or activity of FGFR, and/or VEGFR
or to sensitisation of a pathway to normal FGFR, and/or VEGFR activity, or to
upregulation of these growth factor signalling ys such as growth factor ligand
levels or growth factor ligand activity or to lation of a mical y
downstream of FGFR, and/or VEGFR activation.
Examples of such abnormalities that result in activation or sensitisation of the FGFR,
and/or VEGFR signal include loss of, or inhibition of apoptotic pathways, up-regulation
of the receptors or ligands, or presence of mutant variants of the receptors or ligands e.g
PTK ts. Tumours with mutants of FGFR1, FGFR2 or FGFR3 or FGFR4 or up-
regulation, in particular over-expression of FGFR1, or gain-of—function mutants of
FGFR2 or FGFR3 may be particularly sensitive to FGFR inhibitors.
For example, point mutations engendering gain-of-function in FGFR2 have been
identified in a number of conditions. In particular activating ons in FGFR2 have
been identified in 10% of endometrial tumours.
In addition, genetic aberrations of the FGFR3 or tyrosine kinase such as
chromosomal translocations or point mutations resulting in ectopically expressed or
deregulated, constitutively , FGFR3 receptors have been identified and are linked
to a subset of multiple myelomas, bladder and cervical carcinomas. A particular
mutation T674l of the PDGF receptor has been identified in imatinib-treated patients. in
addition, a gene amplification of 8p12—p1 1.2 was demonstrated in ~50% of lobular
breast cancer (CLC) cases and this was shown to be linked with an increased
expression of FGFR1. Preliminary studies with siRNA directed against FGFR1, or a
small molecule inhibitor of the receptor, showed cell lines harbouring this amplification to
be particularly sensitive to inhibition of this signalling pathway.
Alternatively, a biological sample taken from a t may be analysed for loss of a
negative regulator or suppressor of FGFR or VEGFR. in the present t, the term
“loss” embraces the deletion of a gene encoding the tor or suppressor, the
truncation of the gene (for example by mutation), the truncation of the transcribed
product of the gene, or the vation of the transcribed product (e.g. by point mutation)
or sequestration by another gene t.
The term up-regulation es elevated expression or over-expression, including gene
amplification (i.e. multiple gene copies) and increased expression by a transcriptional
effect, and hyperactivity and activation, including activation by mutations. Thus, the
patient may be subjected to a diagnostic test to detect a marker characteristic of up-
regulation of FGFR, and/or VEGFR. The term diagnosis includes screening. By marker
we include genetic s including, for example, the measurement of DNA
composition to identify mutations of FGFR, and/or VEGFR. The term marker also
includes markers which are characteristic of up regulation of FGFR and/or VEGFR,
including enzyme activity, enzyme levels, enzyme state (eg. phosphorylated or not) and
mRNA levels of the entioned proteins.
The diagnostic tests and screens are typically ted on a biological sample
selected from tumour biopsy samples, blood samples tion and enrichment of shed
tumour cells), stool biopsies, sputum, some analysis, pleural fluid, peritoneal
fluid, buccal spears, biopsy or urine.
WO 61080 2012/052672
Methods of identification and analysis of mutations and up-regulation of proteins are
known to a person skilled in the art. Screening methods could include, but are not
limited to, standard methods such as reverse-transcriptase polymerase chain reaction
(RT~PCR) or in-situ hybridization such as scence in situ hybridization (FISH).
Identification of an individual carrying a mutation in FGFR, and /or VEGFR may mean
that the patient would be particularly suitable for treatment with a FGFR, and /or VEGFR
inhibitor. s may preferentially be screened for presence of a FGFR, and /or
VEGFR variant prior to treatment. The screening process will typically involve direct
cing, oligonucleotide microarray analysis, or a mutant specific antibody. In
addition, diagnosis of tumours with such mutations could be performed using techniques
known to a person skilled in the art and as described herein such as RT-PCR and FISH.
In on, mutant forms of, for example FGFR or VEGFR2, can be identified by direct
sequencing of, for example, tumour biopsies using PCR and s to sequence PCR
products directly as hereinbefore described. The skilled artisan will recognize that all
such well-known techniques for detection of the over expression, activation or mutations
of the aforementioned proteins could be applicable in the present case.
In screening by RT-PCR, the level of mRNA in the tumour is assessed by creating a
cDNA copy of the mRNA followed by amplification of the cDNA by PCR. Methods of
PCR amplification, the selection of primers, and conditions for amplification, are known
to a person skilled in the art. Nucleic acid manipulations and PCR are carried out by
standard methods, as described for example in Ausubel, PM et al., eds. (2004)
Current Protocols in Molecular Biology, John Wiley & Sons Inc., or Innis, MA. et al.,
eds. (1990) PCR Protocols: a guide to s and applications, Academic Press, San
Diego. Reactions and lations ing c acid techniques are also
described in Sambrook et al., (2001 ), 3rd Ed, Molecular Cloning: A Laboratory Manual,
Cold Spring Harbor tory Press. Alternatively a commercially available kit for RT-
PCR (for example Roche Molecular Biochemicals) may be used, or methodology as set
forth in United States patents 4,666,828; 4,683,202; 531; 5,192,659, 5,272,057,
,882,864, and 6,218,529 and incorporated herein by reference. An example of an in-
situ hybridisation technique for assessing mRNA sion would be fluorescence in-
situ hybridisation (FISH) (see Angerer (1987) Meth. Enzymol., 152: 649).
Generally, in situ hybridization comprises the following major steps: (1) fixation of tissue
to be analyzed; (2) prehybridization treatment of the sample to increase accessibility of
target nucleic acid, and to reduce nonspecific binding; (3) hybridization of the mixture of
nucleic acids to the c acid in the ical structure or tissue; (4) post-
hybridization washes to remove nucleic acid fragments not bound in the ization,
and (5) ion of the hybridized nucleic acid nts. The probes used in such
applications are lly labelled, for example, with radioisotopes or fluorescent
reporters. Preferred probes are sufficiently long, for e, from about 50, 100, or 200
nucleotides to about 1000 or more nucleotides, to enable specific hybridization with the
target nucleic acid(s) under stringent conditions. Standard methods for carrying out
FlSH are described in Ausubel, PM et al., eds. (2004) Current Protocols in Molecular
y, John Wiley & Sons Inc and Fluorescence In Situ Hybridization: Technical
Overview by John M. S. Bartlett in Molecular Diagnosis of Cancer, Methods and
Protocols, 2nd ed.; lSBN: 1-59259—760-2; March 2004, pps. 8; : Methods in
Molecular Medicine.
Methods for gene expression profiling are described by (DePrimo et al. (2003), BMC
Cancer, 3:3). Briefly, the protocol is as s: double-stranded cDNA is synthesized
from total RNA Using a (dT)24 oligomer for priming first-strand cDNA synthesis, ed
by second strand cDNA synthesis with random hexamer primers. The double-stranded
cDNA is used as a template for in vitro transcription of cRNA using biotinylated
ribonucleotides. cRNA is chemically fragmented according to protocols described by
Affymetrix (Santa Clara, CA, USA), and then hybridized overnight on Human Genome
Arrays.
atively, the protein products expressed from the mRNAs may be assayed by
immunohistochemistry of tumour samples, solid phase immunoassay with microtitre
plates, n blotting, 2-dimensional SDS-polyacrylamide gel electrophoresis, ELISA,
flow cytometry and other methods known in the art for detection of specific proteins.
Detection methods would include the use of site specific antibodies. The skilled person
will recognize that all such well-known techniques for detection of upregulation of FGFR,
and/or VEGFR, or detection of FGFR, and/or VEGFR variants or mutants could be
applicable in the present case.
Abnormal levels of proteins such as FGFR or VEGFR can be measured using standard
enzyme assays, for example, those assays bed herein. Activation or
overexpression could also be detected in a tissue sample, for e, a tumour tissue.
By measuring the tyrosine kinase activity with an assay such as that from Chemicon
International. The tyrosine kinase of interest would be immunoprecipitated from the
sample lysate and its activity measured.
Alternative methods for the ement of the over sion or activation of FGFR
or VEGFR including the ms thereof, include the measurement of essel
density. This can for example be measured using methods described by Orre and
Rogers (Int J Cancer (1999), 84(2) . Assay methods also include the use of
markers, for example, in the case of VEGFR these include CD31, CD34 and CD105.
Therefore all of these techniques could also be used to identify tumours particularly
suitable for treatment with the compounds of the invention.
The compounds of the ion are particular useful in treatment of a patient having a
mutated FGFR. The G697C mutation in FGFR3 is observed in 62% of oral squamous
cell carcmonas and causes constitutive activation of the kinase activity. Activating
mutations of FGFR3 have also been identified in bladder carcinoma cases. These
ons were of 6 kinds with varying degrees of prevelence: R2480, 8249C, G372C,
S373C, Y375C, K6520. in addition, a Gly388Arg polymorphism in FGFR4 has been
found to be associated with increased incidence and aggressiveness of prostate, colon,
lung, liver (HCC) and breast cancer.
Therefore in a further aspect the invention includes use of a compound according to the
invention for the manufacture of a medicament for the treatment or prophylaxis of a
disease state or condition in a t who has been screened and has been determined
as ing from, or being at risk of suffering from, a disease or condition which would
be susceptible to treatment with a compound having activity against FGFR.
Particular mutations a patient is screened for include G697C, R2480, 8249C, G372C,
S3730, Y375C, K6520 mutations in FGFR3 and Gly388Arg polymorphism in FGFR4.
In another aspect the ion includes a compound of the invention for use in the
prophylaxis or treatment of cancer in a patient selected from a sub-population
possessing a t of the FGFR gene (for example G697C mutation in FGFR3 and
Gly388Arg polymorphism in FGFR4).
MRI determination of vessel normalization (e.g. using MRI gradient echo, spin echo, and
contrast enhancement to measure blood volume, relative vessel size, and vascular
permeability) in combination with ating biomarkers (circulating progenitor cells
(CPCs), CECs, SDF1, and FGF2) may also be used to identify VEGFRZ-resistant
tumours for treatment with a compound of the invention.
Pharmaceutical Compositions and,Combinations
In view of their useful pharmacological properties, the t compounds may be
formulated into various pharmaceutical forms for administration es.
In one embodiment the pharmaceutical composition (e.g. formulation) comprises at
least one active compound of the invention together with one or more
pharmaceutically acceptable carriers, adjuvants, excipients, diluents, fillers, buffers,
stabilisers, preservatives, lubricants, or other materials well known to those skilled in
the art and ally other therapeutic or prophylactic agents.
To prepare the pharmaceutical compositions of this invention, an effective amount of a
nd of the present invention, as the active ingredient is combined in intimate
admixture with a pharmaceutically able carrier, which carrier may take a wide
y of forms depending on the form of preparation desired for administration. The
pharmaceutical compositions can be in any form suitable for oral, parenteral, topical,
intranasal, ophthalmic, otic, rectal, intra—vaginal, or transdermal administration. These
pharmaceutical compositions are desirably in unitary dosage form suitable, preferably,
for administration , ly, percutaneously, or by parenteral injection. For
example, in preparing the compositions in oral dosage form, any of the usual
pharmaceutical media may be employed, such as, for example, water, glycols, oils,
alcohols and the like in the case of oral liquid preparations such as sions, syrups,
elixirs and ons; or solid carriers such as es, sugars, kaolin, lubricants,
binders, disintegrating agents and the like in the case of powders, pills, capsules and
tablets.
Because of their ease in administration, tablets and capsules ent the most
advantageous oral dosage unit form, in which case solid pharmaceutical carriers are
obviously employed. For parenteral compositions, the carrier will usually se
sterile water, at least in large part, though other ingredients, to aid solubility for example,
may be included. lnjectable solutions, for e, may be prepared in which the carrier
comprises saline solution, glucose solution or a mixture of saline and glucose solution.
lnjectable suspensions may also be prepared in which case appropriate liquid carriers,
ding agents and the like may be employed. In the compositions suitable for
percutaneous administration, the carrier optionally comprises a penetration enhancing
agent and/or a suitable g agent, optionally combined with suitable additives of any
nature in minor proportions, which additives do not cause a significant deleterious effect
to the skin. Said additives may facilitate the administration to the skin and/or may be
helpful for preparing the desired itions. These compositions may be
administered in various ways, e.g., as a transdermal patch, as a spot-on, as an
ointment. it is especially advantageous to formulate the aforementioned pharmaceutical
compositions in dosage unit form for ease of administration and uniformity of .
Dosage unit form as used in the specification and claims herein refers to physically
discrete units suitable as y dosages, each unit containing a predetermined quantity
of active ingredient calculated to produce the desired therapeutic effect in association
with the required pharmaceutical carrier. Examples of such dosage unit forms are
tablets (including scored or coated tablets), capsules, pills, powder s, wafers,
injectable solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and
segregated multiples thereof.
It is especially advantageous to formulate the aforementioned pharmaceutical
itions in dosage unit form for ease of administration and mity of .
Dosage unit form as used in the specification and claims herein refers to physically
discrete units suitable as unitary dosages, each unit containing a predetermined quantity
of active ingredient, calculated to produce the desired therapeutic effect, in association
with the required pharmaceutical carrier. Examples of such dosage unit forms are tablets
(including scored or coated tablets), capsules, pills, powder packets, wafers, injectable
solutions or suspensions, teaspoonfuls, tablespoonfuls and the like, and segregated
multiples f.
The compound of the invention is administered in an amount ient to exert its anti-
tumour activity.
Those skilled in the art could easily determine the effective amount from the test results
presented hereinafter. In general it is plated that a therapeutically effective
amount would be from 0.005 mg/kg to 100 mg/kg body weight, and in particular from
0.005 mg/kg to 10 mg/kg body weight. it may be appropriate to ster the required
dose as single, two, three, four or more sub-doses at appropriate intervals throughout
the day. Said sub—doses may be formulated as unit dosage forms, for example,
containing 0.5 to 500 mg, in ular 1 mg to 500 mg, more in particular 10 mg to 500
mg of active ingredient per unit dosage form.
Depending on the mode of administration, the pharmaceutical composition will
preferably se from 0.05 to 99 % by weight, more preferably from 0.1 to 70 °/o by
weight, even more preferably from 0.1 to 50 % by weight of the compound of the present
invention, and, from 1 to 99.95 % by weight, more preferably from 30 to 99.9 % by
weight, even more preferably from 50 to 99.9 % by weight of a pharmaceutically
acceptable carrier, all percentages being based on the total weight of the ition.
As another aspect of the present invention, a combination of a compound of the present
ion with r anticancer agent is envisaged, especially for use as a medicine,
more specifically for use in the treatment of cancer or related diseases.
For the treatment of the above conditions, the compounds of the invention may be
advantageously employed in combination with one or more other medicinal agents,
more particularly, with other anti-cancer agents or adjuvants in cancer therapy.
es of anti-cancer agents or adjuvants (supporting agents in the therapy) include
but are not limited to:
- platinum nation compounds for example cisplatin optionally combined with
amifostine, carboplatin or oxaliplatin;
WO 61080
- taxane compounds for example paclitaxel, paclitaxel protein bound particles
(AbraxaneTM) or docetaxel;
- omerase I inhibitors such as camptothecin compounds for example
ecan, SN-38, topotecan, topotecan hcl;
- topoisomerase II inhibitors such as anti-tumour epipodophyllotoxins or
podophyllotoxin derivatives for example etoposide, etoposide phosphate or
teniposide;
- anti-tumour vinca alkaloids for example vinblastine, vincristine or vinorelbine;
— anti-tumour nucleoside derivatives for example 5-fluorouracil, leucovorin,
gemcitabine, gemcitabine hcl, capecitabine, cladribine, fludarabine, nelarabine;
- alkylating agents such as nitrogen mustard or nitrosourea for example
cyclophosphamide, chlorambucil, carmustine, pa, mephalan (melphalan),
ine, altretamine, busulfan, dacarbazine, estramustine, ifosfamide
optionally in combination with mesna, pipobroman, procarbazine, streptozocin,
telozolomide, uracil;
- anti-tumour anthracycline derivatives for example daunorubicin, doxorubicin
optionally in combination with oxane, doxil, idarubicin, mitoxantrone,
epirubicin, icin hcl, valrubicin;
- molecules that target the lGF-1 receptor for example odophilin;
— tetracarcin derivatives for example tetrocarcin A;
— glucocortico'iden for example prednisone;
~ antibodies for example trastuzumab (HER2 antibody), rituximab (CD20
antibody), gemtuzumab, gemtuzumab ozogamicin, cetuximab, pertuzumab,
zumab, alemtuzumab, umab, ibritumomab an, nofetumomab,
panitumumab, tositumomab, CNTO 328;
— estrogen or antagonists or selective estrogen receptor modulators or
inhibitors of estrogen synthesis for e tamoxifen, fulvestrant, toremifene,
droloxifene, ex, raloxifene or letrozole;
— aromatase tors such as exemestane, anastrozole, letrazole, testolactone
and vorozole;
- differentiating agents such as retinoids, vitamin D or retinoic acid and retinoic
acid metabolism blocking agents (RAMBA) for example accutane;
— DNA methyl transferase inhibitors for example azacytidine or decitabine;
- antifolates for example premetrexed disodium;
- antibiotics for example antinomycin D, bleomycin, mitomycin C, omycin,
carminomycin, daunomycin, sole, plicamycin, mithramycin;
- antimetabolites for example clofarabine, aminopterin, cytosine arabinoside or
methotrexate, azacitidine. bine, fioxuridine, pentostatin, thioguanine;
- apoptosis inducing agents and antiangiogenic agents such as Bel-2 tors for
example YC 137, BH 312, ABT 737, gossypol, HA 14—1, TW 37 or decanoic acid;
- tubuline-binding agents for example combrestatin, colchicines or nocodazole;
- kinase tors (e.g. EGFR (epithelial growth factor receptor) inhibitors, MTKl
(multi target kinase inhibitors), mTOR inhibitors) for e eridol,
imatinib mesylate, erlotinib, gefitinib, dasatinib, lapatinib, lapatinib ditosylate,
sorafenib, sunitinib, sunitinib maleate, olimus;
- farnesyltransferase tors for example tipifarnib;
— histone deacetylase (HDAC) inhibitors for example sodium butyrate,
suberoylanilide hydroxamide acid (SAHA), depsipeptide (FR 901228), NVP-
LA0824, R306465, JNJ-26481585, trichostatin A, stat;
- Inhibitors of the ubiquitin-proteasome pathway for example , MLN .41 or
bortezomib;
- Yondelis;
— Telomerase inhibitors for example telomestatin;
- Matrix metalloproteinase inhibitors for example batimastat, marimastat, prinostat
or at.
- Recombinant eukins for example aldesleukin, denileukin diftitox, interferon
alfa 2a, interferon alfa 2b, peginterferon alfa 2b
- MAPK inhibitors
- Retinoids for example alitretinoin, bexarotene, tretinoin
- Arsenic trioxide
- Asparaginase
- Steroids for example dromostanolone propionate, megestrol acetate, nandrolone
oate, phenpropionate), dexamethasone
— Gonadotropin releasing hormone agonists or antagonists for example abarelix,
goserelin acetate, histrelin acetate, leuprolide acetate
- Thalidomide, lenalidomide
- Mercaptopurine, mitotane, pamidronate, pegademase, pegaspargase,
rasburicase
- BH3 cs for e ABT-737
- MEK inhibitors for e PD98059, AZD6244, Cl-104O
— colony-stimulating factor analogs for example filgrastim, pegfilgrastim,
sargramostim; erythropoietin or analogues thereof (e.g. darbepoetin alfa);
interleukin 11; oprelvekin; zoledronate, zoledronic acid; fentanyl;
bisphosphonate; palifermin.
- a steroidal cytochrome P450 17alpha-hydroxylase-17,20-lyase inhibitor (CYP17),
e.g. abiraterone, erone acetate.
The compounds of the present invention also have therapeutic applications in
sensitising tumour cells for radiotherapy and chemotherapy.
Hence the compounds of the present invention can be used as "radiosensitizer" and/or
sensitizer” or can be given in combination with another "radiosensitizer" and/or
“chemosensitizer”.
The term "radiosensitizer", as used herein, is defined as a molecule, ably a low
molecular weight molecule, stered to animals in therapeutically effective s
to increase the sensitivity of the cells to ionizing radiation and/or to promote the
treatment of es which are treatable with ionizing radiation.
The term “chemosensitizer”, as used herein, is defined as a molecule, ably a low
molecular weight molecule, administered to animals in therapeutically ive amounts
to increase the sensitivity of cells to chemotherapy and/or promote the treatment of
diseases which are treatable with chemotherapeutics.
Several mechanisms for the mode of action of ensitizers have been suggested in
the literature including: hypoxic cell radiosensitizers ( e.g., 2- nitroimidazole compounds,
and benzotriazine dioxide compounds) mimicking oxygen or alternatively behave like
bioreductive agents under hypoxia; non-hypoxic cell radiosensitizers (e.g., halogenated
pyrimidines) can be analogoues of DNA bases and preferentially incorporate into the
DNA of cancer cells and thereby promote the radiation—induced breaking of DNA
molecules and/or prevent the normal DNA repair mechanisms; and various other
WO 61080
potential mechanisms of action have been hypothesized for radiosensitizers in the
treatment of disease.
Many cancer ent protocols currently employ radiosensitizers in conjunction with
radiation of x-rays. Examples of x-ray activated radiosensitizers include, but are not
limited to, the following: metronidazole, misonidazole, desmethylmisonidazole,
pimonidazole, etanidazole, nimorazole, mitomycin C, RSU 1069, SR 4233, E09,
RB 6145, nicotinamide, odeoxyuridine (BUdR), 5- iododeoxyuridine (lUdR),
bromodeoxycytidine, fluorodeoxyuridine (FudR), hydroxyurea, cisplatin, and
therapeutically effective analogs and derivatives of the same.
Photodynamic therapy (PDT) of cancers s visible light as the radiation activator
of the sensitizing agent. Examples of photodynamic radiosensitizers include the
following, but are not d to: hematoporphyrin derivatives, rin, benzoporphyrin
derivatives, tin etioporphyrin, pheoborbide-a, bacteriochlorophyll-a, naphthalocyanines,
phthalocyanines, zinc phthalocyanine, and therapeutically effective analogs and
derivatives of the same.
Radiosensitizers may be administered in conjunction with a therapeutically effective
amount of one or more other compounds, including but not limited to: compounds which
promote the incorporation of radiosensitizers to the target cells; compounds which
control the flow of therapeutics, nutrients, and/or oxygen to the target cells;
chemotherapeutic agents which act on the tumour with or without additional ion; or
other therapeutically effective nds for treating cancer or other diseases.
Chemosensitizers may be administered in conjunction with a eutically effective
amount of one or more other compounds, including but not limited to: nds which
promote the incorporation of chemosensitizers to the target cells; compounds which
control the flow of eutics, nts, and/or oxygen to the target cells;
chemotherapeutic agents which act on the tumour or other therapeutically effective
compounds for treating cancer or other disease. Calcium antagonists, for example
verapamil, are found useful in combination with antineoplastic agents to establish
chemosensitivity in tumor cells resistant to accepted chemotherapeutic agents and to
potentiate the efficacy of such compounds in drug—sensitive malignancies.
in view of their useful cological properties, the components of the combinations
according to the invention, i.e. the one or more other medicinal agent and the compound
according to the present invention may be formulated into various pharmaceutical forms
for administration es. The components may be formulated separately in individual
pharmaceutical compositions or in a unitary pharmaceutical composition containing all
ents.
The present invention therefore also relates to a pharmaceutical composition comprising
the one or more other medicinal agent and the compound according to the t
invention together with a pharmaceutical r.
The present invention further relates to the use of a combination according to the
invention in the manufacture of a pharmaceutical composition for inhibiting the growth of
tumour cells.
The present invention further relates to a product containing as first active ingredient a
compound ing to the invention and as further active ingredient one or more
anticancer agent, as a combined preparation for simultaneous, separate or sequential
use in the treatment of patients suffering from .
The one or more other nal agents and the nd according to the present
invention may be administered simultaneously (9.9. in separate or unitary compositions)
or sequentially in either order. In the latter case, the two or more compounds will be
administered within a period and in an amount and manner that is sufficient to ensure
that an advantageous or synergistic effect is achieved. It will be appreciated that the
preferred method and order of administration and the respective dosage amounts and
regimes for each component of the combination will depend on the particular other
nal agent and compound of the present invention being administered, their route
of administration, the particular tumour being treated and the particular host being
treated. The optimum method and order of administration and the dosage amounts and
regime can be y determined by those skilled in the art using conventional methods
and in view of the ation set out herein.
The weight ratio of the compound ing to the present invention and the one or
more other anticancer agent(s) when given as a combination may be determined by the
person skilled in the art. Said ratio and the exact dosage and ncy of
administration depends 0n the particular compound according to the invention and the
WO 61080
other anticancer agent(s) used, the particular condition being treated, the severity of the
condition being treated, the age, weight, gender, diet, time of administration and general
al condition of the particular patient, the mode of administration as well as other
medication the individual may be taking, as is well known to those skilled in the art.
Furthermore, it is evident that the effective daily amount may be lowered or sed
depending on the response of the treated subject and/or depending on the evaluation of
the physician ibing the compounds of the instant invention. A particular weight
ratio for the present compound of formula (l) and another anticancer agent may range
from 1/10 to 10/1, more in particular from 1/5 to 5/1, even more in particular from 1/3 to
3/1.
The platinum coordination compound is advantageously administered in a dosage of 1
to 500mg per square meter (mg/m2) of body surface area, for example 50 to 400 mg/mz,
ularly for cisplatin in a dosage of about 75 mg/m2 and for carboplatin in about
300mg/m2 per course of treatment.
The taxane nd is advantageously administered in a dosage of 50 to 400 mg per
square meter (mg/m2) of body surface area, for example 75 to 250 mg/mz, particularly
for paclitaxel in a dosage of about 175 to 250 mg/m2 and for docetaxel in about 75 to
150 mg/m2 per course of treatment.
The camptothecin compound is advantageously administered in a dosage of 0.1 to
400 mg per square meter (mg/m2) of body surface area, for example 1 to 300 mg/mz,
particularly for irinotecan in a dosage of about 100 to 350 mg/m2 and for topotecan in
about 1 to 2 mg/m2 per course of ent.
The anti-tumour podophyllotoxin derivative is advantageously administered in a dosage
of 30 to 300 mg per square meter (mg/m2) of body surface area, for e 50 to
250mg/m2, particularly for etoposide in a dosage of about 35 to 100 mg/m2 and for
teniposide in about 50 to 250 mg/m2 per course of treatment.
The anti-tumour vinca id is advantageously stered in a dosage of 2 to
mg per square meter (mg/m2) of body surface area, particularly for vinblastine in a
WO 61080 2012/052672
dosage of about 3 to 12 mg/m2 for vincristine in a dosage of about 1 to 2 mg/m2 and
, ,
for vinorelbine in dosage of about 10 to 30 mg/m2 per course of treatment.
The anti—tumour nucleoside derivative is advantageously administered in a dosage of
200 to 2500 mg per square meter (mg/m2) of body surface area, for example 700 to
1500 mg/m2, particularly for 5—FU in a dosage of 200 to 500mg/m2, for abine in a
dosage of about 800 to 1200 mg/m2 and for capecitabine in about 1000 to
2500 mg/m2 per course of treatment.
The alkylating agents such as nitrogen mustard or nitrosourea is advantageously
administered in a dosage of 100 to 500 mg per square meter (mg/m2) of body surface
area, for example 120 to 200 mg/mz, ularly for cyclophosphamide in a dosage of
about 100 to 500 mg/m2 for chlorambucil in a dosage of about 0.1 to 0.2 mg/kg, for
carmustine in a dosage of about 150 to 200 mg/m2 and for lomustine in a dosage of
about 100 to 150 mg/m2 per course of ent.
The anti—tumour anthracycline tive is advantageously administered in a dosage of
to 75 mg per square meter (mg/m2) of body surface area, for example 15 to
60 mg/m2, particularly for doxorubicin in a dosage of about 40 to 75 mg/m2, for
daunorubicin in a dosage of about 25 to 45mg/m2 and for idarubicin in a dosage of
about 10 to 15 mg/m2 per course of treatment.
The antiestrogen agent is advantageously administered in a dosage of about 1 to 100
mg daily depending on the particular agent and the ion being treated. Tamoxifen is
advantageously administered orally in a dosage of 5 to 50 mg, preferably 10 to 20 mg
twice a day, continuing the therapy for sufficient time to achieve and maintain a
therapeutic effect. Toremifene is advantageously administered orally in a dosage of
about 60mg once a day, continuing the therapy for sufficient time to achieve and
maintain a therapeutic effect. Anastrozole is advantageously administered orally in a
dosage of about 1mg once a day. Droloxifene is advantageously administered orally in a
dosage of about 20-100mg once a day. Raloxifene is advantageously administered
orally in a dosage of about 60mg once a day. tane is advantageously
administered orally in a dosage of about 25mg once a day.
132.
Antibodies are advantageously administered in a dosage of about 1 to 5 mg per square
meter (mg/m2) of body surface area, or as known in the art, if different. Trastuzumab is
advantageously administered in a dosage of 1 to 5 mg per square meter (mg/m2) of
body surface area, particularly 2 to 4mg/m2 per course of treatment.
These dosages may be administered for example once, twice or more per course of
treatment, which may be repeated for example every 7, 14, 21 or 28 days.
The compounds of formula (I), the ceutically acceptable addition salts, in
particular pharmaceutically acceptable acid addition salts, and stereoisomeric forms
thereof can have valuable diagnostic properties in that they can be used for detecting or
identifying the formation of a complex between a labelled compound and other
molecules, peptides, proteins, s or receptors.
The detecting or identifying methods can use compounds that are labelled with labelling
agents such as sotopes, enzymes, fluorescent substances, luminous substances,
etc. Examples of the radioisotopes include 125I, 131i, 3H and 14C. Enzymes are y
made detectable by conjugation of an appropriate substrate which, in turn catalyses a
detectable reaction. Examples thereof include, for example, beta-galactosidase, beta-
idase, alkaline phosphatase, peroxidase and malate dehydrogenase, preferably
horseradish peroxidase. The luminous substances e, for example, luminol, l
derivatives, luciferin, in and rase.
Biological samples can be defined as body tissue or body fluids. Examples of body fluids
are cerebrospinai fluid, blood, plasma, serum, urine, sputum, saliva and the like.
General tic Routes
The following es illustrate the present invention but are examples only and are
not ed to limit the scope of the claims in any way.
Experimental Part
Hereinafter, the term ‘CchN’or ‘ACN’ means acetonitrile, ‘DCM’ or ‘CHZCIZ’ means
dichloromethane, ‘K2C03’ means potassium carbonate, ‘NaZCO3’ means sodium
carbonate, ‘CSZCOg’ means cesium carbonate, ‘MgSO4’ means magnesium sulphate,
‘MeOH’ or ‘CHgOH’ means methanol, ‘EtOAc’ means ethyl acetate, ‘EtOH’ means
ethanol, ‘Et3N’ means triethyiamine, ‘THF’ means tetrahydrofuran, ‘POCl3‘means
phosphoric trichloride, ‘NH4Cl’ means ammonium chloride, ‘NaCl' means sodium
chloride, ‘NaOH’ means sodium hydroxide, ‘KOH’ means potassium hydroxide, ‘DMF’
means N,N-dimethylformamide, ‘NaH’ means sodium hydride 60% in mineral oil,
‘NaHC03’ means sodium hydrogen carbonate, ‘TFA’ means trifluoroacetic acid, ‘DMAP’
means 4-dimethylaminopyridine, ‘NaBH4’ means sodium borohydride, ‘LiCl’ means
lithium chloride, ‘Pd(PPh3)4’ or ‘tetrakis’ means tetrakis(triphenylphosphine)palladium,
‘PdCl2(dppf).DCM’ means 1,1'—Bis(diphenylphosphino)ferrocene~palladium(|l)dichloride
dichloromethane complex, ’ means ammonium hydroxide, ‘iPrOH’ means 2-
propanol, ‘DiPE’ means diisopropylethyl ether, ‘COg’ means carbon dioxide, ‘EtZO’
means l ether, ‘HCl’ means hydrochloric acid, ‘BBrg’ means boron tribromide,
‘SiOz’ or ‘SiOH’ means silica, ‘Ng‘ means nitrogen, ‘LiAlH4’ means m aluminium
hydride, ‘M.P.’ means melting point, ‘rt’ means room ature, ‘Bocgo’ means t—
butyl onate, ‘HZO’ means water, ‘NH4HC03’ means ammonium bicarbonate, ‘DME’
means ethylene glycol dimethylether, ‘pH' means potential hydrogen, ‘nBuLi’ means n—
butyllithium, ‘NMP’ means 1—methy|—2—pyrrolidinone, ‘CHCl3’ means chloroform, ‘SFC’
means ritical fluid chromatography, ‘Pd(PtBu3)2’ means bis(tri-tert-butylphosphine
)palladium(0), ‘DIPEA’ means N,N-diisopropylethylamine, ‘DCE’ means 1,2-
dichloroethane, ‘HOBT’ means 1-hydroxybenzotriazole, ‘EDCI means 1-Ethyl(3-
dimethylaminopropyl)carbodiimide hloride, ’ means 2—
Dicyclohexylphosphino—2',4’,6'—triisopropy|biphenyl, ‘Pd2(dba)3’ means
Tris(dibenzylideneacetone)dipalladium and ‘DSC’ means differential scanning
calorimetry.
Some compounds of the present invention were obtained as salt forms or hydrates or
contain some amounts of solvent. Hereinafter, these compounds are reported as
determined based on elemental analysis.
A. Preparation of the intermediates
Example A1
N Br
CIININH\I
a) Preparation of intermediate 1 2
Under N2 flow, N-bromosuccinimide (121 g; 679 mmol) was added dropwise to a mixture
of 6-chloro~2-pyrazinamine (88 g; 679 mmol) in CHCl3 (1000 ml) at 0°C. The reaction
mixture was stirred at room temperature overnight then was poured out onto water and
DCM was added. The organic layer was washed, dried over M9804, filtered and
evaporated. The residue was purified by tography over silica gel (mobile phase :
91% petroleum ether, 9% EtOAc). The pure fractions were collected and the solvent
was evaporated to afford 40 g (28 %) of intermediate 1.
N \
\ 0/
Cl N/ NH
b) Preparation of intermediate 2 2
Under N2 flow, Pd(PtBu3)2 (3g; 5.9 mmol) was added to a mixture of intermediate 1 (41.6
g; 200 mmol), acrylic acid methyl ester (20.6 g; 240 mmol) in triethylamine (50 ml) and
N,N-dimethylformamide (300 ml). The reaction mixture was stirred at reflux for 2 hours
then was poured out onto water and EtOAc was added. The c layer was washed,
dried over M9804, filtered and evaporated. The residue was ed by chromatography
over silica gel (mobile phase : 80% eum, 20% EtOAc). The pure fractions were
collected and the solvent was evaporated to afford 25 g (59 %) of intermediate 2.
Intermediate 2 was also prepared according to the following procedure :
2-Amino—3-bromo—6-chloropyrazine (212779-21—0) (39.78 g; 191 mmol) was diluted in
dry dioxane (400 mL) and DiPEA (53.3 mL; 305 mmol). The solution was degassed with
N2. Then, ibenzylideneacetone)dipalladium(0) (3.50 g; 3.82 mmol), trl—tert-butyl-
phosphonium tetrafluoroborate (2.77 g; 9.54 mmol) and methyl acrylate (34.23 mL; 382
mmol) were added. The mixture was heated at 120°C for 5h30. The reaction mixture
was cooled down to room temperature and a saturated aqueous solution of NaH003
and EtOAc were added. Then the e was decanted. The organic layer was dried
over M9804, filtered and concentrated to dryness. The e was taken up with
diisopropylether. The precipitate was filtered off to give 35.67 g (87%, brown solid) of
intermediate 2 .
Br N N O
0) Preparation of intermediate 3
A mixture of intermediate 2 (1.56 g; 7.32 mmol) in a solution of lc acid in acetic
acid (20 ml) was heated at 45°C for 3 hours. The reaction mixture was evaporated to
give 1.66 g of intermediate 3 which was used in the next step without further purification.
Alternatively, in a round bottom flask, intermediate 2 (100 9; 468.1 mmol) was diluted in
a 33% solution of bromidic acid in acetic acid (7 L). The mixture was d at 40-50°C
for 3 hours. The solvent was evaporated and the residue was washed with methyl ter-
butyl ether to give 110g (92%) of intermediate 3.
d) ation of intermediate 4
Under N2 flow, tetrakis(triphenylphosphine)palladium (0.9 g, 0.75 mmol) was added to a
mixture of the intermediate 3 (1.7 g, 7.4 mmol), 1-methylpyrazoleboronic acid pinacol
ester (1.79, 8.1 mmol), sodium ate (1.6 g, 14.7 mmol) in DME (40 ml) and water
(10 ml). The mixture was heated at 100°C overnight. The solvent was evaporated then
the residue was triturated with methyl-tert—butyl ether, filtered and dried step to give
1.45 g (87%) of intermediate 4. It was used without r purification in the next step.
/ N/ N/ Cl
e) Preparation of intermediate 5
A mixture of ediate 4 (1.56 g, 6.38 mmol) in POCl3 (15 ml) was d and heated
at 70°C for 1 hour. The solvent was evaporated till dryness and the residue was purified
by chromatography over silica gel (mobile phase 50% DCM, 50% EtOAc) The desired
fractions were collected and the solvent was evaporated to give 0.72 g (45%) of
intermediate 5.
Intermediate 5 was also prepared according to the following procedure :
POCl3 (6.4 mL; 68.65 mmol) was added drop wise over a 10 minute period to a
suspension of intermediate 4 (3.9 g; 17.16 mmol) and DMF (2.66 mL; 34.33 mmol) in
1,2—dichloroethane (75 mL) at 80°C. The reaction mixture was heated at 80°C for 3
hours and cooled to room temperature. The reaction mixture was slowly poured onto a
% aqueous solution of K2C03 and ted with DCM/MeOH. The organic layer was
decanted, washed with water, dried over M9804, filtered and dried to dryness yielding
3.1 g (73%) of intermediate 5.
intermediate 5 was also prepared ing to the following procedure :
A mixture of 6-chloropyridine-2,3-diamine (CAS 408514) (10 g; 69.65 mmol), 2-
bromo(1-methyl-1H-pyrazolyl)ethanone (CAS 7068191) (14.1 9; 69.65
mmol) and DIPEA (24 mL; 139.3 mmol) in ACN (280 mL) was heated at 90°C for 18
hours. The heating was stopped and MnOz (18.2 9; 208.95 mmol) was added portion
wise (carefully) and the reaction mixture was d at room temperature for 15 s.
MnOz was removed by filtration through a pad of celite® and the filtrate was
concentrated. The precipitate was filtered, washed with EtZO and dried to give 10.4 g
(61%) of intermediate 5.
Intermediate 5 was also prepared according to the following procedure :
Cl N N Br
a) preparation of intermediate 5a
POCI3 (18.3 mL; 195.47 mmol) was added drop wise to a suspension of intermediate 3
(15 9; 48.87 mmol) and DMF (7.57 mL; 97.74 mmol) in 1,2-dlchloroethane (561 mL)
previously heated at 80°C. The reaction mixture was heated at 80°C for 3 hours and
cooled to room temperature. The reaction mixture was slowly poured onto a saturated
aqueous on of Nchog. DCM was added and the 2 layers were separated. The
aqueous layer was extracted with DCM/MeOH (8/2). The c layer was decanted,
washed with water, dried over M9804, filtered and evaporated to dryness. The residue
was taken up with EtZO. The precipitate was filtered and dried affording 9.059 (76%) of
intermediate 5a which was directly used in the next step without any further purification.
b) A solution of intermediate 5a (20 9; 81.81 mmol), 1-methylpyrazoleboronic acid
pinacol ester (13.6 9; 65.45 mmol), 2M aqueous Na2C03 (205 mL) in 1,2—
dimethoxyethane (798 mL) were degassed under N2. Pd(PPh3)4 (4.73 9; 4.09 mmol)
was added and the reaction mixture was heated at reflux for 2 hours. The mixture was
poured into ice and extracted with EtOAc. The mixture was ed through a pad of
celite® which was washed with DCM. The organic layers were dried over M9804, filtered
and the solvent was evaporated. The residue was taken up with ACN, filtered and dried
to give 15.32 g (76%) of intermediate 5 .
Intermediate 5 was also prepared according to the following procedure :
A solution of 3,6-dichloropyrido[2,3,b]pyrazine 3509252) (129; ), 1-
methylpyrazole-4—boronic acid pinacol ester 9; 60mmol), in s 2M sodium
carbonate (90mL) and 1,2-dimethoxyethane (400mL) was degassed with N2 for 15
minutes. Then Pd(PPh3)4 (3.59; 3mmol) was added and the on mixture was
refluxed for 2 hours, then cooled to room temperature, poured onto a saturated s
NaH003 solution and EtOAc was added. The resulting mixture was filtered through a
pad of celite®. The filtrate was extracted twice with EtOAc and the organic layer was
washed with brine, dried over M9804, filtered and evaporated to dryness.
The residue was crystallized from ACN. The precipitate was filtered off, washed with
EtZO and dried yielding 5g (34%) of intermediate 5.
The filtrate was evaporated to dryness then, taken-up with a mixture of ACN/Eth. The
precipitate was filtered off to give onal 2.3g (16%) of intermediate 5.
Example A2
H N~
/o N N\ N\ \
Preparation of intermediate 6
To a on of intermediate 5 (2 g, 8.14 mmol) in n-propanol (70 ml) was added 3,5—
dimethoxyaniline (2.5 g, 16.3 mmol) and the reaction mixture was heated at 100°C for 4
hours. The reaction mixture was cooled down and poured out onto ice water. The
reaction mixture was extracted with EtOAc, washed with brine, dried over MgSO4,
filtered and concentrated under reduced pressure. The residue (3.6 g) was purified by
tography over silica gel (15-40pm 80 g, mobile phase gradient 97.5% DCM,
2.5% MeOH, 0.1% NH4OH to 97% DCM, 3% MeOH, 0.1% NH4OH). The pure ons
were ted and evaporated till s to afford 2.76 g of intermediate 6 (MP: 174°C
(Kofler)).
Analogous preparation of intermediate 12
Analogous preparation of intermediate 14 F
l Cl N\
o n
UN/N\ j/LN
Analogous preparation of intermediate 16
F N\
doF / N/
Analogous preparation of ediate 17
F "\
o n N
UK/ Nj/LN\
Analogous preparation of intermediate 26 / starting
from intermediate 27.
Analogous preparation of intermediate 47 starting
from intermediate 27
o N N N
i j KIN// \
ous preparation of intermediate 54. . /0
starting from intermediate 55
| H
o N /N N\ \
Analogous preparation of Intermediate 61. . .
starting from intermediate 62
Analogous preparation of intermediate 68
F /
starting from intermediate 62
o N UUr/N Nj/E)
Analogous preparation of intermediate 71
starting from ediate 72
i H
0UU N N N
\ /TO
Analogous ation of intermediate 73
starting from intermediate 55
J) I
U\\/\N
Analogous preparation of intermediate 74
starting from intermediate 75
F /N
l H l
O NNN\
U\/\N
Analogous preparation of intermediate 86
starting from intermediate 75
WO 61080
ous preparation of intermediate 95
o H N N I/”
[j / \
\ N/
starting from intermediate 96
pSN/lkokOE F
/O\I£>/NH N
/ /N]/N\)Ill"’o
Analogous preparation of intermediate 117
(cis) starting from intermediate 119
OQNUZjQ| H
Analogous preparation of intermediate 134
starting from intermediate 90
Example A2A
Preparation of intermediate 129
A solution of HCl 4N in 1,4—dioxane (0.2 ml; 0.8 mmol) was added to a solution of
intermediate 5 (1.96 g; 7.97 mmol) and 3,5-dimethoxymethyl-aniline (2 g; 11.96
mmol) in n-propanol (49 mL). The reaction mixture was heated at 100°C overnight and
cooled to room ature. A 10% aqueous solution of K2003 was added and the
on mixture was extracted with DCM (4 times). The organic layer was decanted,
dried over M9804, filtered and evaporated to dryness. The residue was crystallized
from ACN. The precipitate was filtered, washed with Et20 and dried to give 2.29 g
(76%)of intermediate 129. M.P.: 146°C (kofler).
/ \ /
Preparation of intermediate 7 N_
The reaction was performed twice on the same quantities of intermediate 5 (7.5 g; 30.53
mmol):
To a solution of intermediate 5 (15 g; 61.06 mmol) in n-propanol (375 mL) was added 2-
fluoro-3,5-dimethoxyaniline (10.45 g; 61.06 mmol), then HCI 4M in 1,4—dioxane (1.53
mL; 6.11 mmol) and the reaction mixture was heated at 100°C ght. The on
mixture was cooled down, and the precipitate was filtered, washed with EtZO and dried.
The precipitate was taken up in a 10% aqueous on of K2003 and stirred overnight.
The precipitate was filtered off, washed with water three times, dried, dissolved with
DCM/MeOH (8/2) and evaporated to s. The residue was taken up in ACN. The
precipitate was filtered, washed with EtZO and dried yielding 19.58 g (84%) of
intermediate 7.
Analogous preparation of intermediate 133
starting from intermediate 90
Example A3
Preparation of intermediate 7 N_
To a solution of ediate 5 (1.3 g ; 5.29 mmol) in n-propanol (60 ml) was added 2-
fluoro-3,5-dimethoxybenzenamine (1.8 g ; 10.6 mmol) and the reaction mixture was
heated at 100°C for 4 hours. The reaction mixture was cooled down, poured out onto
ice-water and the on mixture was extracted with EtOAc. The organic layer was
washed with brine, dried (MgSO4), filtered and concentrated under reduced pressure.
The ed residue was purified by chromatography over silica gel (15-40pm 3009,
mobile phase: 98% DCM, 2% MeOH). The desired product ons were collected and
concentrated to afford 800 mg (43%) of intermediate 7 (MP: 212°C (DSC)).
Example A4
NéjiN/inQN/ N (I)
.~ 2
\ /O
Preparation of intermediate 8
Under N2 fiow, NaH (0.037 g, 0.94 mmol, 60% in mineral oil) was added portionwise to a
solution of intermediate 6 (0.17 g, 0.47 mmol) in methylformamide (5 ml) at 5°C.
The reaction mixture was stirred at 5°C for 30 minutes. Then a solution of (2-
bromoethoxy)-tert-butyldimethylsilane (0.2 ml, 0.94 mmol) was added dropwise at 5°C.
The reaction was stirred at room temperature for 15 hours. The on was poured out
onto ice water and EtOAc was added. The organic layer was separated, washed with
brine, dried (MgSO4), filtered and the solvent was evaporated to dryness to give 0.22 g
(91%) of intermediate 8.
><Si
Analogous preparation of intermediate 11 starting
from intermediate 12
0/ \
i H i”‘
o N N\ Nj/QN
Analogous preparation of intermediate 15 / starting
from intermediate 7
ous preparation of ediate 88
starting from intermediate 74
Preparation of intermediate 93 and
N/j/[N/mmN\ \
I Q
/ 5
intermediate 9b X
Under N2 flow, NaH (0.127 g, 3.2 mmol, 60% in mineral oil) was added portionwise to a
on of intermediate 6 (0.5 g, 1.4 mmol) in N,N-dimethylformamide (15 ml) at 5°C.
The reaction mixture was stirred at 5°C for 30 minutes. Then a solution of (3—
bromopropoxy)—tert-butyldimethylsilane (0.66 ml, 2.8 mmol) was added dropwise at 5°C.
The on was allowed to reach room temperature and stirred at for overnight. The
reaction was poured out onto ice water and EtOAc was added. The organic layer was
separated, washed with brine, dried (M9804), ed and the solvent was evaporated till
dryness to give 887mg of a mixture of intermediate 9a and 9b. The mixture was used
without further cation in the next step.
/ IN/ N/ N O
N\ l J) l
Analogous preparation of intermediate 10a and
Ng/[N/ N \N
‘1 (l)
/N F
intermediate 10b X starting from intermediate 12
Example A5
.Q.\
HN F
/ N\
N /
- yo
Alternative preparation of intermediate 12 N_
A solution of intermediate 5 (200 mg ; 0.81 mmol), 2,6-difluoro—3,5-
dimethoxybenzeneamine (308 mg ; 1.63 mmol) and C32C03 (1.339 ; 4.07 mmol) in
NMP (1.2 mL) and dioxane ( 12 mL) was degassed at room temperature under N2 flow.
After 10 minutes, [+-]-2,2’-bis[diphenylphosphino]-1,1’-binaphthalene (105 mg ; 0.16
mmol) and palladium(ll) acetate (18 mg ; 0.081 mmol) were added and the reaction
mixture was heated at 150°C for 30 s using microwave power. The reaction
mixture was poured out onto ice water and EtOAc. The solution was ed through a
pad of Celite®, ted with EtOAc, washed with water, dried (M9804) and
concentrated under reduced pressure. The obtained residue was purified by
chromatography over silica gel (15-40pm 24 9,. mobile phase gradient from 97.5%
DCM, 2.5% MeOH, 0.1% NH4OH to 97% DCM, 2% MeOH, 0.1% NH4OH). The desired
product fractions were ted and the solvent was evaporated to afford 35 mg (11%)
of intermediate 12.
Example A6
Preparation of intermediate 18 R
Et3N (6 mL; 41.69 mmol), enesulfonyl chloride (7.95 g; 41.69 mmol) and DMAP
(424 mg; 3.47 mmol) were added successively to a on of (R)—(-)5-(hydroxymethy|)—
2-pyrrolidinone (CAS 66673—40-3) (4 9; 34.743 mmol) in DCM (60 mL) at 5°C under N2
flow and the reaction mixture was stirred at room temperature for 2 hours. An aqueous
solution of HCl 1N was added. The mixture was extracted with DCM (3 times). The
c layer was dried over M9804, filtered and the solvent was evaporated to dryness.
The residue was purified by chromatography over silica gel (Irregular SiOH, 20-45pm,
80g; mobile phase: 98% DCM, 2% MeOH, 0.2% NH4OH). The pure fractions were
collected and evaporated to give 6.8 g (72%) of intermediate 18.
ExampleA7
| Cl N\
\ \
/ /
Preparation of intermediate 19
A solution of potassium bis(trimethylsilyl)amide 0.5M in toluene (12.2 mL; 6.11 mmol)
was added drop wise to a solution of 2,6-chloro—3-methoxyphenylamine (0.78 g; 4.07
mmol) in THF (20 mL) at 0°C. The reaction mixture was stirred at 0°C at for 1 hour.
Then, intermediate 5 (1 g; 4.07 mmol) was added portion wise at 0°C, after 30 minutes
DMF (20 mL) was added and the reaction mixture was stirred at room temperature for
hours. The on mixture was poured into ice water, brine then EtOAc was added
and the on mixture was stirred at room temperature for 30 minutes. The organic
layer was separated, extracted with EtOAc, washed with brine then dried over M9804,
filtered and evaporated to dryness. The e was purified by chromatography on
silica gel (Spherical Silica, 5pm, 150x30.0mm; mobile phase: gradient from 0.1%
NH4OH, 97% DCM, 3% MeOH). The product fractions were collected and evaporated to
give 0.85 g (52%) of intermediate 19 .
.Q.\
HN F
Preparation of intermediate 12 N
Potassium bis(trimethylsilyl)amide 1M in THF (71 mL; 70 mmol) was added drop wise at
0°C to a solution of 2,6-difluoro-3,5-dimethoxyphenylamine (8.9 g; 46.9 mmol) in DMF
(220 mL). The reaction mixture was stirred at 0°C for 1 hour. Then; intermediate 5 (12 g;
39 mmol) was added portion wise at 0°C and the reaction e was stirred at room
temperature for 24 hours. The reaction mixture was poured into ice water and brine.
EtOAc was added. The mixture was stirred at room temperature for 30 minutes, then
filtered through a pad of ®. The filtrate was extracted with EtOAc. The organic layer
was washed with brine, dried over MgSO4, filtered and evaporated to dryness. The
residue was taken-up with Et20, the precipitate was filtered and dried to give 14 g (90%)
of intermediate 12.
I CI IN\
0&1: N
\ Nj/QN/
Analogous preparation of intermediate 20 F N starting
from intermediate 5
1 Cl ’N\
o N N
\ rtj/E/q
Cl N/
Analogous preparation of ediate 22 / starting
from intermediate 5
| F
Orim“N /N N\j/[CN/
ous preparation of intermediate 30
starting from ediate 27
H lN\
F N N N /N
F\U\/N
Analogous preparation of intermediate 60 F
starting from ediate 5
1F H (\o
orim?/F\N N N My
ous preparation of intermediate 89
starting from intermediate 90
Example A8
Preparation of intermediate 21
Under N2 at 10°C, NaH (33 mg; 0.83 mmol) was added to a solution of intermediate 6
(300 mg; 0.83 mmol) in DMF (10 mL). The solution was stirred at 10°C for 30 minutes.
Then, a solution of 1H—1,2,4—Triazole-3—methanol, 1-(triphenylmethyl)—, 3—
methanesulfonate (CAS: 1630093) (540 mg; 1.29 mmol) in DMF (5 mL) was added
drop wise and the solution was allowed to warm to room temperature and stirred
overnight. The solution was cooled and the reaction mixture was poured into cooled
water and extracted with EtOAc. The organic layer was washed with water, decanted,
dried over M9804, filtered and evaporated to dryness. The residue was purified by
WO 61080
chromatography over silica gel (irregular SiOH, 20—45um, 4509; mobile phase: 0.3%
NH4OH, 97% DCM, 3% MeOH). The product fractions were collected and the solvent
was evaporated to give 0.45 g (79%) of intermediate 21 .
Analogous ation of intermediate 23
Analogous ation of intermediate 24
O 2
\ /Z /2
Analogous preparation of intermediate 112 \
starting from intermediate 6 and intermediate 113
z’2 \
Analogous preparation of intermediate 116 \
starting from intermediate 7 and intermediate 113
Example A8a
,f~ o /
N N
| (l \
O [j N N N I/
/ \
\ N/
Preparation of intermediate 70
NaH (88 mg; 2.21 mmol) was added under N2 at 10°C to a solution of intermediate 6
((400 mg; 1.1 mmol) in DMF (5 mL). The solution was stirred at 10°C for 30 minutes. 5-
chloromethyl—2-trityl-2H-tetrazole (CAS 1609984) (619 mg; 1.72 mmol) was added
portion wise and the solution was allowed to slowly warm to room temperature and
stirred overnight. The solution was cooled, poured into cooled water and extracted with
EtOAc. The organic layer was decanted, washed with brine, dried over M9804, ed
and evaporated to dryness to give 0.76 g (100%) of intermediate 70.
Analogous preparation of intermediate 43
Analogous ation of ediate 78 starting
from intermediate 7 and intermediate 82.
ExampleA9
>\/o
| H
0fijN /N N\j/[TN k/
\ 'N/
Preparation of intermediate 25
In a round bottom flask, intermediate 26 (1.06 g; 2.89 mmol) was diluted in DCM (30
mL). Then, at room ature, Eth (2.07 mL; 14.48 mmol) followed by B0020 (760
mg; 3.4 mmol) were added. The reaction mixture was stirred for 18 hours at room
ature. The reaction mixture was partitioned between water and DCM. The
organic layer was ted, dried over M9804, filtered and evaporated to dryness to
afford a crude which was taken up with EtZO to give after filtration 990 mg (82%) of
intermediate 25 (orange powder). M.P.: 160°C (gum, Kofler).
ExampleA9A
P" 5
F N\
('3 H N N [/N
/ \
\ 'N/
Preparation of intermediate 140
1-(Tert-butoxycarbonyl)(methanesuIfonyloxy)azetidine (CAS: 1416993) (850 mg;
3.38 mmol) was added a solution of intermediate 26 (826 mg, 1.86 mmol) and 052C03
(1.47 g; 4.51 mmol) in ACN (16 mL). The reaction mixture was stirred in a sealed tube at
100°C for 6 hours. The reaction mixture was poured into ice water and extracted with
EtOAc. The organic layer was washed with brine, dried over M9804, filtered and
evaporated to dryness. The residue was purified by tography over silica gel
(irregular SiOH, 15-45um, 12g; mobile phase: gradient from 99% DCM, 1% MeOH to
97% DCM, 3% MeOH). The product ons were collected and evaporated to dryness
yielding 147 mg (15%) of intermediate 140.
Example A10
I /N
CI N N
Preparation of intermediate 27
A mixture of intermediate 5a (7.5 g; 30.68 mmol) and 1-(tetrahydro-2H-pyranyl)—4—
(4,4,5,5-tetramethyI-1,3,2-dioxaborolan—2—yl)—1H-pyrazole (CAS 1003846—21-6) (9.39 g;
33.75 mmol) in a 2M s solution of sodium carbonate (76 mL; 153.39 mmoi) and
DME (310 mL) was degassed with N2 for 15 minutes, then Pd(Ph3)4 (1.77 g; 1.53 mmol)
was added. The reaction mixture was ed overnight, poured into a ted
solution of NaHC03 and extracted with AcOEt. The organic layer was washed with brine,
dried over M9804, filtered and evaporated to dryness. The e was crystallized from
ACN. The precipitate was filtered, washed with Ego and dried yielding 3.06 g (32%) of
intermediate 27 silica gel (irregular
. The filtrate was purified by chromatography over
SiOH, 15-45um, 120g; mobile phase : gradient from 100% DCM, 0% MeOH to 99%
DCM, 1% MeOH). The fractions were collected and evaporated to dryness yielding 4.21
g (43%) of intermediate 27 . (overall yield: 75%).
or N N
UJ/ \
of intermediate 55 N
Analogous preparation starting
from intermediate 5a
or N U,/ Nj/E/\
Analogous preparation of intermediate 72 starting from
intermediate 5a
Example A10 b—1
WO 61080
Cl /N |N\ \
\ N/
Preparation of intermediate 62
A solution of intermediate 5a (1.25 g; 5.10 mmol) and 3-(4,4,5,5-tetramethyl-1,3,2—
dioxoborolanyl)-pyridine (1.1 g; 5.10 mmol) in Na2C03 2M (12.7 mL) and DME (51
mL) were degassed with N2 for 15 minutes. PdCl2(dppf).DCM (373 mg; 0.51 mmol) was
added and the reaction mixture was refluxed for 1 hour. The on mixture was
cooled to room temperature, poured into water and extracted with EtOAc. The organic
layer was decanted, dried over M9804, filtered and the solvent was evaporated. The
residue (1.7 g) was purified by chromatography over silica gel (irregular SiOH, m,
9; mobile phase: 0.1% NH4OH, 97% DCM, 3% MeOH). The product fractions were
collected and the solvent was evaporated to give 330 mg of intermediate 62.
(130
Analogous preparation of intermediate 75 starting from
intermediate 5a
NBoc
Analogous ation of intermediate 96 starting
from intermediate 5a
Example A11
—0 N
\_</ BMW
Preparation of intermediate 29 H
Methanesulfonyl chloride (0.229 mL; 2.96 mmol) was added drop wise to a solution of 2-
ymethyl—1,4,6,7-tetrahydro-imidazo[4,5-c]pyridinecarboxylicacidtert-butylester
(CAS 12510007) (0.250 g; 0.99 mmol) and Eth (0.69 mL; 4.94 mmol) in DCM (10
mL) at 5°C under N2 flow. The reaction mixture was stirred at 5°C for 2 hours. The
reaction mixture was poured into iced water and DCM was added. The organic layer
was separated, dried over M9804, filtered and the solvent was evaporated to give 0.237
g (72%) of intermediate 29. The product was used without purification in the next step.
Example A11A
Preparation of intermediate 113
Methanesulfonyl de (0.75 mL; 9.666 mmol) was added dropwise at 5°C under N2
flow to a solution of 1-(triphenylmethyl)—1H-1,2,3-triazole-4—methanol (CAS 885296)
(2.2 g; 6.444 mmol) and Et3N (1.34 ml; 9.666 mmol) in F 50/50 (45 mL). The
reaction mixture was stirred below 0°C for 1 hour, poured onto ice and extracted with
DCM. The organic layer was decanted, dried over MgSO4, filtered and evaporated to
s yielding 2.4 g (89%) of intermediate 113.
Example A12
a) Preparation of intermediate 33 °
Dimethylsulfamoyl chloride (2.16 mL; 19.98 mmol) was added to a solution of 4-methyl—
-imidazolecarboxaldehyde (CAS 682821) (2 g; 18.16 mmol) and Et3N (4.16 mL;
29.06 mmol) in ACN (20 mL). The reaction mixture was stirred at 50°C ght. The
mixture was poured into water and extracted with EtOAc. The organic layer was washed
with brine, dried over M9804, filtered and evaporated to dryness. The residue was
purified by chromatography over silica gel (irregular SiOH, 15-40pm, 809; mobile phase:
99% DCM, 1% MeOH). The product fractions were collected and evaporated to dryness
yielding 2.35 g (60%) of ediate 33.
b) Preparation of intermediate 32 0”
NaBH4 (491 mg; 12.98 mmol) was added to a solution of intermediate 33 (2.35 g; 10.81
mmol) in MeOH (20 mL) at 5°C under N2 flow. The on mixture was then d at
room temperature 2 hours, poured into ice water and extracted with DCM. The organic
layer was dried over M9804, ed and evaporated to dryness. The crude product was
taken up in EtZO then filtered and dried yielding 1.09 g (46%) of intermediate 32.
‘S\\
2E />N / 0
0) Preparation of intermediate 31 0'
Et3N (8.24 mL; 57.58 mmol), methanesulfonyl chloride (2.67 mL; 34.55 mmol) and
lithium chloride (3.66 g; 86.37 mmol) were added successively to a solution of
intermediate 32 (5.91 g; 28.79 mmol) in THF (145 mL) at 5°C under N2 flow. The
reaction e was stirred at room temperature for 4 hours. The on mixture was
poured into ice water and extracted with EtOAc. The organic layer was washed with
brine, dried over M9804, filtered and evaporated to dryness yielding 6.76 g of
intermediate 31. The crude mixture was used in the next step without any purification.
Example A13
a) Preparation of intermediate 340
Dimethylsulfamoyl chloride (3.09 mL; 28.62 mmol) was added to a solution of 3—
carboxaldehyde pyrazole (2.5 g; 26.02 mmol) and Et3N (5.96 mL; 41.63 mmol) in ACN
(25 mL) and the reaction mixture was stirred at 50°C overnight. The reaction mixture
was poured into ice water and extracted with EtOAc. The organic layer was washed with
brine and dried over MgSO4, filtered and evaporated to dryness. The crude product was
ed by tography over silica gel (irregular SiOH, 15-45um, 80g; mobile phase:
99% DCM, 1% MeOH). The pure fractions were collected and evaporated to dryness
yielding 4.42 g (84%) of intermediate 34.
b) Preparation of intermediate 35 0“
NaBH4 1 mg; 26.1 mmol) was added portion wise to a solution of intermediate 34
(4.42 g; 21.75 mmol) in MeOH (50 mL) at 5°C. The on mixture was then stirred at
room temperature 2 hours, poured out into ice water and extracted with DCM. The
organic layer was decanted, dried over MgSO4, filtered and evaporated to dryness. The
crude product was taken up with EtQO; the precipitate was filtered and dried yielding
3.04 g (68%) of intermediate 35.
0) Preparation of intermediate 36 C'
Eth (4.24 mL; 29.63 mmol), methanesulfonyl chloride (1.38 mL; 17.78 mmol) and
m chloride (1.88 g; 44.45 mmol) were added successively to a solution of
intermediate 35 (3.04 g; 14.82 mmol) in THF (75 mL) at 5°C under N2 flow. The reaction
mixture was stirred at room temperature for 4 hours, poured into ice water and extracted
with EtOAc. The organic layer was washed with brine, dried over M9804, filtered and
evaporated to dryness yielding 3.82 g of intermediate 36 which was used in the next
step without any purification.
Example A14
,N\ ,9 /
O \
a) Preparation of intermediate 37
NaH (214 mg; 5.35 mmol) was added portion wise to a solution of ethyl 4—
lecarboxylate (CAS 90-5) (0.5 g; 3.93 mmol) in DMF (5 mL) under N2 flow
at 5°C. The reaction mixture was stirred at 5°C for 30 minutes. then ylsulfamoyl
chloride (424 pL; 3.93 mmol) was added. The reaction mixture was allowed to warm to
room temperature and stirred at room temperature overnight. The reaction mixture was
poured into ice water and extracted with EtOAc. The organic layer was washed with
brine, dried over M9804, filtered and ated to dryness. The residue was purified by
chromatography over silica gel (irregular SiOH, 15-45um, 259; mobile phase: 99% DCM,
1% MeOH). The product fractions were collected and evaporated to dryness ng
720 mg (82%) of ediate 37.
/N\ ,9 /
\ N‘fi‘N
o \
b) Preparation of intermediate 38 0”
Intermediate 37 (720 mg; 2.91 mmol) in THF (7 mL) was added drop wise to a
suspension of LiAlH4 (221 mg; 5.82 mmol) in THF (6 mL) at room temperature and
d all over the weekend. The reaction e was quenched successively with
water (220 uL), NaOH (220 uL) and water (660 uL), then extracted with EtOAc. The
organic layer was washed with brine, dried over M9804, filtered and evaporated to
dryness yielding 229 mg (38%) of intermediate 38.
c) Preparation of intermediate 39 C'
Eth (0.32 mL; 2.23 mmol), methanesulfonyl chloride (0.104 mL; 1.34 mmol) and lithium
chloride (142 mg; 3.35 mmol) were added successively to a solution of intermediate 38
(229 mg; 1.12 mmol) in THF (5 mL) at 5°C under N2 flow and the reaction mixture was
stirred at room temperature for 4 hours. The reaction mixture was poured into ice water
and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4,
filtered and evaporated to s yielding 245 mg (98%) of intermediate 39. The
residue was used in the next step without any purification.
Example A15
a) Preparation of intermediate 40 °
Dimethylsulfamoyl chloride (CAS 133601) (1.81 mL; 16.78 mmol) was added to a
solution of 2-methyl-1H-imidazole-4—carbaldehyde (CAS 350341) (1.68 g; 15.26
mmol) and Et3N (3.49 mL; 24.41 mmol) in ACN (17 mL) and the reaction mixture was
stirred at 50°C overnight. The reaction mixture was diluted with EtOAc and washed with
water. The organic layer was then dried over M9804, filtered and evaporated to dryness.
The residue was purified by chromatography over silica gel (irregular SiOH, 15-40um,
24g; mobile phase: 100% DCM). The pure fractions were collected and evaporated to
dryness yielding 1.36 g (41%) of intermediate 40.
b) Preparation of intermediate 41 0”
NaBH4 (284 mg; 7.51 mmol) was added n wise to a solution of intermediate 40
(1.36 g; 6.26 mmol) in MeOH (15 mL) at 5°C. The reaction mixture was stirred at room
temperature for 2 hours, poured into ice water, extracted with DCM, dried over M9804,
ed and evaporated to dryness. The crude product was taken up with EtZO; the
precipitate was filtered and dried yielding 795 mg (58%) of intermediate 41.
0) Preparation of intermediate 42 C'
Et3N (1.04 mL; 7.25 mmol), methane yl de (0.337 mL; 4.35 mmol) and LiCl
3 mg; 10.9 mmol) were added successively to a solution of intermediate 41 (795
reaction mixture was stirred at
mg; 3.62 mmol) in THF (18 mL) at 5°C under N2 flow. The
room temperature for 4 hours, poured into ice water and extracted with EtOAc. The
organic layer was washed with brine, dried over M9804, filtered and evaporated to
s yielding 844 mg (98%) of intermediate 42 which was used in the next step
without any purification in the preparation of compound 138.
Example A16
a) Preparation of intermediate 44 0”
A solution of 1-[[2-(Trimethylsilyl)-ethoxy]-methyl]-1H-imidazole—2-carboxaldehyde
(CAS 1012260) (2.25 g; 9.94 mmol) in MeOH (29 mL) was cooled to —20°C and
treated portion wise with NaBH4 (0.45 g; 11.9 mmol). The reaction mixture was
stirred at room temperature for 1 hour, ed by addition of an aqueous solution
of NH4C| and extracted with DCM. The organic layer was dried over M9804, filtered
and the solvent was evaporated to give 2.13 g (94%) of intermediate 44.
\ _/
/ 1.
b) Preparation of ediate 45 c'
Methanesulfonyl chloride (1.07 mL; 13.8 mmol) was added drop wise to a solution of
intermediate 44 (2.1 g; 9.2 mmol) and Et3N (1.92 mL; 13.8 mmol) in DCM (31 mL) at 0°C
under N2 flow. The reaction mixture was stirred below 0°C for 1 hour, poured into ice
and extracted with DCM. The organic layer was separated, dried over MgSO4, filtered
and the solvent was evaporated under vacuum at room temperature to give 2.27 g
(100%) of intermediate 45 which was used t further purification in the next step.
Ni HS?
0 ii N Nj/EéN1 9l\
E :1 I
\ N/
c) Preparation of intermediate 46
NaH (0.13 g; 3.27 mmol) was added portion wise to intermediate 47 (1.14 g; 3.27
mmol) in DMF (11 mL) under N2 flow at room ature. The mixture was stirred for
1.5 hours, then 2-(trimethylsi|yl)-ethoxymethyl chloride (0.58 mL; 3.27 mmol) was added
drop wise. The reaction mixture was stirred at room temperature overnight, quenched
with ice and ted with EtOAc. The organic layer was washed with brine, dried over
M9804, filtered and the t was evaporated to dryness. The residue (1.62 g) was
purified by chromatography over silica gel (irregular SiOH, 15-40 pm, 80g; mobile
phase: gradient from 100% DCM, 0% MeOH to 96% DCM, 4% MeOH. The product
fractions were collected and the solvent was evaporated to give 0.77 g (49%) of
intermediate 46 .
d) Preparation of intermediate 48
NaH (125 mg; 3.13 mmol) was added under N2 at 10°C to a on of intermediate 46
(750 mg; 1.57 mmol) in DMF (10 mL). The solution was stirred at 10°C for 30 minutes.
intermediate 45 (601 mg; 2.44 mmol) was added portion wise and, the on was
allowed to slowly warm to room temperature and stirred overnight. The solution was
cooled, poured into cooled water and extracted with EtOAc. The organic layer was
washed with brine, dried over M9804, filtered and evaporated to dryness. The residue
was purified by chromatography over silica gel (irregular SiOH, 15—40 pm, 809; mobile
phase: gradient from 0% NH4OH, 0% MeOH, 100% DCM to 0.1% NH4OH, 5% MeOH,
95% DCM). The product ons were collected and the solvent was evaporated to give
0.789 (72%) of intermediate 48.
ous preparation of intermediate 66
Analogous preparation of intermediate 94
o g_
\/\ N
KL”\ N\
0 N N N l/N
U\// N
starting from intermediate 95 and intermediate 45
Analogous preparation of intermediate 97
starting from intermediate 7 and intermediate 102
ous preparation of intermediate 107
starting from intermediate 7 and from intermediate 108
/\Si\\//\/OC‘NQUDL
Analogous preparation of intermediate 115
starting from ediate 83 and from intermediate 45
/S|i\/\O/;‘\l 6
t}UTE
Analogous preparation of ediate 145 starting
from intermediate 146 and from intermediate 45
Example A17
Preparation of intermediate 49
A 30% aqueous solution of NaOH (1.99 mL; 19.9 mmol) was added gradually to a
solution of p-toluenesulfonyl chloride (2.6 g; 13.6 mmol) and benzyltriethylammonium
chloride (CAS 561) (0.194 g; 0.85 mmol) in toluene (5 mL) at 5°C. 3-
Oxetanemethanol (CAS 62466) (0.915 mL; 11.35 mmol) was added drop wise
below 10°C. The on mixture was stirred below 10°C for 1 hour and at room
WO 61080
temperature for 5 hours. The reaction mixture was poured into ice and extracted with
DCM (3 times). The organic layer was dried over M9804, filtered and the solvent was
evaporated to give 2.49 g (91%) of intermediate 49.
Example A18
Preparation of intermediate 50
NaH (107 mg; 2.68 mmol) was added to a solution of intermediate 7 (510 mg; 1.34
mmol) in DMF (10 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 30
minutes and a solution of intermediate 53 (554 mg; 2.02 mmol) in DMF (5 mL) was
added at 5°C under N2 flow over a 30 minutes period. The reaction mixture was d
to warm to room temperature and stirred overnight. The reaction mixture was poured
into ice water and extracted with EtOAc. The organic layer was washed with brine, dried
over M9804, ed and ated to dryness. The crude product was purified by
chromatography over silica gel (irregular SiOH, 15-45um, 249; mobile phase: nt
from DCM 99%. MeOH 1% to DCM 98%, MeOH 2%). The product fractions were
collected and evaporated to dryness yielding 200 mg (24%) of intermediate 50 .
Examgle A19
a) Preparation of intermediate 51
NaH (724 mg; 18.11 mmol) was added n wise to a solution of 2—
imidazolecarboxaldehyde (1.16 g; 12.07 mmol) in DMF (58 mL) at 5°C under N2 flow.
The reaction mixture was stirred at 5 °C for 30 minutes and moethoxy)-tert-
butyldimethylsilane (3.11 mL; 14.49 mmol) was added. The reaction mixture was
allowed to warm to room temperature and stirred all over the weekend. The reaction
mixture was poured into ice water and extracted with EtOAc. The organic layer was
washed with brine, dried over MgSO4, filtered and dried. The residue was purified by
chromatography over silica gel (irregular SiOH, 15-45 pm, 40g; mobile phase: DCM
99%, lVleOH 1%). The pure fractions were collected and evaporated to dryness yielding
940 mg (31%) of ediate 51.
b) Preparation of intermediate 52 0“
NaBH4 (168 mg; 4.43 mmol) was added portion wise to a solution of intermediate 51
(940 mg; 3.70 mmol) in MeOH (10 mL) at 5°C under N2 flow. The reaction mixture was
stirred at room temperature 2 hours, poured into ice water and extracted with DCM. The
organic layer was dried over M9804, filtered and evaporated to dryness. The crude
product was taken up with Et20.The precipitate was filtered and dried yielding 597 mg
(63%) of intermediate 52.
0) Preparation of ediate 53 C'
Et3N (666 uL; 4.66 mmol), methanesulfonyl de (216 uL; 2.79 mmol) and LiCl (296
mg; 6.99 mmol) were added successively to a solution of intermediate 52 (597 mg; 2.33
mmol) in THF (12 mL) at 5°C under N2 flow and the reaction mixture was stirred at room
temperature for 4 hours. The on mixture was poured into ice water and extracted
with EtOAc. The c layer was washed with brine, dried over M9804, filtered and
evaporated to dryness yielding 554 mg (87%) of intermediate 53 which was used in the
next step without any purification.
Example A20
\N //
Preparation of intermediate 56
NaH (149 mg; 3.71 mmol) was added portion wise at 5°C under NZ to a soiution of (S)—5-
(Hydroxy-methyi)—2-pyrrolidinone p-toluenesulfonate (CAS 516935) (1 g; 3.71 mmol)
and thane (277 uL; 4.46 mmol) in THF (20 mL). The reaction e was
allowed to warm to room temperature and stirred overnight. The reaction mixture was
quenched with brine and extracted wit EtOAc. The organic layer was decanted, washed
with water then brine, dried over M9304, filtered and evaporated to dryness. The
residue was purified by chromatography over silica gel (irregular SiOH, 30pm, 309;
mobile phase: gradient from 100% DCM, 0% MeOH to 98% DCM, 2% MeOH). The
t fractions were collected and evaporated to give 390 mg (37%) of intermediate
Example A21
Preparation of intermediate 57
NaH (149 mg; 3.71 mmol) was added portion wise at 5°C under N2 to a solution of
intermediate 18 (1 g; 3.71 mmol) and iodomethane (277 uL; 4.46 mmol) in THF (20 mL).
The reaction e was allowed to warm to room temperature and stirred overnight.
The reaction mixture was quenched with brine and extracted with EtOAc. The organic
layer was decanted, washed with water then brine, dried over M9804, filtered and
evaporated to dryness. The residue was purified by chromatography over silica gel
(irregular SiOH, 30pm, 309; mobile phase: gradient from 100% DCM, 0% MeOH to 98%
DCM, 2% MeOH). The pure fractions were collected and evaporated to give 377 mg
(36%) of intermediate 57.
Example A22
a)Preparation of intermediate 59
NaH (30 mg; 0.74 mmol) was added at 0°C to a solution of 2-(trimethylsilyl)—
ethoxymethyl chloride (0.13 mL; 0.74 mmol) and (S)-5—(Hydroxy—methyl)—2-pyrrolidinone
p~toluenesulfonate (CAS 51693-17—5) (0.2 g; 0.74 mmol) in THF (5 mL). The reaction
mixture was stirred 3 hours at 0°C, then partitioned between water and EtOAc. The
organic layer was washed with brine, dried over M9804, ed and evaporated to
s. The residue (0.4 g) was purified by chromatography over silica gel (irregular
SiOH, 15-40pm, 249; mobile phase: 98% DCM, 2% MeOH). The product fractions were
evaporated to dryness to give 0.142 g (48%, colorless oil) of intermediate 59.
b) Preparation of intermediates 67 and 58
/Sl >Si
1 Z
O o
0 o
/ s /
N‘ N\
| |
o N N Nj/LN o N
U11“. out“/N Nj/Ll/N
o o
/ and /
Intermediate 67 ediate 58
NaH (14.9 mg; 0.37 mmol) was added to a solution of intermediate 6 0.09 g; 0.25 mmol)
in DMF (2.25 mL) at 5°C under N2 flow. The on was stirred at 5°C for 30 minutes
and a solution of intermediate 59 (0.149 g; 0.37 mmol) in DMF (1 mL) was added. The
reaction mixture was d to warm to room temperature and stirred during 3 days.
The reaction mixture was partitioned between water and EtOAc. The organic layer was
washed with brine, dried over M9804, filtered and evaporated to dryness. The residue
(0.2 g) was purified by chromatography over silica gel (irregular SiOH, 15-40um, 249;
mobile phase: nt from 98% DCM, 2% MeOH to 95% DCM, 5% MeOH). The
product fractions were collected and evaporated to dryness to give 0.076 g (52%,
orange oil) of intermediate 67 and 0.05 g (20%, orange oil, purity: 60% based on 1H
NMR) of intermediate 58.
Example A23
ation of intermediate 63 and 64
Intermediate 63 and Intermediate 64
ylamine hydrochloride (26 mg; 0.37 mmol) was added to a suspension of
compound 187 (100 mg; 0.25 mmol) and Et3N (52 uL; 0.37 mmol) in EtOH (3 mL). The
resulting mixture was stirred at 80°C overnight. The precipitate was ed and dried to
give 0.08 g (74%) of a mixture intermediate 63 and intermediate 64 (70/30 based on 1H
NMR).
/O AfroH
N /
/ \ j/QNN / N\
F /
/O N/
Analogous preparation of intermediate 139
starting from compound 298
Example A24
NHZNH
/O\©/ /il
Preparation of intermediate 65
Hydrazine monohydrate (1.22 ml, 31.2 mol) was added to a solution of compound 189
(0.7 g, 1.56 mmol) in EtOH (70 ml). The mixture was stirred overnight at reflux. After
cooling down to room temperature, the precipitate was ed off, washed with EtOH
and dried to give 0.56 g (83%) of intermediate 65, which was used without further
purification for the next step.
Analogous preparation of intermediate 106 starting
from compound 234
Example A25
Preparation of intermediate 76 and 77
Sli\
Z 58x
N:\\N N§\ o
/ Nf /
N N
I I I
‘UN N
N\N o N N
/ /
\ 1:0 \ N\\
O\ 0\
lntermediate 76 and lntermediate 77
C32C03 (0.3 g; 0.9 mmol) was added to a solution of compound 71 (0.2 g; 0.45 mmol)
and (2-Bromoethoxy)—tert-butyldimethylsilane (0.22 mL; 0.99 mmol) in DMF (15 mL) at
°C under N2 flow. The reaction mixture was stirred at room ature for 24 hours,
poured into ice water and extracted with EtOAc. The organic layer was washed with
water then brine, dried over MgSO4, filtered and evaporated to dryness. The residue
(609 mg) was purified by chromatography over silica gel (irregular SiOH, 15-40um, 249.
mobile phase: 0.1% NH4OH, 3% MeOH, 97%). The fractions containing the product
were collected and evaporated. The residue (388 mg) was purified again by
chromatography over silica gel (Spherical Silica, 5pm, 150x30.0mm; mobile phase:
gradient from 71% Heptane, 1% MeOH (+10% NH4OH), 28% EtOAc to 0% Heptane,
% MeOH (+10% NH4OH), 80% EtOAc). The product ons were collected and the
solvent was ated to give 0.080 g (29%) of intermediate 76 and 0.175 g (64%) of
intermediate 77.
Example A26
a) Preparation of intermediate 79
NaH (235 mg; 5.88 mmol) was added portion wise to a suspension of 1-Trityl-1H-
imidazole—4-methanol (CAS 33769—07-2) (1 g; 2.94 mmol) in DMF (10 mL) at 5°C under
N2 flow. The reaction mixture was d at 5°C for 30 minutes and bromoethane (219
uL; 2.94 mmol) was added drop wise. The reaction mixture was allowed to warm to
room temperature and stirred ght. The reaction mixture was poured into water.
The precipitate was filtered, washed with water, then ved in ACN and evaporated
to dryness. The residue was taken up twice in EtOH and ated to dryness. The
crude product was purified by chromatography over silica gel ular SiOH, 15-45um,
249; mobile phase: gradient from 99% DCM, 1% MeOH to 97% DCM, 3% MeOH, 0.1%
NH4OH). The product fractions were collected and evaporated to dryness yielding 675
mg (62%) of intermediate 79.
O (QJK/
b) Preparation of intermediate 80
A solution of nBuLi 1.6M in hexane (1.17 mL; 1.87 mmol) was added drop wise to a
solution of intermediate 79 (575 mg; 1.56 mmol) in THF (11 mL) at -78°C under N2 flow.
The reaction e was stirred at -78°C for 10 minutes, then DMF (846 pL; 10.92
mmol) was added drop wise. The reaction mixture was stirred at —78°C for 30 s,
allowed to warm to 0°C over a 3 hour period, quenched with water and extracted with
EtOAc. The organic layer was washed with brine, dried over M9804, filtered and
evaporated to dryness. The residue was purified by chromatography over silica gel
(irregular SiOH, m, 12g; mobile phase: 99% DCM, 1% MeOH). The pure fractions
were collected and evaporated to dryness yielding 556 mg (90%) of intermediate 80.
0) Preparation of intermediate 81
NaBH4 (64 mg; 1.68 mmol) was added n wise to a solution of intermediate 80 (556
mg; 1.40 mmol) in MeOH (5 mL) at 5°C. The reaction mixture was stirred at room
ature for 2 hours, poured out ice water and extracted with DCM. The organic
layer was decanted, dried over M9804, filtered and evaporated to dryness. The residue
was taken up with EtZO. The precipitate was filtered and dried yielding 530 mg (95%) of
intermediate 81 which was used in the next step without any further purification.
0 (K?N OJ
d) Preparation of intermediate 82 cr
Et3N (0.37 mL; 2.66 mmol), methanesulfonyl chloride (124 pL; 1.60 mmol) and LiCl
(169.15 mg; 3.99 mmol) were added successively to a solution of intermediate 81 (530
mg; 1.33 mmol) in THF (10 mL) at 5°C under N2 flow. The reaction mixture was stirred at
room temperature for 4 hours, poured into ice water and extracted with EtOAc. The
organic layer was washed with brine, dried over MgSO4, filtered and evaporated to
dryness yielding 610 mg of intermediate 82 which was used in the next step without any
further purification.
Example A27
Preparation of intermediates 83 and 84
9° ,.
N 1 H I \N
I \ o N N N /
H I
o N N N /N / \
11 // \ |
\ N/
0\ °\
intermediate 83 and intermediate 84
Intermediate 26 (2.08 g, 4.68 mmol), Oxetanyl methanesulfonate (CAS: 1484303)
(1.14 g; 7.49 mmol) and cesium ate (2.29 g; 7.02 mmol) in DMF (35 mL) were
stirred in a sealed tube at 100°C for 6 hours. The mixture was poured into ice and
extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4,
ed evaporated to dryness. The crude product was purified by chromatography over
silica gel (59 of dry loading irregular SiOH 70-200pm, lar SiOH, 15-45um, 25g;
mobile phase : gradient from 98% DCM, 2% MeOH to 97% DCM, 3% MeOH). The
product ons were ted and evaporated to dryness yielding 2 fractions
— Fraction 1: 80 mg of a compound which was dissolved in ACN. crystallized from
CAN. The itate was filtered, washed with ACN then EtZO and dried yielding
27 mg (1%) intermediate 84. M.P.:187-188°C (Kofler).
- Fraction 2: 550 mg of impure intermediate 83 was purified by achiral SFC
(AMINO 6pm 150x21.2mm; mobile phase 0.3% lSOPROPYLAMINE, 75% C02,
% MeOH). The product fractions were collected and evaporated to dryness
yielding 420 mg (21%) of ediate 83.
Example A28
Preparation of ediate 87
Eth (1.4 mL; 9.7 mmol) was added to a solution of 2-(hydroxymethyl)-N,N-dimethyl-1H-
imidazole—1-sulfonamide (CAS 935862—80-9) (1 g; 4.87 mmol) in THF (25 mL). The
reaction e was cooled down to 5°C under N2 and methanesulfonyl chloride (0.45
mL; 5.85 mmol) followed by lithium bromide (1.27 g; 14.62 mmol) were added. The
reaction mixture was stirred at room ature for 2 hours, poured into ice water and
extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4,
filtered and evaporated to dryness. The residue (1.43 g) was purified by chromatography
over silica gel (irregular SiOH, 15-40um, 24g; mobile phase: 99% DCM, 1% MeOH). The
t fractions were collected and evaporated to give 0.92 g (70%) intermediate 87.
Example A29
m UI/N N\ Nd N
Preparation of intermediate 90
A solution of 3,6—dichloropyrido[2,3,b]pyrazine (CAS: 13509252) (14 g; 69.99 mmol),
morpholine (12.32 mL; 139.98 mmol), Eth (19.4 mL; 139.98 mmol) in DCM (500 mL)
was stirred at room temperature for 2 hours. Then, water was added. The c layer
was separated, washed with brine, dried over MgSO4 and filtered. The filtrate was
evaporated to dryness The residue (17g) was purified by chromatography over silica gel
(irregular SiOH, 20-45um, 450g; Mobile phase: 40% Heptane, 10% MeOH (+10%
NH4OH), 50% AcOEt). The product fractions were mixed and the solvent evaporated to
give 2 fractions:
- Fraction 1: 9.7 g (55%) of intermediate 90
- on 2: 4.9 g of impure intermediate 90 which was ed by achirai SFC
(Stationary phase: Chiralpak lA 5pm 250*20mm; Mobile phase: 55% C02, 45%
MeOH) to afford additional 3.3 g (19%) of intermediate 90.
Example A30
Preparation of intermediate 91
A solution of intermediate 65 (316 mg; 0.73 mmol) in trimethyl orthoformate (CAS 149-
73-5) (80 mL; 731.24 mmol) was refluxed (100°C) overnight. The mixture was
ated until dryness yielding 350 mg of intermediate 91 which was directly used in
the next step.
Example A31
Preparation of intermediates 92 and 93
fifi\ y?»
:1"7° ZN
(111% @Url
NaH (50.26 mg; 1.26 mmol) was added portionwise to a solution of a 93/7 mixture of
nd 46 and compound 45 (400 mg; 0.21 mmol) in DMF (8 mL) at 5°C under N2
flow. The reaction mixture was stirred at 5°C for 30 minutes then, (2-bromoethoxy)—tert-
butyldimethylsilane (198 pl; 0.92 mmol) was added dropwise and the reaction mixture
was d at room temperature overnight. The reaction mixture was quenched with iced
WO 61080
water and extracted with EtOAc. The organic layer was separated, dried over M9804,
ed and evaporated to dryness yielding 415 mg (78%) of a mixture of intermediates
92 and 93 which was used without further cation in the next step. In this mixture,
also amounts of nd 218 and 219 were present.
Analogous preparation of intermediate 111 (mixture) starting from compound 53
Intermediate 111
Example A32
a) Preparation of intermediates 98 and 99
N4\ II /
\ N—Is—N\
Li/ 0
N¢\ fl / ‘./
\ N—fi—N\
0 /S|7(
intermediate 98 and intermediate 99
Et3N (3.75 mL; 26.2 mmol) and dimethylsulfamoyi chloride (CAS 133601) (2.26 mL;
21 mmol) were added to a solution of 5~[[[(1,1-dimethylethyl)dimethylsilyl]oxy]methyl]—
1H-imidazole (CA8 127056-45—5) (3.71 g; 17.5 mmol) in ACN (38 mL). The reaction
mixture was stirred at 50°C overnight. The reaction mixture was cooled to room
temperature, poured into water and extracted with EtOAc. The organic layer was
washed with water, dried over M9804, filtered and the solvent was evaporated. The
residue was eptanes by tography over silica gel (irregular SiOH, 15-40 pm,
mobile phase: gradient from 100% DCM, 0% MeOH to 99% DCM, 1% MeOH). The
product fractions were mixed and the solvent was evaporated yielding 2.52 g (45%) of
intermediate 98 and 1.11 g (20%) of intermediate 99.
éi/ N! 020,20 /
O—iT —N\
b) Preparation of intermediate 100
nBuLi 1.6M in hexane (5.85 mL; 9.35 mmol) was added dropwise to a solution of
intermediate 98 (2.49 g; 7.79 mmol) in THF (52 mL) at -78°C under N2 flow. The reaction
mixture was stirred for 30 minutes at -78°C and DMF (3.8 mL; 49.1 mmol) was added.
The e was stirred for 1 hour at -78°C allowing the temperature to warm at room
temperature. The reaction mixture was neutralized with a 10% aqueous solution of
NH4Cl, then water and EtOAc were added. The organic layer was decanted, dried over
MgSO4, filtered and the solvent was evaporated. The residue was purified by
chromatography over silica gel (irregular SiOH, 15-40 pm, 120 9; mobile phase: gradient
from 100% DCM, 0% MeOH to 98% DCM, 2% MeOH). The product fractions were
mixed and the solvent was evaporated yielding: 1.1 g (41%) of intermediate 100.
5W 3 \
0) Preparation of ediate 101
Sodium dride (122 mg; 3.22 mmol) was added to a solution of ediate 100
(1.12 g; 3.22 mmol) in MeOH (32 mL) at 0°C and the reaction mixture was stirred for 1
hour. The reaction mixture was poured into ice and extracted with EtOAc. The organic
layer was washed with brine, dried over M9804, filtered and the solvent was
evaporated. The residue was taken up by DIPE and heptanes, filtered and dried yielding
0.9 g (80%) of intermediate 101.
éi/ N! R /
(vs-Ho
d) Preparation of intermediate 102
iEt3N (0.369 mL; 2.58 mmol), methanesulfonyl de (0.12 mL; 1.55 mmol) and LiCl
(0.164 g; 3.86 mmol) were successively added to a on of intermediate 101 (0.45 g;
1.29 mmol) in THF (10 mL) at 5°C under N2 flow and the reaction mixture was stirred at
room temperature overnight. The reaction mixture was poured into water and extracted
with EtOAc. The c layer was washed with brine, dried over M9804, filtered and
evaporated to dryness yielding 0.47 g (100%) of intermediate 102 which was used
without further purification for the next step.
Example A33
Preparation of intermediates 103, 104 and 105
intermediate 104
intermediate 103
\~/ —sa
/ \O
/|Si‘o
F R N\
I N
/o N N N\ /
U /N
and intermediate 105
CszCog (533.61 mg; 1.64 mmol), then (2-bromoethoxy)—tert-butyldimethylsilane
(211 uL; 0.98 mmol) were added to a solution of ediate 26 (300 mg; 0.82
mmol) in ACN (6 mL) and the reaction mixture was heated at 100°C for 6 hours.
The reaction e was poured into ice water and extracted with EtOAc. The
organic layer was washed with brine, dried over M9804, filtered and evaporated
to dryness. The crude product was purified by chromatography over silica gel
(irregular SiOH, 15-45um, 249; mobile phase: gradient from 99% DCM, 1%
MeOH to 96% DCM, 4% MeOH). The product fractions were collected and
evaporated to dryness yielding 10 mg (2%) of intermediate 105, 70 mg (13%) of
intermediate 103 and 124 mg (29%) of intermediate 104.
Example A34
O/\N
HO\/1§/N\>¥Br
a) Preparation of ediate 109
Sodium borohydryde (3.2 g; 85.89 mmol) was added nwise to a solution of 1H-
lmidazolecarboxylic acidbromo—1-[[2-(trimethylsilyl)ethoxy]methyl] ethyl ester (CA8
954125—17—8) (259; 71.57 mmol) in l (500 mL) at 5°C. The reaction was stirred at
room temperature overnight, poured into ice water and extracted with DCM. The organic
layer was dried over MgSO4, filtered and evaporated to dryness to give 18.65 g (85%) of
intermediate 109.
oldixmN
b) Preparation of intermediate 108
Et3N (466 uL; 3.255 mmol), methanesulfonylchloride (151 uL; 1.953 mmol) and LiCl
(207 mg; 4.882 mmol) were added successively to a solution of ediate 109 (500
mg; 1.627 mmol) in THF (10 mL) at 5°C under N2 flow and the reaction mixture was
stirred at room temperature for 2 hours. The reaction e was poured into ice water
and extracted with EtOAc. The organic layer was washed with brine, dried over M9804,
filtered and evaporated to dryness yielding 539 mg (100%) of intermediate 108 which
was used in the next step without any further purification.
ExampleA35
are.
I F
H /N\
o N N /N
/ \
\ IN/
Preparation of intermediate 110
Isobutylene oxide (155 pL; 1.73 mmol) was added to a solution of ediate 26 (700
mg; 1.58 mmol) and ngC03 (1.03 g; 3.15 mmol) in ACN (10.5 mL). The on
mixture was stirred at 100 °C overnight. The reaction mixture was poured into ice water
and ted with EtOAc. The organic layer was washed with brine, dried over MgSO4,
filtered and evaporated. The crude product was purified by chromatography over silica
gel (irregular SiOH, 15-45um, 249; mobile phase: gradient from 99% DCM, 1% MeOH to
96% DCM, 4% MeOH). The product fractions were collected and ated to dryness
ng 192 mg (28%) of intermediate 110 .
Example A36
\ \N
a) Preparation of intermediate 118 (cis)
A solution of 3,6-dichloropyrido[2,3-b]pyrazine (1 g; 5 mmol), 2,6-dimethylpiperazine
(0.81 mL; 7 mmol), triethylamine (1.39 mL; 10 mmol) in DCM (86 mL) was stirred at 0°C
for 4 hours then at room temperature for 2 hours. Then, water was added. The organic
layer was separated, washed with brine, dried over MgSO4 and filtered. The filtrate was
concentrated under reduced pressure to afford 1.38 g of intermediate 118 (85%) which
was used without further purification in the next step.
O J<
l/I\N/U\Oa
Cl N N Nd,
(Ir\ \N
b) Preparation of intermediate119 (cis)
Di—tert-butyl dicarbonate (1.3 g; 5.96 mmol) was added portion wise to a solution of
intermediate 118 (1.38 g; 4.97 mmol) and N,N-diisopropylethylamine (2 mL; 11.43
mmol) in dioxane (35mL) at room temperature. The mixture was heated at 80°C for 3
hours, then the solution was cooled down to room temperature and poured into iced
water, ted with EtOAc. dried over MgSO4, filtered and evaporated to dryness. The
e (2.41 g) was purified by chromatography over silica gel (irregular 15-40 pm, 40
9, mobile phase: 98% DCM, 2% MeOH). The product fractions were mixed and
concentrated under reduced pressure to afford 700 mg (37 %) of intermediate 119.
Example A37
a) Preparation of intermediate120
A mixture of intermediate 5 (1.54 g; 6.28 mmol) and ofluorobenzoic acid ethyl
ester (CAS 8508078) (2.3 g; 12.56 mmol) in n-propanol (30 mL) was heated at
100°C for 1h. The reaction mixture was cooled down to room temperature, poured into
water and extracted with EtOAc. The organic layer was washed with brine, dried over
MgSO4, filtered and evaporated to dryness. The residue was crystallized from ACN; the
precipitate was filtered, washed with EtZO and dried under vacuum to give 285 mg
(12%) of intermediate 120 . M.P.: 250-260°C (Kofler).
{A\ \
0 N% N\
/\O N N\
/ N/Nj/EéN
b) Preparation of intermediate 121 F
NaH (61 mg; 1.529 mmol) was added at 5°C under N2 flow to a solution of intermediate
120 (300 mg; 0.765 mmol) in DMF (10 mL). The reaction e was stirred at 5°C for
minutes. 2-(chloromethyl)—N,N-dimethyl-1H-imidazolesulfonamide (CAS 935862-
81-0) (0.31 g; 1.376 mmol) was added and the mixture was stirred at room temperature
for 48 hours. The reaction mixture was poured into cooled water, acidified with a 6N
aqueous solution of HCl and ted with EtOAc. The organic layer was dried over
M9804, filtered and evaporated to dryness. The residue (500 mg) was purified by
chromatography over silica gel (irregular SiOH, m, 249; mobile phase: 0.1%
NH4OH, 3% MeOH, 97% DCM). The product fractions were collected and evaporated to
dryness to give 250 mg (56%) intermediate 121.
c) Preparation of intermediate 122
O\\S/N\
(CN"‘o /
o N N\
H N N
HO I j \ \
/ N/Nj/LN
A mixture of intermediate 121 (200 mg; 0.35 mmol), lithium hydroxide monohydrate (25
mg; 1.04 mmol) in THF (8 mL) and water (2 mL) was stirred at room temperature
overnight. The reaction mixture was ied with a 3N aqueous solution of HCI. The
precipitate was filtered, washed with water, then E120 and dried under vaccum to give
200 mg (quantitative) of intermediate 122.
Example A38
t? /
Ot-‘Lq r
a) Preparation of intermediate 124 H
ylamine (1.4 mL; 9.78 mmol), p—toluenesulfonyl chloride (1.86 g; 9.78 mmol) and
4—dimethylaminopyridine (99 mg; 0.815 mmol) were added successively to a solution of
3—[[(1,1-dimethylethyl)dimethylsilyl]oxy](hydroxymethyl)—, (3R,5S)—2-pyrrolidinone
(CAS 13114061) (2 g; 8.15 mmol) in DCM (20 mL) at 5°C under N2 flow and, the
reaction mixture was stirred at room temperature for 18 hours. The on mixture was
diluted with DCM and washed with a 10% aqueous solution of K2003. The organic layer
was decanted, dried over MgSO4, filtered and evaporated to s. The residue (400
mg) was purified by chromatography over silica gel (irregular SiOH, 15—40um, 24g;
mobile phase: gradient from 100% DCM, 0% MeOH to 97% DCM, 3% MeOH). The
product fractions were collected and evaporated to dryness yielding 2.48 g of
ediate 124 (76%).
b) ation of intermediates 125 and 126
/S1\
(($10R /
/o / N\ N Sig/[5NN\ /
0\ intermediate 125
\ intermediate 126
NaH (105 mg; 2.629 mmol) was added to a solution of intermediate 7 (500 mg; 1.314
mmol) in DMF (15 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 15
minutes. A solution of ediate 124 (1 g; 2.629 mmol) in DMF (5 mL) was added
over a 2 hours period and the reaction mixture was allowed to warm to room
temperature and stirred overnight. The reaction mixture was poured onto iced water and
extracted with EtOAc. The organic layer was decanted, washed with brine (twice), dried
over MgSO4, filtered and evaporated to dryness. The e (1 .49) was purified by
chromatography over silica gel (irregular SiOH, 15—40pm, 300g; mobile phase: 0.1%
NH4OH, 5% iPrOH, 95% DCM). The product fractions were collected and evaporated to
dryness yielding 300 mg (37%) of intermediate 125 and 540 mg (56%) of intermediate
126.
Analogous preparation of intermediates 127 and 128
O\ 0\
intermediate 127 and intermediate 128
ng from intermediate 6 and intermediate 124
Example A39
a) Preparation of ediate 130
Methylmagnesium bromide (36.91 mL; 36.91 mmol) was added se at 5°C under
N2 flow to a solution of 2-formyl-N,N-dimethyl-1H-imidazolesulfonamide (CA8
167704—98-5) (5 g; 24.60 mmol) in EtZO (250 mL). The reaction was allowed to raise
room temperature and stirred overnight. The reaction mixture was partionned between
water and EtOAc. The organic layer was dried over M9804, filtered and evaporated to
dryness to give 5.09 g (66%) of intermediate 130 (70% of purity based on 1H NMR).
b) Preparation of intermediate 131
Eth (6.65 mL; 46.43 mmol), methanesulfonyl de (2.16 mL; 27.86 mmol) and
lithium chloride (2.95 g; 69.64 mmol) were added successively at 5°C under N2 flow to a
solution of intermediate 130 (5.09 g; 23.21 mmol) in THF (127 mL) and the reaction
mixture was d at room temperature for 4 hours. The reaction mixture was poured
into ice water and extracted with EtOAc. The organic layer was washed with brine, dried
over M9804, filtered and evaporated to dryness. The residue was purified by
chromatography over silica gel (irregular SiOH, 15-45 pm, 80g; mobile phase: 100%
DCM). The product fractions were collected and evaporated to dryness to give 3.26 g
(84%) of intermediate 131.
Example A40
Preparation of intermediate 132
Methanesulfonyl chloride (0.13 mL; 1.64 mmol) was added se at 5°C under N2
flow to a on of compound 145 (0.275 g; 0.55 mmol) and triethylamine (0.31 mL;
2.18 mmol) in DCM (5 mL). The reaction mixture was stirred at 5°C for 2 hours, poured
out into iced water and extracted with DCM. The organic layer was separated, dried over
M9804, filtered and the solvent was evaporated to dryness at room temperature to give
376 mg of intermediate 132 which was used without purification for the next step.
Example A41
a) Preparation of intermediate 135
NaH (1.55 g; 38.65 mmol) was added dropwise to at 5°C under N2 flow a on of
4,4,5,5-tetramethyl(1H-pyrazolyl)-1,3,2-dioxaborolane (5 g; 25.77 mmol) in DMF
(40 mL). The reaction was d at 5°C for 1 hour, then a solution of N-(3-
bromopropyl)-phthalimide (11 g; 41.23 mmol) in DMF (10 mL) was added dropwise. The
reaction mixture was stirred at room temperature for 4 hours, poured into iced water and
extracted with EtOAc (two times). The organic layer was washed with brine, dried over
MgSO4, filtered and the solvent was evaporated. The residue (11.8 g) was purified by
chromatography over silica gel (irregular SiOH, 20-45um, 450g; mobile phase: 62%
heptane, 3% MeOH, 35% AcOEt). The product fractions were collected and ated
to dryness to give 2.8 g (29%) of intermediate 135.
:i/ \léo
Cl /N /Nj/[>NI
b) Preparation of ediate 136 T\:E~
A solution of intermediate 5a (1.6 g; 6.48 mmol), intermediate 135 (2.6 g; 6.48 mmol) in
a 2M aqueous on of sodium carbonate (16 mL; 32.4 mmol) and 1,2-
dimethoxyethane (65 mL) was degassed with N2 for 15 minutes. Then, PdC|2(dppf).DCM
(0.474 g; 0.65 mmol) was added. The reaction e was refluxed for 1h30, cooled to
room temperature, poured out into water, filtered over a pad of ® and extracted
with EtOAc. The organic layer was dried over M9804, filtered, and the solvent was
evaporated untill dryness. The residue (2.6 g) was purified by chromatography over
silica gel (irregular SiOH, 20-45pm, 4509; mobile phase: gradient from 0.1% NH4OH, 1%
MeOH, 99% DCM to 0.1% NH4OH, 98% DCM, 2% MeOH). The product fractions were
collected and evaporated to dryness to give 1 g (37%) of intermediate 136.
/O NH N N :\
0) Preparation of intermediate 137 °\
A solution of HCI 4M in 1,4-dioxane (0.06 mL; 0.24 mmol) was added to a solution of
intermediate 136 (1 g; 2.39 mmol) in n-propanol (15 mL). 2—fluoro-3,5—dimethoxyaniline
(0.82 g; 4.78 mmol) was added and the reaction e was heated at 100°C for 18
hours. The reaction mixture was poured into iced water, basified with an aqueous
solution of NH4OH and extracted with DCM. The organic layer was dried over MgSO4,
filtered and evaporated till dryness. The residue (1.84 g) was dissolved in DCM. The
precipitate was filtered and dried to give 0.81 g (61%) of intermediate 137. The filtrate
was concentrated and the resulting residue was purified by chromatography over silica
gel (irregular SiOH, 15-40um, 409; mobile phase: 0.1% NH4OH, 2% MeOH, 98% DCM).
The product ons were collected and evaporated to dryness to give additional 0.479
g (36%) of intermediate 137.
d) ation of intermediate 138
Intermediate 137 (1.2 g, 2.17 mmol) and hydrazine monohydrate (1 mL, 21.7 mmol) in
EtOH (8 mL) were heated at 80°C for 2 hours. The reaction mixture was cooled down,
poured into cooled water and extracted with DCM. The organic layer was dried over
M9804, filtered and evaporated to s to give 1 g of intermediate 138 which was
used without further purification in the next step.
Example A42
O>/—wo/“3°
3) Preparation of intermediate 141
NaH (1.88 g; 47.2 mmol) was added to a solution of 1H-[1,2,4]triazolecarboxylic acid
methyl ester (5 g; 39.3 mmol) in DMF (60 mL). The reaction mixture was stirred at 25°C
for 20 minutes followed by 1 hour at 70°C. 1-(Tert-butoxycarbonyl)
(methanesulfonyloxy)azetidine (CAS: 1416993) was added and the reaction mixture
was heated at 70°C for 48 hours. The solution was cooled to 0°C and the ble
material was removed by filtration. The filtrate was diluted with DCM and washed with
water, brine, dried over Na2804, filtered and evaporated to dryness. The residue was
purified by tography over silica gel (mobile phase: eum ether/ethyl acetate
1/5) to give 2 g (18%) of intermediate 141.
pox?
b) Preparation of intermediate 142
Sodium borohydrlde (1.07 g; 28.3 mmol) was added at 0°C to a solution of intermediate
141 (2 g; 7.09 mmol) in MeOH (50 mL). The reaction mixture was stirred at 25°C for 1
hour, then refluxed for 40 hours. The reaction was cooled to 0°C and water (50 ml) was
slowly added. The solution was extracted with DCM. The organic layer were dried over
NaZSO4, filtered and evaporated to s. The residue was purified by
chromatography over silica gel (mobile phase: OH 30/1) to give 0.781 g (43%)
of intermediate 142
o N/N
7K my
0 o
c) Preparation of ediate 143
esulfonyl chloride (0.27 mL; 3.461 mmol) was added dropwise at 5°C under N2
flow to a solution of intermediate 142 (440 mg; 1.73 mmol) and triethylamine (0.72 ml;
.191 mmol) in DCM (15 mL). The reaction mixture was stirred at room temperature
overnight, poured into ice and extracted with DCM. The organic layer was decanted,
dried over M9804, filtered and evaporated to dryness yielding 500 mg (87%) of
intermediate 143 which was used without further purification in the next step.
d) Preparation of intermediate144
NaH (168 mg; 4.2 mmol) was added to a on of intermediate 7 (798 mg; 2.1 mmol)
in DMF (21 mL) at 5°C under N2 flow. The reaction mixture was stirred at 5°C for 30
minutes. A solution of ediate 143 (1.21 g; 3.66 mmol) in DMF (7 mL) was added at
°C under N2 flow over a 2 hours period and the reaction mixture was allowed to warm
to room temperature and stirred overnight. The reaction mixture was poured onto iced
water and extracted with EtOAc. The organic layer was decanted, washed with brine
(twice), dried over MgSO4, filtered and evaporated to dryness. The e was purified
by chromatography over silica gel (irregular SiOH, m, 409; mobile phase: 0.5%
NH4OH, 5% MeOH, 95% DCM). The product fractions were coiiected and evaporated to
dryness yielding 560 mg (60%) of intermediate 144.
Example A43
t1uN. 1 ID
Preparation of intermediate 146
Glycidyl isopropyl ether (207 uL; 0.1.64 mmol) was added to a solution of intermediate
26 (500 mg; 1.37 mmol) and cesium carbonate (889.36 mg; 2.73 mmol) in ACN (7.5 mL)
and the reaction mixture was stirred at 80°C overnight. The reaction mixture was poured
into an aqueous solution of 10% K2003 and extracted with EtOAc. The organic layer
was washed with brine, dried over M9804 and evaporated to dryness. The crude
product was ed by chromatography over silica gel (irregular SiOH m, 24g
Grace; mobile phase: gradient from 98% DCM, 2% MeOH, 0.2% NH4OH to 97% DCM,
3% MeOH, 0.3% NH4OH). The product fractions were collected and evaporated to
dryness. The residue (200 mg) was crystallized from ACN. The itate was filtered,
washed with ACN then EtZO and dried to afford 44 mg of intermediate 146 (7%). MR:
150°C r). The mother liquor was evaporated to give additional 156 mg (24%) of
intermediate 146.
B. Pre aration of the com ounds
Example B1
/LNH
o “N
“@115N rd
Preparation of compound 1
To a solution of intermediate 6 (498 mg ; 1.37 mmol) in 2-methyltetrahydrofuran (15 ml)
and water (1 ml) were added at room temperature, 1-butanaminium, N,N,N-tributyl-
bromide (1:1) (111 mg ; 0.34 mmol) and KOH (1.36 g ; 20.6 mmol). The reaction
mixture was stirred at 50°C for 1 hour and N-(2-ch|oroethy|)propanamine
hydrochloride (304 mg ; 1.9 mmol) was added. The reaction mixture was stirred at 50°C
for 22 hours. The reaction mixture was cooled down to room temperature, poured out
onto water and extracted with EtOAc. The organic layer was washed with brine, dried
(M9804), filtered and trated under reduced pressure. The obtained residue was
purified by chromatography over silica gel (5pm, mobile phase, gradient from 0.2%
NH4OH, 98% DCM, 2% MeOH to 1.1% NH4OH, 88% DCM, 11% MeOH). The desired
product fraction were collected and ated till dryness. The residue was taken up in
EtZO to afford 128 mg (21%) of compound 1.
F N\
I N
/o NU \/N N /
Analogous preparation of nd 2
Example B2
o F $
— N
-0 F CW1“
Preparation of compound 3 N‘ and
compound 4 N
To a solution of intermediate 12 (716 mg ; 1.8 mmol) in tetrahydromethylfuran (15 ml)
and water (1 ml) were added at room temperature, 1-butanaminium, N,N,N-tributyl-,
bromide (290 mg ; 2.7 mmol) and KOH (1.8 g; 27 mmol). The reaction mixture was
stirred at 50°C for 1 hour and N-(2-chloroethyl)-methylamine hydrochloride (252 mg ;
2.7 mmol) was added. The reaction mixture was stirred for 20 hours at 50°C. The
on mixture was cooled down to room temperature, poured out onto water and
extracted with EtOAc. The organic layer was washed with brine, dried (M9804), filtered
and concentrated under reduced pressure. The residue was purified by chromatography
over silica gel (15-40pm 3009; mobile phase, gGradient from 0.5% NH4OH, 95% DCM,
5% MeOH to 0.5% NH4OH, 90% DCM, 10% MeOH). The desired product fractions were
collected, concentrated and residue (1.3g) was purified by l SFC on e phase
0.3% isopropylamine, 82% C02, 18% MeOH). The two desired product fractions were
collected, evaporated till dryness to provide Fraction 1 (83 mg, 10%) and Fraction 2
(226 mg, 26%).
Fraction 1 (was taken up in EtZO to afford 42 mg of compound 4(MP:174°C (DSC)).
Fraction 2 was taken up in EtZO to afford 154 mg of compound 3(MP: 134°C (DSC))
C22H23F2N702.0.97H20.0.027Et20.
Alternatively, compound 3 and 4 were also prepared as s :
A solution of KOH (12.4 g; 188 mmol) in 2-methyltetrahydrofuran (200 mL) was stirred
for 10 minutes at room temperature. Water (20 mL), intermediate 12 (5 g; 12.6 mmol)
followed by tetrabutyiammonium bromide (1.62 g; 5 mmol) were added at room
temperature. The reaction mixture was stirred at 50°C for 1 hour and oroethyl)-
methylamine hydrochloride (3.3 g; 25 mmol) was added. The reaction mixture was
stirred for 24 hours at 50°C. The reaction mixture was cooled down to room
ature, poured into water and extracted with EtOAc. The organic layer was
washed with brine, dried over MgSO4, filtered and concentrated under reduced
pressure.
The residue (5.6 g) was purified by chromatography over silica gel (Irregular SiOH, 20-
45um, 4509; mobile phase: gradient from 0.1% NH4OH, 90% DCM, 10% MeOH to 0.5%
NH4OH, 90% DCM, 10% MeOH). The product fractions were collected and the solvent
was evaporated to dryness ing 0.6g (10%) of compound 4 and 2g of an
intermediate residue which was crystailized from EtZO to give 1.64 g (29%) of compound
3 . M.P.: 159°C (DSC). 022H23F2N702 . 0,09 EtZO . 0,02 DCM.
Analogous preparation of compounds 107 and 108 starting from
ediate 30
compound 107 and compound 108
Analogous preparation of nd 236 and 237 starting from intermediate
NH2 NH2
S / Kl /
N N
I I \N I I \N
o N N N / o N N N /
/ N/ \ N/
/° /°
compound 236 and compound 237
Example 82a
611%
Preparation of compound 44
Water (0. 5 mL), intermediate 17 (0.17 g; 0.51 mmol) followed by tetrabutylammonium
bromide (41 mg; 0.13 mmol) were added at room temperature to a mixture of potassium
hydroxide (0.50 g; 7.63 mmol) in 2—methyltetrahydrofuran (5 mL). The on mixture
was stirred for 10 minutes at room temperature, then stirred at 50°C for 1 hour and (2-
chloroethyl)—methylamine hydrochloride (CAS 45354) (0.119 g; 0.92 mmol) was
added. The reaction e was stirred for 24 hours at 50°C. The reaction mixture was
cooled down to room temperature, poured into water and extracted with EtOAc. The
organic layer was washed with brine, dried over M9804, filtered and evaporated to
dryness. The residue was ed by chromatography over silica gel (Spherical SiOH,
10um, 60g; mobile phase: gradient from 0.5% NH4OH, 97% DCM, 3% MeOH to 0.5%
NH4OH, 95% DCM, 5% MeOH). The pure fractions were collected and evaporated to
WO 61080
give 30 mg (15%) which was taken up EtZO and evaporated to give 29 mg (14%) of
compound 44 M.P.: 80°C (gum, Kofler).
Example BB
F N\
/o N /N
\ N\ N\
l/ U/
F N
Preparation of compound 5 O\ and
/LNH
\ ~/
/o N
\ N\ Nj/E/UN
compound 6 0\
To a solution of intermediate 12 (400 mg ; 1.0 mmol) in tetrahydromethylfuran (10
ml) and water (0.66 ml) were added at room ature, 1—butanaminium, N,N,N-
tributyl-bromide (81 mg; 0.25 mmol) and KOH (994 mg; 15.1 mmol). The reaction
mixture was stirred at 50°C for 1 hour and N-(2-chloroethyl)propanamine
hydrochloride (222 mg ; 1.4 mmol) was added. The reaction mixture was stirred for 22
hours at 50°C. The reaction mixture was cooled down to room temperature, poured out
onto water and extracted with EtOAc. The organic layer was washed with brine, dried
(M9804), filtered and concentrated under d pressure. The residue was purified by
chromatography over silica gel (15-40um 909; mobile phase, 0.5% NH4OH, 95% DCM,
% MeOH). The d fractions were collected, concentrated and residue (165 mg)
was ed by achiral SFC (20pm 430g, mobile phase 0.3% isopropylamine, 75% C02,
% MeOH). The product fractions were collected and evaporated as Fraction 1 (120
mg) and Fraction 2, yielding 16 mg (3%) of compound 6. Fraction 1 was taken up in
EtZO to afford 107 mg (22%) of compound 5(MP: 183°C (DSC)).
Analogous preparation according to procedure 82 or B3 of compounds 37
and 2 starting from intermediate 7
/LNH ANH
/ /
F 3
Nj/[éN~\ F 5 ~\
/0 N\ N /o N N\ Nj/E/N
0\ °\
nd 37 and Compound 2
Analogous preparation ing to procedure BZ or B3 of compounds 38
and 39 starting from intermediate 7
R /
F N\
I /
N HN
/O N\ N
F Kl N{
(1) N
/ N\
N I
/ Nj/E/qN/
o\ /0
compound 38 and compound 39
Analogous ation according to procedure B2 or B3 of compounds 67
and 68 starting from intermediate 12
NH NH
2 2
/ /
F N\ F N\
I I | I
O N N N /N O N N N /N
/ \
\ / U\\
F N F N/
Compound 67 and compound 68
Analogous ation according to procedure B2 or BB of compounds 69
and 70 starting from intermediate 20
HN/ HN/
/ /
Cl H
Nj/EyNN\ | c: H N\
| I
oUU\
N N N N /N
N/ O\©:N \ U\ F F N/
nd 69 and compound 70
Analogous preparation according to ure B2 or B3 of compounds 81
and 82 starting from intermediate 22
HN/ HN/
/ /
| Cl N\
| c: N\
I I
o N N N /N o N N N /N
U\\ / U\\ /
Cl N Cl N
/o /0
Compound 81 and compound 82
Analogous preparation according to procedure 82 or BB of compounds 83
and 84 starting from intermediate 19
HN/ HN/
/ /
c: H
NIL”N\ Cl 1) N\
N N N N N ’/N
Cl N/ \
Cl N/
/O /0
Compound 83 and nd 84
Analogous preparation according to procedure BZ or BB of compounds 167
and 168 starting from intermediate 7
NH2 NH2
/ /
F Nj/EyNN\ I F N\
I I I
o N N o N N Nj/LN
compound 167 and compound 168
2012/052672
Example B4
ation of compound 7 \
To a solution of intermediate 6 (352 mg ; 0.97 mmol) in DMF (10 ml), was added under
N2 at 5°C, NaH (39 mg ; 0.97 mmol, 60% in mineral oil). The reaction mixture was stirred
at 5°C for 45 minutes then 2—(methoxymethyl)—oxirane (0.082 ml; 0.92 mmol) was added
dropwise at 5°C. The reaction mixture was stirred them at 5°C then allowed to reach
room temperature. The reaction was stirred at 80°C overnight. The reaction mixture was
cooled down, poured out onto ice—water and the reaction mixture was extracted with
EtOAc. The organic layer was washed with brine, dried (MgSO4), filtered and
trated under reduced re. The residue was purified by chromatography
over silica gel (5pm; mobile phase, gGradient from 100% DCM to 0.8% NH4OH, 92%
DCM, 8% MeOH). The desired fractions were collected and were purified by achiral SFC
on (2 ethylpyridine 6pm, mobile phase, 0.3% isopropylamine, 78% 002, 22% MeOH).
The product fraction weres collected and the solvent was evaporated, yielding 46 mg
(10%) of compound 7 (MP:65°C (Kofler)).
F F
HO /N.
/ /
Analogous ation of compound 8
Example B4a
RS /
F OH
| ’N\
o N N N /N
U\/\ N
Preparation of compound 29 and
or:3
RS /
I F OH IN\
0 N N N /N
U\// N
preparation of compound 30
NaH (56 mg; 1.39 mmol) was added to a solution of ediate 7(560 mg; 1.47 mmol)
in DMF (25 mL) under N2 at 5°C. The reaction mixture was stirred at 5°C for 30 s
then 1,2-epoxy-3,3,3-trifluoropropane (CAS 3591) (0.12 mL; 1.39 mmol) was added
drop wise at 5°C. The reaction mixture was d for 1 hour at 5°C, then d to
reach room temperature and stirred for 6 hours. The reaction mixture was poured into
ice water and extracted with EtOAc. The organic layer was washed with brine, dried
over M9804, filtered and concentrated. The residue (929 mg) was purified by
chromatography over silica gel (Sphericai Silica, 5pm, 150x30.0mm; mobile phase:
gradient from 71% Heptane, 1% MeOH, 28% EtOAc to 0% Heptane, 20% MeOH, 80%
EtOAc). The product fractions were collected and the solvent was evaporated to give 23
mg (3%) of compound 29, M.P.: gum at 100°C (kofler), and 66 mg (9%) of compound
. M.P.: 202°C (kofler)
Example B4b
F OH
I ”(N
/O N%[N;[N\ /
\ N/
Preparation of compound 31
To a on of intermediate 7 (1 g ; 2.51 mmol) in DMF (25 mL) was added under N2 at
°C, NaH 60% in mineral oil (95.4 mg ; 2.38 mmol). The reaction mixture was stirred at
°C for 45 minutes then oxy-3,3,3-trif|uoropropane (0.21 mL ; 2.38 mmol) was
added drop wise at 5°C. The reaction mixture was stirred for 1 hour at 5°C, overnight at
room temperature and 3 hours at 50°C. The reaction mixture was poured into ice water
and extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4,
filtered and trated under reduced pressure.
The residue (1 .699) was purified by chromatography over silica gel (irregular SiOH, 15-
40um, 309; Mobile phase: 20% eptanes, 80% EtOAc). The t fractions were
mixed and the solvent was concentrated to afford 92 mg of an intermediate fraction
which was ed by achiral SFC on (2 ETHYLPYRIDINE 6pm 150x21 .2mm; Mobile
phase: 80% C02, 20% MeOH) to give 40 mg of a compound which was was crystallized
from EtZO. The precipitate was filtered and dried to afford 35mg (3%) of compound 31.
M.P.:200°C (kofier)
Example 840
Preparation of compound 8 and
preparation of compoundCF33 / and
studSorRKt\
compound 34
NaH (99 mg; 2.46 mmol) was added to a solution of intermediate 6(940 mg; 2.59 mmol)
in DMF (25 mL) under N2 at 5°C. The reaction mixture was stirred at 5°C for 30 minutes
then 1,2-epoxy-3,3,3-trifluoropropane (0.21 mL; 2.46 mmol) was added drop wise at
°C. The reaction mixture was d for 1 hour at 5°C, then allowed to reach room
temperature. The reaction was then stirred at 50°C for 15 hours. The reaction e
was poured into ice water and extracted with EtOAc. The organic layer was washed with
brine, dried over M9804, filtered and evaporated till s. The residue (1.41 g) was
purified by chromatography over silica gel (irregular SiOH, 15-40um; mobile phase 0.1%
NH4OH, 98% DCM, 2%MeOH to 0.1% NH4OH, 97% DCM, 3% MeOH). The pure
ons were ted and evaporated to dryness. The residue (0.59 g) was purified by
achiral SFC (DIETHYLAMINOPROPYL, 5pm, 150x21.2mm; mobile phase: 93% C02,
7% MeOH). The product fractions were collected and evaporated to dryness ng
219 mg (18%) of compound 8.
300 mg of compound 32 ned from 7.4 mmol of intermediate 6) were purified by
chiral SFC (CHlRALPAK AD-H, 50m, 250x20mm; mobile phase: 60% C02, 40%
MeOH). The product fractions were collected and evaporated to dryness to give 2
fractions:
- Fraction A: 135 mg which were llized from EtZO to give 112 mg (3%) of
compound 33 . M.P.: 208°C (DSC)
- Fraction B: 147 mg which were crystallized from EtZO to give 127 mg (4%) of
compound 34 . M.P.: 208°C (DSC).
Example B4d
RS /
I F OH N\
o N N
U\/ N/Nj/E//N
Preparation of compound 50 / and
RS /
I F OH N\
I N
o N N /
\ /
preparation of compound 51
NaH (201 mg; 5.02 mmol) was added to a solution of intermediate 12 (2 g; 5.02 mmol)
in DMF (35 mL) at 5°C under N2 flow. The reaction e was stirred at 5°C for 30
minutes, then a solution of glycidyl methyl ether (0.42 mL; 4.77 mmol) in DMF (15 mL)
was added drop wise at 5°C. The mixture was stirred at 5°C for 1 hour, then allowed to
warm to room temperature and stirred at 80°C overnight. The reaction mixture was
cooled down, poured into ice-water and extracted with EtOAc. The organic layer was
washed with brine, dried over M9804, filtered and evaporated to dryness. The crude
t was purified by chromatography over silica gel (irregular SiOH, 15-40um, 3009;
mobile phase: 0.2% NH4OH, 98% DCM, 2% MeOH). The pure fractions were collected
and evaporated to dryness to give 250 mg of fraction 1 e) and 60 mg of on 2
(impure).
Fraction 1 was purified by i SFC (2 ETHYLPYRlDlNE, 6pm, 150x21.2mm; mobile
phase 80% C02, 20% MeOH). The residue was taken up in ACN and crystallized from
ACN. The precipitate was filtered, washed with EtZO and dried to give 78 mg (3%) of
compound 50 . M.P.: 162—163°C (Kofler).
Fraction 2 was purified by achirai SFC (2 ETHYLPYRlDlNE, 6pm, 150x21 .2mm; mobile
phase 80% C02, 20% MeOH). The e was taken up in ACN and crystallized from
ACN. The precipitate was filtered, washed with EtZO and dried to give 28 mg (1%) of
compound 51 . M.P.: 180°C (Kofler).
Example B4e
Preparation of compound 59, 58 and 60
/ /
compound 59 compound 58
(El l/Co N/
° 111%I;(INTC
compound 60 and compound 57
NaH (105 mg; 2.63 mmol) was added to a solution of intermediate 7 (1 g; 2.63 mmol) in
DMF (15 mL) at 5°C under N2 flow. The reaction mixture was stirred at 5°C for 30
minutes, then a solution of glycidyl methyl ether (0.22 mL; 2.50 mmol) in DMF (5 mL)
was added drop wise at 5°C. The mixture was stirred at 5°C for 1 hour, then allowed to
warm to room temperature and d at 80°C overnight. The reaction mixture was
cooled down, poured into ice-water and extracted with EtOAc. The organic layer was
washed with brine, dried over M9804, filtered and evaporated to s. The crude
product was purified by chromatography over silica gel (irregular SiOH, 15-40pm, 300g;
mobile phase: gradient from 0.1% NH4OH, 98% DCM, 2% MeOH to 0.1% NH4OH, 96%
DCM, 4% MeOH). The product fractions were collected and evaporated to dryness to
give 2 fractions:
- Fraction A: 243 mg of compound 57 which was purified by chiral SFC
LPAK AD-H, 50m, 250x20mm; mobile phase: 60% C02, 40% iPrOH).
The product fractions were collected and evaporated to give 51 mg (4%) of
compound 58 ; M.P.: 94-95°C (Kofler); and 51 mg (4%) of compound 59 ; M.P.:
C (Kofler).
- Fraction B: 227 mg of of compound 60 which was purified by achiral SFC (2
ETHYLPYRlDlNE 6pm 150x21.2mm; mobile phase 85% C02, 15% MeOH. The
product fractions were mixed and the solvent was evaporated. The resulting
residue was taken up in EtZO. The precipitate was filtered and dried yielding 76
mg (6%) of compound 60 . M.P.: 114°C (kofler)
Analogous preparation of compounds 61, 62, 63 and 64 ng from
intermediate 12
compound 63 and nd 64
Example B4e1
Preparation of compound 75 ,76, 77, 78 and 79
Rs / OH 0t
F OH N\ /
I N F N\
o N N N / | 1
U\ N
o N /N N\ /
/o /0
Compound 75 compound 76
Compound 77 compound 78 and compound 79
NaH (210 mg; 5.26 mmol) was added to a solution of intermediate 7 (2 g; 5.26 mmol) in
DMF (35 mL) at 5°C under N2 flow. The reaction mixture was stirred at 5°C for 30
minutes,then, a solution of glycidyl isopropyl ether (0.63 mL; 5.00 mmol) in DMF (15 mL)
was added drop wise at 5°C. The mixture was stirred at 5°C for 1 hour, then allowed to
warm to room temperature and d at 80°C ght. The reaction mixture was
cooled down, poured into ter and extracted with EtOAc. The organic layer was
washed with brine, dried over M9804, filtered and evaporated to dryness. The residue
was purified by chromatography over silica gel (irregular SiOH, 15-40um, 3009; mobile
phase: 0.3% NH4OH, 97% DCM, 3% MeOH). The product fractions were collected and
the solvent was evaporated to give 2 fractions:
- Fraction 1: 600 mg of an intermediate residue which was purified by achiral SFC
(2—ETHYLPYRlDlNE, 6pm, 150x21.2mm; mobile phase: 90% C02, 10% MeOH).
The product fractions were collected and the solvent was evaporated to give 2
ons:
0 Fraction A: 271 mg which were crystallized from ACN to give, after
filtration and , 171 mg (7%) of compound 77 (M.P.: C, Kofler)
0 Fraction B: 82 mg which were taken up in EtZO to afford after Et20
washing, filtration and drying 59 mg (2%) of compound 76 .
M.P.: 137-
138°C (Kofler).
- Fraction 2: 1.35 g of an impure residue which was ed by l SFC (2-
ETHYLPYRlDlNE, 6pm, 150x21.2mm; mobile phase: 85% C02, 15% MeOH).
The t fractions were collected and the t was ated to dryness.
The resulting compound (404 mg) was crystallized from ACN. The precipitate
was filtered, washed with EtZO and dried yielding 390 mg (15%) of compound 75
M.P.: 148-149°C (Kofler).
Compound 75 was purified by chiral SFC LPAK AD—H, 5pm, 250x20mm;
mobile phase: 60% C02, 40% MeOH). The product fractions were collected and
evaporated to give 2 fractions:
0 Fraction C: 169 mg of a compound which was dissolved in ACN and
crystallized from ACN. The precipitate was washed with Et20 and dried to
give 92 (4%) mg of compound 78 (M.P.: 143-144°C, Kofler)
0 Fraction D: 161 mg of a compound which was dissolved in ACN and
crystallized from ACN. The precipitate was washed with Etgo and dried to
give 86 mg (3%) of compound 79 (M.P.: 142°C, Kofler).
Examgle B5
Preparation of compound 9 N_ N\
Under N2, NaH (142 mg ; 3.55 mmol, 60% in mineral oil) was added to a solution of
intermediate 7 (450 mg; 1.2 mmol) in DMF (10 ml) at 5°C. The on mixture was
stirred 30 minutes at 5°C and a solution of 2-(chloromethyl)pyrlmidine (390.5 mg ; 2.4
mmol) in DMF (5 ml) was added. The reaction mixture was d to reach room
temperature and stirred for 20 hours. The reaction mixture was poured out onto ice
water and extracted with EtOAc. The organic layer was washed with brine, dried
(M9804), filtered and concentrated under reduced pressure. The obtained residue was
purified by chromatography over silica gel (15-40um 150g, mobile phase 40% Heptane,
50% EtOAc. 10% MeOH (+10% NH4OH)). The desired fractions were collected,
concentrated under reduced pressure to provide 430 mg (77%) of compound 9. This
nd was taken up in EtZO, a solid was filtered and dried to afford 305 mg of
compound 9 (MP:227°C (DSC)).
Analogous preparation of compound 10
starting from ediate 12
Analogous preparation of compound 11 \ starting
from intermediate 12
| Nj/Ex/NN\ oUUN N\
Analogous preparation of compound 12 starting
from intermediate 6
0/ N: ”’1 N\
in N
_O F /_\ \ / T/
Analogous preparation of compound 13 N‘ starting
from intermediate?
/ ”jg/ha
o N‘ o
O~ N
_o /_\ \ / fil/
Analogous preparation of nd 14 N‘ starting
from intermediate 6
Analogous preparation of compound 15 starting
from intermediate 12
/N\ 1,0
’/S\
0 59N \
F U UN N\ Nj/[éN
Analogous preparation of compound 28 F starting
from intermediate 14
/N\ 00
’IS\
I Cl (KNN/\> N\
o N N\ Nj/Ey"
Analogous preparation of compound 43 starting
from ediate 16
/N\ ,,0
’,s\
0 N
(KN/>\ /
Cl N\
l l
o N /N N\ /N
Analogous preparation of compound 66 C' N ng
from intermediate 19
/N\ ,,0
l (k?N \ N\
O N UN/N\ Nj/CflN
Analogous preparation of compound 72 starting
from intermediate 6
WO 61080
N\ «,0
N N‘
o N /N
\ Nj/[yN
Analogous preparation of compound 74 F N starting
from intermediate 20
°fij€1 /"HN/Q /
Analogous preparation of compound 80 starting
from intermediate 7
:13 N/
Analogous preparation of compound 99 / starting
from intermediate 22
Analogous ation of compound 105 starting
from intermediate 29
WO 61080
Analogous preparation of compound 110
starting from intermediate 7
”f” /
I F M
1 N
N N N /
/ \
\ N/
. /0
Analogous preparation of compound 128
starting from intermediate 7
F N NIL”N\ i l
o N N
/ \
\ N/
Analogous preparation of compound 131
starting from intermediate 7
\N/\
\ \,~
F N N‘
i / N
o N N N /
/ \
\ N/
Analogous preparation of compound 132
ng from intermediate 7
Analogous preparation of nd 136
starting from intermediate 7
0\ IN,
NI \0
£\F /
F N
I Nj/QNN‘l o N /N
\ N/
Analogous preparation of nd 138 starting
from intermediate 7
/N\ 00
,,S\
(I) RN
N N N
E j / \
\ N/
Analogous preparation of compound 153
starting from intermediate 54
A“fl /
0/ ~\
l I N
oQupN N N /
/ \
Analogous preparation of compound 174.
starting from intermediate 6.
/N\ 00/>
(111%O//\N
Analogous preparation of nd 176
starting from intermediate 60
1111116
Analogous preparation of compound 177
starting from intermediate 7
\N /N
o N N UU/ Nj/Q\
Analogous ation of compound 183
starting from intermediate 61
Analogous preparation of compound 191
/N\ //O
O K0N
\ N
F N /
o NU\N N \
\ /
starting from intermediate 68
ous preparation of compound 199
starting from ediate 71
Analogous preparation of compound 201
starting from intermediate 73
Analogous preparation of compound 203
starting from intermediate 74
Analogous preparation of compound 210
starting from intermediate 83
/N\ ,0
O N \
i (Q / l“
O N /N N\ \
\ N/
Analogous preparation of compound 212
starting from intermediate 86 and ediate 87
/N~ f?
Analogous ation of compound 216
starting from intermediate 89
Analogous preparation of compound 220
starting from intermediate 7
Analogous preparation of compound 224
starting from intermediate 84
F o N\
o N N N [/N
/ \ \
/ N/
Analogous preparation of compound 225
starting from intermediate 7
Analogous preparation of compound 241
starting from intermediate 110
Analogous preparation of compound 260
(cis) ng from intermediate 117
ous preparation of compound 274
starting from intermediate 129
Analogous ation of compound 281 starting
from intermediate 6 and intermediate 131
O\\S/\N\
/ \\
/ N 0
I QY
0upN N\
/ rNj/I://N
Analogous preparation of compound 288
starting from intermediate 7 and intermediate 131
(\)\ /N\
/S§O
</\N/
0 N N\ N\ N0°
ol / I
F N
Analogous preparation of compound 292
starting from ediate 133
?\ /\N\
/S:O
0UN N\ N\ N0°
/ NI
Analogous preparation of compound 294
starting from ediate 134
\N ‘1
/ 07/S\N§ NH2
I F k” NJJ
O N N\ N\ \
/ N/
Analogous preparation of compound 296
starting from intermediate 138
2012/052672
Example B5a
Preparation of compounds 102 and and 101
02:3 o ,S N
Xi’é‘i”3 V0 0’13 W4]
K (k: N
[/N (I)fij
.1”.Nj/CN
Compound 102 and compound 101
NaH (49 mg; 1.22 mmol) was added to a solution of intermediate 25 (0.38 g; 0.82 mmol)
in DMF (8 mL) at 5°C under N2 flow. The reaction mixture was stirred for 30 minutes at
°C and a solution of 2-(chloromethyl)—N,N-dimethyl-lH—imidazole—l-su1fonamide (CAS
9358620) (0.219 g; 0.98 mmol) in DMF (2 mL) was added drop wise. The reaction
mixture was allowed to warm to room temperature and stirred for 4 hours. The reaction
mixture was partitioned n water and EtOAc. The organic layer was washed with
brine, dried over MgSO4, filtered and evaporated to dryness. The e was purified by
chromatography over silica gel (Irregular SiOH, 15-40um, 40g; mobile phase: gradient
from 99% DCM 1% MeOH 0.1% NH4OH to 95% DCM 5% MeOH 0.5% NH4OH). The
product fractions were collected and the solvent was evaporated to give 0.294 g (55%) of
compound 102 (orange oil) and 83 mg (14%) of compound 101 w oil).
Example B5b
Preparation of nds 254 and 255
F N\
o N N N [/N
FU\/N
compound 254
F N\
o N N I
N /N
\ N/
compound 255
NaH (100 mg; 2.51 mmol) was added to a solution of intermediate 12 (500 mg; 1.255
mmol) in DMF (11 mL) at 5°C under N2 flow. The reaction mixture was stirred at 5°C for
minutes. Then, a solution of iodomethane (195 uL; 3.138 mmol) in DMF (4 mL) was
added at 5°C under N2 flow over a 2 hours period and the reaction mixture was allowed
to warm to room temperature and d overnight. The reaction mixture was poured
onto iced water and extracted with EtOAc. The organic layer was decanted, washed with
brine (twice), dried over M9804, filtered and evaporated to dryness. The residue (530
mg) was purified by chromatography over silica gel (spherical , 5pm 150x30.0mm;
mobile phase: gradient from 98% DCM, 2% MeOH, 0.2% NH4OH to 92% DCM, 8%
MeOH, 0.8% NH4OH). The t fractions were collected and evaporated to dryness
yielding 2 fractions:
- Fraction 1: 90 mg of a compound which was crystallized from ACN/EtZO. The
itate was filtered and dried to give 60 mg of compound 255 (11%),
MP=199°C r).
- Fraction 2: 300 mg of a compound which was crystallized from ACN/Etgo. The
precipitate was filtered and dried to give 230 mg of compound 254 (44%),
MP=210°C (Kofler).
WO 61080
Analogous preparation of compound 256 and 257 starting from intermediate 12
I NM
0 N
/ UK / / /
F N
compound 256
/o N§£N:[N\ /
\ /
F N
compound 257
Example B6
0 F g
o: E N
WVN /N
Preparation of compound 16 N“ and
O F
—oQRka/V F W\N /
,fll/ N compound 17
To a solution of a e of intermediate 10a and 10b (429 mg ; 0.75 mmol) in THF (10
ml) was added dropwise at room temperature, 1-butanaminium, tributyl- fluoride
(0.9 ml ; 0.90 mmol). The reaction mixture was stirred at room temperature for 3 hours.
The mixture was poured out into ice water and EtOAc and the mixture was basified with
an aquous solution of K2C03 (10%). The reaction mixture was extracted, the organic
layer was washed with brine, dried (M9804), filtered and concentrated under reduced
pressure. The residue was purified by chromatography over silica gel (5pm,. mobile
phase, gradient from, 100% DCM, to 0.8% NH4OH, 92% DCM, 8% MeOH). Two product
fractions were collected and trated under reduced pressure to afford 91 mg
(26%) of compound 17 as Fraction 1 and 117 mg (34%) of comound 16 as Fraction 2.
Fraction 1 was taken up in Eth, trlturated, filtered and dried to afford 38 mg of
nd 17 (MP:206°C (DSC)) in EtZO triturated, filtered
. Fraction 2 was taken up
and dried to afford 53 mg of compound 16 (MP:208°C (DSC))..
nd 19 N"
Analogous preparation of compound 20
Analogous preparation of compound 21 /
Analogous preparation of compound 40 starting from
intermediate 15
Analogous preparation of nd 145 starting
from intermediate 50
l H / l‘
o N /N N\ \
ous preparation of compound 213 starting
from intermediate 88
Example B6a
N’\\
KKN/N /
o N N N [/N
\ \
/ /
Preparation of compound 204
A 1M solution of tetrabutylammonium fluoride in THF (0.31 mL; 1 mmol) was added to a
solution of ediate 76 (0.08 g; 0.13 mmol) in THF (3 mL) at 10°C. The mixture was
stirred at room temperature for 2 hours, poured into cold water, basified with a 10%
aqueous solution of K2C03 and extracted with EtOAc. The organic layer was washed
with a 10% aqueous solution of K2C03, dried over M9804, filtered and evaporated to
dryness. The residue (10 mg) was taken up with Et20 and evaporated to give 0.006 g
(9%) of compound 204.
Analogous preparation of compound 205 starting from intermediate 77
emfN/\N/fOH
Example B6b
Preparation of compounds 218 and 219
©1119@1115U .OZNO
compound 218 and compound 219
A 1M solution of tetrabutylammonium fluoride in THF (3.26 mL; 3.26 mmol) was added
to a solution of intermediates 92 and 93 (415 mg; 0.65 mmol) in THF (20 mL). The
reaction mixture was stirred at room temperature overnight, poured into ice water and
extracted with EtOAc. The organic layer was washed with brine, dried over M9804,
filtered and evaporated to dryness. The residue was purified by chromatography over
silica gel (irregular SiOH, m, 309; mobile phase: 0.1% NH4OH, 3% MeOH, 97%
DCM). The product ons were collected and evaporated to dryness yielding 2
fractions:
- Fraction 1: 80 mg (23%) of compound 218 ;M.P.: 130°C (gum, Kofler)
— Fraction 2: 136 mg of an impure compound which was ed by achiral SFC (2
ETHYLPYRIDINE, 6pm, 150x21 .2mm; mobile phase: 85% COZ, 15% MeOH).
The product fractions were ted and evaporated to dryness ng 18 mg
(5%) of compound 219 M.P.: 112°C (gum, Kofler).
Analogous preparation of compounds 247 and 53 starting from intermediate 111
01 i?
F R F
/O MEN/\[N /O
O\ 0\
compound 247 and compound 53
Example B6c
F R N\
I N
/o N IN\ N\ /
/ N/
Preparation of nd 233
A 1M solution of tetrabutylammonium fluoride in THF (1.03 mL; 1.03 mmol) was added
to a solution of intermediate 103 (70 mg; 0.10 mmol) in tetrahydrofuran (1 mL) and the
reaction mixture was refluxed overnight. The reaction mixture was poured into a 10%
aqueous solution of K2C03 and extracted with EtOAc. The organic layer was washed
with brine, dried over M9804, ed and evaporated to dryness. The crude product was
ed by chromatography over silica gel-(spherical silica, 5pm, 150x30.0mm; mobile
phase: nt from 0.2% NH4OH, 2% MeOH, 98% DCM to 1% NH4OH, 10% MeOH,
90% DCM). The product fractions were collected and evaporated to dryness yielding 29
mg (62%) of compound 233. M.P.:194°C (Kofler).
Example B6d
WO 61080
gig:R O N/
/o /<1 UVN N\ N\j/[/\N/
Preparation of compound 269 O\
A mixture of intermediate 126 (450 mg; 0.74 mmol) and a on of 1M
tetrabutylammonium fluoride in THF (3.7 mL; 3.702 mmol) in THF (10 mL) was stirred at
room temperature overnight. The on mixture was diluted with DCM and quenched
with a 10% aqueous solution of K2C03. The organic layer was decanted, dried over
M9804, filtered and evaporated to dryness. The residue (420 mg) was purified by
chromatography over silica gel (irregular SiOH, 15-40um, 409; mobile phase: 95% DCM,
% MeOH, 0.5% NH4OH). The product fractions were ted and evaporated to
dryness. The residue (354 mg) was crystallized from ACN. The precipitate was filtered
and dried yielding 324 mg (89%) of compound 269 . M.P.: gum at 160°C (kofier).
S /
F E N\
/0 / N\ N Nj/E//N
Analogous preparation of compound 270 starting
from intermediate 125
s /
E N\
/oUN N\ Nj/LN
ous preparation of nd 271 starting
from intermediate 127
N N/
/ogUN.N\ N N\Hj/E/\N/
Analogous preparation of compound 272 starting
from intermediate 128
Example B7
Preparation of intermediate 13 and compound 22
// \ é
| / 1):“:“1— I /
o N N N \ 0 N
U v vN\ N\ N/jfiN—
O O
/ /
intermediate 13 and compound 22
Under N2, to a solution of ediate 6 (980 mg ; 2.7 mmol) in DMF (20 ml) was
added at 5°C, NaH (217 mg ; 5.4 mmol). The reaction mixture was stirred for 30 minutes
at 5°C and 3-bromo(trimethylsilyl)—1-propyne (0.97 ml ; 6.2 mmol) was added
dropwise. The reaction mixture was stirred for 1hour 30 minutes at 5°C. The reaction
mixture was poured out into ice water and extracted with EtOAC. The c layer was
washed with brine, dried (M9804), filtered and concentrated under reduced pressure.
The obtained residue (1.22 g) is a mixture of intermediate 13 and compound 22. The
e was ed by chromatography over silica gel (15-40pm 3009, ). Mobile phase,
60% Heptane, 5% MeOH, 35% EtOAc). The desired fractions were ted, and
evaporated to afford 644 mg (59%) of compound 22.
Example 88a
ation of compounds 45 and 46
I O
F hi
NjLN F 8% |\/l
/0 N N /o N N Nj/LN
0\ 0\
compound 45 and nd 46
NaH (841 mg; 21.03 mmol) was added to a solution of intermediate 7 (2 g; 5.26 mmol)
in DMF (35 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 30 minutes. A
solution of (S)—5-(Hydroxy-methyl)pyrrolidinone p-toluenesulfonate (CAS 51693-17—
) (2.1 g; 7.89 mmol) in DMF (15 mL) was added at 5°C under N2 flow over a 4 hour
period and the reaction mixture was allowed to warm to room temperature and stirred
overnight. The reaction mixture was quenched with iced water and extracted with
EtOAc. The organic layer was decanted, dried over MgSO4, filtered and evaporated to
dryness. The e was ed by chromatography over silica gel (irregular SiOH,
-40pm, 509; mobile phase: gradient from 0.1% NH4OH, 98% DCM, 2% MeOH to
0.2% NH4OH, 97% DCM, 3% MeOH). The t fractions were collected and
evaporated to give 169 mg (7%) of compound 45 M.P.: 127°C (gum, Kofler) and 157
mg (6%) of compound 46 . M.P.: 131°C (gum, Kofler).
Analogous preparation of compound 158 and 159 starting from intermediate
7 and intermediate 56
0 o
/ S /
F N‘
I Nj/[¢N F N\
o N N o N /N Nj/E4N
/0 /0
compound 158 and compound 159
ous preparation of compound 192 and 193 starting from intermediate
12 and intermediate 18
0 0
/ R /
N /
\ \ \ \
l |
/0 /0
Compound 192 and compound 193
Analogous preparation of compound 285 and 286 starting from intermediate
2:: 1
fit;2ij cIUL
compound 285 and compound 286
Example B8a1
| (Q
o N N out\Nj/RN\
ation of compound 49
NaH (552 mg; 13.80 mmol) was added to a solution of intermediate 6 (2 g; 5.52 mmol)
in DMF (35 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 30 minutes. A
solution of (S)(Hydroxy-methyl)pyrrolidinone p-toluenesulfonate (CAS 516935)
(3.7 g; 13.80 mmol) in DMF (15 mL) was added at 5°C under N2 flow over a 2 hour
period and the reaction mixture was allowed to warm to room temperature and stirred
overnight. The reaction mixture was quenched with iced water and extracted with
EtOAc. The organic layer was decanted, dried over MgSO4, filtered and evaporated to
dryness. The residue was ed by chromatography over silica gel (irregular SiOH, 20—
45um, 4509; mobile phase: gradient from 30% e, 15% MeOH, 55% EtOAc to
% Heptane, 18% MeOH, 52% . The product fractions were collected and
evaporated to dryness. The residue (375 mg; 15%) was crystallized from ACN/EtZO to
give 302 mg (12%) of nd 49 . M.P.:182°C (Kofler).
RS /N\ o~<—
/o“@1138N /N /N]/E/N‘<>N_<O
Analogous preparation of compound 300
starting from intermediate 140
Example B8b
ation of compound 47 and compound 48
compound 47 and compound 48
NaH (502 mg; 12.55 mmol) was added to a solution of intermediate 12 (2 g; 5.02 mmol)
in DMF (35 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 30 minutes. A
on of (S)(Hydroxy—methyl)pyrrolidinone p-toluenesulfonate (CAS 51693-17—5)
(2 g; 7.53 mmol) in DMF (15 mL) was added at 5°C under N2 flow over a 1hour period
and the reaction mixture was allowed to warm to room temperature and stirred
overnight. The reaction mixture was quenched with iced water and extracted with
EtOAc. The organic layer was decanted, dried over M9804, ed and evaporated to
dryness. The residue was purified by chromatography over silica gel (irregular SiOH, 15-
40pm, 3009; mobile phase: 0.3% NH4OH, 97% DCM, 3% MeOH). The product fractions
were collected and evaporated to give 478 mg (19%) of compound 47 M.P.: 169°C
(Kofler) and 1 g (40%) of compound 48 . M.P.: 134°C (gum, Kofler).
Example B80
Preparation of compound 52 and compound 53
/0 O
H N H N
N/ N/
F F
I R I \N I R I \N
O N N N / O N N N /
U\ \ \
\ N/ / N/
/O /0
compound 52 and compound 53
NaH (79 mg; 1.97 mmol) was added to a solution of ediate 7 (500 mg; 1.31 mmol)
in DMF (10 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 30 minutes. A
solution of intermediate 18 (531 mg; 1.97 mmol) in DMF (5 mL) was added at 5°C under
N2 flow over a 1 hour period and the reaction mixture was allowed to warm to room
temperature and d overnight.
The reaction mixture was quenched with iced water and extracted with EtOAc. The
organic layer was decanted, dried over M9804, filtered and evaporated to s. The
residue was purified by chromatography over silica gel (Spherical , 5pm,
150x30.0mm; mobile. phase: nt from 70% Heptane, 2% MeOH (+10% NH4OH),
28% EtOAc to 0% Heptane, 20% MeOH (+10% NH4OH), 80% EtOAc). The product
fractions were collected and ated to give 140 mg (22%), which was crystallized
from ACN/DiPE, filtered and dried to give 96 mg (15%) of compound 53 . M.P.: 176°C
(Kofler) and 208 mg (33%) of compound 52 . M.P.: 190°C (Kofler).
Analogous preparation of compounds 160 and 161 starting from intermediate
7 and intermediate 57.
0 o
\ / \ //
N N
/ R /
| F N\ F N\
o “1% N o N /N
I Nj/[yN I Nj/[//N
/0 /0
compound 160 and compound 161
Example B801
Preparation of compound 54
NaH (83 mg; 2.07 mmol) was added to a solution of intermediate 6 (500 mg; 1.38 mmol)
in DMF (12 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 30 minutes. A
solution of ediate 18 (557 mg; 2.07 mmol) in DMF (3 mL) was added at 5°C under
N2 flow over a 1 hour period and the reaction mixture was allowed to warm to room
temperature and stirred overnight. The reaction mixture was quenched with iced water
and extracted with EtOAc. The c layer was decanted, dried over M9804, filtered
and evaporated to dryness. The residue was purified by chromatography over silica gel
(Spherical Silica, 5pm, 150x30.0mm; mobile phase: gradient from 0.2% NH4OH, 98%
DCM, 2% MeOH to 1.3% NH4OH, 87% DCM, 13% MeOH). The t fractions were
collected and evaporated to dryness yielding 20 mg (3%) of compound 54 . M.P.: 125°C
(gum, Kofler).
Example B8d
Preparation of compounds 55 and 56
13 13
(f / /
F NjLNN‘ | F N‘
I l (f l
o N\ N o N /N INjLN
/0 /0
nd 55 and compound 56
NaH (113 mg; 2.82 mmol) was added to a solution of intermediate 12 (750 mg; 1.88
mmol) in DMF (18 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 30
minutes. A on of 1-[3-[(methylsulfonyl)oxy]propyl]—2-pyrrolidinone (625 mg; 2.824
mmol) in DMF (5 mL) was added at 5°C under N2 flow over a 1 hour period and the
reaction e was allowed to warm to room temperature and stirred all over the week
end. The reaction mixture was poured onto iced water and extracted with EtOAc. The
organic layer was ed, washed with brine, dried over M9804, filtered and
evaporated to dryness. The residue was purified by chromatography over silica gel
(Irregular SiOH, 20-45um, 4509; mobile phase: 95% DCM, 5% MeOH). The t
fractions were collected and evaporated to dryness yielding 215 mg (22%) which was
crystallized from ACN to give 169 mg (17%) of compound 55 ; M.P.: 227°C (Kofler) and
207 mg (21%) of compound 56 . M.P.: 99°C (gum, Kofler).
Analogous preparation of nds 119 and 120 starting from intermediate 7.
o o
73 D\
/ /
| F Kr ”\ F
1 I (r N\
O N N Nj/QN O N N Nj/£¢N
0\ 0\
Compound 119 and compound 120
Analogous preparation of compounds 133 and 134starting from intermediate 6
o 0
i3 13
A “Hip J, {N NYC
OUN/ QQN/
/O /0
compound 133 and compound 134
Analogous preparation of nds 150 and 151 starting from intermediate 6.
compound 150 and compound 151
Analogous preparation of compounds 156 and 157 ng from intermediate 7
o 0
N N
/ /
F N\ F N\
I I N 1 l N
o N N N / o N N N /
\ \ / \
/o /0
compound 156 and compound 157
Example B8e
Preparation of compounds 111 and 112
Compound 111 and compound 112
Under N2, NaH (0.289 g; 7.22 mmol) was added to a solution of intermediate 7 (0.915 g;
2.41 mmol) in DMF (8 mL) at 0°C and the solution was stirred at room temperature for
minutes. (S)—(2-oxooxazolidinyl)methyl 4-methylbenzenesulfonate (CAS -
49-5 ) (0.784 g; 2.89 mmol) was added and the solution was stirred for 18 hours. The
reaction mixture was poured into water and extracted with EtOAc. The organic layer was
washed with brine, dried over M9804, filtered and concentrated under reduced
silica gel (irregular
pressure. The e (1.1 g) was purified by chromatography over
SiOH, 15-40Hm, 3009; mobile phase: 42% Heptane, 8% MeOH, 50% EtOAc). The
t fraction were collected and evaporated to give 2 fractions:
- Fraction 1: 98 mg of a compound which was taken up with Et20. The precipitate
was filtered and dried to give 0.093 g (8%) of compound 112 . M.P.: 207°C
(DSC).
- on 2: 215 mg of an impure compound which was purified by reverse phase
chromatography (X-Bridge-C18, 5pm, 30*150mm; mobile phase: gradient from
85% NH4HC03 0.5%, 15% ACN to 0% NH4HC03 0.5%, 100% ACN). The
product fractions were collected and evaporated to dryness. The residue (0.13 g)
was crystallized from EtZO. The itate was filtered and dried to give 0.108 g
(9%) of compound 111 . M.P.: 202°C (DSC).
Analogous preparation of compounds 123 and 124 starting from intermediate
7 and (R)-(2-oxooxazolidiny|)methyl 4-methylbenzenesulfonate
o o
// //
HN/\ HN’\
RKK/o / /
N N
F F
l i \N l RKK/o i \N
O N% N N\ / O N /N N\ /
I l
\ N. U,/
/o /0
nd 123 and compounds 124
Example 89
/> /
N ”\
I A
oQN /N
\ psi/EN
Preparation of compound 71
TFA (3.3 mL; 43.31 mmol) was added to a solution of intermediate 21 (0.45 g; 0.66
mmol) in DCM (15 mL) and stirred at room temperature for 24 hours. The reaction
mixture was poured into ice, basified with a 10% aqueous solution of K2C03 and
extracted with DCM. The c layer was decanted, dried over MgSO4, filtered and the
solvent was evaporated. The residue was purified by chromatography over silica gel
(Spherical Silica, 5pm, 150x30.0mm; mobile phase: nt from 0.2% NH4OH, 98%
DCM, 2% MeOH to 1% NH4OH, 90% DCM, 10% MeOH). The t fractions were
collected and the solvent was evaporated. The residue (185 mg) was crystallized from
ACN and EtZO. The precipitate was filtered and dried to give 0.125 g (43%) of
compound 71 . M.P.:238°C (DSC)
F N
I #9 (N‘
o N /N
\ Nj/LN
F N/
Analogous preparation of compound 85 starting from
intermediate 23.
Analogous preparation of compound 86 / starting from
ediate 24.
HN OJ
F N ”\
| Ku¥
o N /N Nj/LN
Analogous preparation of compound 206 starting
from intermediate 78
Example 89a
l :N /
F N N\
i 1
o N N N /N
/ \
\ N/
Preparation of compound 140
A solution of HCI 4M in 1,4-dioxane (2.63 mL; 10.5 mmoi) was added to a solution of
intermediate 43 (740 mg; 1.05 mmol) in ACN (26 mL). The reaction mixture was heated
at 50°C for 15 hours. The reaction e was poured into a saturated aqueous solution
of K2C03 and ted with DCM. The organic layer was dried over M9804, filtered and
evaporated to s. The residue (0.76 g) was purified by chromatography over silica
gel (Spherical Silica, 5pm, 150x30.0mm; mobile phase: gradient from 0.5% NH4OH,
95% DCM, 5% MeOH to 1.8% NH4OH, 82% DCM, 18% MeOH). The product fractions
were collected and the solvent was evaporated. The residue (0.214 g) was crystallized
from MeOH. The precipitate was filtered and dried to give 0.106 g (22%) of compound
140 . M.P.: 149°C (gum, Kofler).
Analogous preparation of compound 197
starting from intermediate 70
Example B10
Preparation of compounds 87 and 88
0 //
p/ HN
HM S /
/
6' KO
°' "\ l
l l ”N
0 /
o N\ N TL“CUM ”(EEK/c1 N/
/o /0
compound 87 and compound 88
A solution of KOH (2.4 g; 36 mmol) in 2—methyltetrahydrofuran dry (40 mL) and water (4
mL) was stirred for 10 minutes at room temperature. Intermediate 22 (1 g; 2.32 mmol)
followed by utyl ammonium bromide (309 mg; 0.96 mmol) were added. The
reaction mixture was stirred at 50°C for 1 hour and (S)-(+)(hydroxymethyl)
pyrrolidinone p-toluenesulfonate (CAS 516935) (1.3 g; 4.8 mmol) was added. The
reaction mixture was d for 48 hours at 50°C. The reaction mixture was cooled down
to room temperature, poured into water and extracted with EtOAc. The organic layer
was washed with brine, dried over MgSO4, filtered and ated to dryness. The
residue (0.85 g) was purified by chromatography over silica gel (irregular SiOH, 15-
40pm, 300g; mobile phase: 0.1% NH4OH, 96% DCM, 4% MeOH). The product fractions
were collected and the solvent was evaporated to afford 2 ons:
- Fraction 1: 86 mg of an intermediate compound which was crystallized from EtZO
to give 50 mg of nd 87 . M.P.: 160°C (kofler).
— Fraction 2: 95 mg of an intermediate compound which was crystallized from EtzO
to give 75 mg of impure compound 88. The precipitate and the mother layer were
dissolved in DCM and the solution was evaporated to dryness. The resulting
residue was purified by achiral SFC (DIETHYLAMINOPROPYL, 5pm,
150x21.2mm; mobile phase: 80% C02, 20% MeOH). The product fractions were
collected and evaporated to dryness. The residue (31 mg) was crystallized from
EtzO to give 22 mg (2%) of compound 88 . M.P.: 175°C-180°C (Kofier).
Example B11
Preparation of compounds 89, 90 and 91
O O
' ‘3' "‘N C' C'
I I
OUUTL UU:rL UUILCl \
l 1 i
N\ N N / 0 N N N / 0 N N N\ /
/ /
N Cl N Cl N
compound 89 and compound 90 and compound 91
A solution of KOH (1.97 g; 29.91 mmoi) in 2-methyltetrahydrofuran dry (40 mL) and
water (4 mL) was stirred for 10 minutes at room temperature. Intermediate 19 (800 mg;
1.99 mmol) followed by tetrabutyi ammonium bromide (257 mg; 0.80 mmol) were added
at room temperature. The reaction mixture was d at 50°C for 1 hour and )—5-
(hydroxymethyl)pyrro|idinone p—toluenesulfonate (CAS 516935) (1.07 g; 3.99
mmoi) was added. The reaction mixture was heated in a seated reactor at 120°C using a
multimode cavity ave (CEM MARS system) with a power output ranging from 0 to
400 W for 1h30. The reaction mixture was cooled down to room temperature, poured
into water and extracted with EtOAc. The organic layer was washed with brine, dried
over M9804, filtered and concentrated under reduced pressure. The residue (1.2 g) was
purified by tography over silica gel (irregular SiOH, m, 300g; mobile
phase: 0.5% NH4OH, 95% DCM, 5% MeOH). The product fractions were collected and
evaporated to dryness to give 2 fractions:
— Fraction 1 : 225 mg of a nd which was crystallized from EtZO to give
168 mg (17%) of compound 89 . M.P.:183OC (DSC)
- Fraction 2: 250 mg of a compound which was crystallized from Et20. The
precipitate was filtered off and dried under vaccum. The resulting residue (0.192
g) was purified by chiral SFC (CHIRALPAK AD-H, 5pm, 250x20mm; mobile
phase: 60% C02, 40% . The product ons were collected and
ated to s to give 0.072 g (7%) of compound 90 (M.P.: 160°C,
gum, Kofler) and 0.075 g (8%) of compound 91 (M.P.: 160°C, gum, Kofler).
Analogous preparation of compounds 92, 93 and 94 starting from
intermediate 19
/0/ HN
K13HM /
R /
Cl R
or N. I N\N
TXUYLl ”UNU“ / I / /
Cl N/ C[ilorS
compound 92 and compound 93
C‘ R IN‘N
/ONUUN\ /
c1 N/
SorR
compound 94
Example B12
Preparation of compound 97
A solution of KOH (1.84 g; 27.82 mmol) in 2-methyltetrahydrofuran dry (25 mL) and
water (5 mL) was stirred for 10 minute at room temperature. Intermediate 22 (800 mg;
1.86 mmol) followed by utyl ammonium bromide (239 mg; 0.74 mmol) were added.
The reaction mixture was stirred at 50°C for 1 hour and toluene-4—sulfonic acid (R)—5-
oxopyrrolidin-Z—ylmethyl ester (CAS 1288990) (1 g; 3.71 mmol) was added. The
on mixture was heated in a sealed reactor at 120°C using a multimode cavity
microwave (CEM MARS system) with a power output ranging from 0 to 400 W for 1h30.
The reaction mixture was cooled down to room temperature, poured into water and
extracted with EtOAc. The c layer was washed with brine, dried over MgSO4,
filtered and concentrated under reduced pressure.
WO 61080
The residue (1.2 g) was purified by column chromatography over silica gel (irregular
SiOH, 15-40um, 40g; mobile phase: 96% DCM, 4% MEOH, 0.1% . The product
fractions were collected and the solvent was evaporated to dryness to give 80 mg (8%)
of a compound which was llized from EtZO to give, after filtration, 59 mg (6%) of
compound 97. M.P.: 150°C (Kofler).
Example B13
Preparation of compounds 35 and 36
compound 35 and compound 36
NaH (105 mg; 2.63 mmol) was added to a solution of intermediate 7 (500 mg; 1.31
mmol) in DMF (10 mL) at 5°C under N2 flow. The reaction e was stirred for 30
minutes at 5°C and a solution of oromethyl)—N,N-dimethyl-1 H-imidazole
sulfonamide (CA8 1610177) (472 mg; 2.11 mmol) in DMF (3 mL) was added drop
wise. The reaction mixture was allowed to warm to room temperature and stirred
overnight. The reaction mixture was poured into ice water and extracted with EtOAc.
The c layer was washed with brine, dried over MgSO4, filtered and evaporated till
dryness. The residue was purified by chromatography over silica gel (Irregular SiOH, 20-
45um; mobile phase: 40% Heptane, 10% MeOH, 50% EtOAc). The pure fractions were
collected and concentrated to give 70 mg (9%) of compound 35 and 590 mg (79%) of
compound 36 . M.P.: 100°C (gum, Kofler).
\ /
I F
o N N N /N
/ \
\ IN/
. 0\
Analogous preparation of compound 113 and
\ /
I F
i ‘
o N N N /N
\1L\
compound 114
..——— O\ IN
I (K)i I
o N N N /N
/ \
\ IN/
Analogous preparation of nd 116 and
'— O\ IN
/ N/
I F
I \
o N N N /N
compound 117 using intermediate 36.
/N\ ,9 /
\ N—s-N
n \ N
I F
O I \
o N N N /N
/ \
\ N/
Analogous preparation of compound 126 and
/ 0* IN
/3:0
i /N N/
o : .N N N /N
U\\ N/
/o . .
compound 127 starting from Intermediate 7 and
intermediate 39
I /N N/
(I) \
N N
UN// NJLN\
Analogous preparation of nd 178 and
i \
N /
I [N\
o N N N x"
compound 179 starting from intermediate 7
[7/0 /
l F M
o N N N /N
/ \
\ IN/
Analogous preparation of compound 180 and
MlI /
F N‘
o N N N /N
\1L\
compound 181 starting from intermediate 7
\ /
F N\
I l
o N N N /N
Analogous ation of compound 184 and
(w /
l F
l ‘N
o N N N /
/ \
\ N/
compound 185
Analogous preparation of compound 195 and
\NN /
I F l”\
o K: U\/\N N Nj/E/l
compound 196 starting from intermediate 7
WO 61080
Example B14
compound 130
NaH (46 mg; 1.15 mmol) was added to a solution of intermediate 6 (208 mg; 0.57
mmol) in DMF (5 mL) under N2 at 10°C. The on was stirred at 10°C for 30
minutes and 2H—Pyranmethanol tetrahydro(4—methylbenzenesulfonate) (CAS
754348) (241 mg; 0.89 mmol) was added portion wise. The solution was allowed
to slowly warm to room temperature, overnight, poured into ice and extracted with
EtOAc. The organic layer was washed with brine, dried over M9804, filtered off and
the solvent was evaporated. The e (0.69 g) was purified by chromatography
over silica gel (Spherical Silica, 5pm, 150x30.0mm; mobile phase: gradient from
0.2% NH4OH, 98% DCM, 2% MeOH to 0.8% NH4OH, 92% DCM, 8% MeOH). The
product fractions were collected and the solvent was evaporated to give 2 fractions:
- Fraction 1: 110 mg of a compound which was crystallized from acetone and
EtZO. The precipitate was filtered and dried to give 83 mg (31%) of
compound 129 . M.P.: 137°C r).
- Fraction 2: 12 mg of an impure compound which was purified by achiral SFC
(amino, 6pm, 150x21.2mm; mobile phase: gradient from 0.3% isopropylamine,
82% C02, 18% MeOH to 0.3% pylamine, 70% C02, 30% MeOH). The
product fractions were collected and the solvent was evaporated to give 8 mg
(3%) of compound 130 (94% of purity based on .MP: 210°C (kofler)
Analogous preparation of compounds 143 and 144 starting from intermediate 7
and intermediate 49
(U N/ (U N/
I F
I F
O N N N O N N Nj/E/h/
\ \
I j/E/N/ / \
/o /0
Compound 143 and compound144
ous preparation of compounds 165 and 166 starting from intermediate 6
Q(IN N NJLN (I)
Q(1N N Nj/Ef‘
Compound 165 and compounds 166
e B14a
RS /
F N‘
I l
o N N N /N
/ \
\ N/
Preparation of compound 139
NaH (87 mg; 2.19 mmol) was added under N2 at 10°C to a solution of intermediate 7
(208 mg; 0.55 mmol) in DMF (5 mL). The solution was stirred at 10°C for 30
minutes. Tetrahydro—2H-pyranylmethyl 4-methylbenzenesulfonate (CAS 75434-
63—8) (443 mg; 1.64 mmol) was added portion wise and the solution was allowed to
slowly warm to room temperature and d overnight. The reaction e was
poured into ice and extracted with EtOAc. The organic layer was washed with brine,
dried over MgSO4, filtered and evaporated to dryness. The residue (0.25 g) was
purified by chromatography over silica gel (Spherical Silica, 5pm, 150x30.0mm;
mobile phase: gradient from 0% NH4OH, 0% MeOH, 100% DCM to 0.8% NH4OH,
92% DCM, 8% MeOH). The product fractions were collected and the solvent was
evaporated to give 0.024 g (9%) of compound 139 . M.P.: 94°C (Kofler).
Analogous preparation of compound 142 starting from intermediate 6 and
. /0
Analogous preparation of compound 187
starting from intermediate 7
AOJH N\/
/0 N N\
Analogous preparation of compound 189
starting from intermediate 6
F o Nj/QNN\ l I
o N N
/ \
\ N/
ous ation of compound 214
starting from intermediate 7
Analogous preparation of compound 234
starting from intermediate 7
Example B15
Preparation of compound 141
A solution of tetrabutylammonium fluoride 1M in THF (6.53 mL; 6.53 mmol) was added
to a solution of intermediate 48 (450 mg; 0.65 mmol) in THF (47 mL). The reaction
mixture was refluxed for 18 hours, poured into ice and extracted with EtOAc. The
organic layer was washed with a saturated on of NaHC03, then with brine, dried
over M9804, filtered and the solvent was evaporated. The residue (1.13 g) was ed
by tography over silica gel (irregular SiOH, 20-45pm, 4509; mobile phase: 0.5%
NH4OH, 93% DCM, 7% MeOH). The product fractions were collected and the solvent
was evaporated. The residue (0.128 g) was taken up with ACN. The itate was
filtered and dried to give 0.088 g (31%, yellow solid) of compound 141. M.P.: 285°C
(DSC).
Analogous preparation of compound 248 starting from
intermediate 67.
I F (H N‘
l N
o N N N /
/ \
\ N/
Analogous preparation of compound 190 starting.
from intermediate 66
Analogous preparation of compound 228 starting from intermediate 94
£9HN \
I N
/o N N\ N\ /
/ N/
\ Br /
I (KN N\
o N N
I \ \ N/
ous preparation of compound 238 starting
from intermediate 107
(/7N p
l N\
I /N
o N N\ N\
F N/
Analogous preparation of compound 253 starting
from intermediate 1 15
NH \
| K9 (LC)
0 N /N /Nj/©N >—
ufiumI
Analogous preparation of compound 302 starting
from intermediate 145 (the reaction was performed in the presence of
tetrabutylammonium fluoride at room temperature)
Example B16
H /
o N N
\E 9/ UN// \
I NJLN
Preparation of compound 146 l and
N r; I/N
compound 147 2.76 HCI
NaH (41 mg; 1.04 mmol) was added to a solution of intermediate 6 (250 mg; 0.69
mmol) in DMF (5 mL) at 5°C under N2 flow and the on mixture was stirred at
5°C for 30 minutes. A solution of 4-(2-chloroethyl)morpholine (CAS 32406) (155
mg; 1.04 mmol) in DMF (3 mL) was added at 5°C under N2 flow over a 1 hour period
and the reaction mixture was allowed to warm to room temperature and stirred
overnight. The on mixture was poured onto iced water and extracted with
EtOAc. The organic layer was ed, washed with brine, dried over MgSO4,
filtered and evaporated to dryness. The residue (460 mg) was purified by
chromatography over silica gel (irregular SiOH, 15—40um, 309; mobile phase: 0.5%
NH4OH, 97% DCM, 3% MeOH). The product fractions were collected and
ated to dryness yielding 2 fractions:
WO 61080
— Fraction 1: 107 mg of a compound which was dissolved in ACN. The solution
was cooled in an ice bath and a 4N solution of HCl in 1,4-dioxane was added.
The hydrochloride salt was filtered, washed with Eth and dried yielding 109 mg
(28%) of compound 146 . M.P.: 143°C (gum, Kofler). CZ5H29N703 .
1.66HCI .
2.11H20
- Fraction 2: 167 mg of an impure compound which was purified by achiral SFC
(CYANO, 6pm, 150x21.2mm; mobile phase: 0.3% isopropylamine, 82% C02,
18% MeOH). The t ons were collected and evaporated to dryness.
The e was dissolved in ACN. The solution was cooled in an ice bath and a
4N solution of HCI in 1,4—dioxane was added. The hydrochloride salt was filtered,
washed with Et20 and dried yielding 72 mg (17%) of compound 147 . M.P.:
162°C (gum, Kofler). 025H29N7O3 . 2.76HCI . 2.41H20.
Analogous preparation of
l F H N\
o N N N /N
\MK\
compound 148 2.37HCI and
I F R IN‘
0 N UK/N Nj/EflN
compound 149 1.71 HCl
starting from intermediate 7
Example B17
F N\
I l
o N N N /N
FU\ N/
Preparation of compound 154
NaH (161 mg; 4.02 mmol) was added portion wise to a solution of intermediate 12 (0.8
g; 2.01 mmol) in DMF (25 mL) under N2 at 5°C. The reaction mixture was stirred for 30
minutes at 5°C and a solution of 3-bromomethyl-tetrahydro-furan (484 mg; 4.02 mmol) in
DMF (5 mL) was added drop wise. The reaction mixture was allowed to reach room
temperature and stirred for 48 hours. The reaction mixture was poured into ice water
and extracted with EtOAc. The organic layer was decanted, washed with brine (twice),
dried over M9804, filtered and evaporated to dryness. The residue (1 g) was purified by
chromatography over silica gel (irregular SiOH, 15-40um, 409; mobile phase: 0.1%
NH4OH, 3% MeOH, 97% DCM). The product fractions were collected and evaporated to
give 0.15 g (15%) of an ediate compound which was llized from EtZO to give
48 mg (5%) of compound 154 . M.P.: 226°C r).
on'f/O
F N\
I N
o N |N\ N /
/ \
/ /
Analogous preparation of compound 226 starting
from ediate 7
Example B17a
Preparation of compounds 169, 170, 171 and 172
I F
o N N N
Q U\/\ j/C/N
compound 169
RS /
I IN‘
0 N N N /N
U\\ N/
compound 170
RorS /
I F IN
0 N N N /N
U\/\ N
compound 171
S orPO /
F N\
I l N
O N N N /
/ \
\ /
nd 172
NaH (109 mg; 2.73 mmol) was added portion wise to a on of intermediate 7 (260
mg; 0.68 mmol) in DMF (5 mL) at 5°C under N2. The reaction mixture was stirred for 30
minutes at 5°C and a solution of 3-bromomethyl-tetrahydro—furan (CAS 165253-29—2)
(450 mg; 2.73 mmol) in DMF (3 mL) was added drop wise. The reaction mixture was
allowed to reach room temperature and stirred for 48 hours. The reaction mixture was
poured into ice water and EtOAc was added. The organic layer was decanted, washed
with brine (twice), dried over MgSO4, filtered and ated to dryness. The residue
(0.35 g) was purified by chromatography over silica gel (irregular SiOH, 15-40pm, 30g;
mobile phase: 40% Heptane, 8% MeOH, 52% EtOAc). The product fractions were
ted and the solvent was evaporated to give 2 fractions:
- Fraction 1: 56 mg (18%) of compound 169 (M.P.: 80°C, gum, kofler)
- Fraction 2: 80 mg of a compound which was taken-up with Et20 to give, after
tion, 70 mg (22%) of compound 170 . M.P.: 80°C (gum, Kofler).
52 mg of compound 170 were purified by chiral SFC (CHIRALPAK AD-H, 5pm,
250x20mm; mobile phase: 50% C02, 50% MeOH). The t ons were
collected and the solvent was evaporated to give 2 additional fractions:
0 Fraction 3: 26 mg of compound 171 . MP : 172°C (kofler)
0 Fraction 4: 26 mg of compound 172 . MP : 170°C (kofler)
Example B18
/N /
l F
I \N
o N N N /
F N/
Preparation of compound 173
A solution of KOH (1.74 g; 26.36 mmol) in 2-methyltetrahydrofuran dry (15 mL) was
stirred for 10 minutes at room temperature. Water (2.5 mL), intermediate 12 (700 mg;
1.76 mmol) followed by tetrabutylammonium bromide (142 mg; 0.44 mmol) were added.
The reaction e was stirred at 50°C for 1 hour and bromoacetonitrile (0.22 mL; 3.16
mmol) was added. The reaction mixture was stirred for 24 hours at 50°C, cooled to room
temperature, then poured into ice water and extracted with EtOAc. The organic layer
was decanted, washed with brine (twice), dried over MgSO4, filtered and evaporated to
dryness. The residue (0.8 g) was purified by chromatography over silica gel (irregular
SiOH, 15-40pm, 509; mobile phase: 0.1% NH4OH, 3% MeOH, 97% DCM). The
resulting residue (0.4 g) was again purified by chromatography over silica gel (Spherical
Silica, 5pm, 150x30.0mm; mobile phase: nt from 0.1% NH4OH, 99% DCM, 1%
MeOH to 0.7% NH4OH, 93% DCM, 7% MeOH). The product fractions were collected
and evaporated to give 65 mg of a nd which was crystallized from Et20 ng
44 mg (6%) of compound 173,. MP: 250°C (Kofler).
/ N /
I / I
o N N N f\N
Analogous preparation of compound 298
starting from intermediate 7
Example B19
Preparation of compound 217
A solution of ediate 91 (350 mg; 0.74 mmol) in xylene (40 mL) was refluxed for 36
hours. The reaction mixture was poured into water and extracted with EtOAc. The
organic layer was washed with brine, dried over M9804, filtered and evaporated to
dryness. The residue was purified by chromatography over silica gel ical silica,
5pm, 150x30.0mm; mobile phase: gradient from 0.1% NH4OH, 1% MeOH, 99% DCM to
0.8% NH4OH, 8% MeOH, 92% DCM). The product fractions were collected and
ated to dryness. The residue (75 mg) was taken up in ACN. The precipitate was
ed, washed with ACN then EtZO and dried yielding 48 mg (15%) of compound 217 .
M.P.: 240°C (Kofler).
Example B20
Preparation of compound 251
A solution of HCl 4N in 1,4-dioxane (0.84 mL; 3.349 mmol) was added to a solution of
intermediate 112 (319 mg; 0.335 mmol) in ACN (8 mL) and the reaction mixture was
heated at 50°C for 18 hours. The reaction mixture was poured into a 10% cold aqueous
solution of K2C03 and extracted with EtOAc. The organic layer was decanted, washed
with brine, dried over M9804, filtered and evaporated to s. The residue was
purified by chromatography over silica gel (irregular SiOH, 15-40um, 249; mobile phase:
gradient from 95%DCM, 5% MeOH, 0.1% NH4OH to 95%DCM, 5% MeOH, 0.5%
NH4OH). The product fractions were ted and evaporated to dryness. The e
(120 mg, 81%) was gathered with 50 mg coming from another batch (performed on 415
mg of intermediate 112). The resulting residue was crystallized from ACN. The
precipitate was filtered, washed with Eth and dried yielding 120 mg (29% based on the
2 batches) of compound 251 (81%), MP=247°C (Kofler).
I /,N /
F N
I N\N
/o N N\ N\ /
/ N/
Analogous preparation of nd 258
starting from intermediate 116
Example B21
ation of compounds 207 and 208
He“ rem Hg... //<OH
F N\ F N\
(I) N\ N NjLN (I) N /N Nj/DN
0\ 0\
compound 207 and compound 208
intermediate 26 (300 mg; 0.82 mmol), isobutylene oxide (3 mL; 33.62 mmol) and
082C03 (267 mg; 0.82 mmol) were heated at 100°C in a sealed tube for 5 hours. The
reaction mixture was poured into water and extracted with EtOAc. The organic layer was
washed with brine, dried over M9804, filtered and evaporated to dryness. The residue
was ed by chromatography over silica gel (Spherical Silica, 5pm, 150x30.0mm;
mobile phase: gradient from 0.2% NH4OH, 2% MeOH, 98% DCM to 1% NH4OH, 10%
2012/052672
MeOH, 90% DCM). The product fractions were collected and evaporated to dryness
yielding 2 fractions:
- Fraction1: 13 mg (3%) of compound 207 (MR: 154°C, Kofler)
— on 2: 139 mg of a compound which was crystallized from ACN, yielding 98
mg (22%) of compound 208 . M.P.: 124°C (gum, Kofler).
Analogous preparation of compounds 245 and 246 starting from intermediate 7
/ /
F OH N\ F 0H ”\
(I) I N I N
N N N / (I) N N N /
U\\ / U\\ /
N N
°\ °\
compound 245 and compound 246
Analogous preparation of compounds 276 and 277 starting from intermediate 6
fl 7 X N/
(I) OH
N N Nj/[ZN (I) N N
01L j/[ZN
/° /0
compound 276 and compound 277
Analogous preparation of compounds 278 and 279 starting from intermediate 12
OH OH
/ /
F N F N
l I \N I I \N
o N N N / o N N N /
U\/ U\ \
F N/ F N/
nd 278 and compound 279
Example 821a
Preparation of nd 250
(by CH
N N N /N
\ \
. 0.98 HCI
Glycidyl isopropyl ether (87 uL; 0.689 mmol) was added to a solution of intermediate 47
(200 mg; 0.574 mmol) and cesium carbonate (299.2 mg; 0.92 mmol) in ACN (3 mL) and
the reaction mixture was stirred at 100°C overnight. The reaction mixture was filtered.
The filtrate was extracted with EtOAc. The organic layer was washed with brine, dried
over M9804, filtered and evaporated to dryness.
The residue (0.259) was purified by tography over silica gel (stationary phase:
stability Silica 5pm 150x30.0mm; mobile phase: gradient from 0.2% NH4OH, 98% DCM,
2% MeOH to 1% NH4OH, 90% DCM, 10% MeOH). The product fractions were mixed
and the solvent was evaporated affording an intermediate nd which was treated
with a solution of HCI 4N in dioxane. The solvent was concentrated to give 48 mg of
nd 250 MP: gum at 96°C (kofler). C30H40N605
, . 0.98 HCI . 0.9 H20 . 0.05
C4H802
Example BZlb
Preparation of compound 252 and intermediate 114
(511%
compound 252
RS>_
(511%
intermediate 114
Glycidyl isopropyl ether (51 uL; 0.41 mmol) was added to a solution of intermediate 26
(150 mg; 0.34 mmol) and cesium carbonate (219.9 mg; 0.68 mmol) in ACN (2 mL) and
the reaction mixture was stirred at room temperature overnight. Then, the reaction
mixture was refluxed for 6 hours, poured into ice water and extracted with AcOEt. The
organic layer was washed with brine, dried over MgSO4, filtered and evaporated to
s. The crude product was purified by chromatography over silica gel (irregular
SiOH, 15-40pm, 30g; mobile phase: nt from 0.1% NH4OH, 99% DCM, 1% MeOH
to 0.3% NH4OH, 97% DCM, 3% MeOH). The product fractions were collected and
evaporated to dryness yielding to:
- Fraction A: 38 mg of an impure intermediate which was crystallized from ACN.
The precipitate was ed, washed with ACN then EtZO and dried to afford 26
mg of (16%) of ediate 114 MP: gum at 100°C (kofler)
- Fraction B: 32 mg of impure compound 252 which was purified by achiral SFC
(Stationary phase: 2 ETHYLPYRIDINE 6pm 150x21.2mm; mobile phase : 80%
C02, 20% MeOH). The product fractions were collected and evaporated to
dryness yielding 22 mg (11%) of compound 252 M.P.: 60°C (kofler), gum.
Example B22
Preparation of compound 186
A 21% solution of sodium ethoxide in EtOH (0.971 mL; 2.6 mmol) was added to a
mixture of intermediate 63 and intermediate 64 (0.113 g; 0.26 mmol) in EtOH (10 mL)
and EtOAc (0.102 mL). The mixture was refluxed ght, poured into ice and
extracted with EtOAc. The organic layer was washed with brine, dried over MgSO4,
filtered and the solvent was evaporated. The residue (0.18 g) was purified by
chromatography over silica gel (irregular SiOH, 15-40pm, 309; mobile phase: 0.3%
NH4OH, 3% MeOH, 97% DCM). The t fractions were ted and the solvent
was evaporated. The residue was crystallized from Et20 and ACN. The itate was
filtered and dried to give 0.053 g (44%) of compound 186, M.P.: 177°C (Kofler).
Analogous preparation of compound 297
starting from intermediate 139
Example B23
Preparation of compound 188
Cyanogen bromide (0.012 g; 0.12 mmol) followed by a solution of NaH003 (0.01 g; 0.12
mmol) in water (0.6 mL) were added to a mixture of intermediate 65 (0.05 g; 0.12 mmol)
in 1,4—dioxane (1 mL) at room temperature. The reaction e was d for 5 hours
and extracted with EtOAc. The c layer was decanted, dried over MgSO4, ed
and evaporated till dryness. The residue was taken up with Et20. The precipitate was
filtered and dried, then purified by chromatography over silica gel (irregular SiOH, 15—
40um, 309; mobile phase: 0.5% NH4OH, 6% MeOH, 94% DCM). The product fractions
were collected and the solvent was evaporated to give 0.033 g of a compound which
was crystallized from Et20 and ACN. The precipitate filtered and dried to give 0.025 g
(47%) of nd 188,. M.P.: 246°C (Kofler).
Example B23a
NH~N
040% N\/
/O N
:l N\ NjLN
lj l/ N/
Preparation of compound 229
A mixture of intermediate 65 (0.55 g; 1.27 mmol) and 1,1’-carbonyldiimidazole (0.267 g;
1.65 mmol) in 1,4-dioxane (10 mL) was heated at 80°C overnight. The mixture was
poured into ice and the precipitate was filtered, washed with water and dried yielding
0.59 g (99%) of compound 229 which was used without further purification for the next
step. M.P.: 232°C (kofler)
NH~N
040% N\/
//ou.N N\\
I / ij//fl:;7N./
Analogous preparation of compound 284
starting from intermediate 106
Example B24
2012/052672
\ N/
F o
I \
/o N |N\ N\ /
/ /
Preparation of compound 239
Potassium tert—butoxyde (118 mg; 1.05 mmol) was added to a solution of intermediate 7
(0.2 g; 0.526 mmol) in THF (22 mL) at 5°C under N2 flow. The reaction mixture was
stirred for 30 minutes at 5°C and 2-bromoacetamide (109 mg; 0.789 mmol) was added
portionwise. The reaction mixture was allowed to warm to room temperature and stirred
overnight. The reaction mixture was poured into ice and extracted with EtOAc. The
organic layer was washed with brine, dried over MgSO4, filtered and the solvent was
evaporated. The residue (0.28 g) was purified by chromatography over silica gel
(spherical , 5pm, 150x30.0mm, mobile phase: nt from 0.2% NH4OH, 2%
MeOH, 98% DCM to 1.2% NH4OH, 12% MeOH, 88% DCM). The product fractions were
mixed and the solvent was evaporated. The residue was taken up by EtZO. The
precipitate was filtered and dried to give 0.114 g (48%) of compound 239 . M.P.: gum at
145°C (kofler).
Example B25
Preparation of nds 267 and 268
N/ N/
F F
I \N l \N
/O NUN\ / /0 /
\ N/ NUN\ /
F F N/
O\ 0\
compound 267 and compound 268
NaH (60 mg; 1.506 mmol) was added to a solution of intermediate 12 (300 mg; 0.753
mmol) in DMF (9 mL) at 5°C under N2 flow. The reaction was stirred at 5°C for 30
minutes. A solution of bromomethylcyclopropane (353 mg; 1.311 mmol) in DMF (1 mL)
was added over a 2 hours period and the reaction mixture was allowed to warm to room
temperature and stirred overnight. The reaction mixture was poured onto iced water and
extracted with EtOAc. The organic layer was decanted, washed with brine (twice), dried
over MgSO4, ed and evaporated to dryness. The e (410 mg) was purified by
chromatography over silica gel (irregular SiOH, 15—40 um 30 9; mobile phase: 98%
DCM, 2% MeOH). The product fractions were collected and evaporated to dryness to
give 2 fractions:
- Fraction 1: 35 mg of a compound which was crystallized from ACN/DiPE ng
29 mg of nd 267 (9%) (M.P.: 195°C, kofler)
- Fraction 2: 162 mg of a compound which was crystallized from ACN/DiPE
yielding 129 mg of compound 268 (38%) M.P.: 212°C (kofler).
Examgle 826
Preparation of compound 261
HOBT (29 mg; 0.218 mmol) then EDCli (41.7 mg; 0.218 mmol) were added n wise
at 10°C to a solution of intermediate 122 (100 mg; 0.181 mmol) in DMF (10 mL) and
Eth (51 pL; 0.363 mmol). The on mixture was stirred for 10 min. A solution of
methylamine 2M in THF (272 uL; 0.544 mmol) was added and the reaction mixture was
stirred for 15 hours. Additionnal HOBT (29 mg; 0.218 mmol), EDCl (41.7 mg; 0.218
mmol), Et3N (51 uL; 0.363 mmol) and a solution of methylamine 2M in THF (272 uL;
0.544 mmol) were added and the reaction mixture was d onal 72 hours. The
reaction mixture was poured into water and extracted with EtOAc. The organic layer was
washed with brine, dried with MgSO4, filtered and evaporated to dryness. The residue
was purified by chromatography over silica gel (irregular SiOH, 15-40um, 30g; mobile
phase: 0.5% NH4OH, 4% MeOH, 96% DCM) to give 16 mg (19%) of compound 261 .
M.P.180°C (kofler).
Example 827
a) Preparation of mixture of intermediate 123 and compound 266
NOOQS/Qo 0%Soé
ééo_NQ\ °\\S/
__N N\\O
Intermediate 123 compound 266
2—bromoethyl-methylsulfone (306 mg; 1.64 mmol) was added to a on of
ediate 26 (500 mg; 1.37 mmol) and C52C03 (667.02 mg; 2.05 mmol) in ACN (8
mL) and the reaction e was stirred at room temperature overnight. The on
mixture was poured into a 10% aqueous solution of K2C03 and extracted with EtOAc.
The organic layer was washed with brine, dried over MgSO4, filtered and evaporated to
dryness. The crude product was purified by chromatography over silica gel (irregular
SiOH, 15-45um, 249; mobile phase: 97% CH2C|2, 3% MeOH). The product fractions
were ted and evaporated to dryness leading to a 1/1 mixture of ediate 123
and compound 266 which was used without further purification in the next step.
b) Preparation of compounds 265 and 266
compound 265 compound 266
NaH (25.39 mg; 1.06 mmol) was added to a solution of a mixture of intermediate 123
and compound 266 (500 mg; 0.53 mmol) in DMF (15 mL) at 5°C under N2 flow. The
reaction mixture was stirred for 30 minutes at 5°C and a solution of oromethyl)—
N,N-dimethyl-1H—imidazoIesulfonamide (CAS 9358620) (250 mg; 1.12 mmol) in
DMF (10 mL) was added dropwise. The reaction mixture was allowed to warm to room
temperature and stirred overnight. The reaction mixture was poured into ice water and
extracted with EtOAc. The organic layer was washed with brine, dried over M9804,
filtered and evaporated to s. The residue was purified by chromatography over
silica gel (spherical silica, 5pm, 150x30.0mm; mobile phase: gradient from 0.2% NH4OH,
2% MeOH, 98% DCM to 1% NH4OH, 10% MeOH, 90% DCM). The product fractions
were collected and evaporated to s yielding 159 mg (46%) of compound 265 and
115 mg of an intermediate nd which was llized from ACN to afford 83 mg
of compound 266 (27%). M.P.: 180°C (kofler).
Example B28
Preparation of compound 275
2-bromoethylmethylsulfone (129 mg; 0.689 mmol) was added to a solution of
ediate 47 (200 mg; 0.574 mmol) and cesium carbonate (374 mg; 1.15 mmol) in
ACN (3 mL) and the reaction mixture was stirred at room temperature overnight. The
reaction mixture was poured into a 10% aqueous solution of K2C03 and extracted with
EtOAc. The organic layer was washed with brine, dried over M9804, filtered and
evaporated to dryness. The residue was ed by chromatography over silica gel
(spherical silica, 5pm, 150x30.0mm; mobile phase: gradient from 0.2% NH4OH, 2%
MeOH, 98% DCM to 1% NH4OH, 10% MeOH, 90% DCM. The t fractions were
mixed and the solvent was evaporated to dryness yielding 46 mg of an impure
compound which was purified by achiral SFC (2-ethylpyridine, 6pm, 150x21 .2mm;
mobile phase: 82% C02, 18% MeOH). The product fractions were mixed and the solvent
was evaporated to give 0.036 g (11%) of compound 275 . M.P.: 172°C (kofler).
Example B29
/OemN N\ Nj/E/UN
Preparation of compound 289 °\
A mixture of ediate 132 (0.317 g; 0.55 mmol) and a 2M solution of methylamine in
THF (10.9 mL; 21.76 mmol) was heated in a sealed tube at 70°C for 18 hours. The
WO 61080
reaction e was cooled down, poured into iced water and extracted with EtOAc.
The organic layer was washed with brine, dried over M9804, filtered and evapoprated to
dryness. The residue (0.242 g) was purified by chromatography over silica gel (irregular
SiOH, 15-40um, 24g; mobile phase: 0.5% NH4OH, 5% MeOH, 95% DCM). The product
fractions were collected and evaporated to dryness. The residue was crystallized from
ACN. The precipitate was ed and dried to give 0.049 g of compound 289 (17%).
M.P.: 92°C (gum, kofler).
Exam gle 830
Preparation of compound 301
4M HCI in 1,4—dioxane (2.27 mL; 9.08 mmol) was added dropwise to a solution of
intermediate 144 (560 mg; 0.908 mmol) in ACN. The reaction mixture was stirred at
room temperature for 2 hours, diluted with DCM and poured onto a cold 10% aqueous
solution of K2003. The organic layer was decanted, washed with water, dried over
M9804, ed and evaporated to dryness. The residue (0.629) was purified by
chromatography over silica gel (irregular SiOH, 15—40um, 40g; mobile phase: 0.5%
NH4OH, 5% MeOH, 95% DCM). The product fractions were collected and evaporated to
dryness. The resulting residue (415 mg) was purified by chromatography over silica gel
(irregular SiOH, 15-40um, 30g; mobile phase: 1% NH4OH, 92% DCM, 7% MeOH). The
product fractions were collected and evaporated to dryness. The e was taken up
with EtQO. The precipitate was filtered and dried yieiding 137 mg of (29%) of compoumd
301 M.P.: 126°C r)
C. Pregaration of the comgounds
2012/052672
Conversion 1
Preparation of compound 23
To a solution of compound 13 (350 mg; 0.62 mmol) in ACN (13 ml) was added dropwise
at 5°C, HCI (4M in Dioxane) (1.54 ml; 6.2 mmol). The reaction mixture was then heated
at 50°C for 18 hours. The reaction mixture was cooled down to room temperature and
then concentrated under reduced pressure. The on mixture was taken up with
DCM and water and was basified with an aquous solution of ammonia. The aqueous
solution was extracted and the organic layer washed with brine, dried (M9804), filtered
and concentrated under reduced pressure. The residue was purified by chromatography
over silica gel (5pm, mobile phase, gradient from 0.1% NH4OH, 99% DCM, 1% MeOH
to 1% NH4OH, 90% DCM, 10% MeOH). The desired fractionswere collected and
trated under reduced pressure. The residue was triturated in EtZO, filtered and
dried to afford 170 mg (60%) of compound 23 (MP:228°C (DSC)).
Alternatively, compound 23 was also prepared as follows :
The reaction was performed three times on the same quantities of compound 13 (7.34 g;
12.93 mmol)
HCI 4M in 1,4—dioxane (32.31 mL; 129.25 mmol) was added drop wise at 5°C to a
solution of compound 13 (7.34 g; 12.93 mmol) in ACN (250 mL). The reaction mixture
was then heated at 50°C for 6 hours and cooled down. The 3 batches were mixed; the
precipitate was filtered off and stirred in 10% aqueous K2C03 overnight. The precipitate
was again filtered off, washed with water, then ACN, ved in DCM/MeOH (9/1) and
evaporated to s. The ing residue (16.28 g) was solubilized by ing in
ACN (950 mL) and crystallized allowing the temperature to reach room temperature.
The precipitate was filtered, washed with ACN, then Et20 and dried yielding g of 9.39
(51%) of compound 23. MP. = 226°C (DSC), C23H21FN802 . 0.13 CH3CN.
The filtrate was evaporated to dryness. The residue (6.7 g) was solubilized by refluxing
in ACN (300 mL) and crystallized allowing the ature to reach room temperature.
The precipitate was filtered, washed with ACN, then EtZO and dried yielding additional
1.92 g (11%) of compound 23. MP. = 226°C (DSC), C23H21FN802 . 0.1 CH3CN
2012/052672
The filtrate was evaporated to dryness affording 4.679 of an onal fraction of
(impure) nd 23, which was purified by chromatography over silica gel (irregular
SiOH, 20—45um, 4SOg;mobile phase: 96% DCM, 4% MeOH, 0.1% NH4OH). The product
fractions were collected and evaporated to dryness ng 3.35 g of additional
compound 23 (18%) which was solubilized by refluxing in ACN (250 mL) and crystallized
allowing the temperature to reach room temperature.The precipitate was filtered,
washed with CAN, then EtZO and dried yielding 2.33 g (13%) of additional compound 23
231°C (DSC)
The filtrate was evaporated to dryness yielding 770 mg of impure compound 23.
Alternatively, compound 23 was also prepared as follows.
The experiment was performed from 2 batches of compound 13 (6.69 g; 11.78 mmol):
HCI 4M in 1,4—dioxane (30 mL; 120 mmol) was added drop wise at 5°C to a solution of
compound 13 (6.69 g; 11.78 mmol) in ACN (235 mL). The on mixture was heated
at 50°C for 6 hours. The 2 batches were combined. After cooling down, the precipitate
was filtered and stirred in a saturated solution of K2C03 10% overnight. The precipitate
was filtered, washed with water, then ACN and dissolved in DCM/MeOH (9/1). The
solvent was evaporated, and the residue was taken up in ACN, filtered, washed with
EtZO and dried. The resulting residue was dissolved in DCM/MeOH (8/2) (350 mL) and
washed twice with water. The organic layer was evaporated until crystallization. The
solid was ed and washed with ACN, then Et20 and dried to afford 8.94 g (76%) of
compound 23 (M.P.: 132°C, DSC). C23H21FN802 . 2.02H20.
The filtrate was purified by chromatography over silica gel (irregular SiOH, 15—40um,
3009; mobile phase: 0.1% NH4OH, 97% DCM, 3% MeOH). The pure fractions were
collected and evaporated to dryness yielding additional 740 mg (7%) of compound 23 .
Analogous preparation of compound 135 starting
from compound 136
W0 2013/061080
I )2 /
N N
I I \
o N N N /N
U\\ N/
Analogous preparation of compound 137 starting
from compound 138
(QHN N l
E 1 Up/ \
. /0
Analogous preparation of compound 152 starting
from compound 153
0 F K
: N N
/ \
_o F Qt: f’f/
Analogous preparation of compound 25 Na
“23 /
N N\
F N N\
/ N/
Analogous preparation of nd 27 F starting from
compound 28.
i (EN) / ”(N
O N N\ N\ /
Analogous preparation of compound 41 starting from
compound 36.
I Cl KKN N\
o N N\
/ N/Nj/E/l
Analogous preparation of compound 42 / starting from
compound 43.
HNX /
l (KN N\
o i N /N
\ Nj/EéN/
Analogous preparation of compound 65 C' N starting from
compound 66.
I (KNHN/\> N\
o N /N
\ Nj/CéN
Analogous ation of compound 73 F N starting from
nd 74.
(RNHN’\> /
Cl N\
I I
O N N
\ Nj/EflN
Cl N/
Analogous preparation of compound 98 starting from
compound 99.
HN \
| F (K? [NAN]
o N 1L/N Nji/q
Analogous preparation of compound 100 / ng
from compound 101.
I /> /
I F N N\
I N
o N N N /
LL/ \
Analogous preparation of compound 109 starting
from compound 110.
i (UNI/N/ I \
o N N N /N
MN// \
Analogeous preparation of compound 118 ng
from compound 116
\ N/
i 1 ‘
o N N N /
Mp/ \
Analogous preparation of compound 125 starting
from compound 126 .
(g3HN /
F N N\
F N
FKIN//N | NjLN
Analogous preparation of compound 175 F starting
from compound 176.
N /
i Q
o N Up/N N\j);j
ous preparation of compound 182 starting
from compound 183
F K“ Nj/KJ/ I
o N /N
\ IN/
starting. Analogous preparation of compound 190a
from compound 191
HN \
, d9
o N N NED
U/ \
\ IN/
Analogous preparation of compound 198 starting
from nd 199
HN/\>
| Kg”
0 N N N
/ \
Analogous preparation of compound 200 starting
from compound 201
(g?HN \ / N
I 1
o N /N N\ \
Analogous preparation of nd 202 starting
from compound 203
Analogous preparation of nd 209
starting from compound 210
Analogous ation of compound 211 starting
from compound 212
KGHN fi
F N N\
I /N
0 N N N
/ N/
Analogous preparation of compound 223
starting from compound 224
l (K?HN \ N‘
O N
O 11/N/N Nj/[%N
Analogous preparation of compound 240
starting from compound 241
Analogous preparation of compound 232
starting from ediate 97
Analogous preparation of compound 259
(cis) starting from compound 260
ous preparation of compound 264
starting from compound 265
N23 N
o N N N \
/ \
i \/ \
Analogous preparation of compound 273
starting from compound 274
Analogous preparation of compound 280 starting from
compound 281
Analogous ation of nd 287 starting from
compound 288
/N/NH
Analogous preparation of compound 293 starting from
compound 294
Compound 24 was prepared as follows :
To a solution of nd 14 (545 mg ; 0.99 mmol) in ACN (20 mL) was added drop
wise, at 5°C, HCI 4M in 1,4—dioxane (2.5 ml ; 9.9 mmol). The reaction mixture was
heated at 50°C for 18 hours and then concentrated under reduced pressure. The
reaction mixture was taken up with DCM, washed with 10% aqueous K2C03 and brine,
dried over M9804, filtered and trated under reduced pressure. The residue (488
mg) was purified by chromatography over silica gel (irregular SiOH, 15-40um, 309;.
Mobile phase : 0.1% NH4OH, 97% DCM, 3% MeOH). The product fractions were mixed
and concentrated affording 230 mg of an intermediate compound which was taken up in
EtZO. The precipitate was filtered, ved in DCM and water. The mixture was
basified with a 30% a solution. The aqueous layer was extracted and the
organic layer washed with brine, dried over MgSO4, filtered and concentrated under
reduced pressure to afford 121 mg of an intermediate on which was taken up in
EtZO. The precipitate was filtered to afford 108 mg (24%) of compound 24. MR: 228°C
Alternatively, compound 24 was prepared as follows :
The ment was performed from 2 batches of compound 14 (3.55 g; 6.46 mmol):
HCl 4M in 1,4-dioxane (16.1 mL; 64.6 mmol) was added drop wise at 5°C to a solution
of compound 14 (3.55 g; 6.46 mmol) in ACN (140 mL).The reaction mixture was then
heated at 50°C for 18 hours. The two reaction mixtures were combined and cooled
down to 40°C, then poured into ice water, basified with a 30% ammonia solution, stirred
at room temperature for 30 minutes and d to llize overnight. The precipitate
was filtered, washed with water, ACN and Et20, then dried under vaccum to give 3.8 g
(67%) of compound 24. MP: 246°C (DSC). The filtrate was also allowed to crystallize
overnight. The precipitate was filtered, washed with water, ACN and Et20 affording after
drying additional 1.35g (24%) of nd 24. MP: 244°C (DSC), C23H22N802.
Alternatively, compound 24 was also prepared as follows.
To a solution of compound 14 (700 mg ; 1.27 mmol) in ACN (26 mL) was added drop
wise at 5°C, HCl 4M in 1,4-dioxane (3.18 ml ; 12.7 mmol). The reaction mixture was
heated at 50°C for 4 hours and then d with DCM/MeOH (9/1). The reaction mixture
was basified at 0°C with 10% aqueous solution of K2C03. The aqueous layer was
extracted several times with a mixture of OH (9/1). The organic layers were
mixed, dried over M9804, filtered and concentrated to afford an intermediate residue
(0.7g, yellow solid) which was taken up with ACN. The precipitate was filtered, dried
yielding 0.44g (78%; yellow solid) of compound 24. MP. > 260°C (kofler).
Cz3H22N802 . 0.15H20 . 0.015 CH2Cl2 . 0.056 dioxane.
Conversion 1a
| M ”f
o N N
\upNIL“\
Preparation of compound 115 HCI
A solution of HCI 4M in oxane (0.44 mL; 1.74 mmol) was added drop wise at 5°C
to a solution of compound 117 (0.1 g; 0.18 mmol) in ACN (4 mL). The reaction mixture
was then heated at 50°C for 6 hours and cooled to room temperature. The precipitate
was filtered, washed with EtZO and dried yielding 70 mg (72%) of nd 115 . M.P.:
130°C (gum, Kofler). C23H21FN802 . 0.65H20 . 2.14HCl
Analogous preparation of compound 155
I p .1 F NjLNl ‘
o N\ N
.1.91HC1
Conversion 1b
Preparation of compound 215
Aqueous HCl SN (2 mL) was added to a solution of compound 216 (1.1 g ; 1.58 mmol) in
dioxane (10 mL) at 5°C. The reaction mixture was then heated at 100°C for 1 hour. The
reaction e was poured into ice water and basified with NaOH 3N. The product was
extracted with EtOAc, washed with brine, dried over MgSO4, filtered and trated
under reduced pressure. The residue (19) was purified by chromatography over silica
gel (15-40um, 409; mobile phase: DCM/MeOH/NH4OH: 97/3/01 to 95/5/01) The
product fractions were collected and evaporated to s to give 0.587 g (77%) of an
intermediate compound which was crystallized from EtZO. The precipitate was filtered
and dried to give 0.5179 (67%) of compound 215 . M.P.: gum at 140°C (kofler).
| CL
o 0.
Analogous preparation of nd 291 starting
from compound 292
9.NH\ NH2
/\(f
o\érNUTEN N \
/ N/
Analogous preparation of compound 295
starting from compound 296
Conversion 2
/O \ O\
\ N 1
1 / N
/ / \N—
\\ N N N \
O \ \
\ l
/ /
Preparation of nd 26, N
A solution of compound 22 (422 mg; 1.05 mmol), 2-bromo—3-methoxypyridine (180 mg;
0.95 mmol) and triethylamine (1.6 ml; 11.5 mmol) in DMSO (10 ml) was degassed under
N2 for 10 minutes. Then, dichlorobi(triphenylphosphine)palladium (ll) (135 mg ; 0.19
mmol) and copper(l) iodide (18.3 mg; 0.09 mmol) were added and the reaction mixture
was stirred at 90°C for 40 minutes. The reaction mixture was cooled down to room
temperature and poured out onto ice water and EtOAc and filtered through a pad of
Celite®. The s layer was extracted with EtOAc and the organic layer was washed
with brine, dried (M9804), filtered and concentrated under reduced pressure. The
residue was purified by chromatography over silica gel (5pm, mobile phase, gradient
100% DCM to 0.5% NH4OH, 95% DCM, 5% MeOH). The desired t fractions were
collected, concentrated under reduced pression to provide 116mg (24%) ofcompound
26. This comound eptane was ated in EtZO, the precipitate was filtered and dried
to afford 52.6 mg of nd 26 (MP:190°C).
Conversion 3
(QHN /
F N N\
H0 N N
/ \
\ N/Nj/[yN
and compound 96
The reaction was performed twice on the same quantity of compound 23 (1 g; 2.17
mmol) and the batches were mixed for the purification.
A solution of 1M BBr3 in DCM (11.94 mL; 11.94 mmol )was added dropwise to a
solution of compound 23 (1 g; 2.17 mmol) in DCM (55 mL) at 5°C under N2 flow. The
solution was allowed to warm to room temperature and stirred for 1h30. The reaction
mixture was diluted with DCM, an aqueous solution of NaOH 30% was added until basic
pH and the reaction mixture was evaporated to dryness. The crude products coming
from the 2 batches were mixed and the resulting residue was ed by
chromatography over silica gel (Irregular SiOH, 20—45pm, 450g; mobile phase: gradient
from 0.5% NH4OH, 97% DCM, 3% MeOH to 0.5% NH4OH, 93% DCM, 7% MeOH). The
product fractions were collected and evaporated to dryness yielding 2 fractions:
Fraction 1: 310 mg of a compound which was taken up in ACN. The precipitate
was filtered, washed with EtQO and dried. The resulting solid (274 mg) was
refluxed in 15 mL of ACN and 1.5 mL of MeOH. The solution was cooled down.
The precipitate was filtered, washed with ACN then EtZO and dried to afford 274
mg (13%) of nd 95 . M.P.: 218°C (DSC).
Fraction 2: 105 mg of a compound which was taken up in ACN. The precipitate
was filtered, washed with Ego and dried yielding 86 mg (4%) of nd 96 .
M.P.: 192°C (gum, Kofler).
H /
F ”\
o N N
\ NYE/V
F N/
Analogous preparation of compound 122 CH
starting from compound 3
sion 3a
Preparation of compound 103 0”
A solution of 1M BBr3 in DCM (8.70 mL; 8.70 mmol) was added drop wise to a solution
of compound 24 (700 mg; 1.58 mmol) in DCM (40 mL) at 5°C under N2 flow. The
solution was allowed to slowly warm to room temperature and stirred for 1h30. The
reaction e was diluted with DCM. A 30% aqueous solution of NaOH was added
until basic pH and the reaction mixture was evaporated to dryness. The crude product
(10 g) was purified by tography over silica gel (Dry loading (70-200pm, 209)
irregular SiOH, 15-45um, 709; mobile phase: 97% DCM, 3% MeOH). The fractions were
collected and evaporated to dryness. The impure residue (240 mg) was purified by
achiral SFC (2—ETHYLPYRIDINE, 6pm, 150x21.2mm; mobile phase: 80% C02, 20%
MeOH). The product fractions were collected and evaporated to dryness. The residue
(102 mg) was llized from ACN. The precipitate was filtered, washed with EtZO and
dried yielding 86 mg (13%) of compound 103 . M.P.: 172°C (gum, Kofler).
Conversion 4
Preparation of compounds 162 and 163
2012/052672
HNLo oQNLo
H N/ K N/
F NJLN\ o F
(I) I /N\
N N N N N
\ \
F N/ F N/
compound 162 and compound 163
Sodium triacetoxyborohydride (0.204 g; 0.96 mmol) and acetic acid (0.015 mL; 0.25
mmol) were added to a solution of compound 67 (0.265 g; 0.6 mmol) and 3-oxetanone
(0.036 mL; 0.6 mmol) in 1,2-dichloroethane (10 mL) at 5°C under N2 flow. The reaction
mixture was stirred at 60°C overnight, poured into ice water, basified with a 10%
aqueous solution of K2CO3 and extracted with DCM. The c layer was dried over
M9804, filtered and evaporated to dryness. The residue (268 mg) was purified by
chromatography over silica gel (Spherical Silic,a 5pm, 150x30.0mm; mobile phase:
gradient from 0.2% NH4OH, 98% DCM, 2% MeOH to 1.2% NH4OH, 88% DCM, 12%
MeOH). The product ons were collected and the t was evaporated to give 2
fractions:
- Fraction 1: 0.033 g of a compound which was crystallized from Et20 to give 51
mg (17%) of compound 162 (M.P.: 183°C, DSC)
- Fraction 2: 0.068 g of a compound which was crystallized from EtZO to give 20
mg (6%) of compound 163 . M.P.: 182°C (DSC).
H /
l N
F N/
. /0
Analogous preparation of nd 221
OQN/C/O
H /
l N
F N/
/o .
and compound 222 starting from
compound 168
sion 43
Preparation of compound 164
Sodium triacetoxyborohydride (0.144 g; 0.68 mmol) and acetic acid (0.011 mL; 0.18
mmol) were added to a solution of nd 68 (0.187 g; 0.43 mmol) and 3-oxetanone
(0.026 mL; 0.43 mmol) in 1,2-dichloroethane (7 mL) at 5°C under N2 flow. The reaction
mixture was stirred at 60°C overnight, poured into ice water, basified with a 10%
aqueous solution of K2003 and extracted with DCM. The organic layer was dried over
MgSO4, filtered and evaporated to dryness. The residue (0.154 g) was purified by
chromatography over silica gel (Spherical Silica, 5pm, 150x30.0mm; mobile phase:
gradient from 0.2% NH4OH, 98% DCM, 2% MeOH to 1% NH4OH, 90% DCM, 10%
MeOH). The product fractions were collected and the solvent was evaporated to give
0.032 g of a compound which was crystallized from EtZO. The precipitate was filtered
and dried to give 0.016 g (7%) of compound 164 . M.P.: 218°C (DSC).
sion 4b
0&NH
H N/
/O N
UKN\
NjLUN
Preparation of compound 290
A solution of compound 236 (280 mg; 0.69 mmol), 3-oxetanone (62 uL; 1.04 mmol) and
AcOH (22 uL; 0.38 mmol) in 1,2-dichloroethane (26 mL) was heated at 50°C for 24
hours. The on mixture was cooled to room temperature and sodium
triacetoxyborohydride (220 mg; 1.04 mmol) was added. The reaction mixture was
heated at 60°C for 2 hours. The reaction mixture was ioned between a 10%
aqueous solution of K2C03 and DCM. The aqueous layer was extracted once with DCM.
The combined organic layers were dried over M9804, filtered and evaporated to
s. The residue was purified by chromatography over silica gel ical silica,
5pm, 150x30.0mm; mobile phase: gradient from 70% heptanes, 2% MeOH (+10%
NH4OH), 28% EtOAc to 0% eptanes, 20% MeOH (+10% NH4OH), 80% EtOAc). The
product fractions were evaporated to dryness to afford 34 mg (21%) of compound 290
M.P.: gum at 66°C (kofler).
Conversion 5
HNJR
l \N
O N /
UK/ / N
Preparation of compound 235
Acetylchloride (24 uL; 0.33 mmol) was added to a solution of compound 236 (122 mg;
0.3 mmol) and Et3N (64 uL; 0.45 mmol) in DCM (5 mL) under N2 at 5°C. The reaction
e was stirred at 10°C for 3 hours, poured into cooled water and extracted with
DCM. The organic layer was dried over M9804, filtered and evaporated to dryness. The
residue (0.13 g) was purified by chromatography over silica gel (irregular SiOH, 15-
40um, 129; mobile phase: 97% DCM, 3% MEOH). The product fractions were collected
and evaporated to dryness. The residue (0.1 g) was crystallized from Et20. The yellow
WO 61080
precipitate was filtered and dried under vaccum to give 87 mg (65%) of compound 235 .
M.P.: 193°C (DSC).
(I) HN
/N Nj/[fl‘
Analogous preparation of compound 242
starting from compound 168
)kNH
H /
F N\
(I) N N N [/N
U\/\ N
Analogous ation of compound 243
starting from compound 167
sion 6
/ NH
N=S N
l \N
/oml:N |N\ / Nj/CyN/
Preparation of compound 104
Trifluoroacetic acid (0.49 mL; 6.56 mmol) was added to a solution of compound 105
(0.085 g; 0.14 mmol) in DCM (7 mL) at room temperature. The mixture was stirred at
room temperature for 2 hours. The solution was poured into iced water, basified by
NH4OH and extracted with DCM. The organic layer was dried over MgSO4, filtered and
evaporated till dryness. The residue (70 mg) was purified by chromatography over silica
gel (stability Silica 5pm 150x30.0mm, mobile phase: gradient from 0.2% NH4OH, 98%
DCM, 2% MeOH to 1.3% NH4OH, 87% DCM, 13% MeOH). The product ons were
collected and evaporated to dryness. The residue (46 mg) was crystallized from EtQO.
The precipitate was filtered and dried to give 0.027 g of compound 104 (36%). MR:
gum at 60°C (Kofler).
(QHN \ l
I N
/o N N\ N\ /
E 1 Up
Analogous preparation of compound 227
starting from compound 228
F #0 N\
I N
/o N / UpN\ N\
Analogous preparation of compound 262
starting from compound 263
95$Rs /N
/0KmN /N \N—<>NHI
Analogous preparation of compound 299 starting
from compound 300
sion 7
I H [N\
o N N
/ [\
F\ Nj/QN/
Preparation of compound 106 .2HC1
At 5°C, a solution of HCI 5/6N in iPrOH (0.88 mL; 4.36 mmol) was added to a solution of
compound 108 (0.38 g; 0.73 mmol) in MeOH (6 mL). The reaction mixture was stirred at
room temperature for 6 hours. The reaction e was concentrated, then the residue
was taken—up with EtZO. The precipitate was filtered and dried under vacuum to give
0.348 g (92%) of compound 106 . 2HCl . 0.39H20
. M.P.: 250°C (DSC). C21H21F2N702
Analogous preparation of compound 121 starting fromcompound 107
l H [N\
o N N N /N
FU\ N/
/ I
Conversion 8
Preparation of compound 230
Compound 231 (0.19; 0.228 mmol), 1~(3—dimethylaminopropyl)—3—ethylcarbodiimide
hydrochloride (0.053 g; 0.342 mmol), DMAP (0.003 g; 0.023 mmol), Et3N (0.082 mL;
0.57 mmol) and lamine (0.028 mL; 0.456 mmol) were mixed in DCM. The
resulting red suspension was stirred overnight at room temperature. The reaction
mixture was d with DCM. The c layer was successivelly washed with a 3N
aqueous solution of HCI then, a saturated aqueous of NaHC03, dried over M9804,
filtered and evaporated to dryness. The residue (0.06 g) was purified by chromatography
over silica gel (irregular SiOH, 15-45um, 129; mobile phase: nt from 97% DCM,
3% MeOH, 0.3% NH4OH to 90% DCM, 10% MeOH, 1% NH4OH). The product fractions
were collected and evaporated to dryness yielding 6.6 mg (6%) of compound 230 M.P.:
258°C (Kofler).
/LNH
F \o N\
I /N
o N N N
/ \ \
/ /
Analogous preparation of compound 249
starting from compound 231
/o N N\ N\ /
/ N/
Analogous preparation of compound 263
starting from compound 231
ConversionQ
F (go N\
I N
/o N N\ N\ /
/ N/
Preparation of compound 231
m hydroxyde monohydrate (56 mg; 2.34 mmol) was added to a solution of
compound 214 (0.2129; 0.47 mmol) in a mixture of THF (5 mL) and water (2 mL). The
reaction mixture was stirred overnight at room temperature and neutralized with an
aqueous solution of HCI 3N. The reaction e was nned between water and
EtOAc. The organic layer was dried over M9804, filtered and evaporated to dryness.
The residue was taken up with ACN to afford 0.188 g (91%) of compound 231 >
. M.P.:
260°C (Kofler).
Conversion 1O
2012/052672
F OH N\
l ] N
o N N N /
/ \
\ N/
Preparation of compound 244
Sodium borohydride (60 mg; 1.577 mmol) was added to a suspension of compound 225
(660 mg; 1.314 mmol) in MeOH (30 mL) at room ature. The reaction mixture was
stirred at this temperature for 2 hours, quenched with iced water and extracted with
DCM. The organic layer was decanted, dried over M9804, ed and evaporated to
dryness. The residue was purified by chromatography over silica gel (irregular SiOH, 15—
40pm, 249; mobile phase: gradient from 100% DCM, 0% MeOH to 95% DCM, 5%
MeOH). The product ons were collected and evaporated to dryness. The resulting
residue (0.1 g) was purified by chromatography over silica gel (spherical silica, 5pm,
150x30.0mm; mobile phase: gradient from 0.2% NH4OH, 98% DCM, 2% MeOH to 1.2%
NH4OH, 88% DCM, 12% MeOH). The product fractions were collected and evaporated
to dryness. The e was taken up with EtZO. The precipitate was filtered and dried
ng 59 mg (9%) of compound 244 . M.P.: gum at 101°C (Kofler).
Conversion 11
//\NH,< J}
O N/
OH \
/o N
(L N\ Nj/DN
Preparation of compound 282
(Benzotriazolyloxy)tris(dimethylamino)phosphonium hexafluorophosphate (454 mg;
1.03 mmol) was added at room temperature to a e of compound 229 (0.383 g;
0.789 mmol), ethanolamine (0.115 mL; 1.58 mmol) and DlPEA (0.261 mL; 1.58 mmol) in
THF (8 mL). The mixture was stirre overnight, poured into ice and extracted with EtOAc.
The organic layer was washed with brine, dried over M9804, filtered and the solvent
was evaporated. The residue (0.36 g) was purified by chromatography over silica gel
(spherical silica, 5pm, 150x30.0mm; mobile phase: gradient from 0.2% NH4OH, 2%
MeOH, 98% DCM to 1.2% NH4OH, 12% MeOH, 88% DCM). The product fractions were
mixed and the solvent was evaporated. The residue was taken up by EtZO. The
precipitate was filtered and dried yielding 0.111 g (28%) of compound 282 (28%). M.P.:
104°C (gum, kofler).
F N
Analogous ation of compound 283
starting from compound 284
Conversion 12
1 /°/
R /
F "\
l I /N
O N N N
/ \
\ N/
ation of compound 194
NaH (59 mg; 1.476 mmol) was added portion wise to a solution of compound 53 (470
mg; 0.984 mmol) in DMF (10 mL) at 5°C under N2 flow. The reaction mixture was stirred
at 5°C for 30 s, then (2-bromoethoxy)—tert-butyldimethylsilane (232 uL; 1.08
mmol) was added dropwise. The reaction mixture was stirred at room temperature
overnight, quenched with iced water and extracted with EtOAc. The organic layer was
decanted, dried over M9804, filtered and evaporated to dryness.
A 1M solution of tetrabutylammonium fluoride in THF (4.45 mL; 4.45 mmol) was added
to a solution of the residue obtained previously in THF (27 mL). The reaction mixture
was stirred at room temperature overnight, poured into ice and extracted with EtOAc.
The organic layer was washed with brine, dried over MgSO4, filtered and the solvent
was ated. The residue was purified by chromatography over silica gel (irregular
SiOH, m, 30g; mobile phase: 0.1% NH4OH, 4% MeOH, 96% DCM). The product
WO 61080
fractions were collected and the solvent was evaporated to give 130 mg (26%) of
compound 194, . M.P.: 102°C (gum, Kofler).
Conversion 13
/ at.
Salt Preparation of nd 23W
a) Preparation of sulfate salt of compound 23
A solution of concentrated sulfuric acid (24 uL; 0.434 mmol) in ethanol (3.5 mL) was
added slowly to a solution of free base of compound 23 (100 mg; 0.217 mmol) in C (6.5
mL) at 50°C and the resulting solution was d to cool to room temperature and
stirred overnight. The solution was evaporated to dryness and the e was
crystallized in an ice bath from ACN (2 mL). The precipitate was filtered, washed with
EtZO and dried yielding 69 mg (47%) of compound 23 as a sulfate salt, M.P.: 198°C
(gum, Kofler). C23H21FN802 . 2HZSO4 . 1H20 . 0.06 EtZO . 0.03 DMF.
b) ation of hydrochloric acid salt of compound 23
A pre-cooled solution of concentrated hydrochloride acid (36 uL; 0.434 mmol) in EtOH
(3.5 mL) was added slowly to a solution of free base of compound 23 (100 mg; 0.217
mmol) in ACN (6.5 mL) at 50°C and the resulting solution was allowed to cool to room
temperature and stirred overnight. The solution was evaporated to dryness and the
e was taken up with ACN (2 mL). The precipitate was filtered, washed with EtZO
and dried yielding 92 mg (78%) of compound 23 as a hydrochloric acid salt,. M.P.:
216°C (DSC). cngmFNgog. 1.76HCl . H20
0) Preparation of phosphate salt of compound 23
A pre-cooled on of 17M phosphoric acid (26 uL; 0.434 mmol) in EtOH (3.5 mL) was
added slowly to a on of free base of compound 23 (100 mg; 0.217 mmol) in ACN
(6.5 mL) at 50°C and the resulting solution was allowed to cool to room temperature and
stirred overnight. The precipitate was filtered, washed with ACN then EtZO and dried
yielding 78 mg (51%) of compound 23 as a phosphate salt, . M.P.: 175°C (gum, Kofler).
Cz3H21FN302 . 2.5H3PO4
d) Preparation of lactate salt of compound 23
A pre-cooled on of 85% lactic acid (CAS 505) (41 uL; 0.434 mmol) in EtOH
(3.5 mL) was added slowly to a solution of free base of compound 23 (100 mg; 0.217
mmol) in ACN (6.5 mL) at 50°C and the resulting solution was allowed to cool to room
temperature and stirred overnight. The solution was ated to dryness and the
residue was taken up with ACN (2 mL). The itate was ed, washed with EtZO
and dried yielding 74 mg (60%) of compound 23 as a lactate salt, M.P.: 118°C (DSC).
023H21FN802. C3H603 . H20.
e) ation of te salt of compound 23
A oled on of fumaric acid (50 mg; 0.434 mmol) in EtOH (3.5 mL) was added
slowly to a solution of free base of compound 23 (100 mg; 0.217 mmol) in ACN (6.5 mL)
at 50°C and the resulting solution was allowed to cool to room temperature and stirred
overnight. The precipitate was filtered, washed with ACN then EtZO and dried yielding 70
mg (60%) of compound 23 as a fumarate salt, . M.P.:186°C (DSC). C23H21FN802 .
0.5C4H4O4 . H20.
Salt Preparation of compound 24
f) Preparation of sulphate salt of compound 24
Free base of compound 24 (150 mg; 0.339 mmol) was diluted in a mixture of EtOH (10
mL) and ACN (5 mL) and the reaction mixture was refluxed until dissolution. The
solution was cooled down to 10°C, then a solution of concentrated sulfuric acid (36 ul;
0.68 mmol) in EtOH (150 pl) was added and the reaction mixture was allowed to stand
overnight. The precipitate was filtered, washed with EtZO and dried under vaccum and to
give 155 mg (81%) of compound 24 as a sulphate salt. M.P.: 266°C (DSC). C23H22N302
. 1.03HZSO4. 1.17H20
g) Preparation of phosphate salt of compound 24
Free base of compound 24 (150 mg; 0.339 mmol) was d in EtOH (10 mL) and the
reaction mixture was refluxed until dissolution. The solution was cooled down to 10°C,
then a solution of phosphoric acid 85% (47pl; 0.68 mmol) in EtOH (0.5 mL) was added
and the mixture was allowed to stand for 4 days. The precipitate was ed, washed
with EtZO and dried under vaccum to give 133 mg (71%) of compound 24 as a
phosphate salt. M.P.: 253°C (DSC). C23H22N802 . 1.13H3PO4 . 0.06 Et20
h) Preparation of DL- tartrate salt of compound 24
Free base of compound 24 (150 mg; 0.339 mmol) was diluted in EtOH (10 mL) and the
reaction mixture was refluxed until dissolution and the solution was cooled down to
°C. A solution of DL-tartric acid (102 mg; 0.678 mmol) in EtOH (5 mL) at 50°C was
added to the previous solution and the reaction mixture was allowed to stand for 4 days.
The precipitate was filtered, washed with EtQO, dried under vaccum and to give 163 mg
(70%) of compound 24 as a DL- tartrate salt M.P.: 176°C (Kofler). C23H22N802 .
1.4C4H606 . 1.8HZO
i) Preparation of fumarate salt of compound 24
Free base of compound 24 (150 mg; 0.339 mmol) was diluted in EtOH (10 mL) and the
reaction mixture was refluxed until dissolution and the solution was cooled down to
°C. A on of fumaric acid (78.7 mg; 0.678 mmol) in EtOH (5 mL) at 50°C was
added to the previous solution and the reaction mixture was allowed to stand for 4 days.
The precipitate was filtered, washed with EtZO, dried under vaccum and to give 114 mg
(61%) of compound 24 as a fumarate salt. M.P.: 222°C (DSC). C23H22N802. 0.9C4H4O4 .
0.25HZO
j) Preparation of hydrochloric acid salt of compound 24
A 4M solution of hloride acid in oxane (4.6 mL; 18.195 mmol) was added
se to a cooled solution of compound 14 (1 g; 1.819 mmol) in ACN (36 mL). The
reaction mixture was heated at 50°C for 18 hours and cooled to room temperature. The
precipitate was filtered, washed with EtZO and dried yielding 570 mg (65%) of nd
24 as a hydrochloride sait 100 mg of the residue was recrystallized from MeOH (4 mL).
The solid was filtered and dried under vaccum yielding 68 mg of compound 24 as a
hYdrOChloride salt. M..P> 260°C (K) C23H22N802 . I . 0.86H20.
The following compounds were prepared ing to reaction protocols of one of the
above Examples using alternative starting materials as appropriate.
In the table =CoX (or =BX) indicates that the preparation of this compound is bed
in Conversion X (or Method BX).
In the table ~CoX (or ~BX) indicates that this compound is prepared according to
Conversion X (or Method BX).
As understood by a person skilled in the art, compounds synthesised using the protocols
as ted may exist as a e e.g. hydrate, and/or contain residual solvent or minor
impurities. Compounds isolated as a salt form, may be integer stoichiometric i.e. mono—
or di-salts, or of intermediate stoichiometry.
Table A1: compounds and physico-chemical data
MP MP HPLC MS LC/GC/
Comp
Compound Struct. Method (°C) (°C) Rt M+ (H+) MS
(min) Method
Kofler DSC
23 QQfl =C1 228°C 2.3 461 1
//0RS
“KI/Q/N\N7 /° N
7 |“\ =B4 65°C 2.5 451 1
/ N/
/ N"(/N
9 =85 227°C 2.5 473 1
MP MP LC/GC/
0321p nd Struct. Method (°C) (°C) MS
(min) Method
Kofler DSC
o F g
16 N =86 208°C
/ \
—o F /
— \ /'|“
/LNH
o N N N ’2” =33 183°C
/ \ \
1/ /
F N
0\ #;
/ /N
o F
QN 218°
~85
/ \
70 F /
— \ /“|‘
/ a”
o NZg
2%?" 2.35 443 1
/ \
_O N /
_ \ / T
/ N\ N
o F
~C1 248°C 2.3 479 1
W0 2013/061080 2012/052672
MP MP HPLC MS LC/GC/
Com p
Compound Struct. Method (°C) (°C) Rt m+(H+) MS
(mm). Method
Kofler DSC
/O O\
1 /N /N 1900
26 s =C2 2.75 508 1
N N \N~
’N C
/’ N/
/ OH
0 F g
QN ~86 220°C 2.35 443 1
NJ’CN
g /
1 /O ; N N =B1 2.31 448 1
\ \
/ NJLN
g /N
(I) N N N \N~
21 \ \ ~B6 2.43 407 1
/ N/
19 ON NM ~86 157°C 2.71 421 1
_ /
0 g
18 ON ~86 169°C 2.54 421 1
. N
_.O \ N /
_ NfCN/ h“
F F
Hg /N
8 /o N N\ Nj/QN— ~B4 186°C 2.89 475 1
Q 1/ N.
WO 61080
HPLC MS LC/GC/
Compound Struct. Rt M+ (H+) MS
(min) Method
2.54 455 1
2.61 457 1
2.31 466 1
2.39 484 1
2.27 456 1
2.15 456 1
W0 2013/061080
MP MP HPLC MS LC/GC/
Comp
Compound . Method (°c) (0c) Rt m+ (14*) MS
(mm). Method
Kofler DSC
/ NH
0 F §
3a N =32 159°C
/ ”\
—° F /
_ HT
0 /
/ \é/N
/ (\N/u \
0 Ni O
13 N ~B5
/ \
22 o F WT/
J o
o//S\N/\> /
\u " 1
14 (I) NW: 1;” ~35 215 2.81 550
Q N\
/ N/
0 /
(\N’\\§\’N\
—O F N7 0
GM ~85
/ \
O\ F /
m N\ /’.“
é N
/ \NM
| /
0 N N\ N\ \
22 U | :87
/ /
“p /
N N\
F N N N I/” 1
27 U 1\ \ 130 2.38 419
/ /
F i
WO 61080
LC/GC/
Compound Struct. Method MS
Method
WO 61080
MP MP HPLC MS LC/GC/
ComNop
Compound Struct. Method (00) (0C) Rt M+(H+) MS
' (min) Method
Kofler D80
33 F
F F
Rors N/
N /\N 1
‘N\ \ 208 2.87 475
_J___
or /
I “\N 1
|”\ Nj/Q 208 2.87 475
/ N/
(Q ~/
cu N l/\N
N\ N\ / 1
| TL 245 2.37 477
/ /
I \u 1
N N\ N\ / 190 2.32 478
/ N/
53 //°
“(Q N/
I I \N 1
o N\ N N\ / 176 2.53 478
50 (I)
F OH
cl) RF]: ’9" 162- 1
N 2.42 487
N\ N\ 163
F N/
51 (I,
\ 1
180 2.66 487
MP MP LC/GC/
nd Struct. Method (OC) (°C)
Method
Kofler DSC
1 ——‘
127 2.53 478
128 2.29 496
181 2.52 496
MP MP HPLC MS LC/GC/
ComNop
Compound Struct. Method (°C) (°C) Rt M+(H+) MS
' (min) Method
Kofler DSC L
44 M
a I
F I \N 1
80 2.23 396
F N;
59 I
sag I
('3 1
N N 94-95 2.45 469
/ N/Nj/IQN
58 |
“'21 I
('J 1
N 94-95 2.45 469
N\ Nj/DN
/ N/
56 °b
I N/ 99 1
I F W IN 2.43 524
o N N\ N\ / (gum)
I IN/
55 ‘b
g "I 1
I F j/E 227 2.67 524
c N\ N N\ /
FmN/
54 //°
R N/
('3 125 1
N N I)”
N\ 2.36 460
U \ I (gum)
/ N/
86 v“
Kw /
(I) F
N I: N I)" 1
\ \ 155 2.24 462
/ N/
LC/GC/
nd Struct. Method MS
Method
WO 61080
MP MP HPLC MS LC/GC/
ComNop
Compound Struct. Method (°C) (°C) Rt M+(H+) MS
' (min) Method
Kofler D80
77 Y
(I) F g 1
96-97 2.95 497
N N E” I}.
81 HN/
/ T
l 0' NH N N ’>“ 80°C 1
\ \ 2.25 488
I |
/ / gum
Cl ‘N/
82 HN/
j) “' NH 1}" 100°
N N 1
“LI\ C 2.38 488
CI N/ gum
80 “Q 150°
Kg "/ C’
F N
(I) ’/"\ 1
N N\ N\ >230o 2.59 511
I l
/ / N/ polym
/o orph
75 Y
fl 1/ 148 1
(I) 1/1 2.71 497
(N /N\ N\ 149
/ N/
73 1—.-
(QHN N/
<1: 0'
UN N N I)"
|\ \
F N/
72 “/9
(K "/
1 I \N
o N N\ N\ / >260
Q1/ N
2012/052672
MP MP HPLC MS LC/GC/
ComNop
Compound Struct. Method (°C) (°C) Rt M+(H+) MS
' (min) Method
Kofler DSC
234 2.27 444
130 2.12
138 2.30 442
169 2.06 442
68 N/
C!) F HNHQ
N N
FumAll/[2" 198 2.17 442
(I) 0' (k;HN/\>
fig1 2.37 481
/ N/NYC"
61 Y
176 2.67 515
MP MP HPLC MS LC/GC/
ComNop
Compound . Method (°C) (°C) Rt M+(H+) MS
' (min) Method
Kofler DSC
78 Y j
RWKSE /
143 1
i Nj/E/l)” 2.71 497
N N\ 144
/ N/
79 Y
Sz’nj: N/ 1
(I) I /\” 142 2.71 497
N N\ N\
/ N/
__1__
87 //°
W N/ a
J) 1
N\ N Nj/L’?“ 160 2.65 528
88 ;
s N/
' 1
N |N\ Nj/L’)" 112% 2.42 528
c1 N/
89 /°
N/
(IfI I \N 1
N N\ / 183 2.74 498
CUN/
92 //°
R N/
I I \N 1
o N\ N N\ / 2.74 498
(1.119
95 HN/\> /
| ‘ Kk" I "\N
O N N\ N\ /
I 230 2.07 447 1
/ N/
2012/052672
MP MP HPLC MS LC/GC/
ComNop
Compound Struct. (°C) (°C) Rt M+(H+) MS
' (min) Method
Kofler DSC
97 7
R N/
J) \
N ’/"
N\ N\ 150 2.42 528 1
ct N/
98 HN/Q> /
I °‘ (H ("\N
O N N\ N\ /
‘ 210 2.40 511 1
/ /
C! N
100 @
wo 2013/061080
MP MP HPLC MS LC/GC/
ComNop
Compound . Method (°C) (°C) Rt M+(H+) MS
' (min) Method
Kofler DSC
112 4°
o /
1 (k/ MN
0 N N N\ /
UM 207 2.54 480 1
113 p /
([3 F\ N N\/N\ £2“
1/ 1/ j 212 2.48 475 1
114 N46 k
1 . HQ ["1
o N N N\ /
U/ 222 2.73 475 1
115 v“
N .1 F
(I) N N N I)" 130
U\ 2.61 461 1
\ (gum)
118 v“
M ./
| f 1x
0 N /“ INTL
220 2.43 461 1
\ N/
119 °
(I) F 226 2.68 506 1
N NJN3/131./
120 0
(f /
| F 80’
2.45 506 1
o N N\ N\ / gum
/ N/j/CN
W0 61080
fi—___
MP MP HPLC MS LC/GC/
Comp
Compound Struct. Method Rt MS
N0 (°C) (°C) M+(H*)
Method
Kofler DSC [(min)
121 HN/
I F
N f N :31
U\ 239 2.13 442 1
F N/
122 HN/
I F H IN\N
° N 2* “K ’ 80
'N/ 187' 442 1
\ gum
123 °
Raw/{O /
I My IN‘N
o N N N\ / 215 2.54 480 1
124 /0
RHN o /
I (b INN
o N /~ ~\ / 197 2.33 480 1
\ N/
125 :"m /
F N\
I I
o N /N N\ /N
I 202 2.33 461 1
\ N/
128 /
I /
I F (K) I"‘
o N /N Nj/QN 194 2.50 475 1
\ IN/
129 “(EU /
I °
I "\N
0 / UN /N N\
l 137 2.95 461 1
\ /
2012/052672
MP MP HPLC MS LC/GC/
0fimp
Compound Struct. Method (°C) (°C) Rt M+(H+) M3
(min) Method
Kofler DSC
131 \
F £3N 7
1 I 1.
° N /" “K / 235 2.33 475 1
\ IN/
132 \
(I) F 9
N N N [/\N
/ \ 235 2.14 476 1
\ N/
133 0
| J 230 2.71 488 1
O N\ N N\TC”/
[ 3 UN/
134 °
J 7
| 142 2.50 488 1
O / QN /N N\
\ ,/IL“
135 (”13‘ /
N N\ W
(I) I /N
N N N
/ \
1 145 130 2.34 475 1
\ /
137 H
KU‘ /
F N
I IN‘/N
/” 185-
\ 2.27 475 1
I 185
RSp /
(I) I
N N N :'\N
/ \ 94 2.88 479 1
\ /
MP MP HPLC MS LC/GC/
Comp
Compound Struct. Method
No (’0) (°C) Rt M+(H+) MS
' (min) Method
Kofler DSC
140 ”,1
| (MN I"{
o N N N /N 149
/ IND/L\ 1.90 463 1
\ (gum)
141 (Q.m (L N N I/“
/ N\
I 285 2.21 429 1
\ N/
142 (Q0 /
UN /N | 150
\ yN
2.53 433 1
(gum)
143 (Q0 /
(I) F
N I)”
N\11/N\
174 2.75 451 1
144 (Q0 /
F “\
A N /N N\ I/N
\ IN/ 213 2.48 451 1
145 ”OZ
2, F (k3 TC“N3
fij \ .N/
146 °
,2 /
0N /N \ Nj/[yN
MP MP HPLC MS LC/GC/
ComNop
Compound . Method (°C) (°C) Rt M+(H+) MS
' (min) Method
Kofler DSC
147 0
~\ 162
(I) NH ”TEN 2.78 476 1
Q(IN\ (gum)
148 0
F ~\ 190
A NH Nj/lL/N 2.76 494 1
~\ (gum)
149 °
F NH/N INj/DN“\ 156
A 2.48 494 1
(gum)
\ /
150 ("Xe
(L NH UN 200 202 2.63 474 1
1Q 11N\ N\
151 Q80
(L NH N Nj/L‘N 106 113 2.41 474 1
Q/ w \ /
152 ""3
| I/LN
0ON /N N\
I 252 2.82 439 1
\ /
154 “(C0) /
(I) N N
FuN/\ 1\raj/L5" 226 2.87 483 1
[MP MP HPLC MS LC/GC/
Comp
Compound Struct. Method Rt MS
No (°C) (°C) M+(H+)
' (min) Method
Kofler DSC
155 H
° I 1. 160 2.62 461 1
\ N/
156 C540
I F H I "‘N
o N / 211 207 2.61 492 1
N\ElfN\
157 CK)
I H I ”\N
o N / 222 224 2.38
/N N\ 492 1
\ IN/
158 o
F N‘
I 1
o N N
UN/N\
/N 199 2.62 492 1
/° J_
159 o
S /
F N‘
I I
o N /N N\ /N 120 2.32 492 1
\ N/
160 o 198 2.62 492 1
F N‘
I I
o N N N\ /N
161 110 2.32 492 1
\ /o
RN /
F ”\
o N [/N
/N N\
\ N/
2012/052672
MP MP HPLC MS LC/GC/
ComNop
Compound Struct. Method (°c) (°c) Rt M+(H+) M3
' (min) Method
Kofler DSC
162 0 183 2.26 k HN/C/ 498 1
F N\
(I) NH/N
\ Nj/LN
F N/
163 0ANL0 182 2.39 554 1
F N\
(I) NKf/N
\ Nj/Ey"
F N/
164 (11 Lo 218 2.66 554 1
6” ~/
(I) F \
N\ N
l NjLN
165 155 3.11 461 1
(I) N\ N
Q 12%NjLN
166 158 2.79 461 1
0 N/
(I) (O
[: N /N
\ IN/Nj/E/UN
167 2% 169 2.19 424 1
F Nj/DNN\ (I) N\ N
168 NH: 170 2.08 424 1
F N\
WO 61080
LC/GC/
M+ (H+) MS
Method
WO 61080
_.T______
MP MP HPLC MS LC/GC/
Com9
Compound Struct. Method (°C) (°C) Rt M+(H+) MS
(min) Method
Kofler DSC
17g 185 2.65 490 1
I/N N/
(I) F \
N /N
\ Nj/Efl‘N/
179 262 2.98 490 1
(I) F \
N\ N
KIN/Nj/H/V/N
180 N”0 182 2.68 476 1
A N /N
\ IN/Nj/[fl‘
181 To 190 2.94 476 1
('3 N\ N
MN/NTE/f'
182 HN |—'
(K? 250 2.36 440 1
| I
OQN /N N\ \
184 04; 180 2.92 476 1
(I) N\ N
\ IN/Nj/QN
185 0'N\ 207 2.64 476 1
(I) N /N
\ Nj/LN/
WO 61080
MP LC/GC/
Cfironp Compound Struct. Method (°C) MS
Method
Kofler
171 0 172 1
RM /
I (O N‘
I N
1903 245
MP MP HPLC MS LC/GC/
ComN09
nd Struct. Method (00) (’0) Rt M+(H+) MS
' (min) Method
Kofler DSC
195 JVA“ 197 2.44 475 1
. .\
(I) N /N
\ iN/Nj/[yN
196 (g/”"11- 162 2.78 475 1
F N\
(I) N\ N Nj/LN
197 H 249 1.92 445 1
,,N /
.1 K: TC”
198 H113 232 2.60 442 1
200 ”N3 236 2.81 457 1
| F Kg”
0fijN /N N\
\ IN.
202 H113 2.36 440 1
1, (5': N :1"
204 HoZ 2.25 488 1
MP MP HPLC MS LC/GC/
Com p
nd Struct. Method (’0) (°C) Rt M+(H+) MS
(mm). Method
211 “N \ 252 2.34 458 1
I (01>
0 N /N
213 0” 203 2.46 404 1
l H
MP MP HPLC MS LC/GC/
Cramp
Compound Struct. Method (°C) (°C) Rt M+(H+) MS
0' (min) Method
Kofler DSC
214 0/ 98, 2.60 453 1
/ gum
1 (K0
O N /N N\ /
\ fbi
215 ”N’\> 222 2.31 484 1
F \N o
. NI
217 Nro 240 2.4 445 “I 1
0 NaU N
./Nj/E:N
L L
218 ”01 130 2.24 522 1
/O N I/N
a? N\ N\
/ ./
219 ”° 112 2.47 522 1
SENSEO /
I /N
/O N N
(111”.N\I
208 74°“ 124 108,123 2.59 511 1
| (k N
O N /N N\
\ IN/
96 192 2.05 447 1
_l______
MP MP HPLC MS LC/GC/
Comp
nd Struct. Method (°C) (°C) Rt M+(H+) MS
(mm). Method
Kofler DSC
220 M 153 2.9 533 1
f5" /
Me: \Nfi
(Z. N
I\ N]/[:\N\ / ./
221 “ML0 151 2.3 480 1
2 ~<
/oKlN N\
/ raj/Ky"./
222 °ANL0 - - 3.01 536 2
2 ~/
/0figN N\ Njin
/ N.
223 ”"3 124, 3.01 475 2
F (KN IN‘N guml
(j I: TLN
225 \ 220 2.43 503% 1
MF’ MP HPLC MS LC/GC/
Cfimp
Compound . Method (°C) (°C) Rt M+ (11*) MS
(min) Method
Kofler DSC
91 0 176 2.41 498 1
S /
c1 N\
0&1:| N\
Sor l Nj/DN
93 O 160 2.41 498 1
/o\<:EN\£N:ENj/E¢NC1 R N\
Cl N/
RorS
94 o 176 2.41 498 1
HN gum
C] R N\
Cl N/
SorR
227 236 2.74 512 2
(”NOB
0 N I: N:7L
I /\N
my 1:
23o “Non/V 258 2.77 482 2
F N\
/ N/
232 OH
H~ 2.11 491 1
\ 147,
F fiwrc 9““
233 H 194 2.17 455 1
MP MP HPLC MS LC/GC/
ComNop
Compound Struct. Method (°C) (°C) Rt M+(H+) MS
' (min) Method
Kofler DSC —l
>260 2.43 439 2
235 193 2.29 448 1
HMj;
a ~/
/0U uN N\ Nj/EéNN.
733 an 128 2.58 539 1
239 ”"2 145 2.15 438 1
240 3g 180 1 2.27 519 1
HN \
F (K? N‘
o N /N \1 N/
._..—I——
242 ° 131 2.26 466 1
243 o 195 2.47 466 1
MP MP HPLC MS LC/GC/
0fimp
nd Struct. Method (°C) (°C) Rt M+(H+) MS
(min) Method
Kofler DSC
244 / 101, 2.26 505 1
h” gum
F OH
O N /N N\j/E/W/
1...
249 208 2.46 480 1
F (K0 “f
/o N N\
/ .rNj/[//N
37 172 2.43 466 1
\N /
I /N
/O N
UKN\
38 W 140 2.27 438 1
(I) N\ MKJ I /N
QJQN/N\|
.1 L
104 60 2.01 516 1
_‘Kl’fl /
/O /\N
QN\ N\
/ N/
284 M 252 2.29 479 1
oé< \ /
O N\
/O N QN\ N\ /N
/ N/
245 200 2.57 453 1
I Hyg I N‘N
MP MP HPLC MS LC/GC/
Comp
Compound . Method MS
No (00) (°C) Rt M+(H+)
' (min) Method
Kofler DSC
246 2% 114— 2.78 453 1
I IN‘N 115
O N N N /
QFUN/|\
247 HO O 108 2.43 522 1
Xfib gum
F R
,oU UNN N Nij
250 any 12% 96
«R i
235 2.26 503 1
199 2.8 413 1
W0 61080
MP MP HPLC MS LC/GC/
ComNop
Compound Struct. Method (°C) (°C) Rt M+(H+) MS
‘ 1(min) Method
Kofler D80
254 210 2.54 413 1
F \
/O [11 [/N
N\ N\
F N/
257 205 2.99 427 T. 1
F W N.
/o N N N [/N
256 207 2.67 427 1
F \ N3
/0 N I/N
N\ N\
F N/
258 n >260 1‘229 462 1
W” /
F N N\
/0 N I/N
N\ N\
/ N/
___l
259 154 2.08 493 1
NH :
N“ 2
I F (\NH
0 N N\ N\ \j
1/ NI
261 180 1.97 458 1
o (j;N
N N N )/\N
HN \ \
262 0 100—1 2.03 507 1
.3110!»/% N
/ N/
o\ L
WO 61080
MP MP HPLC MS LC/GC/
Com p
Compound Struct. Method
N (°C) (°C) Rt M+(H+) MS
(mm). Method
Kofler DSC
1 0.x 180 2.36
3.16 ’753
2.83 453
2.14 TL 494 1
270 CH 216 2.31 494 1
F fio
/o N N KL
UNl ,
271 160 2.16 476 1
WO 61080
MP MP 1 HPLC MS LC/GC/
Com 9
Compound Struct. Method (°C) (°C) Rt M+ (H+) MS
No '
(min) Method
Kofler DSC
272 03 135 2.33 476 1
([8 gum
s :O
/O N§ N (J :1N\
O\ L
273 (13> 133 2.41 457 1
/o N N\ N\ \
/ /
275 172 2.39 561 1
DN/N /N / (fig/:00
/” /
/0 (/19
277 174 2.82 435 T 1
X /
Cl) N N 01:: I /N
276 217 2.65 435 1
7% /
('3 HO I
N /N /N /N
U I
\ \N
278 234 2.52 471 1
| %\OH N\
O N /N /N /N
F \N
280 238 2.32 457 1
é (UN;
N/ N\
N N\ N\ /N
UI / N/
WO 61080
MP MP HPLC MS LC/GC/
Com p
Compound Struct. Method (°C) (°C) Rt M+ (H+) MS
(mm). Method
Kofler DSC
282 flN/éfi” 104 2.15 504
Ho : Ofi I gum
N N :‘N
/ UU :IL
283 162 145 2.12 522
Hoflfljfifi
/O N N N /\N
UI : :
285 ° 1 14 2.28 536
HN HO>§ gum
F N\
/o N N\ Nj/QN
/ N/
286 f 1 10 2.48 536 1
HN HOK gum
F N\
I /N
/o N N
UMN\
264 o§s/\ 126 2.22 553 1
(:NH gum [4
I NJ\ I N‘N
287 (FX( 213 2.3 475 1
c IMP MP HPLC MS LC/GC/
fimp Compound . Method (°C) (°C) Rt M+ (11*) MS
(min) Method
Kofler DSC
290 2.3 462 1
0Q\NH 66
R Ni
/0UUN/N N\ Nj/QN
291 190 2.28 466 1
(01HN \ O
293 162 2.31 448 1
HN/\§
295 Hm 171 1.98 504 1
UI: :
297 N—0 170 2.53 477 1
(MN/>\ \/ gum
/O N l/N
1% N\ N\
/ N.
299 /7> 133- 2.05 519 1
£0 134
/OE;EN\CEij:/\Ng<>w gum
’\ I
301 3; 126 1
V> 1
/0 N N N ‘/\N
1: E
"-_T
MP MP HPLC MS LC/GC/
Comp
Compound . Method (°C) (°C) Rt MHH”) MS
(min) Method
Kofler DSC
Gum 2.41 563 1
(“3 (£0 at 92
60 114 2.68 469 1
Analytical Part
LC/GC/NMR
The LC/GC data ed in Table A1 were determined as follows.
General procedure A
The LC measurement was med using a UPLC (Ultra Performance Liquid
Chromatography) Acquity (Waters) system comprising a binary pump with er, an
autosampler, a array detector (DAD) and a column as specified in the respective
methods below, the column is hold at a temperature of 40°C. Flow from the column was
brought to a MS detector. The MS detector was configured with an electrospray
ionization source. The ary needle voltage was 3 kV and the source temperature
was maintained at 130 °C on the Quattro (triple quadrupole mass spectrometer from
Waters). Nitrogen was used as the nebulizer gas. Data acquisition was performed with a
Waters-Micromass MassLynx-Openlynx data system.
Method 1
in addition to the general procedure A: Reversed phase UPLC was carried out on a
Waters Acquity BEH (bridged ethylsiloxane/silica hybrid) C18 column (1.7 um, 2.1 x
100 mm) with a flow rate of 0.343 mI/min. Two mobile phases (mobile phase A: 95 %
7 mM ammonium acetate / 5 % acetonitrile; mobile phase B: 100 % acetonitrile) were
employed to run a gradient condition from 84.2 % A and 15.8 % B (hold for
0.49 minutes) to 10.5 % A and 89.5 % B in 2.18 s, hold for 1.94 min and back to
the initial conditions in 0.73 min, hold for 0.73 minutes. An injection volume of 2 pl was
used. Cone voltage was 20V for positive and negative ionization mode. Mass spectra
were acquired by scanning from 100 to 1000 in 0.2 seconds using an interscan delay of
0.1 seconds.
General ure B
The LC measurement was performed using a UPLC (Ultra mance Liquid
Chromatography) H-Class (Waters) system comprising a nary pump with
degasser, an autosampler, a diode-array detector (DAD) and a column as specified in
the respective methods below, the column is hold at a ature of 40°C. Flow from
the column was brought to a MS detector. The MS detector was configured with an
electrospray ionization source. The capillary needle voltage was 3. kV and the source
temperature was maintained at 130 °C on the SQD2 e quadrupole mass
spectrometer from Waters). Nitrogen was used as the nebulizer gas. Data acquisition
was performed with a Waters-Micromass MassLynx—Openlynx data system.
Method 2
In addition to the general procedure B: Reversed phase UPLC was carried out on a
Waters Acquity BEH (bridged ethylsiloxane/silica hybrid) C18 column (1.7 pm, 2.1 x
100 mm) with a flow rate of 0.343 ml/min. Two mobile phases (mobile phase A: 95 %
7 mM ammonium acetate / 5 % acetonitrile; mobile phase B: 100 % itrile) were
employed to run a nt condition from 84.2 % A and 15.8 % B (hold for
0.49 minutes) to 10.5 % A and 89.5 % B in 2.18 minutes, hold for 1.94 min and back to
the l conditions in 0.73 min, hold for 0.73 minutes. An injection volume of 2 Di was
used. Cone voltage was 20V for ve and negative ionization mode. Mass spectra
were acquired by scanning from 100 to 1000 in 0.15 seconds using an interscan delay
of 0.05 seconds.
3O DSC:
For a number of compounds reported in Table A1, melting points (m.p.) were
determined with a DSC1 Stare System (Mettler—Toledo). Melting points were measured
with a temperature gradient of 10 °C/minute. Maximum temperature was 350 °C. Values
are peak values.”
Optical Rotation (OR) was measured with a polarimeter 341 Perkin Elmer.
The polarized light was passed through a sample with a path length of 1 decimeter and
a sample concentration of 0.250 to 0.500 gram per 100 milliliters.
dT : (red rotation x 100) / (1.000 dm x concentration).
d is sodium D line (589 nanometer).
T is the temperature (°C)
- Co. 33: [01]d: —10.78 ° (c 0.306 w/v %, DMF, 20 °C)
- Co. 34: [51d : +8.86 ° (C 0.271 w/v %, DMF, 20 °C)
52 [01]d: +4803 ° (589 - Co. nm, c 0.279 w/v %, DMF, 20 °C)
— Co. 53: [01]d: ~18.15 ° (589 nm, 0 0.336 w/v %, DMF, 20 °C)
- Co. 49: [01]d: -117.78 ° (589 nm, c 0.343 w/v %, DMF, 20 °C)
- Co. 48: [01]d: 2731 ° (589 nm, c 0.3735 w/v %, DMF, 20 °C)
- Co. 47: [01]d: +8272 ° (589 nm, 0 0.272 w/v %, DMF, 20 °C)
° (589
— Co. 46: [01]d: —46.92 nm, 0 0.3325 w/v %, DMF, 20 °C)
Co.45: [01]d:+16.12 ° (589 — nm, c 0.3785 w/v %, DMF, 20 °C)
— Co. 192: [aldz +2685 ° (589 nm, 0 0.406 w/v %, DMF, 20 °C)
- Co. 193: -84.89 ° (589 nm, c 0.2945 w/v %, DMF, 20 °C)
- Co. 59: [a]d: precision to low
— Co. 58: [01]d: ion to low
+108.08 ° (589 - Co. 54: [01]d: nm, 0 0.198 w/v %, DMF, 20 °C)
- Co. 62: [01]d: —31,87 ° (589 nm, c 0,251 w/v %, DMF, 20 °C)
Co. [01]d: +31 ° (589 - 63: nm, c 0,2645 w/v %, DMF, 20 °C)
- Co. 78: [01]d: precision to low
— Co. 79: Mid: precision to low
Co. 87: [a]d: +67.18 ° (589 - nm, c 0.262 w/v %, DMF, 20 °C)
° (589
- Co. 88: [01]d: -23.68 nm, 0 0.228 w/v %, DMF, 20 °C)
- Co. 89: [01]d: +6788 ° (589 nm, 0 0.33 w/v %, DMF, 20 °C)
- Co. 92: [01]d: -68.09 ° (589 nm, c 0.3525 w/v %, DMF, 20 °C)
- Co. 97: [01]d: +18.15 ° (589 nm, c 0.303 w/v %, DMF, 20 °C)
- Co. 123: [011dz -30.89 ° (589 nm, C 0.3075 w/v %, DMF, 20 °C)
Co. +2382 ° (589 - 124 [0].; nm, 0 0.319 w/v %, DMF, 20 °C)
Co. 158: [odd ° (589
- : +2358 nm, c 0.335 w/v %, DMF, 20 °C)
Co. 159 laid: -158.03 ° (589 - nm, c 0.274 w/v %, DMF, 20 °C)
- Co. 160: [G]d2 —24.04 ° (589 nm, 0 0.312 w/v %, DMF, 20 °C)
Co. 161: [G]d2 +147.79 ° (589 - nm, 0 0.272 w/v %, DMF, 20 °C)
- Co. 218: [01],,2 -137.19 ° (589 nm, 0 0.199 w/v %, DMF, 20 °C
- Co. 90: [Ci]d2 -20.09 ° (589 nm, 0 0.3185 w/v %, DMF, 20 °C)
Co. 91: [d] :-34.93 ° (589 - d nm, 0 0.292 w/v %, DMF, 20 °C)
° (589
- Co. 93: [or] D. : +20.07 nm, 0 0.294 w/v %, DMF, 20 °C)
° (589
— Co. 94: [d] d: +3667 nm, 0 0.3 w/v %, DMF, 20 °C)
NMR Data
The below NMR experiments were carried out using a Bruker Avance 500 and a Bruker
Avance DRX 400 spectrometers at ambient temperature, using internal deuterium lock
and equipped with reverse triple—resonanoeCH, N TXI) probe head for the 500MHz
and with reverse double—resonance (H, 13C, SEi) probe head for the 400MHz.
Chemicai shifts (6) are reported in parts per million (ppm).
Compound 3
1H NMR (500 MHz, 6) 6 9.04 (s, 1H), 8.64 (s, 1H), 8.27 (s, 1H), 8.07 (br.s, 1H),
7.14 (t, J = 8.0Hz, 1H), 6.68 (br.s, 1H), 3.94—4.13 (m, 11H), 2.77 (t, J = 7.4 Hz, 2H), 2.29
(s, 3H).
Compound 1
1H NMR (500 MHz, 6) 6 8.95 (s, 1H), 8.61 (s, 1H), 8.25 (s, 1H), 7.92 (d, J: 9.2
Hz, 1H), 6.78 (d, J = 9.2 Hz, 1H), 6.62 (d, J = 2.2 Hz, 2H), 6.55 (t, J = 2.2 Hz, 1H), 4.12
(t, J = 6.9 Hz, 2H), 3.94 (s, 3H), 3.77 (s, 6H), 2.82 (t, J = 6.9 Hz, 2H), 2.69 (spt, J = 6.2
Hz, 1H), 1.77 (br.s, 1H), 0.95 (d, J: 6.2 Hz, 6H).
Compound 2
1H NMR (400 MHz, DMSO-d6) 6 8.98 (s, 1H), 8.61 (s, 1H), 8.25 (s, 1H), 8.00 (d, J: 9.2
Hz, 1H), 6.53-6.92 (m, 3H), 4.10 (t, J = 7.0 Hz, 2H), 3.94 (s, 3H), 3.89 (s, 3H), 3.79 (s,
3H), 2.81 (t, J = 7.0 Hz, 2H), 2.69 (spt, J: 6.1 Hz, 1H), 1.62 (br.s, 1H), 0.94 (d, J: 6.1
Hz, 6H).
Compound 23
1H NMR (500 MHz, DMSO-d6) 6 11.82 (br.s, 1H), 9.03 (s, 1H), 8.63 (s, 1H), 8.27 (s,
1H), 8.07 (d, J = 9.1 Hz, 1H), 6.80 —- 7.16 (m, 3H), 6.77 (dd, J: 6.7, 3.0 Hz, 1H), 6.59
(dd, J = 5.5, 3.0 Hz, 1H), 5.27 (br.s, 2H), 3.93 (s, 3H), 3.86 (s, 3H), 3.69 (s, 3H).
Compound 24
1H NMR (500 MHz, DMSO-d6) 6 12.72 (br.s, 1H), 9.02 (s, 1H), 8.61 (s, 1H), 8.25 (s,
1H), 8.03 (d, J = 9.2 Hz, 1H), 7.08 (s, 2H), 6.92 (d, J = 9.2 Hz, 1H), 6.66 (d, J = 2.2 Hz,
40 2H), 6.52 (t, J = 2.2 Hz, 1H), 5.43 (s, 2H), 3.93 (s, 3H), 3.73 (s, 6H).
Compound 52
1H NMR (500 MHz, s) 5 9.02 (s, 1H), 8.62 (s, 1H), 8.26 (s, 1H), 8.03 (d, J = 9.1
Hz, 1H), 7.81 (s, 1H), 6.82 (br. s., 2H), 6.65 - 8.78 (m, 1H), 3.72 - 4.12 (m, 12H), 2.05 -
2.27 (m, 3H), 1.80 (br. s., 1H)
Compound 53
1H NMR (500 MHz, DMSO—da) 5 8.72 (s, 1H), 8.54 (s, 1H), 8.24 (s, 1H), 7.83 (s, 1H),
7.54 (d, J =10.1 Hz, 1H), 6.61 (dd, J = 1.58, 10.09 Hz, 1H), 6.37 - 6.43 (m, 1H), 6.06 -
6.13 (m, 1H), 4.70 (dd, J = 6.9, 12.6 Hz, 1H), 4.56 (dd, J = 6.9, 12.6 Hz, 1H), 4.14 - 4.23
(m, 1H), 3.94 (s, 3H), 3.82 (s, 3H), 3.72 (s, 3H), 2.28 - 2.40 (m, 1H), 1.95 - 2.15 (m, 3H)
Compound 47
1H NMR (500 MHz, DMSO-ds) 5 8.78 (s, 1H), 8.57 (s, 1H), 8.26 (s, 1H), 7.85 (s, 1H),
7.61 (d, J = 9.8 Hz, 1H), 6.69 (t, J = 7.9 Hz, 1H), 6.57 (d, J = 9.8 Hz, 1H), 4.60 - 4.77 (m,
2H), 4.13 - 4.24 (m, 1H), 3.94 (s, 3H), 3.86 (s, 6H), 2.27 - 2.40 (m, 1H), 1.97 - 2.14 (m,
3H)
nd 46
1H NMR (500 MHz, DMSO-da) 5 9.02 (s, 1H), 8.62 (s, 1H), 8.26 (s, 1H), 8.03 (d, J = 9.1
Hz, 1H), 7.81 (s, 1H), 6.79 - 6.91 (m, 2H), 6.66 - 6.78 (m, 1H), 3.74 - 4.16 (m, 12H), 2.05
- 2.26 (m, 3H), 1.80 (br. s., 1H)
Compound 55
1H NMR (500 MHz, DMSO-de) 5 8.78 (s, 1H), 8.57 (s, 1H), 8.24 (s, 1H), 7.60 (d, J = 10.1
Hz, 1H), 6.68 (t, J = 8.0 Hz, 1H), 6.57 (d, J =10.1 Hz, 1H), 4.50 - 4.61 (m, 2H), 3.95 (s,
3H), 3.86 (s, 6H), 3.34 - 3.42 (m, 4H), 2.18 (t, J = 8.0 Hz, 2H), 1.92 - 2.02 (m, 2H), 1.81 -
1.91 (m, 2H)
Compound 86
1H NMR (500 MHz, DMSO—de) 5 13.84 (s, 1H), 9.03 (s, 1H), 8.62 (s, 1H), 8.46 (br. s.,
1H), 8.26 (s, 1H), 8.07 (d, J = 9.1 Hz, 1H), 6.82 — 7.03 (m, 1H), 6.78 (d, J = 3.5 Hz, 1H),
6.70 (br. s., 1H), 5.36 (br. s., 2H), 3.82 - 3.97 (m, 6H), 3.72 (s, 3H)
Compound 95
1H NMR (500 MHz, DMSO-de) 5 11.80 (br. s., 1H), 9.67 (s, 1H), 9.02 (s, 1H), 8.63 (s,
1H), 8.26 (s, 1H), 8.06 (d, J = 9.1 Hz, 1H), 7.02 (s, 1H), 6.71 — 6.90 (m, 2H), 6.57 (d, J =
4.4 Hz, 1H), 6.39 (d, J = 2.2 Hz, 1H), 4.22 - 6.00 (m, 2H), 3.93 (s, 3H), 3.81 (s, 3H)
Compound 111
1H NMR (500 MHz, DMSO-ds) 5 9.04 (s, 1H), 8.63 (s, 1H), 8.27 (s, 1H), 8.04 (d, J = 9.1
40 Hz, 1H), 7.89 (br. s., 1H), 6.59 - 6.93 (m, 3H), 4.03 - 4.57 (m, 5H), 3.95 (s, 3H), 3.89 (s,
3H), 3.79 (s, 3H)
Compound 221
1H NMR (500 MHz, DMSO-ds) 5 8.99 (s, 1H), 8.62 (s, 1H), 8.26 (s, 1H), 8.00 (d, J = 9.1
45 Hz, 1H), 6.81 (dd, J = 2.8, 6.6 Hz, 1H), 6.71 - 6.77 (m, 2H), 4.60 (t, J = 6.6 Hz, 2H), 4.28
(t, J = 6.6 Hz, 2H), 4.06 (br. s., 2H), 3.94 (s, 3H), 3.86 - 3.91 (m, 4H), 3.78 (s, 3H), 2.76
(br. s., 2H), 2.54 - 2.67 (m, 1H)
Compound 242
50 1H NMR (500 MHz, DMSO-de) 5 9.01 (s, 1H), 8.62 (s, 1H), 8.26 (s, 1H), 8.09 (t, J = 5.52
Hz, 1H), 8.03 (d, J = 9.14 Hz, 1H), 6.82 (dd, J = 3.0, 6.8 Hz, 1H), 6.73 — 6.80 (m, 1H),
6.70 (dd, J = 3.0, 5.2 Hz, 1H), 3.98 - 4.15 (m, 2H), 3.94 (s, 3H), 3.98 (s, 3H), 3.79 (s,
3H), 3.37 - 3.47 (m, 2H), 1.74 (s, 3H)
Pharmacological part
Biological assays A
FGFR1 (enzymatic assay)
In a final reaction volume of 30 uL, FGFR1 (h) (25 ng/ml) was incubated with 50 mM
HEPES pH 7.5, 6mM MnCIz, 1 mM DTT, 0,1 mM Na3VO4, 0,01% Triton-X-100, 500 nM
t3 and 5 pM ATP in the presence of nd (1% DMSO final). After
incubation for 60 minutes at room temperature the reaction was stopped with 2.27 nM
EU-anti P-Tyr, 7 mM EDTA, 31.25 nM SA-XL-665 and 0.02% BSA which was present
for 60 minutes at room temperature. Time—Resolved Fluorescence Resonance Energy
Transfer (TR-FRET) signal (ex340 nm. Em 620 nm, em 655 nm) was measured
afterwards and results are sed in RFU (Relative Fluorescence Units). In this
assay, the inhibitory effect of different compound concentrations (range 10 0M to 0.1
nM) was determined and used to calculate an |C5o (M) and plC50 (~IoglC50) value.
FGFR2 (enzymatic assay)
In a final reaction volume of 30 uL, FGFR2 (h) (150 ng/ml) was ted with 50 mM
HEPES pH 7.5, 6mM MnC|2, 1 mM DTT, 0,1 mM Na3VO4, 0,01% Triton-X-100, 500 nM
Btn-Flt3 and 0.4 pM ATP in the presence of compound (1% DMSO final). After
incubation for 60 minutes at room temperature the on was stopped with 2.27 nM
EU-anti P-Tyr, 7 mM EDTA, 31.25 nM 665 and 0.02% BSA which was present
for 60 minutes at room temperature. Time-Resolved Fluorescence Resonance Energy
Transfer (TR—FRET) signal (ex340 nm. Em 620 nm, em 655 nm) was measured
afterwards and results are expressed in RFU (Relative Fluorescence . In this
assay, the inhibitory effect of different compound concentrations (range 10 pM to 0.1
nM) was determined and used to ate an |C50 (M) and plC5o (-Iog|C50) value.
FGFR3 (enzymatic assay)
In a final reaction volume of 30 uL, FGFR3 (h) (40 ng/ml) was incubated with 50 mM
HEPES pH 7.5, 6mM MnClg, 1 mM DTT, 0,1 mM Na3VO4, 0,01% Triton-X—1 00, 500 nM
Btn-Flt3 and 25 pM ATP in the presence of compound (1% DMSO final). After
WO 61080
incubation for 60 minutes at room temperature the reaction was stopped with 2.27 nM
EU-anti P-Tyr, 7 mM EDTA, 31.25 nM SA-XL-665 and 0.02% BSA which was present
for 60 minutes at room ature. Time-Resolved Fluorescence Resonance Energy
Transfer ET) signal (ex340 nm. Em 620 nm, em 655 nm) was measured
afterwards and results are expressed in RFU (Relative Fluorescence Units). In this
assay, the inhibitory effect of different compound concentrations (range 10 uM to 0.1
nM) was determined and used to calculate an lC50 (M) and plC50 (-loglC50) value.
FGFR4 (enzymatic assay)
in a final on volume of 30 uL, FGFR4 (h) (60 ng/ml) was ted with 50 mM
HEPES pH 7.5, 6mM MnClg, 1 mM DTT, 0,1 mM Na3VO4, 0,01% Triton-X400, 500 nM
Btn-Flt3 and 5 uM ATP in the presence of compound (1% DMSO final). After incubation
for 60 minutes at room temperature the reaction was stopped with 2.27 nM EU-anti P-
Tyr, 7 mM EDTA, 31.25 nM SA-XL-665 and 0.02% BSA which was t for 60
minutes at room temperature. Time-Resolved Fluorescence Resonance Energy
Transfer (TR-FRET) signal (ex340 nm. Em 620 nm, em 655 nm) was measured
aften/vards and results are expressed in RFU (Relative scence Units). in this
assay, the inhibitory effect of different compound concentrations (range 10 pM to 0.1
nM) was ined and used to calculate an IC50 (M) and plC50 C50) value.
KDR 2) (enzymatic assay)
In a final reaction volume of 30 uL, KDR (h) (150 ng/ml) was incubated with 50 mM
HEPES pH 7.5, 6mM MnClz, 1 mM DTT, 0,1 mM Na3VO4, 0,01% Triton-X-100, 500 nM
Btn-Flt3 and 3 uM ATP in the presence of compound (1% DMSO final). After incubation
for 120 minutes at room temperature the reaction was stopped with 2.27 nM EU-anti P-
Tyr, 7 mM EDTA, 31.25 nM SA-XL-665 and 0.02% BSA which was present for 60
minutes at room temperature. Time-Resolved Fluorescence Resonance Energy
Transfer (TR-FRET) signal (ex340 nm. Em 620 nm, em 655 nm) was measured
afterwards and results are sed in RFU (Relative Fluorescence Units). in this
assay, the inhibitory effect of different compound concentrations (range 10 uM to 0.1
nM) was determined and used to calculate an IC50 (M) and pleo (-loglC50) value.
Ba/F3-FGFR1 (minus |L3 or plus lL3) (cellular proliferation assay)
In a 384 well plate, 100 nl of compound on in DMSO was sprayed before adding 50
ul cell e medium (phenol red free RPMl—1640, 10 % FBS, 2 mM L-Glutamine and
50 ug/ml Gentamycin) containing 20000 cells per well of Ba/F3-FGFR1-transfected
cells. Cells were put in an incubator at 37°C and 5 % C02. After 24 hours, 10 pl of
Alamar Blue solution (0.5 mM K3Fe(CN)5, 0.5 mM K4Fe(CN)6, 0.15 mM Resazurin and
100 mM Phosphate ) was added to the wells, incubated for 4 hours at 37°C and
% C02 before RFU’s (Relative Fluorescence Units) (ex. 540 nm., em. 590 nm.) were
measured in a flurorescence plate reader.
In this assay, the inhibitory effect of different compound concentrations (range 10 uM to
0.1 nM) was determined and used to calculate an |C50 (M) and plC50 (~loglC50) value.
As a counterscreen the same experiment was performed in the ce of 10 ng/ml
murine lL3.
Ba/F3-FGFR3 (minus lL3 or plus lL3) (cellular proliferation assay)
In a 384 well plate, 100 nl of compound dilution in DMSO was sprayed before adding 50
ul cell culture medium (phenol red free RPMl-1640, 10 % FBS, 2 mM L-Glutamine and
50 ug/ml Gentamycin) containing 20000 cells per well of FGFR3-transfected
cells. Cells were put in an incubator at 37°C and 5 % C02. After 24 hours, 10 pl of
Alamar Blue solution (0.5 mM K3Fe(CN)6, 0.5 mM K4Fe(CN)6, 0.15 mM Resazurin and
100 mM Phosphate Buffer) was added to the wells, incubated for 4 hours at 37°C and
% C02 before RFU’s (Relative Fluorescence Units) (ex. 540 nm., em. 590 nm.) were
measured in a escence plate reader.
In this assay, the inhibitory effect of different compound concentrations (range 10 (M to
0.1 nM) was determined and used to ate an lC5o (M) and plC5o (~logleo) value.
As a counterscreen the same experiment was performed in the presence of 10 ng/ml
murine lL3.
Ba/F3-KDR (minus |L3 or plus lL3) (cellular proliferation assay)
In a 384 well plate, 100 nl of compound dilution in DMSO was sprayed before adding 50
ul cell culture medium (phenol red free RPMl—1640, 10 % FBS, 2 mM L—Glutamine and
50 ug/ml ycin) containing 20000 cells per well of Ba/F3—KDR-transfected cells.
Cells were put in an incubator at 37°C and 5 % C02. After 24 hours, 10 ul of Alamar
Blue solution (0.5 mM K3Fe(CN)6, 0.5 mM K4Fe(CN)6, 0.15 mM Resazurin and 100 mM
Phosphate Buffer) was added to the wells, incubated for 4 hours at 37°C and 5% C02
WO 61080
before RFU’s (Relative Fluorescence Units) (ex. 540 nm., em. 590 nm.) were measured
in a escence plate reader.
In this assay, the inhibitory effect of different compound concentrations (range 10 pM to
0.1 nM) was determined and used to calculate an leo (M) and pleo (-logleo) value.
As a counterscreen the same experiment was performed in the presence of 10 ng/ml
murine lL3.
Ba/F3-Flt3 (minus |L3 or plus lL3) (cellular proliferation assay)
in a 384 well plate, 100 nl of compound dilution in DMSO was sprayed before adding 50
pl cell culture medium l red free RPMl-1640, 10 % FBS, 2 mM L-Glutamine and
50 pg/ml Gentamycin) containing 20000 cells per well of Ba/F3-Flt3-transfected cells.
Cells were put in an incubator at 37°C and 5 % 002. After 24 hours, 10 pl of Alamar
Blue solution (0.5 mM K3Fe(CN)5, 0.5 mM K4Fe(CN)6, 0.15 mM Resazurin and 100 mM
Phosphate Buffer) was added to the wells, incubated for 4 hours at 37°C and 5% 002
before RFU’s (Relative Fluorescence Units) (ex. 540 nm., em. 590 nm.) were measured
in a flurorescence plate reader.
in this assay, the inhibitory effect of different compound concentrations (range 10 pM to
0.1 nM) was determined and used to calculate an lC50 (M) and plC5o (-logleo) value.
As a counterscreen the same experiment was performed in the presence of 10 ng/ml
murine lL3.
Ba/F3-FGFR4 lar proliferation assay)
In a 384 well plate, 100 nl of nd dilution in DMSO was sprayed before adding 50
pl cell culture medium (phenol red free RPMl-1640, 10 % FBS, 2 mM L-Glutamine and
50 pg/ml Gentamycin) containing 20000 cells per well of BalF3—FGFR4—transfected
cells. Cells were put in an incubator at 37°C and 5 % C02. After 24 hours, 10 pl of
Alamar Blue solution (0.5 mM K3Fe(CN)6, 0.5 mM K4Fe(CN)6, 0.15 mM Resazurin and
100 mM Phosphate Buffer) was added to the wells, incubated for 4 hours at 37°C and
% C02 before RFU’s (Relative FluorescenCe Units) (ex. 540 nm., em. 590 nm.) were
ed in a flurorescence plate reader.
In this assay, the tory effect of different compound trations (range 10 pM to
0.1 nM) was ined and used to calculate an |C5o (M) and pleo (-loglC50) value.
Data for the compounds of the invention in the above assays are provided in Table A2.
WO 61080
BLANK UPON FILING
WO 61080
m5 E a? Rs mm? 8.7 mv 8s mg 8.0 .3? 8o 8.?
$<m 12;“. €95qu man; m.__ $03 mv mv mv mv mv mv mv
2m -E<m min. 2:): NE. 803 arm 8m mv mv E mv mg
mm:_m> .25 max man: NE 803 mv mv mv mv mv mv mv
mmEo>m 2:):
.852 -muzm A: 303 E 3m 3 moo 3 3 no mv moo we E 3 mm mm om cm
995 .245 $7.0; man: a: 303 mv mv mv mv av mv mv mv mv mv mv mv mv mv mv mv
8:28
“55:6 .35 $7.0“. 2:): me 803 E N? ms 3 of 3 ill ms mom: 3 9w 3 E m: mg E E
Lo -mnzm Elem man: mv
uconEoo -mnzm ENE“. 2:): mm
L8 EomS E9: 803 E m.“ ox E as E to 3 3 3“ ms E we mg N.“ 3
8E: N
# Ll
23:3: Na S 9% E S 3w .3 3 3 3 mm 3 M:
86650 Mg N.“ Ow mg E 3 to 3 g 5 3 2w 3
295 E m: as mg S mm 3 0w
g m: E mg S m: ow Qm
$32. m S mm : mm cm t o
$<m E0”. v 803 S: RN RN RN N: RN Nos mws Now was
$<m INS“. min: A2. $03
-$<m 3d 2:): a... 303
-mn_<m max man: a: 803 mv mv mv mv mv mv mv mv mv
$<m 2:2on 65 803 No «.0 1m Ni NS Nmm m3 m3 ammo m3 who mod
-muam NEE man: A2. 805 mv mv mv mv mv mv mv mv mv mv mv mv
LEE NEE 2.5: 8: 303 9w ow mm 3N2 on was EN m3: HNN 3m: 91w: N32
-muEm Ema“. 93$ m2. 803 mv mv mv mv mv mv mv mv mv mv mv mv
-E<m Eton. 2:): 8.: 803 3 ow ms mam 9% rll 3.x NEW me 2% 9% mg 3w
1 fil
Eom> £9va sea E ow NN 8s RE SN «ms mm: mm.“ m3 m; 2.»
E0“. 803 to a; mam N3 «.3 Nam mm
v 3 3 .
m Now 8d 5m
E0”. 803 mm mm 3m NNN mg 3.? 2
N mm mod .
m 5m Emlr SN
E0; N 803 mm mm 3w 5w mmm mg EN 3w mm
m 8w 5w mm.m
E8 F omoa 3 to 3 kg oNN :3 EN mam mq
m oN.m m3 fog
.8 .02 N 9 v m «N IF! 022E 28: .28 =8 -«N m I738.NN 29% :8 .N -5 QWEE =3 .N 9552 :3 N -mN
9 9
WO 61080
$<m E0... v 803 2.x wms E m3 mod m: m2 mm.“ 8.? $6 oms who
$<m 13d m3: AMI: 963. mv mv mv mv mv mv
-mnzm 9d 2:): A3 $03 mv mv mv mv mv mv
fl 4!
-m“_<m_ max m3: a; Boa mv mv mv mv mv mv mv mv mv mv mv mv
.25 2:2on 8g 8% mos H3 Bo m3 mv Rm. $.m mod o3 mv 5m. H3
-muzm «Eon. moi A2. $03 mv mv mv mv mv mv mv mv mv mv mv mv
-mn_<m «Eon. 2:): A2. 303 3.? 3w: 5m: 3.? Sam: Dz? ems mg we? 8.0 S? 3?
mv mv mv mv filmv mv mv mv mv mv
-m“_<m_ ENG“. 2:): 8.: Boa m3 «3 m3 mg 3.9THE mmx 92w 8x mg rm: m?
Emm> EEK 8%. o; 2w 2.x mg 03 Rs a: m3 N: mg ems «ms
E3 v aoa :3 8.x cam 3m max Nww mmwltfi mod mg m3 mg as
E0“. m 8%. 8m. m3 8.0.: 85 2% 3m 8.” m3 and 9% Rm _|mo.w
E0“. N 803 NEW. 3.x g mm.” m; 8.x m3 5” 8.x 3mm 9% mg
E8 r 803 mmm. mg N? ova N: 9m mg mg mod 9.” 3% mg
.8 .02 099E 25: 20m 2mm -8 98% 92 2mm .8 293 :mw -mm Ewes :82 .3 9992 3% R 8 on 8 8 3H on 5
WO 61080
$<m E0“. : 303 Em m5 :3 :1 m3 my 8.: 8.: mmm m3 05m 93 Em Rx 8.: mwm mm.m
mam 12:“. mafia Am: so: my my
gem/E m5; 2:): 8: 803 my my
? P
-muzm me: min: Am: 803 my my my my my my my my my my my my my my my my my
.33 2:):
8.: 803 2m ill 2m: 8m Em 93 my wmm Sm mmma mmm m3 mom mam mam mNm mmm mmm
-muzm ENG”. ms: 6.: 803 my my my my my my my my my my my my my my my my my
$<m Bio“. 2:); Am: 803 Rm 8.? :3 mom m
me my mom: w: 8.: N: mm? 3.? mmmz 8.? Sm; «ms 3.:
-mn.<m Egon. man: a: $03 my my my my my my my my my my my my my my my my my
: H sir!
-E<m Euom z:>_v 3.: 80.: 23 3.: 8.: mm: mm.” Sm Sm m: is mm.“ mm: 8.x m3 m; Sm DE o:
EomS 29: $03 m: mm: m: Rm mom my Em mm.“ as mm: 8.: 8.: NS Sm mm: as 8.:
E0: w 803 m: m? Sm Sm wa mm.m 8m mmw 2% 2% «mm mm.w 03 wNm 9% m; Nmm
P A
Eon m so: m3 9% Sm mmm Sm $2 mmm Sm gm gm 8.? Rm 0; 0mm 3w mmm Em
E8 N 80.: «mm Rm mwm mg mm.m mom Sm 8.x NS Sm mmm Sm Km mmm Sm mum Sm
E8 : 803 Hg mmm Em 3% mwm 3m m3 :3 mmm Em mmm 8m 9% mm 2.x 3w mmm
.8 .oz mm 8 o: E N: 3 m2 N2 m: m: 3 3 a: :m om mm mm
WO 61080
-25 EB v sea
$<m twin. min; 8: 803
$<m.3: 2:): A2. 203
$<m-mn: man: 8g 803 mv mv mv my mv mv mv mv mv mv mv mv mv mv mv
$<m 2:2on :3. 9.63 mm.m m: 8.9 :3 m3 30 3m 8.0 $6 MS, m? mm.m m3 mmm Hmd
$<m«NEE min: A2. 803 mv mv mv mv mv mv mv mv mv mv
$<mmama“. 2.5: A2 303 m3 2.x E o:
$<mWEE m3: 8.: 303 mv Sm mv mv mv
$<mWEE 2:); Nflllllll 803 $3 Nam mm.“ Es 8s 8s 5m 8s 03
E9; E93 803 m: 03 :.w a: am: m: N3 ems :3 a mm.“ OE mos
E0“. v 803 a? mg X;
E8 m sea New Rd 93
E0“. N 303 :3 03 m3 m3
E0; F sea 3.x N31modi
8.02 «m mm om. Q
WO 61080
.828 E0“: v sea mm: a}. ohm 0?. a: N3 mv mv 8.: mms mos 8E $8 mv mv 88 man
2%. .85: moi: 8.: 305
.228 85“: 2:2: 8.: $03
$3: m9: win: 8: 303 mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mV
2:2: r!
.928 8: 30:: m; mv mom mv 83 H3 mv mv mi: :3 m3 m3 a} mv mv 38 in
-348 mama“. mad: 8.: 80.: mv mV mv mv mv mv mv mv mv mv mv mv mv mv mv 88v mv
-928. 8E8 2:2: 8.: 80.: mow 8.? $8 $4”. as 2.8 :82 $82 3.8 :l 8.? o: mos mm? 38 3mg 3.82 Dem
.928 Ema”. moi: 8: 303 mv mv mv mv mv mv mv mv mv mv mv mv 38v my mv m: mv
-E<m Egon 2:2: 8.: 80:: a? $8 3.: 38 8.: 8.8 38 :3 mg :2 8: wmx $3 $8 mv 88.8 m3
Ewm> 8.9:: 303 max 8.8 :8 av 88 9: 8v av 2.8 28 mm: $8 8...: 23 3.0 8.8 8...:
N 4!!
Emu. v 80:: 8.8 :3 m: $8 NS: $8[ITIII 9} 8.8 $8 $8 8.8 2.8 H: mama 83 R8 Rs
E0“. 8 80:: Ea mm.“ 8.8 83: 8.8 2.8 3.8 m3 $8 88 $8 8; :88 SN ms m3 :8
E0: N sea 3.8 3.: :3 mmo 88 :8 8.8 Hm.“ $8 £8 8.8 $8 Nam m: mm.“ No.0. 3.8
E8 F 80:: $8 mm.“ mg NE 3.8 $8 8.8 N: 88 8.8 8.8 $8 88.8 8.: 3.: mg mm.“
L g |:
.oo .oz 8 mm 8 E 8 No «w 88 mm IT1 8 E 2 8 8 mm mm mm
WO 61080
m3 3.? Ed $.92 mo? Rs Bo 86 is 3.? on? mg :3 86 Sm
mv mv mv mv mv mv mv mv mv mv mv iv mv mv mv
II.|_|.|I| -nu.<m 2.5;
$4. emu—Q mm.m m3 :3 9% Sm mm.m 8.? 3m $6. mm.m 8.? m3 8.9 N32 OS mmm mv
-mnzm ammo; man: 3 Ono—Q mv mv mv mv mv mv mv mv mv mv mv mv mv Ev mv mv mv
mm: mm.“ 8.x: 8.? 2.? mo? mm.“ R? NS 8.? SN 3.? 5m: m: wwm mod
mv mv B.mv mv mv mv mv mv mv mv mv mv vmv mv mv mv
N: 8.x Ham one a? m? EN mm.“ m: m: 2.? 8.x 8.? Rs mm.“ Ed
Eom> E9: coo—Q 8x w: 8.x Rm mm...“ 8x o: EN Rx WEI; 3m m3 a; 2w N: E am.“
_.. _
E3 ¢ coo—Q mmx 2.x m3 mom 2d 86. 9% mm
m New
_77 ~
E0; m emu—Q m3 3m Ed 5m mmm mg mg cod flog
E0“. N emu—Q wdm 9mm 5m mam 9% Ex «3 ohm wwm 3m mum 9% mam mg mg mam 9;
Eon F Ono—Q mg 2%: 93 2}. 3m m; 3w «3 8w 0; mod m; N3 mg mg a; mg
.oo .
02 B m: m: a: om? RF «3
_ 4
WO 61080
.25 E0". v 1&9: $8 $.82 3.? N: 88.8 No.8 m3- m3 mm 88 8N.“ $8 mv
m o: 03 3m mg
$<m .85“. mad: 8: 803
-muzm 8E 2:2: 8: 30::
$<m me: mag 8.: 803 mv mv mv mv mv mv mv mv mv mv mV mv mv mv mv mv mv
.25 2:):
8.: 303 3m 9R HS :3 mm.m Sm mm.m m3 8 mv mv my
m $8 m3 mm.m 5m mam
-25 8E9: min: 8: 80.: mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv
.95 8E0“: 2:2: 8: 803 o: 2.? 5:? 8.8 3:? m2 $.82 mm? :8
oz mam $8 888 2.82 9mm $8 m3
$<m Ewe”: man: 8.: 303 mv mv mv mv mv mv mv mv mv mv mv my mv mv mv mv mv
$<m FEE 2:2: 8.: 803 2.: 2.? 8.: 8.8 3.? N: $8 08.: m: mv
o $8 :82 92 2.8 a} 8:}. $8
Eme E9: 803 of. NS 8.8 3.8 mm: NE 8.: mg m:
8.8 3: «ms mm: mm.“ m: 88 «.3
E0“. w 80.: 38 8.8 8.8 $8 :8 8; m: 8.8 mm
N 8.8 Km 888 mm: Nam E 38 £8
E0”: m 30.: mg 38 83 8.8 3.8 N:
w 88.8 08.8 3.8 £8 38 E8 NE E8
E0“. N 803 8.8 No.8 83 $8 8.8 E
8 m; 8.8 $8 £8 88 8.8 88 38
E0“. : so... 88.8 88 $8 3.8 88 co
m 8.8 88.8 8.8 max gm m? 8.8 $8
.8 .oz mm: :8 mm: mm: mm: [L8: N? 82 :8: 88 8: m8: 2: 2; NVD 83 3:
£6 HE NHH mg a}. m: Q? mo.w 86 mod mg 0N6 was m: 3.?
$<m win. 93% A: 303
LEE E: z__>_v a: 803 l
LEE me. wig A2 80.0. mv mv mv mv
-$<m 2:):
A2. $03 3». mg. Dd o3
-$<m mama“. moi
_ Ego“. 2:):
-E<m ENG... m3: Ill!
-E<m ENG; 2:): A2. $03 Rs 59 m3 mm.“ mvN 8.0 3m 85 E maw Ex 2.0 m: mod was 3.0 3s
E9; 89: 803 3; mm.“ mg 02 wa E 03 NM: m3 0% mow
1 llLIII 3w
E6“. w omoa m3 m? 9% a; mmd m? as 3m Ham med _m:vmmw
Eon. m 2% m3 3w mg 5 «3 :6 mm.m 3.x mm.»
Em: N $03 9.x m3 mew N? mam m3 wa 8.x 9.;
H: 5m mam and o: M3
E «2 E; mm? 5? mg
WO 61080
-mHZm Ema v $03 N2 8.? m3 3.0 H3 NE ON.“ 9% E;. 3m m3 m3 m3 mm.m S9 SK mmx
$<m '3: many le._._ $03
-m“.<m Ed 2%: a... 303
-m“.<m max man: N2. 8% mv mv mv mv mv mv mv mv m
v mv mv my mv mv Nmmv mv mv
LEE 2:):
8: 803 Hg m3 o3 5m 3m Rm 9% 0mm w? mv mam mv Em mv Semv mm.m 5m
$5 9E0“. mafia AB. 803 mv mv mv mv mv mv mv mv mv mv mv mv mv mv ~me mv mv
:95 mEom 2:); 8.: 803 «ms mws N2 moo mum o3 3: m3 3w: 5m Sm owe o: m3 mnmv mm.“ mow
.95 Emom 23% A2. 803 mv mv mv mv mv mv mv mv mv mv mv my mv mv va mv my
-E<m Ewe“. 2.5; 8.: 803 mm.“ 8w mms NE «E m: mg N3 8m 3m 03 two NE 03 Nmmv m: fix
Eom> $9; 803 2% 2% 8w SN a: own mg as mow mos 0: 8.9
E8 v 803 9% :3 9% mow wmw Ew 86. How Ed H: 8» Now 3m H: 9% w; mam
E0“. m 803 m3 mod m3 wow wow 8» mg 3% 2d SK Ex 0; 5m 2% O3 5m 3%
Eon N 803 N; Ex New 03 8w 8w mg Sm 8.x NS m; m; 3m and 8w
E8 r 803. 8.0. 3w <3 mg m; Rm 8.? 3w 8.? 3m m; mm.“ mm.m 8w Nwm
.8 .02 me «9 mm: 9: t: 8; 2: 0: at mt N: Jill! mt at 2: x:
WO 61080
LEE Emu v 303 mmm mom SK omm man 3?. 9m
$<m IE: min: m.__ goa
-25 min. 2:): N9. 8%.
.975 max mafia A2. my my my my my my my my I my
-25 2:2on 8.: $03 mmm 2% am 2m mum 2% my mmm mmm HE my
-muzm Elem man: 3. $03 my my my my my my my my my my my my my my my my my
-25 «Eon 2:); N3 203 mm? m3: E man 8.? 2.? m3: mama fix m3 mom 8.? my m3: m? 3.? mom
-mn_<m_ Emmi m3”: N2 803 my my my my my my my my my my my my my my IflI
Lem/E Emmi 2:): 2. 803 8s «m? mms 0: «mm mos mum 2m «ms om.m mom mm.m my 3m Rm DE m3
E9; 893 803 m: N3 m: <sz SE ems E 2w ems 8m Ex 8m :3 «3 Sm: E Nmm
E0”. mam 8m m; n? N3 m; mmm mm.m mmx mom mom; m: 3m mm; mm.m N3.
Em Em 3% mm.m mmm mom :3 as 35 3% Em mm.“
E0“. N $03 mm.m mm; mm.m 3.x 3m mm: am Km m3 mm.“
E9 F 803 Rm Sm Bm Sm m2 mmm mm.“ mmm Rm mom mmx
8.2 mm: a: mm: 9: m2 m2 5F m2 08 mom 3N
WO 61080
[m2 fi
8m 86 N3 m3 m3 N3 «ms 86 m3 m3 8:0 EN
$<m twin. man; 803
-muzm «E 2:); j 305
-m“_<m an: moi 5. 303 mv mv mv mv mv mv mv mv mv mv mv mv mv
$<m 2:):
A3 805 2% «mm H3 Em Nwm SmLSam 3m mam 3m m3 Sm mmm N3
.345 manna man: a: 303 my mv mv mv mv mv mv 3 mv mv mv mv mv
-25 mEE 2:): a... 803 03 ~32 Ea mg H32 $2 3.? mam m3: $5 8s 3.? 8.x:
.35 Ewan. man: a: 803 mv mv mv mv mv mv mv mv mv mv mv mv mv
.95 Egon 2.5; a... 89a H3 an 9: H; wow Re mos mg m3 Es Rs 33 mow N3 mm.“ N3 m3
«58> 29: 303 2: em.“ wow NEW 3: So SE mg m3 Rx 92w H: as omx mm? mm.“ mam
E8 v sea mm.“ mnw onm m3 3m a: was 5w mos 3.x NEW m: m; mm.“ mg as 3m
E9 m 805 3K 8w m3 mam N3 NEW New 8.? 2% mg 2% 3.x Ba mow mg 2% 8.x
E0; N 803 m3 mg 8w 3m mow: 3m mg mm.» m3 mg mm; mg 93 3.x 3w mg gm
E0“. F 803 3w 93 8d Ed 85 5m New mam o3 9% mod 3% mg mg Nam $.m 3m
8 .2. mom com SN SN :N 2m EN ma EN gm 2N wow 8 EN EN NNN mmm
WO 61080
$<m Eon q 803 84”, 8d mv mv Sm mv 86 a}, mum mom Sue 33 8w 33 as
2%ImE min; 2. 803 i8.0
.35 Ed 2.3:
mv mv mv mv mv mv mv mv mv mv mv mv mv mV mv
.85 2:);
A2. mv mv mv mv m3. mv :3. 3m 8.», mv mv Sm. 9% Rm 23
-muzm «Eon. 93$ 3 mv mv mv mv mv mv my mv mv mv mv mv mv mv mv
$<m male“. 2:);1 203 m3 3.? m3. an 3m: on? m: m3
$<m FEE mafia 803 mv mv mv mv mv mv mv mv
-m“_<m Egon 2:): A2. 803 So me 3m m3 3m Nam m: 5m
E9; E9: 303 03 Ed
E8 v Boa 3: ov mm:
E0; m 8% HEW 3w 93 3d 9%
Eon N 8% m3: 8.x 23 33 NE Hm.“ :3 mg 2% 3m: R.»
E8 F 803 m3 3m who
8.02 mmm 0% om
WO 61080
-mnzm E0”. go: NE EN H3 <3 HE new 8.0 53 Bo m3 03 «ms m: mm
m ems mos m3
3% :95“. min: A3 203
-E<m 3: 2:); A3 805
$5 me. min: a: $03 mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv
$<m 2.3
8.: 803 a} cod mom. mm.m 3m $.m 8m. Sm mm.m $.m N3 N3 mam om
max o 03 No.0 m3,
$5 mEmE min: 303 mv mv mv mv mv mv mv mv mv :lllr| mv mv mv mv mv mv mv mv
$45 Emmi 2.5: 2.? mama m5 Bx m2 Ea m3 8.? 0.? N: mmwz wmw mow 8
m2 m; asTm:
-E<m ENE“. 93$ mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv
$<m Emmi 2:): mm.“ m? who 93 mg Hm.“ 03 mg 30 is 8.x as no.“ wm
m mow mm.“ mm.“
Ewm> E9: mms g 98 NE NE N3 30 N3 SN 8s was aw mws om
w mow as 30
E8 v mg HS m: om.“ SW «3 w: 8.x 3w 2 «m
m N; Ed 8m m 3m $3 mm.“
E9. m mg 3w m3 mg cam 3w NS N3 8d mm
m R» 3d mg TI3mm 25 Ed «mm
E9 N mg a; 8w mg .23 8.x Now N3 3m R «5 :6. mg mm w; 3% $.m 1|. w m
Eon r mg 86 m3 3% 26 Nam 3.x mg ww.m K wq
m NE $6 mm.m m 3m 3m mow
.oo .02 g @N EN SN gm SN 2% 8N EN «mm 8N mmm EN 5mm 8N wmm 8N
.25 Eon w 803 Rd Sm m3 mms owe 93 9% 8;“. an o: m3 Rd 3m H: as mv mv
Pam I3: man: a: 803
92m.3: z__>: a... 303
8%-mox waiv 8.: onoa mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv mv
$<m z__>:
5g 8% Sm mom mv 5o m3 N3. 3m mv mom 3% mv 9} 8m N3. mod mv jv
a“. min: A2. omoa mv mv flmv mv mv mv mv mv mv mv mv mv mv mv mv mv mv
$<m«Halon. 2:); A2. omo_o_ E? 5.? m3 8.x Es d? 8s Rm mum 8.? own 2x 3.0 m: 8.? mv gm
$<mWEE 9:0: A2. 803 mv mv mv mv mv mv mv mv mv my mv mv mv mv mv mv mv
E<mwhen. 2:); a... 303 8s :3 m3 was 3: NE N: 85 v3 3% $.m a...“ £6 m: 3m mv m3
EomS E9: 803 mm.“ $6 N3 $3 om: om.“ m3 wad
Eon. w 303 mg mm.“ mmm $3 fig gm wad SKI?
E0; m 8% NS a: Rm 3.x mg 5m 03 Ex 3% 8w 2% 8.x wow mg mg mm.“ 2.x
E8 N 803 3.? 3.x 3.x 5m 35 a; 8.x 9% 9% NEW a; 8.» 3w mg mg N: mm.»
Eon F 803 «.3 3.x 3% 2; S; m; H; 3% :3 2; a: m; 5m w: mama
oo.02 EN mom SN EN 8N 9% EN Km NR «R BN RN QR 3N 0mm «mm 8N
WO 61080
8&8 E6“. v $05 28 $8 m: 8
o mm
m Bo N8 mos o SN 8.8 Nmm o:
9:8 .85“. man: 8.: $03
.38 85“. 2:): 8: 803
-muzm me: mad: 8: 805 mv mv mv m
v mv mv mv mv mv mV mv
.35 2%: 8: 803 8mm m3 mam S 88 8
me: . mv
m mam 3m m m3 woo
$48 8E0“. man: 8.: so: mv mv mv mv mv mv mV mv mv mv mv
-858 8E0“. 2:): 8: 305 $3 8s 88 «m. N3 mos m: mm
m3. 3m
z l|+lll :8 28
-23: Egon man: 8.: 3% mv mv mv mv mv mv mv mv mv mv mv
-248 Ema”. z:>: 8: ads. wmd Es m: $8 8.0 88 88 S
u $8 o: 8.8
Eom> 8.9: 303 m: was 8.8 a: 88 £8 88 8
8 8.8 m: 8.8
N 88
Eon: q 303 3.8 $8 38 $8 :3 mm.” 2% mm
m No.8 38 38 3.8
Eon. 8 805 can $8 £8 $8 mm.“ £8 $8 om
m $8 Km $8 mg
E0“. N 803 mew $8 mg 3.8 8.8 £8 38 E
m ohm m; $8 8.0.
E0: : 80.: 88 :32 mg Ba 8me 5% mod E
m mg 1T! 8.8 m; mg
.8 .oz am SN :8 N
mm 8m 0mm 5N 88 8N 5N 28 8
Claims (1)
1. A compound of formula (l-A) or (l-B): N N N Y / / (R2)Q N ” (l-Al l n _ ((-8) including any eric or stereochemically isomeric form thereof. wherein 10 each R2 is independently selected from hydroxyl. halogen, ‘C1-4aIkyl, 02.4alkenyl, C2-4alkynyl, CMalkoxy, hydroxyC1-4alkyl, hydroxyCMalkoxy, haloCMalkyl, haloC1- talkoxy, yhaloC1_4alkyl, hydroxyhaloC1-4alkoxy, C1_4alkoxy01_4alkyl, haloC1. 4alkoxyC1_talkyl, Ci.4alkoxyci.4alkyl wherein each CMalkyl may ally be substituted With one or two hydroxyl groups. hydroxyhaloC1-4alkoxyC1.4alkyl, R”, Ci. 15 4alky| substituted with R13, CMalkyl substituted with -C(=O)-R‘3, CMalkoxy substituted with with R13, CMalkoxy tuted with -C(=O)-R‘3, ~C(=O)-R13, CMalkyl substituted -NR7R8, CMalkyl substituted with —C(=O)-NR7R8, CMalkoxy substituted with -NR7R5, koxy substituted with —C(=O)-NR7RB, -NR7R8 and -C(=O)-NR7R8; or when two atoms they may be taken together to form a groups are attached to adjacent carbon 20 radical of formula: (C<R")zip-O-; -X~CH=CH-; or -X-CH=N-; wherein R17 represents hydrogen or fluorine. p represents 1 or 2 and X represents 0 or S; Y represents ~CR18=N-OR19 or -—E-D; SUBSTITUTE SHEET (RULE 26) 2012/052672 3 to 12 D represents a 3 to 12 ring membered clic or bicyclic carbocyclyl or a ring membered monocyclic or bicyclic heterocyclyl containing at least one heteroatom selected from N, O or 8. n said carbocyclyl and heterocyclyl may each optionally substituted by one or more (e.g. 1, 2 or 3) R1 groups; E ents a bond, R23)n-, Cz.4alkenediyl Optionally tuted with R22, CZ. -NR22- 4alkynediyl optionally substituted with R22, —CO-(CR22R23)s-, -(CR22R23)S.Co-, (CR22R23)5-, '(CR22R23)5'NR22‘, ‘O'(CR22R23)5‘, “(CR22R23)5‘O‘, 'S(O)m'(CR22R23)s', _ (CR22R23)s-S(O)m-, —(CR22R23)5-CO-NRzz-(CR22R23)S- or R23)s-NR22-CO— 10 (CR22R23)5'; R1 represents hydrogen, halo, cyano, Ciealkyl. C1.6alkoxy, -C(=O)-O- Cigalkyl, CZ- 4aikenyi, hydroxthealkyl, haloC1-6aikyl, yhalocmalkyl, cyanoCMalkyl, Ci- saikoxycmaikyi wherein each Chealkyl may optionally be substituted with one or two 15 hydroxyi groups, -NR4R5, Cmaikyi substituted with -O-C(=O)- C1_6alkyl, C1-5alkyi substituted substituted with -NR4R5, —C(=O)-NR4R5, —C(=O)-Cmaikyl-NR4R5, Ci.ealkyi with -C(=O)-NR“R5, -S(=O)2-Ct-6alkyi, -S(=O)2-haioct-eaikyi, —S(=0)2-NR”R‘5, ct. salkyl substituted with —S(=O)2-C1_6alkyl, Ct-eaikyl substituted with -S(=O)2-haioC1.5aikyi, C1.6alkyl substituted with —S(=O)2-NR“R‘5, Chealkyl substituted with -NH-S(=O)2-Ct- with — 20 ealkyl, 01.6alkyl substituted with —NH-S(=O)2-haloCi.6alkyl, Ci_6a|ky| substituted NR‘2—3(=oiz—NR“R‘S, R6, 01.6alkyl substituted with R5, —C(=O)—R6, Ct_5alkyl substituted with - with —C(=O)-R6, hydroxth-6aikyl substituted with R6, Cmalkyi substituted with Si(CH3)3, 01.6aikyl substituted with ~P(=O)(OH)2 or C1_5alkyl substituted — P(=O)(OCi.eaikyl)2; R3 represents hydroxyl, 01.6alkoxy, yC1_5aikoxy, Cmaikoxy substituted with -NR‘°R“, Cmalkyl, C2.6alkenyl, Cz_saikynyl, haioCi.6aikyi optionally tuted with —O- C(=O)-C1.Galkyl, hydroxth.6aikyl optionally tuted with -O-C(=O)~Ct.eaikyi, hydroxyCz_6alkenyl, yCZ.5alkyny|, hydroxyhalocmalkyl, cyanoC1.6alkyt, kyl 30 substituted with carboxyl, Cmalkyl substituted with -C1_6a|kyl, Ct_ealkyl substituted with —C(=O)—O—Ct.5alkyl, Cmalkyl substituted with C1.salkoxyCmalkyI-O- tuted with C(=O)—, 01-5aikyi substituted with C1-5alkoxyC1.6aikyl-C(=O)-, Chealkyl —O-C(=O)—C1_5alkyi, Ci_6aikoxy01_6alkyl wherein each C1.5alkyl may optionally be substituted with one or two hydroxyl groups or with ——O-C(=O)—C1.5alkyl, C2.5alkenyl substituted 35 substituted with 01.5alkoxy, Czealkynyi tuted with Ct_eaikoxy. C1.6alkyl SUBSTITUTE SHEET (RULE 26) with R9 and optionally substituted with -O-C(=O)-Ci.6alkyi, i tuted with — C(=O)-R9, Cisalkyl substituted with hydroxyl and R9, Czealkenyi substituted with R9, C2. salkynyl substituted with R9, ky| substituted with --NR‘°R“, 02.6alkenyl substituted with -NR‘°R“, Czsaikynyi substituted with -NR1°R”, Cheaikyl tuted with hydroxyl and -NR‘°R“, Cmalkyl substituted with one or two halogens and -NR‘°R“, -Ci_6aikyl- =N-o-R‘2, Cmalkyi substituted with -NR‘°R“. Ci_5alkyl substituted with —o-C(=0)-NR’°R“, —S(=O)2-C1.6alkyl, —S(=O)2-haioCisalkyl, —S(=0)2-NR”R‘5, C1. salkyl substituted with -S(=O)2-Ci_5aikyi, Ci_ealkyl substituted with -S(=O)2-haioci_5alkyl, 10 Cisalkyl substituted with —S(=O)2-NR”R‘5, Ci_6alkyi substituted with ~NR’2—S(=O)2-Ci_ salkyl, Cisalkyl substituted with —NH-S(=O)2-haloci.salkyl. 01.5alkyl substituted with —NR‘2-S(=O)2-NR”R15, R”, Cmaikyl substituted with —P(=O)(OH)2 or c,_6aikyi substituted with (OC1.eaikyi)2; 15 R4 and R5 each independently represent hydrogen, C1-6aikyi, C1_5aikyl substituted with - NR14R‘5,hydroxyCi.6aikyi, haloCi.6alkyl, hydroxyhaloCi-6aikyl. Ci_6aikoxy01.aaikyi wherein each Cmalkyi may optionally be substituted with one or two hydroxyl groups, — S(:O)2-Ci.salkyi, —S(=O)2—haioci.5alkyl, —S(=O)2-NR”R15, —C(=oi—NR‘4R‘5, -C(=O)-O- Cisalkyl, -C(=O)-R13, C1_5alky| substituted with -S(=O)2-C1-eaikyl, Cmalkyi substituted 2O with -S(=O)2-hal001_5alkyl, 01.5alkyl substituted with 2-NR”R’5, Ci_5alkyl substituted with =O)2-Ci.5alkyl, Ci.5alkyl substituted with —NH-S(=O)2-haloCi. salkyl, C1-6alkyl substituted with —NH- S(=O)2-NR”R‘5, R13 or Ci_salkyl substituted with R13; 25 R6 represents Cg_8cycloalkyi, Ca.8cycioaikenyl, , 4 to ered monocyciic heterocyciyi containing at least one heteroatom selected from N, O or 8; said Ca. acycloalkyi, 03.8cycioalkenyi, phenyi, 4 to 7-membered monocyciic heterocyclyl, optionally and each independently being tuted by 1, 2, 3, .4 or 5 substituents, each substituent independently being selected from cyano, C1_5aikyi, cyanoC1_5alkyi, 30 hydroxyl, carboxyl, hydroxyCmalkyl, halogen, haloC1_6alel, hydroxyhaloci_5alkyi, C1. ealkoxy, C1.6alkoxy01.5alkyl, C,_6alkyl-O-C(=O)-, -NR“R‘5, -C(=O)-NR“‘R'5, c,_6aii<yi substituted with -NR“R‘5, C1-eaikyl substituted with -C(=O)-NR‘4R‘5, -S(=O)2-Ci_6alkyl, —S(=O)2-haioci-6aikyl, —si=0)2-NR‘4R‘5, kyi tuted with 2-C,_5alkyl, c1. saikyl substituted with —S(=O)2-haioCi-6alkyi, Ci-6alkyi substituted with z- SUBSTITUTE SHEET (RULE 26) NR”R‘5. 01.5alkyl substituted with =O)2-C1.salkyl, Cmalkyl substituted with —NH- S(=O)2-hal001_salky| or Cisalkyl substituted with -NH-si=0)2-NR?“R‘5; R7 and R8 each independently represent hydrogen, 01.5alkyl, hydroxyCi.ealkyl, haloC1_ saikyl, hydroxyhaloC1_6alkyl or 01.6alkoxyC1_6alkyl; R9 represents C3-8cycloalkyl, Cucycloalkenyl, phenyl, naphthyl. or 3 to 12 membered monocyclic or bicyclic heterocyclyl containing at least one atom ed from N, O or 8, said loalkyl. Ca.8cycloalkenyl, phenyl, naphthyl, or 3 to 12 membered 10 monocyclic or bicyclic heterocyclyl each optionally and each independently being substituted with 1, 2, 3, 4 or 5 substituents, each substituent independently being ed from =0, CMaIkyl, hydroxyl, carboxyl, hydroxyCi_4alkyl, cyano, cyanoCMalkyl, C1-4alkyl-O-C(=O)-, CMalkyl substituted with C1.4alkyi-O-C(=O)-, C1_4alkyi-C(=O)-, Cit 4alkoxyCMalkyl wherein each kyl may optionally be substituted with one or two 15 hydroxyl groups, halogen, alkyl, hydroxyhaloC1.4alkyl, —NR”R‘5, -C(=O)- NR‘4R‘5. CMalkyl substituted with -NR“‘R‘5, Ci.4alkyl substituted with -c<=0)-NR‘4R‘5, CMalkoxy, 2-C1§4alkyl, —S(=O)2-haloci.4alkyl, -S(=O.)2-NR”R15, CMalkyl substituted with —S(=0)2-NR”R15, CMalel tuted with—NH-S(=0)2-c1..4aikyi, ct. dalkyl tuted with —NH-S(=O)2-haloci.4alkyl, Ci_4alkyl substituted with —NH-S(=O)2- 20 NR‘4R15, R13, -C(=O)-R‘3, CMalkyl substituted with R“, phenyl optionally substituted with R16, phenle1_5alkyl wherein the phenyl is optionally substituted with R‘ia 5 or 6- membered aromatic monocyclic heterocyclyl containing at least one heteroatom selected from N, O or 3 wherein said heterocyclyl is optionally substituted with R16; or when two of the substituents of R9 are attached to the same atom, they may be 25 taken together to form a 4 to 7-membered saturated monocyclic heterocyclyl containing at least one heteroatom selected from N, O or S; R10 and R“ each ndently represent hydrogen, yl, Cisalkyl, cyanoCmalkyl, C1_5alky| substituted with —NR”R15. Ci-ea|kyl substituted with —C(=O)—NR”R15, haloCi. 30 Galkyl, hydroxyC1.Balkyl, hydroxyhaloCi-6alkyl
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552888P | 2011-10-28 | 2011-10-28 | |
GBGB1118656.6A GB201118656D0 (en) | 2011-10-28 | 2011-10-28 | New compounds |
GB1118656.6 | 2011-10-28 | ||
US61/552,888 | 2011-10-28 | ||
PCT/GB2012/052672 WO2013061080A1 (en) | 2011-10-28 | 2012-10-26 | Anticancer pyridopyrazines via the inhibition of fgfr kinases |
Publications (2)
Publication Number | Publication Date |
---|---|
NZ622702A NZ622702A (en) | 2016-08-26 |
NZ622702B2 true NZ622702B2 (en) | 2016-11-29 |
Family
ID=
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10272087B2 (en) | Pteridines as FGFR inhibitors | |
US9757364B2 (en) | Naphthyridine derivative compounds | |
US10045982B2 (en) | Substituted pyrido[2,3-b]pyrazines as FGFR kinase inhibitors | |
US9737544B2 (en) | Compounds | |
AU2014259151B2 (en) | Quinazolinone derivatives useful as FGFR kinase modulators | |
DK2776397T3 (en) | QUINOLINES AS FGFR CHINA MODULATORS | |
EP2776408B1 (en) | Anticancer benzopyrazines via the inhibition of fgfr kinases | |
EP2646432A1 (en) | Substituted benzopyrazin derivatives as fgfr kinase inhibitors for the treatment of cancer diseases | |
AU2011247047A1 (en) | Pyrazolyl quinoxaline kinase inhibitors | |
NZ622702B2 (en) | Anticancer pyridopyrazines via the inhibition of fgfr kinases |